fluoxetine has been researched along with Depression in 1007 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Post-stroke apathetic and depressive symptoms respond differently to fluoxetine treatment." | 9.69 | Does fluoxetine reduce apathetic and depressive symptoms after stroke? An analysis of the Efficacy oF Fluoxetine-a randomized Controlled Trial in Stroke trial data set. ( Lundström, E; Markus, HS; Mårtensson, B; Tay, J, 2023) |
| "Our findings parallel results from trials from higher income settings that fluoxetine does not significantly improve post-ischemic stroke depression, although our sample size was small." | 9.51 | Efficacy of Fluoxetine for Post-Ischemic Stroke Depression in Tanzania. ( Chiwanga, F; Ismail, S; Kapina, B; Massawe, E; Mateen, FJ; Mworia, NA; Okeng'o, K; Rice, DR; Wasserman, M, 2022) |
| "The EFFECTS (Efficacy of Fluoxetine—a Randomised Controlled Trial in Stroke) recently reported that 20 mg fluoxetine once daily for 6 months after acute stroke did not improve functional outcome but reduced depression and increased fractures and hyponatremia at 6 months." | 9.41 | Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial. ( Borg, J; Dennis, MS; Greilert Norin, N; Hackett, ML; Hankey, GJ; Isaksson, E; Lundström, E; Mårtensson, B; Mead, GE; Näsman, P; Norrving, B; Sunnerhagen, KS; Wallén, H; Wester, P, 2021) |
| "To investigate whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by clinically significant symptoms of depression after stroke." | 9.41 | Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial. ( Almeida, OP; Etherton-Beer, C; Flicker, L; Ford, A; Hackett, M; Hankey, GJ, 2021) |
| "To investigate the effects of WAA combined with fluoxetine in the clinical treatment of post-stroke depression (PSD) ." | 9.34 | Wrist-ankle acupuncture and Fluoxetine in the treatment of post-stroke depression: a randomized controlled clinical trial. ( Qian, X; Shu, S; Yao, F; You, Y; Zhang, T; Zhou, S, 2020) |
| " angustifolia effect similar to fluoxetine in mild to moderate depression." | 9.34 | A double-blind, randomized pilot study for comparison of Melissa officinalis L. and Lavandula angustifolia Mill. with Fluoxetine for the treatment of depression. ( Alijaniha, F; Araj-Khodaei, M; Emadi, F; Emaratkar, E; Faghihzadeh, S; Kamalinejad, M; Naseri, M; Noorbala, AA; Parsian, Z; Yarani, R, 2020) |
| " Fluoxetine is one of the main first-line medications used for depression, and it is hypothesized that it participates in the decrease of pro-inflammatory cytokines." | 9.22 | Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis. ( García-García, ML; Genis-Mendoza, AD; González-Castro, TB; Juárez-Rojop, IE; López-Nárvaez, ML; Martinez-Magaña, JJ; Ramos-Méndez, MÁ; Ruiz-Quiñones, JA; Saucedo-Osti, AS; Tovilla-Zárate, CA; Villar-Soto, M, 2022) |
| "Fluoxetine was approved for depression in children and adolescents based on two placebo-controlled trials, X065 and HCJE, with 96 and 219 participants, respectively." | 9.22 | Restoring the two pivotal fluoxetine trials in children and adolescents with depression. ( Gøtzsche, PC; Healy, D, 2022) |
| "These results suggest that although chronic fluoxetine treatment proves positive effects in animal models of depression, it may simultaneously increase anxiety in adolescent animals in a dose-related manner." | 9.22 | Effects of chronic fluoxetine treatment on anxiety- and depressive-like behaviors in adolescent rodents - systematic review and meta-analysis. ( Chocyk, A; Kryst, J; Majcher-Maślanka, I, 2022) |
| " Furthermore, sequential fluoxetine treatment, compared with standard fluoxetine treatment, resulted in significantly lower levels of depressive symptoms throughout smoking cessation treatment (p < ." | 9.19 | Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers. ( Abrantes, AM; Brown, RA; Kahler, CW; Miller, IW; Niaura, R; Price, LH; Strong, DR, 2014) |
| "Short-term therapy with saffron capsules showed the same antidepressant efficacy compared with fluoxetine in patients with a prior history of PCI who were suffering from depression." | 9.19 | A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. ( Abbasi, SH; Akhondzadeh, S; Arjmandi-Beglar, A; Farokhnia, M; Forghani, S; Gougol, A; Kassaian, SE; Mahmoodian, M; Noorbala Tafti, AA; Saroukhani, S; Shahmansouri, N; Yekehtaz, H, 2014) |
| "EA treatment for depression is as effective as a recommended dose of fluoxetine." | 9.17 | Effects of electroacupuncture on depression and the production of glial cell line-derived neurotrophic factor compared with fluoxetine: a randomized controlled pilot study. ( Bao, F; He, W; Ma, C; Sun, H; Wang, DH; Zhang, J; Zhang, YX; Zhao, H, 2013) |
| "This study is the first trial of classical homeopathy that will evaluate the efficacy of homeopathic individualized treatment using C-potencies versus placebo or fluoxetine in peri- and postmenopausal women with moderate to severe depression." | 9.17 | Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial. ( Aguilar-Faisal, L; Asbun-Bojalil, J; Macías-Cortés, Edel C, 2013) |
| "Fluoxetine and Citalopram can effectively reduce the severity of depression in diabetic patients without an adverse effect on glycemic control." | 9.15 | Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? ( Khazaie, H; Najafi, F; Rahimi, M; Rezaei, M; Tahmasian, M; Tatari, F, 2011) |
| " Depression could result from changes in tryptophan availability caused by activation of the kynurenine pathway as a result of inflammation." | 9.14 | Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. ( Bridel, MA; Christofides, J; Cowlard, R; Darlington, LG; Forrest, CM; Mackay, GM; Mitchell, S; Stone, TW, 2009) |
| "This study is to investigate the clinical therapeutic effects and safety of treating mild or moderate depression with somatic symptoms with electroacupuncture combined with Fluoxetine." | 9.14 | Efficacy evaluation for depression with somatic symptoms treated by electroacupuncture combined with Fluoxetine. ( Chen, LP; Duan, DM; Tu, Y; Wu, ZJ, 2009) |
| "The authors set up two groups, the treatment group and the control group, to observe the influence of electro-acupuncture on the side effects produced by fluoxetine in the treatment of depression." | 9.14 | Influence of electro-acupuncture on the side effects of fluoxetine on depression patients. ( Liu, LY; Lu, Q; Wang, LL, 2009) |
| "Fluoxetine may improve the poststroke emotional disturbances." | 9.13 | Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. ( Choi, J; Choi-Kwon, S; Kang, DW; Kim, JS; Kwon, SU, 2008) |
| "To study on clinical therapeutic effect and safety of electroacupuncture and Fluoxetine for treatment of mild or moderate depression with physical symptoms." | 9.13 | [Assessment of effectiveness of electroacupuncture and fluoxetine for treatment of depression with physical symptoms]. ( Chen, LP; Duan, DM; Tu, Y, 2008) |
| "The efficacy and safety of the selective serotonin reuptake inhibitor fluoxetine have rarely been studied in the treatment of poststroke emotional disturbances." | 9.12 | Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. ( Choi, JM; Choi-Kwon, S; Han, SW; Kang, DW; Kim, JS; Kwon, SU, 2006) |
| "Fluoxetine combined with CBT had greater efficacy than did placebo and CBT according to changes on the Childhood Depression Rating Scale-Revised (effect size, 0." | 9.12 | A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. ( Davies, RD; Klein, C; Lohman, M; Mikulich-Gilbertson, SK; Riggs, PD; Stover, SK, 2007) |
| "Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder." | 9.11 | Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. ( Borrelli, B; Cook, JW; Hitsman, B; Keuthen, NJ; Kristeller, J; McChargue, DE; Niaura, R; Spring, B, 2004) |
| "Efficacy and tolerability of Hypericum LI 160 was compared to fluoxetine and placebo in mild to moderate Major Depression (DSM-IV) in a 4-week randomized, double-blind trial." | 9.11 | Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. ( Alken, RG; Bjerkenstedt, L; Edman, GV; Mannel, M, 2005) |
| " Moderate to severe depressed patients (determined by Hamilton Depression Scale (HDS) > 15, the Beck Depression Inventory (BDI) and the Clinical Global Impression (CGI) Scale) were randomized to receive either 20 mg/d fluoxetine or placebo for 3 months." | 9.10 | Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. ( Baumhackl, U; Fruehwald, S; Gatterbauer, E; Rehak, P, 2003) |
| "To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression." | 9.10 | Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. ( Baker, RW; Beymer, K; Bowden, C; Breier, A; Calabrese, J; Centorrino, F; Dube, S; Evans, AR; Ketter, TA; Mitchell, PB; Risser, R; Sachs, G; Tohen, M; Tollefson, GD; Vieta, E, 2003) |
| "Reduction in depression symptoms was significantly greater in patients treated with fluoxetine compared with those receiving placebo (BDI, -14." | 9.09 | Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. ( Clouse, RE; Freedland, KE; Griffith, LS; Lustman, PJ, 2000) |
| " Recent hemiplegic patients (<3 months) suffering from major depressive disorder (determined by International Classification of Diseases, 10th Revision, and Montgomery-Asberg Depression Rating Scale [MADRS] >19) were randomized to receive either 20 mg/d fluoxetine (FLX) or placebo for 6 weeks." | 9.09 | Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. ( Barat, M; Joseph, PA; Mazaux, JM; Petit, H; Wiart, L, 2000) |
| "It is postulated that the initial recovery of the HPA axis during the treatment of depression with fluoxetine is mediated via restoration of glucocorticoid negative feedback on ACTH levels." | 9.09 | Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. ( Donald, RA; Inder, WJ; Joyce, PR; Mulder, RT; Prickett, TC, 2001) |
| "We have investigated proton magnetic resonance spectra of the basal ganglia in 41 medication-free outpatients with major depression, prior to starting an 8-week standardized trial of open-label fluoxetine, and 22 matched comparison subjects." | 9.08 | Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. ( Babb, SM; Bonello, CM; Christensen, JD; Cohen, BM; Fava, M; Lafer, B; Moore, CM; Nierenberg, AA; Pillay, SS; Renshaw, PF; Rosenbaum, JF; Rothschild, AJ; Stoll, AL; Yurgelun-Todd, DA, 1997) |
| "This study tested the effectiveness of fluoxetine as a treatment for depression in a population of methadone-maintained opioid addicts." | 9.08 | Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. ( Carroll, KM; Gordon, L; Kosten, T; Nich, C; Petrakis, I; Rounsaville, B, 1998) |
| "To assess the possible efficacy of fluoxetine hydrochloride in severe PMS (premenstrual syndrome, luteal phase dysphoric disorder), an open trial of this medication was undertaken on women with severe PMS." | 9.07 | Open trial of fluoxetine therapy for premenstrual syndrome. ( Elks, ML, 1993) |
| "Amitriptyline reduces the pain caused by peripheral-nerve disease, but treatment is often limited by side effects related to the drug's many pharmacologic actions." | 9.07 | Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 8.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) versus fluoxetine on depression." | 8.91 | Comparison between herbal medicine and fluoxetine for depression: a systematic review of randomized controlled trials. ( Cao, H; Ren, Y; Wu, J; Zheng, R; Zhu, C, 2015) |
| "To assess the effects of fluoxetine in comparison with all other antidepressive agents for depression in adult individuals with unipolar major depressive disorder." | 8.89 | Fluoxetine versus other types of pharmacotherapy for depression. ( Barbui, C; Cipriani, A; Furukawa, TA; Gastaldon, C; Magni, LR; Papola, D; Purgato, M, 2013) |
| "To determine the efficacy of fluoxetine, compared with other ADs, in alleviating the acute symptoms of depression, and to review its acceptability." | 8.82 | Fluoxetine versus other types of pharmacotherapy for depression. ( Barbui, C; Brambilla, P; Cipriani, A; Furukawa, T; Geddes, J; Gregis, M; Hotopf, M; Malvini, L, 2005) |
| "Fluoxetine has shown superior efficacy compared with placebo in the treatment of depression in patients with HIV/AIDS, diabetes mellitus or stroke; however, it has not significantly improved depressive symptoms versus placebo in patients with cancer." | 8.81 | Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. ( Cheer, SM; Goa, KL, 2001) |
| "Compare the effects of LAT and fluoxetine on depression-like behaviors in mice exposed to CSDS." | 8.31 | Isoalantolactone relieves depression-like behaviors in mice after chronic social defeat stress via the gut-brain axis. ( Cai, Q; Li, K; Ni, Z; Sun, Y; Wang, M; Wang, S; Wang, Y; Xu, L; Zhang, L, 2023) |
| "Selective serotonergic reuptake inhibitors, including fluoxetine (FLX), are the most commonly used for the treatment of major depression." | 8.12 | Galanin (1-15) Enhances the Behavioral Effects of Fluoxetine in the Olfactory Bulbectomy Rat, Suggesting a New Augmentation Strategy in Depression. ( Cantero-García, N; Díaz-Cabiale, Z; Flores-Burgess, A; Fuxe, K; Gago, B; García-Durán, L; Millón, C; Narváez, JA; Puigcerver, A; Santín, L, 2022) |
| "A high-performance liquid chromatography-tandem mass spectrometry(LC-MS/MS) was developed for simultaneously determining the components(magnoflorine, jatrorrhizine, berberrubine, coptisine, berberine) of Jiaotai Pills and Fluoxetine in plasma of rats with chronic unpredictable mild stress(CUMS)-induced depression to investigate the pharmacokinetic herb-drug interaction of Jiaotai Pills and Fluoxetine in the rats." | 8.12 | [Pharmacokinetic interaction of Jiaotai Pills and Fluoxetine in rats with CUMS-induced depression]. ( Cao, Y; Chen, SS; Dai, GL; Ju, WZ; Li, FR; Li, Y; Liu, MC; Wang, YQ; Yang, XY, 2022) |
| " Regular use of fluoxetine apparently prevented the onset of anxiety, depression, aggressiveness, and suicide ideation, even with the concurrent use of AAS." | 8.02 | Effective treatment and prevention of attempted suicide, anxiety, and aggressiveness with fluoxetine, despite proven use of androgenic anabolic steroids. ( Amaral, JMX; Aquino Neto, FR; Baker, JS; Chagas, SV; Cruz, MS; Mullen, C; Padilha, MC; Vieira Neto, L, 2021) |
| " This study aimed to evaluate the anti-depressant effect of Cerebrolysin (CBL) in Reserpine-induced depressed rats, its effect on oxidative stress, inflammation, regulatory cyclic AMP-dependent response element binding protein (CREB)/brain derived neurotropic factor (BDNF) signaling pathways, brain monoamines and histopathological changes was assessed." | 8.02 | Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Behavioral, biochemical, molecular and immunohistochemical evidence. ( Ahmed-Farid, OA; El Awdan, SA; El-Marasy, SA; Hassan, A; Ogaly, HA, 2021) |
| " A randomized controlled trial of simple acupuncture combined with fluoxetine in the treatment of poststroke depression will be selected." | 8.02 | Simple acupuncture combined with fluoxetine in the treatment of poststroke depression: A protocol for systematic review and meta-analysis. ( Bi, J; Gao, L; Gong, P; Ma, X, 2021) |
| "The metformin treatment counteracted the development of depression-like behaviors in mice suffering SDS when administered alone and enhanced the anti-depressant effect of fluoxetine when combined with fluoxetine." | 7.96 | Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation. ( Chen, X; Dai, X; Fang, W; Hong, L; Huang, W; Ye, Q; Zhang, J, 2020) |
| " Fluoxetine, a commonly used antidepressant for treatment of depression, is known to regulate several important structural and neurochemical aspects of hippocampal functions." | 7.96 | Fluoxetine increases hippocampal neural survival by improving axonal transport in stress-induced model of depression male rats. ( Nahavandi, A; Zavvari, F, 2020) |
| "The study was designed to find out the effect of thymoquinone (TQ) alone and combination of TQ + fluoxetine in depression of type-2 diabetic rats." | 7.91 | Thymoquinone and fluoxetine alleviate depression via attenuating oxidative damage and inflammatory markers in type-2 diabetic rats. ( Alam, MF; Anwer, T; Khan, G; Masmali, AUM; Qumayri, HM; Safhi, MM; Siddiqui, R, 2019) |
| "To explore the pathogenesis of depression and the possible mechanism of the effects of selective serotonin reuptake inhibitors (SSRIs) on the myelinated fibers and myelin sheaths in the white matter during the antidepressant action of fluoxetine." | 7.91 | Changes in white matter and the effects of fluoxetine on such changes in the CUS rat model of depression. ( Chao, FL; Chen, LM; Du, L; Gao, Y; Huang, CX; Liang, X; Luo, YM; Ma, J; Qi, YQ; Tang, J; Tang, Y; Wang, SR; Xiao, Q; Yao, Y; Zhang, L; Zhang, Y, 2019) |
| "The aim of this study was to determine the effects of maternal fluoxetine treatment on anxiety-like and depressive-like behaviours in adolescent offspring as well as associated glutamatergic markers, using a clinically relevant rodent model of depression." | 7.91 | Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviours and alters glutamatergic markers in the prefrontal cortex and hippocampus of male adolescent rats: A comparison between Sprague-Dawley rats and the Wistar-Kyoto rat model o ( Fernandez, F; Lum, JS; Millard, SJ; Newell, KA; Weston-Green, K, 2019) |
| " The influences of N-acetylcysteine (NAC) on neuroinflammation associated depression-like behavior have not been investigated yet, and associated biochemical changes are currently unclear." | 7.91 | N-acetylcysteine attenuates neuroinflammation associated depressive behavior induced by chronic unpredictable mild stress in rat. ( Fernandes, J; Gupta, GL, 2019) |
| "We evaluated the effect of the co-administration of fluoxetine (5 mg/kg) and flurbiprofen (5 mg/kg) or fluoxetine (5 mg/kg) and celecoxib (5 mg/kg) in the chronic escape deficit (CED) model of depression after 7 days of treatment." | 7.88 | Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression. ( Alboni, S; Benatti, C; Brunello, N; Capone, G; Tascedda, F, 2018) |
| " Fluoxetine (FLX) is the first selective serotonin reuptake inhibitor to be widely available for the treatment of depression." | 7.88 | Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression. ( Liu, J; Pan, SJ; Tan, YL; Xin, Y; Xiong, J; Yang, X; Yao, SW, 2018) |
| "To further explore the underlying antidepressant mechanism of ginseng total saponins (GTS), this study observed the effects on hippocampal astrocyte structural plasticity and hippocampal volume in the corticosterone-induced mouse depression model." | 7.85 | Preventive Effects of Ginseng Total Saponins on Chronic Corticosterone-Induced Impairment in Astrocyte Structural Plasticity and Hippocampal Atrophy. ( Chen, L; Dai, JG; Huang, YF; Lin, ZX; Wang, X; Zhao, YN, 2017) |
| "Administration of leonurine (60 mg/kg) for 4 weeks significantly alleviated depression-like behaviors of chronic mild stress mice, including increased sucrose preference and reduced immobility time in forced swimming test and tail suspension test." | 7.85 | Leonurine Exerts Antidepressant-Like Effects in the Chronic Mild Stress-Induced Depression Model in Mice by Inhibiting Neuroinflammation. ( Chen, M; Ding, J; Ding, X; Du, R; Hu, G; Jia, M; Li, C; Lu, M; Zheng, Y, 2017) |
| "This study evaluated the chronic effects of fluoxetine, a commonly prescribed SSRI antidepressant, on the peripheral and central levels of inflammatory cytokines including IL-1β, IL-6, TNF-α and IL-17 over a 4-interval in a rat model of chronic mild stress (CMS) which resembles the human experience of depression." | 7.85 | Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression. ( Chua, AN; Ho, CS; Ho, RC; Liu, X; Lu, Y; McIntyre, RS; Wang, W, 2017) |
| "Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepressants, has been thought to be effective for treating post-stroke depression (PSD)." | 7.85 | Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression. ( He, QW; Hu, B; Jin, HJ; Li, M; Li, YN; Mao, L; Pei, L; Wan, Y; Xia, YP; Yang, S; Yue, ZY; Zheng, H, 2017) |
| "To observe the depression in patients with malignant tumor and influencing factors of the disease, as well as to investigate the effects of fluoxetine on depressive symptoms in cancer patients and the immune function." | 7.85 | Study of prevalence and influencing factors of depression in tumor patients and the therapeutic effects of fluoxetine. ( Dai, J; Liao, N; Shi, J; Tao, JQ, 2017) |
| "The present study was undertaken to examine whether brexpiprazole could augment antidepressant effects of the SSRI fluoxetine in an inflammation model of depression." | 7.85 | Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation. ( Dong, C; Futamura, T; Hashimoto, K; Ma, M; Ohgi, Y; Ren, Q; Yang, C; Yao, W; Zhang, JC, 2017) |
| " The aim of this study was to investigate whether anxiety or depression-like behavior can be found in rat strains with different susceptibility to audiogenic seizures (AS) and whether chronic fluoxetine treatment affects this co-morbidity." | 7.85 | Genetic background contributes to the co-morbidity of anxiety and depression with audiogenic seizure propensity and responses to fluoxetine treatment. ( Fedotova, IB; Kostina, ZA; Nikolaev, GM; Perepelkina, OV; Poletaeva, II; Sarkisova, KY; Surina, NM, 2017) |
| "The current study assessed whether antidepressant and/or antinociceptive drugs, duloxetine, fluoxetine as well as (±)-8-hydroxy-2-[di-n-propylamino] tetralin (8-OH-DPAT), are able to reverse depression-like behaviour in animals with chronic neuropathic pain." | 7.83 | Duloxetine and 8-OH-DPAT, but not fluoxetine, reduce depression-like behaviour in an animal model of chronic neuropathic pain. ( Ceci, A; Doods, H; Hu, B; Treede, RD, 2016) |
| "A new (aryloxyalkyl)adenine derivative Adeprophen (9-[2-(4-isopropylphenoxy)ethyl]adenine, VMA-99-82) has a strong antidepressant effect on the model of reserpine-induced depression in rats (single dose 4 mg/kg, intraperitoneally)." | 7.83 | Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats. ( Bagmetova, VV; Chernysheva, YV; Ozerov, AA; Tyurenkov, IN, 2016) |
| " We report a patient with persistent congenital hyperinsulinism (CHI) who developed recurrent hypoglycaemia following fluoxetine therapy." | 7.83 | Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy. ( Didi, M; Giri, D; Price, V; Senniappan, S; Yung, Z, 2016) |
| "The aim of this study was to compare the effects of treatment with fluoxetine and 1-methyl-L-tryptophan (1-MT) on Bacillus Calmette-Guerin (BCG)-induced inflammatory model of depression in mice." | 7.83 | Comparison of fluoxetine and 1-methyl-L-tryptophan in treatment of depression-like illness in Bacillus Calmette-Guerin-induced inflammatory model of depression in mice. ( Banerjee, BD; Bhattacharya, SK; Deshmukh, P; Jain, S; Mediratta, PK; Rana, P; Sharma, AK, 2016) |
| "Fluoxetine is widely used to treat depression, including depression in pregnant and postpartum women." | 7.83 | Risk of prenatal depression and stress treatment: alteration on serotonin system of offspring through exposure to Fluoxetine. ( Lin, S; Liu, L; Pei, S; Shang, J; Wang, H; Zhong, Z, 2016) |
| "The present study was carried out to determine the role of thymoquinone (TQ) in modulating the levels of neurotransmitter and reducing the oxidative stress in animal models of depression." | 7.81 | Antidepressant Effect of Thymoquinone in Animal Models of Depression. ( Akhtar, M; Aquib, M; Najmi, AK, 2015) |
| "Major depression is diagnosed in 18% of patients following myocardial infarction (MI), and the antidepressant fluoxetine is shown to effectively decrease depressive symptoms and improve coronary heart disease prognosis." | 7.81 | Effect and mechanism of fluoxetine on electrophysiology in vivo in a rat model of postmyocardial infarction depression. ( Chen, J; Chen, Y; Hu, D; Liang, J; Qu, C; Shi, S; Wang, F; Yang, B; Yuan, X, 2015) |
| " We found that chronic treatment of a mouse model of anxiety/depression (CORT model) with a selective serotonin reuptake inhibitor (SSRI, fluoxetine, 18mg/kg/day) reversed CORT-induced anxiety/depression-like behavior in mice." | 7.81 | Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression. ( Ali, ZE; Damiens, MH; David, DJ; Gardier, AM; Kerdine-Römer, S; Mendez-David, I; Pallardy, M; Tritschler, L, 2015) |
| " We compared the effects of chronic treatment with the preferential nNOS inhibitor 7-nitroindazole (7-NI) with those evoked by the conventional antidepressant fluoxetine on alterations that are considered as markers of depression (immobility in the forced swimming test, FST, decreased body weight gain and increased plasma corticosterone concentration) and cardiovascular changes caused by CVS." | 7.81 | Effects of nitric oxide synthesis inhibitor or fluoxetine treatment on depression-like state and cardiovascular changes induced by chronic variable stress in rats. ( Almeida, J; Crestani, CC; Duarte, JO; Oliveira, LA, 2015) |
| " At 12 months, but not earlier, DEX-exposed mice displayed depression-like behavior and impaired hippocampal neurogenesis, not reversible by the antidepressant fluoxetine (FLX)." | 7.81 | Alterations in circadian entrainment precede the onset of depression-like behavior that does not respond to fluoxetine. ( Bose, R; Ceccatelli, S; Conti, M; DuPont, C; Onishchenko, N; Raciti, M; Spulber, S, 2015) |
| "Postnatal treatment with the selective serotonin reuptake inhibitor fluoxetine, evokes anxiety and depressive behavior in rodent models in adulthood." | 7.80 | Postnatal fluoxetine-evoked anxiety is prevented by concomitant 5-HT2A/C receptor blockade and mimicked by postnatal 5-HT2A/C receptor stimulation. ( Chachra, P; Sarkar, A; Vaidya, VA, 2014) |
| "Several epidemiological studies have reported an association between arsenic exposure and increased rates of psychiatric disorders, including depression, in exposed populations." | 7.80 | Fluoxetine treatment ameliorates depression induced by perinatal arsenic exposure via a neurogenic mechanism. ( Allan, AM; Solomon, BR; Tyler, CR; Ulibarri, AL, 2014) |
| " Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes." | 7.80 | Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| " Magnolol is the main constituent identified in the bark of Magnolia officinalis, which has been used for the treatment of mental disorders, including depression, in Asian countries." | 7.79 | Magnolol treatment reversed the glial pathology in an unpredictable chronic mild stress-induced rat model of depression. ( Li, LF; Ma, SP; Qu, R; Yang, J, 2013) |
| "To observe the effect of hesperidin on behavior and hypothalamic-pituitary-adrenal (HPA) axis of ratmodel of chronic stress-induced depression." | 7.79 | [Effect of hesperidin on behavior and HPA axis of rat model of chronic stress-induced depression]. ( Cai, L; Li, R; Wu, QQ; Wu, TN, 2013) |
| "To investigate the effects of Sini San and fluoxetine on the levels of central and peripheral 5-HT in a rat model of depression, and provide new insight into the treatment of depression with integrated Chinese-Western Medicine." | 7.79 | Effects of Sini San used alone and in combination with fluoxetine on central and peripheral 5-HT levels in a rat model of depression. ( Chen, J; Guo, S; Li, Y; Ma, X; Ouyang, Y; Sun, Y; Wang, W; Wu, Z; Xue, X; Zhang, W, 2013) |
| " We have developed a mouse model of anxiety/depression based on addition of corticosterone to drinking water." | 7.78 | Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration. ( David, DJ; Gardier, AM; Guiard, BP; Nguyen, HT; Quesseveur, G; Rainer, Q, 2012) |
| " In the present study, pain sensitivity was assessed in a mouse model of anxiety/depression on the basis of chronic corticosterone (CORT) administration through the drinking water (CORT model)." | 7.78 | Antinociceptive effects of fluoxetine in a mouse model of anxiety/depression. ( Coudoré, F; David, DJ; Gardier, AM; Guiard, BP; Hache, G; Le Dantec, Y; Orvoën, S, 2012) |
| " The present study was undertaken to investigate effects of chronic administration of tianeptine or olanzapine on unpredictable chronic mild stress (UCMS)-induced depression-like behavior in mice compared to a widely used SSRI antidepressant, fluoxetine." | 7.78 | Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice. ( Akar, F; Celikyurt, IK; Erden, F; Gumuslu, E; Kır, HM; Kokturk, S; Mutlu, O; Ulak, G, 2012) |
| "In C6 glioma cells, we studied acute administration of SSRI antidepressants - fluoxetine, sertraline and citalopram." | 7.78 | Effect of fluoxetine and adenosine receptor NECA agonist on G alpha q/11 protein of C6 glioma cells. ( Kováru, F; Kovárů, H; Lisá, V, 2012) |
| " To further investigate these neuropeptides in depression-like behaviour, NPY and galanin gene expression was studied in brains of mice subjected to chronic restraint stress (CRS) and concomitant treatment with the antidepressant fluoxetine (FLX)." | 7.77 | Fluoxetine reverts chronic restraint stress-induced depression-like behaviour and increases neuropeptide Y and galanin expression in mice. ( Christiansen, SH; Olesen, MV; Woldbye, DP; Wörtwein, G, 2011) |
| "Weight gain during olanzapine/fluoxetine combination (OFC) therapy is very common." | 7.77 | Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. ( Case, M; Degenhardt, EK; Jamal, HH; Tormey, S, 2011) |
| "Selective serotonin reuptake inhibitors, such as fluoxetine, have demonstrated the ability to alleviate behavioral depression in the forced swim test; however, the sites and mechanisms of their actions remain to be further elucidated." | 7.77 | Fluoxetine alleviates behavioral depression while decreasing acetylcholine release in the nucleus accumbens shell. ( Chau, DT; Hoebel, BG; Kim, K; Kosloff, RA; Rada, PV, 2011) |
| " This study investigated the effects of agomelatine and fluoxetine in a genetic model of depression called H/Rouen mice Male and female H/Rouen (helpless line) and NH/Rouen (nonhelpless line) mice, received once daily for 3 weeks agomelatine (10 and 50 mg/kgi." | 7.77 | Chronic agomelatine and fluoxetine induce antidepressant-like effects in H/Rouen mice, a genetic mouse model of depression. ( Dubois, M; El Yacoubi, M; Gabriel, C; Mocaër, E; Vaugeois, JM, 2011) |
| "Status epilepticus was induced in the rats by administration of pilocarpine 350 mg/kg i." | 7.77 | Piperine protects epilepsy associated depression: a study on role of monoamines. ( Nayak, S; Pal, A; Sahu, PK; Swain, T, 2011) |
| "Neonatal treatment with clomipramine (CMI) in rats induces multiple behavioral alterations during adulthood that resemble certain symptoms of human depression, such as impairments of pleasure-seeking behaviors." | 7.76 | Circadian activity of corticosterone in an animal model of depression: response to muscarinic cholinergic stimulation. ( Arteaga-Silva, M; Bonilla-Jaime, H; Hernández-González, M; Retana-Márquez, S; Vázquez-Palacios, G, 2010) |
| "The aim of this study was to investigate the relationship between plasma glutamate, glutamine and gamma-aminobutyric acid (GABA) levels in female patients with major depression treated with S-citalopram or fluoxetine." | 7.75 | The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. ( Calişkan, M; Gören, MZ; Kaplan, OK; Küçükibrahimoğlu, E; Saygin, MZ; Unsal, C, 2009) |
| " Here we describe a mouse model of an anxiety/depressive-like state induced by chronic corticosterone treatment." | 7.75 | Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. ( Antonijevic, IA; Artymyshyn, RP; Craig, DA; David, DJ; Drew, M; Gardier, AM; Gerald, C; Guiard, BP; Guilloux, JP; Hen, R; Leonardo, ED; Marsteller, D; Mendez, I; Rainer, Q; Samuels, BA; Wang, JW, 2009) |
| " We report a case of recurrent priapism that was treated with Fluoxetine and low dose Perphenazine." | 7.74 | Treatment of idiopathic recurrent priapism with fluoxetine and low dose Perphenazine. ( Ahmadi, A; Khazaie, H; Moradi, M; Tahmasian, M, 2008) |
| " Male Wistar rats were subjected to LiCl and pilocarpine status epilepticus (SE)." | 7.74 | Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. ( Baldwin, RA; Caplan, R; Mazarati, A; Sankar, R; Shin, D; Siddarth, P, 2008) |
| "To investigate the effects of fluoxetine on depression-induced changes of mast cell morphology and protease-1 (rMCP-1) expression in rats." | 7.74 | Effects of fluoxetine on mast cell morphology and protease-1 expression in gastric antrum in a rat model of depression. ( Chen, JH; Chen, ZH; Huang, YL; Luo, HS; Wang, GH; Wang, XP; Xiao, L, 2008) |
| "To investigate changes in vasoactive intestinal polypeptide (VIP) and corticotrophin releasing factor (CRF) in the plasma and duodenum of chronic stress-induced depressed rats and the effects of fluoxetine hydrochloride (fluoxetine) treatment on depression-induced changes in VIP and CRF." | 7.74 | Effect of fluoxetine on depression-induced changes in the expression of vasoactive intestinal polypeptide and corticotrophin releasing factor in rat duodenum. ( Chen, ZH; Huang, YL; Wang, GH; Wang, Q; Xiao, L; Yu, JP, 2007) |
| "A dysregulated hypothalamic-pituitary-adrenal axis (HPA) has been implicated in major depressive disorder and most commonly used animal models of depression have been shown to elevate circulating levels of plasma corticosterone." | 7.74 | Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. ( Hutson, PH; Murray, F; Smith, DW, 2008) |
| "The effects of acute and chronic fluoxetine treatment in intact and anxiety-depressive male and female inbred mice of the C57BL/6J strain were studied." | 7.74 | [Effects of acute and chronic introduction of fluoxetine on anxiety-depressive condition of male and female mice]. ( Avgustinovich, DF; Kovalenko, IL; Tolstikova, TG, 2007) |
| " We initially assessed four inbred mouse strains for their behavioral response to chronic treatment with the selective-serotonin reuptake inhibitor fluoxetine (0, 5, 10 mg/kg/day in drinking water), which is used for the treatment of mood and anxiety disorders." | 7.72 | Effects of chronic fluoxetine in animal models of anxiety and depression. ( Dulawa, SC; Gundersen, B; Hen, R; Holick, KA, 2004) |
| "The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder." | 7.71 | Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. ( Ancione, M; Avenoso, A; Gatti, G; Madia, A; Perucca, E; Scordo, MG; Spina, E, 2002) |
| "We report a case of a 32-year-old woman who developed paroxysmal episodes of right hemidystonia 2 days after taking fluoxetine." | 7.71 | Acute paroxysmal dystonia induced by fluoxetine. ( Callejo, JM; Domínguez-Morán, JA; Fernández-Ruiz, LC; Martínez-Castrillo, JC, 2001) |
| "To study the effect of fluoxetine on dendrite atrophy of hippocampal neurons in rat depression model." | 7.71 | Fluoxetine inhibits dendrite atrophy of hippocampal neurons by decreasing nitric oxide synthase expression in rat depression model. ( Luo, L; Tan, RX, 2001) |
| "Efficiency of fluoxetine (one of the selective serotonin reuptake inhibitors) was examined in the course of treatment of 24 patients with atypical depressions that were characterized by prevalence of either negative (12 patients) or positive (12 patients) affectivity." | 7.70 | [Effectiveness of fluoxetine (portal) in atypical depressions]. ( Andriushchenko, AV, 1998) |
| "Previously, we observed specific alterations of neuropeptide Y (NPY) and Y1 receptor mRNA expression in discrete regions of the Flinders Sensitive Line rats (FSL), an animal model of depression." | 7.70 | Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression. ( Caberlotto, L; Fuxe, K; Hurd, YL; Jimenez, P; Mathé, AA; Overstreet, DH, 1999) |
| " In addition, hypericum extracts, as well as standard antidepressants such as the tricyclic, impramine, and the selective serotonin reuptake inhibitor, fluoxetine, have been reported to be of therapeutic benefit in the treatment of alcoholism, as these compounds may reduce alcohol craving and/or intake in particular subgroups of patients." | 7.70 | Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. ( de Beun, R; De Vry, J; Jentzsch, KR; Maurel, S; Schreiber, R, 1999) |
| "A 17-year-old boy with type 1 diabetes mellitus developed new loss of hypoglycemia awareness while being treated with fluoxetine hydrochloride for depression." | 7.70 | Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. ( Burgart, V; Sawka, AM; Zimmerman, D, 2000) |
| "This study modelled the economic impact of mirtazapine, compared to amitriptyline and fluoxetine, in the management of moderate and severe depression in the UK, as well as the costs related to discontinuation of antidepressant treatment." | 7.70 | Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. ( Borghi, J; Guest, JF, 2000) |
| "Fluoxetine is a selective serotonin reuptake inhibitor that often is associated with a modest weight loss when used for the treatment of depression, although it also has been reported to have the opposite effects of weight gain and hyperphagia in some patients." | 7.69 | Hyperphagia and weight loss during fluoxetine treatment. ( Braun, BG; Fichtner, CG, 1994) |
| "To describe two cases of stomatitis related to fluoxetine given for the treatment of depression that were detected in the hospital emergency department." | 7.69 | Fluoxetine-associated stomatitis. ( Martínez-Mir, I; Morales-Olivas, FJ; Palop, V; Sancho, A, 1997) |
| " We here report a case of interferon-alpha-induced depression in a 40-yr-old man with hepatitis C successfully treated with the antidepressant fluoxetine, which allowed completion of interferon treatment." | 7.68 | Fluoxetine treatment of depression caused by interferon-alpha. ( Fallon, HJ; Levenson, JL, 1993) |
| "Two women being treated for depression with fluoxetine developed psoriasis after 6 and 12 months' exposure." | 7.68 | Fluoxetine-induced psoriasis. ( Hemlock, C; Rosenthal, JS; Winston, A, 1992) |
| "A 12-week open trial of fluoxetine in 61 obsessive-compulsive disorder patients significantly improved depressive and obsessive-compulsive symptoms." | 7.67 | Open trial of fluoxetine in obsessive-compulsive disorder. ( Baer, L; Buttolph, L; Holland, A; Jenike, MA; Ricciardi, J, 1989) |
| "Effective treatment of depression is a key target for suicide prevention strategies." | 7.01 | Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people. ( Berk, M; Chanen, A; Cotton, S; Davey, CG; Dean, O; Hetrick, S; Madsen, T; McGorry, PD; Witt, K, 2021) |
| "Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear." | 6.90 | The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. ( Amminger, GP; Berk, M; Catania, L; Chanen, AM; Cotton, SM; Davey, CG; Dean, OM; Harrison, BJ; Hetrick, SE; Kazantzis, N; Kerr, M; Koutsogiannis, J; McGorry, PD; Mullen, E; Parker, AG; Phelan, M; Quinn, AL; Ratheesh, A; Rice, S; Weller, A, 2019) |
| "Depression is a common affective disorder or mood disorder, which seriously affects people's physical and mental health and the quality of life." | 6.87 | Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation. ( Xiaoling, Z; Yingdong, L; Yunping, H, 2018) |
| "Fluoxetine was not different from placebo in Greene Climacteric Scale." | 6.80 | Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial. ( Aguilar-Faisal, L; Asbun-Bojalil, J; Llanes-González, L; Macías-Cortés, Edel C, 2015) |
| "Imipramine seems to be a better cost-utility antidepressant option for treating depressive disorders in primary care." | 6.74 | Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care? ( Haro, JM; Peñarrubia, MT; Pinto-Meza, A; Serrano-Blanco, A; Suárez, D, 2009) |
| "Machado-Joseph Disease (MJD/SCA3) is an autosomal dominant spinocerebellar degeneration that evolves to disability and death." | 6.71 | Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. ( Ferro, A; Jardim, LB; Monte, TL; Pereira, ML; Rieder, CR; Rockenback, I; Sequeiros, J; Silveira, I; Tort, AB, 2003) |
| "Fluoxetine was superior to placebo on all outcome measures." | 6.69 | Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression. ( Ackerman, DL; Bystritsky, A; Greenland, S; Small, GW, 2000) |
| " As indicated by the significant decrease in the Hamilton Depression scale and the Montgomery Asberg Depression scale, fluoxetine showed similar antidepressant effects to amitriptyline with significantly fewer adverse effects." | 6.67 | Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables. ( Czarka, M; de Maertelaer, V; Kerkhofs, M; Linkowski, P; Mendlewicz, J; Rielaert, C, 1990) |
| "Fluoxetine was superior to placebo on all clinical measures except for sleep disorder, but the differences were not statistically significant." | 6.67 | Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. ( Copping, W; Dinicola, VF; Ferguson, HB; Simeon, JG, 1990) |
| "When treating a patient with treatment-resistant depression, the clinician needs to consider all factors which may contribute to an inadequate response to an antidepressant." | 6.44 | Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. ( Berk, M; Dodd, S, 2008) |
| " In particular, patients beginning therapy with fluoxetine are more likely to receive treatment regimens that meet minimum recommended guidelines for dosage and duration and are less likely to require treatment switching/augmentation than those receiving tricyclic antidepressants or other SSRIs as initial therapy." | 6.40 | Fluoxetine. A pharmacoeconomic review of its use in depression. ( Benfield, P; Wilde, MI, 1998) |
| "Gabapentin is a commonly prescribed antiepileptic agent for seizures, which is also used for pain and addiction management." | 5.91 | Effect of Gabapentin-Fluoxetine Derivative GBP1F in a Murine Model of Depression, Anxiety and Cognition. ( Ali, G; Alkahramaan, YMSA; Arif, M; Gohar, A; Khan, MS; Rashid, U; Rauf, K; Sewell, RDE, 2023) |
| "Major depression is a leading contributor to the global burden of disease." | 5.72 | Lower antidepressant response to fluoxetine is associated with anxiety-like behavior, hippocampal oxidative imbalance, and increase on peripheral IL-17 and IFN-γ levels. ( Becker, G; Bochi, GV; Camargo, LFM; da Silva Carlotto, M; Dos Santos, BM; Fialho, MFP; Oliveira, SM; Pereira, GC; Pillat, MM; Piton, E; Ramanzini, LG; Trevisan, G; Zanchet, EM, 2022) |
| "Fluoxetine is a highly prescribed selective serotonin reuptake inhibitor (SSRI) in the treatment of depression and is reported to be a risk factor for fractures." | 5.72 | Fluoxetine improves bone microarchitecture and mechanical properties in rodents undergoing chronic mild stress - an animal model of depression. ( Chua, AN; Ho, CS; Ho, RC; Kumarsing, RA; Lam, RW; McIntyre, RS; Wong, HK, 2022) |
| "Fluoxetine treatment was applied in chronic variable mild stress (CVMS)-exposed (environmental hit) CD1 mice carrying one mutated allele of pituitary adenylate cyclase-activating polypeptide gene (genetic hit) that were previously exposed to maternal deprivation (epigenetic hit) vs." | 5.72 | Fluoxetine treatment supports predictive validity of the three hit model of depression in male PACAP heterozygous mice and underpins the impact of early life adversity on therapeutic efficacy. ( Berta, G; Csernus, V; Farkas, J; Füredi, N; Gaszner, B; Gaszner, T; Hashimoto, H; Kormos, V; Kovács, LÁ; Kun, D; Reglődi, D; Ujvári, B, 2022) |
| "Post-stroke apathetic and depressive symptoms respond differently to fluoxetine treatment." | 5.69 | Does fluoxetine reduce apathetic and depressive symptoms after stroke? An analysis of the Efficacy oF Fluoxetine-a randomized Controlled Trial in Stroke trial data set. ( Lundström, E; Markus, HS; Mårtensson, B; Tay, J, 2023) |
| "Fluoxetine resulted in a faster reduction of patients' inflammation without association with depression and anxiety." | 5.69 | Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial. ( Ala, S; Alizadeh Arimi, F; Elyasi, F; Ghasemian, R; Mehravaran, H; Moosazadeh, M; Sedighi, F; Zarghami, M, 2023) |
| "Fluoxetine treatment exhibited antidepressant effects and ameliorated the molecular changes induced by LPS." | 5.62 | Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression. ( Ali, T; He, K; Li, N; Li, S; Li, W; Liu, Z; Rahman, SU; Ren, Q; Shah, FA; Yu, ZJ; Zheng, C, 2021) |
| "Stroke is the leading neurologic cause of burden operationalized in terms of disability-adjusted life-years." | 5.62 | Fluoxetine for Stroke: A Mixed Bag of Outcomes. ( Andrade, C, 2021) |
| "Depression was induced via six weeks of CUMS in male ICR mice, and drug therapy was given simultaneously for the last three weeks." | 5.62 | Baicalin ameliorates chronic unpredictable mild stress-induced depression through the BDNF/ERK/CREB signaling pathway. ( Cao, Z; Chen, Y; Chu, L; Jia, Z; Lu, Y; Pei, L; Yang, J; Zhang, J; Zhang, S; Zhao, J, 2021) |
| "Inflammation has been associated with the progression of many neurological diseases." | 5.56 | Inflammation-induced behavioral changes is driven by alterations in Nrf2-dependent apoptosis and autophagy in mouse hippocampus: Role of fluoxetine. ( Adhikary, A; Chattopadhyay, S; Choudhury, S; Chowdhury, O; Das, A; Ghosh, S; Gupta, P; Mukherjee, S; Sain, A, 2020) |
| "Depression is one of the most common associated diseases, which aggravates psoriatic skin lesions and affects the life quality of patients." | 5.56 | Depressive-like behaviors in mice with Imiquimod-induced psoriasis. ( Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J, 2020) |
| "This single-center, randomized, single-blind, parallel-controlled study aimed to analyze the changes in resting-state functional connectivity (RSFC) in young patients with a suicide attempt caused by depression before and after cognitive-behavioral therapy (CBT) combined with fluoxetine or fluoxetine alone by functional magnetic resonance imaging (fMRI)." | 5.51 | Changes of functional connectivity of the subgenual anterior cingulate cortex and precuneus after cognitive behavioral therapy combined with fluoxetine in young depressed patients with suicide attempt. ( Bi, B; Kuang, L; Liu, J; Shu, Y; Wu, G; Xiong, J, 2022) |
| "Our findings parallel results from trials from higher income settings that fluoxetine does not significantly improve post-ischemic stroke depression, although our sample size was small." | 5.51 | Efficacy of Fluoxetine for Post-Ischemic Stroke Depression in Tanzania. ( Chiwanga, F; Ismail, S; Kapina, B; Massawe, E; Mateen, FJ; Mworia, NA; Okeng'o, K; Rice, DR; Wasserman, M, 2022) |
| " Other study measures included age, sex, marital status, living arrangements, function before the stroke, depression before the stroke, modified Rankin Scale (mRS) score, and treatment with fluoxetine or placebo for 26 weeks." | 5.51 | Measures Associated With Early, Late, and Persistent Clinically Significant Symptoms of Depression 1 Year After Stroke in the AFFINITY Trial. ( Almeida, OP; Etherton-Beer, C; Flicker, L; Ford, AH; Hackett, ML; Hankey, GJ, 2022) |
| "Depression is a debilitating psychiatric disorder with a huge socioeconomic burden, and its treatment relies on antidepressants including selective serotonin reuptake inhibitors (SSRIs)." | 5.48 | Melatonin Augments the Effects of Fluoxetine on Depression-Like Behavior and Hippocampal BDNF-TrkB Signaling. ( Ji, YT; Li, K; Li, XY; Shen, S; Wang, XD; Zhang, LS, 2018) |
| "Depression is very common in asthmatic patients and may increases risk for morbidity and mortality." | 5.48 | Fluoxetine protects against OVA induced bronchial asthma and depression in rats. ( Abo-Youssef, AM; Ismaiel, IE; Salama, AAA; Sherkawy, MM, 2018) |
| "Chronic stress and depression are challenging conditions to treat, owing to their complexity and lack of clinically available and effective therapeutic agents." | 5.46 | Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. ( Liu, H; Sun, Y; Zhang, C; Zhu, X, 2017) |
| "Recently, depression has been envisioned as more than an alteration in neurotransmitters centered around receptor signaling pathways." | 5.46 | Fluoxetine coupled with zinc in a chronic mild stress model of depression: Providing a reservoir for optimum zinc signaling and neuronal remodeling. ( Omar, NN; Tash, RF, 2017) |
| "Effects of enriched environment (EE) combined with fluoxetine in a chronic unpredictable stress (CUS) rat model were examined in our study." | 5.46 | Enriched environment combined with fluoxetine ameliorates depression-like behaviors and hippocampal SYP expression in a rat CUS model. ( Feng, YY; Gu, JY; Han, JH; Li, Y; Liu, C; Lv, TT; Shao, QJ; Wang, CH; Yan, FL; Zhang, XY; Zhao, LQ, 2017) |
| "Objectives Depression is tightly associated with cardiovascular comorbidity and accounts for high financial and social burden worldwide." | 5.46 | Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine. ( Amiri, S; Anoush, M; Bergen, H; Haj-Mirzaian, A; Hosseini, MJ; Jafarian, I; Rahimi-Balaei, M; Sonei, N, 2017) |
| "Depression has become a common public health problem that is showing increasing prevalence." | 5.46 | Evaluation of the antidepressant-like effect of musk in an animal model of depression: how it works. ( Ayuob, NN, 2017) |
| "Ferulic acid is a hydroxycinnamic acid that widely presents in plant cell wall components." | 5.46 | Elevation of synaptic protein is associated with the antidepressant-like effects of ferulic acid in a chronic model of depression. ( Hu, CY; Li, YC; Liu, YM; Shen, JD; Wu, SH; Yi, LT, 2017) |
| "Juvenile depression is of great concern with only limited treatment currently approved." | 5.46 | Long-lasting effects of fluoxetine and/or exercise augmentation on bio-behavioural markers of depression in pre-pubertal stress sensitive rats. ( Brink, CB; Harvey, BH; Schoeman, JC; Steyn, SF, 2017) |
| "The pharmacological treatment of major depression is mainly based on drugs elevating serotonergic (5-HT) activity." | 5.46 | Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression. ( Borroto-Escuela, DO; Díaz-Cabiale, Z; Flores-Burgess, A; Fuxe, K; Gago, B; Mengod, G; Millón, C; Narváez, JA; Narváez, M; Santín, L, 2017) |
| "Using a depression comorbidity of chronic pain rat model induced by spinal nerve ligation (SNL), we investigated the potency of T10 for the treatment of comorbid depression in comparison with a widely used antidepressant, fluoxetine (FLX)." | 5.46 | The novel and potent anti-depressive action of triptolide and its influences on hippocampal neuroinflammation in a rat model of depression comorbidity of chronic pain. ( Dong, Y; Hu, X; Jin, X; Li, J; Shi, J; Zhang, C; Zhang, T; Zhao, J, 2017) |
| "Takotsubo cardiomyopathy is an acute coronary syndrome that is believed to be brought on by stress." | 5.43 | The Use of Fluoxetine in a Patient With Takotsubo Cardiomyopathy. ( Catalano, G; Catalano, MC; Conrad, SK, 2016) |
| "Fluoxetine treatment exerted antidepressant effect in all rat lines irrespective of its effect on AS." | 5.43 | Effect of chronic fluoxetine treatment on audiogenic epilepsy, symptoms of anxiety and depression in rats of four lines. ( Fedotova, IB; Nikolaev, GM; Perepelkina, OV; Poletaeva, II; Sarkissova, KY; Surina, NM, 2016) |
| "Laquinimod is a novel oral immunomodulatory drug for the treatment of multiple sclerosis (MS)." | 5.42 | Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models. ( Amit, BH; Gil-Ad, I; Gueta, RU; Hayardeni, L; Taler, M; Tarasenko, I; Weizman, A, 2015) |
| "Treatment with fluoxetine had no effect on tumor growth, muscle wasting, fatigue behavior, or cytokine expression in the brain." | 5.42 | Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue. ( Bicer, S; Devine, R; Godbout, JP; Jing, R; McCarthy, DO; Norden, DM; Reiser, PJ; Wold, LE, 2015) |
| "A sample of 236 patients with chronic periodontitis and clinical depression were assessed for clinical parameters of periodontal disease." | 5.42 | Effect of Fluoxetine on Periodontal Status in Patients With Depression: A Cross-Sectional Observational Study. ( Bhatia, A; Khurana, H; Narula, SC; Sharma, RK; Tewari, S, 2015) |
| " In the present study, we examined whether fluoxetine, a type of commonly used antidepressant agent, alters mTOR signaling following chronic administration in different brain regions, including the frontal cortex, hippocampus, amygdala and hypothalamus." | 5.42 | Fluoxetine regulates mTOR signalling in a region-dependent manner in depression-like mice. ( Geng, D; Liu, BB; Liu, Q; Liu, XL; Luo, L; Mu, RH; Yi, LT, 2015) |
| "The EFFECTS (Efficacy of Fluoxetine—a Randomised Controlled Trial in Stroke) recently reported that 20 mg fluoxetine once daily for 6 months after acute stroke did not improve functional outcome but reduced depression and increased fractures and hyponatremia at 6 months." | 5.41 | Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial. ( Borg, J; Dennis, MS; Greilert Norin, N; Hackett, ML; Hankey, GJ; Isaksson, E; Lundström, E; Mårtensson, B; Mead, GE; Näsman, P; Norrving, B; Sunnerhagen, KS; Wallén, H; Wester, P, 2021) |
| "To investigate whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by clinically significant symptoms of depression after stroke." | 5.41 | Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial. ( Almeida, OP; Etherton-Beer, C; Flicker, L; Ford, A; Hackett, M; Hankey, GJ, 2021) |
| " in acute, subchronic and chronic administration in the FST." | 5.38 | Alterations on the morphology, nitric oxide synthesis and activity of platelets reproduced in rats as possible biomarkers for depression are reversed by fluoxetine. ( Alvarado-Vásquez, N; Estrada-Camarena, E; González-Trujano, ME; López, G; Martínez-Mota, L; Mendoza-Sotelo, J; Moreno, J, 2012) |
| "Depression is associated with increased risk of coronary heart diseases." | 5.38 | Chronic fluoxetine treatment affects gene expression of catecholamine enzymes in the heart of depression model rats. ( Dronjak, S; Jovanovic, P; Spasojevic, N, 2012) |
| "Depression is associated with hippocampus (HC) volume loss." | 5.37 | The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression. ( First, M; Gil-Ad, I; Novak, N; Taler, M; Tarasenko, I; Weizman, A, 2011) |
| " This was combined with two different doses of fluoxetine (10 and 20 mg/kg)." | 5.37 | Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats. ( Ghorpade, S; Manjrekar, N; Sonawane, D; Tripathi, R, 2011) |
| "The fluoxetine treatment reduced B(max) in all three rat strains when the saline and respective fluoxetine groups were compared (e." | 5.36 | Chronic fluoxetine treatment has a larger effect on the density of a serotonin transporter in the Flinders Sensitive Line (FSL) rat model of depression than in normal rats. ( Diksic, M; Kovacević, T; Skelin, I, 2010) |
| "The response frequency to mechanical allodynia in mice was measured with von Frey hairs." | 5.36 | Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. ( Jesse, CR; Nogueira, CW; Wilhelm, EA, 2010) |
| "Fluoxetine treatment decreased immobility in the TST and latency to eat in the NIH test, but only the highest dose of fluoxetine significantly altered behavior in both tests." | 5.36 | Fluoxetine treatment induces dose dependent alterations in depression associated behavior and neural plasticity in female mice. ( Hill-Smith, TE; Hodes, GE; Lucki, I, 2010) |
| "To investigate the effects of WAA combined with fluoxetine in the clinical treatment of post-stroke depression (PSD) ." | 5.34 | Wrist-ankle acupuncture and Fluoxetine in the treatment of post-stroke depression: a randomized controlled clinical trial. ( Qian, X; Shu, S; Yao, F; You, Y; Zhang, T; Zhou, S, 2020) |
| "In this sample of children and adolescents with epilepsy and depressive disorders, we observed that SSRIs are a good therapeutic option, considering their efficacy in remission of depressive symptoms, their few adverse effects, and their maintenance of satisfactory seizure control." | 5.34 | Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. ( Kuczynski, E; Thomé-Souza, MS; Valente, KD, 2007) |
| "Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test." | 5.32 | Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004) |
| "Helping oncologists to identify and treat depression is an important step in improving the overall care of people with cancer." | 5.31 | Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients. A demonstration project. ( Donaghy, K; Dugan, W; Edgerton, S; Holtsclaw, E; Kirsh, KL; Passik, SD; Theobald, D, 2002) |
| " Eligible participants are those who: are between the ages of 18 and 74 years; have had at least two episodes of depression; and have been taking antidepressants for 9 months or more and are currently taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg but are well enough to consider stopping their medication." | 5.30 | A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes ( Bacon, F; Clarke, CS; Donkor, Y; Duffy, L; Freemantle, N; Gilbody, S; Hunter, R; Kendrick, T; Kessler, D; King, M; Lanham, P; Lewis, G; Mangin, D; Marston, L; Moore, M; Nazareth, I; Wiles, N, 2019) |
| "The goal of the current study is evaluate the consistency of the number of depressive symptom dimensions and examine the effect of depression treatment on the change in dimensions by seeing if this dimensional structure is the same for groups that were given a placebo and groups that were given an active drug, fluoxetine." | 5.24 | Understanding the Impact of Treatment on the Dimensions of Childhood Depression. ( Bernstein, I; Emslie, G; Isa, A; Kennard, B; Mayes, T; Trivedi, M, 2017) |
| " Fluoxetine is one of the main first-line medications used for depression, and it is hypothesized that it participates in the decrease of pro-inflammatory cytokines." | 5.22 | Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis. ( García-García, ML; Genis-Mendoza, AD; González-Castro, TB; Juárez-Rojop, IE; López-Nárvaez, ML; Martinez-Magaña, JJ; Ramos-Méndez, MÁ; Ruiz-Quiñones, JA; Saucedo-Osti, AS; Tovilla-Zárate, CA; Villar-Soto, M, 2022) |
| "Although fluoxetine and, in the USA, escitalopram are approved for depression in adolescence, substantial concern surrounds antidepressant use in youth." | 5.22 | Controversies in the Pharmacotherapy of Adolescent Depression. ( Masi, G, 2022) |
| "These results suggest that although chronic fluoxetine treatment proves positive effects in animal models of depression, it may simultaneously increase anxiety in adolescent animals in a dose-related manner." | 5.22 | Effects of chronic fluoxetine treatment on anxiety- and depressive-like behaviors in adolescent rodents - systematic review and meta-analysis. ( Chocyk, A; Kryst, J; Majcher-Maślanka, I, 2022) |
| " Furthermore, sequential fluoxetine treatment, compared with standard fluoxetine treatment, resulted in significantly lower levels of depressive symptoms throughout smoking cessation treatment (p < ." | 5.19 | Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers. ( Abrantes, AM; Brown, RA; Kahler, CW; Miller, IW; Niaura, R; Price, LH; Strong, DR, 2014) |
| " To determine whether effective depression treatment could reduce the frequency of sexual risk behavior, we analyzed secondary outcome data from a 36-week, two-arm, parallel-design, randomized controlled trial, in which homeless and marginally housed, HIV-infected persons with comorbid depressive disorders were randomized to receive either: (a) directly observed treatment with the antidepressant medication fluoxetine, or (b) referral to a local public mental health clinic." | 5.17 | Does effective depression treatment alone reduce secondary HIV transmission risk? Equivocal findings from a randomized controlled trial. ( Bangsberg, DR; Charlebois, ED; Dilley, JW; Hammer, GP; Karasic, DH; Mimiaga, MJ; Safren, SA; Sorensen, JL; Tsai, AC, 2013) |
| "To study the effect of early intervention of liver-soothing and Blood-activating decoction combined with acupuncture in improving neurological functions, depressive symptom and life quality of patients with post-stroke depression, and compare with fluoxetine hydrochloride." | 5.17 | [Effect of early intervention of liver-smoothing and blood-activating decoction combined with acupuncture on patients with post-stroke depression]. ( Bi, XL; Chen, CJ; Fan, ZJ; Hu, JF; Liu, TF; Liu, Y; Yang, PQ; Yu, ZH, 2013) |
| "Fluoxetine and Citalopram can effectively reduce the severity of depression in diabetic patients without an adverse effect on glycemic control." | 5.15 | Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? ( Khazaie, H; Najafi, F; Rahimi, M; Rezaei, M; Tahmasian, M; Tatari, F, 2011) |
| " A total of 75 cases of mild or moderate depression were randomly assigned to two groups: the EA group which received EA combined with Fluoxetine; the Fluoxetine group which received Fluoxetine only as the control." | 5.15 | The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with Fluoxetine intervention - A randomized, controlled trial. ( Duan, DM; Jiao, S; Qin, W; Tu, Y, 2011) |
| "This study compared the best available treatment for bulimia nervosa, cognitive-behavioural therapy (CBT) augmented by fluoxetine if indicated, with a stepped-care treatment approach in order to enhance treatment effectiveness." | 5.15 | Stepped care and cognitive-behavioural therapy for bulimia nervosa: randomised trial. ( Agras, S; Bryson, S; Crow, S; Fairburn, CG; Halmi, K; Kraemer, H; Mitchell, JE, 2011) |
| " Depression could result from changes in tryptophan availability caused by activation of the kynurenine pathway as a result of inflammation." | 5.14 | Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. ( Bridel, MA; Christofides, J; Cowlard, R; Darlington, LG; Forrest, CM; Mackay, GM; Mitchell, S; Stone, TW, 2009) |
| "This study is to investigate the clinical therapeutic effects and safety of treating mild or moderate depression with somatic symptoms with electroacupuncture combined with Fluoxetine." | 5.14 | Efficacy evaluation for depression with somatic symptoms treated by electroacupuncture combined with Fluoxetine. ( Chen, LP; Duan, DM; Tu, Y; Wu, ZJ, 2009) |
| "The authors set up two groups, the treatment group and the control group, to observe the influence of electro-acupuncture on the side effects produced by fluoxetine in the treatment of depression." | 5.14 | Influence of electro-acupuncture on the side effects of fluoxetine on depression patients. ( Liu, LY; Lu, Q; Wang, LL, 2009) |
| "Fluoxetine may improve the poststroke emotional disturbances." | 5.13 | Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. ( Choi, J; Choi-Kwon, S; Kang, DW; Kim, JS; Kwon, SU, 2008) |
| "Based on available RCTs of fluoxetine and citalopram, SSRIs used for 6 months doubled the risk of fractures in stroke survivors." | 5.12 | Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. ( Almeida, OP; Hankey, GJ; Jones, JS; Kimata, R, 2021) |
| "The efficacy and safety of the selective serotonin reuptake inhibitor fluoxetine have rarely been studied in the treatment of poststroke emotional disturbances." | 5.12 | Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. ( Choi, JM; Choi-Kwon, S; Han, SW; Kang, DW; Kim, JS; Kwon, SU, 2006) |
| "Data from a randomized double-blind 8-week study of bipolar I depression were examined post hoc in patients who received placebo (PLA, n = 355), olanzapine (n = 351) (OLZ, 5 to 20 mg/d), or olanzapine-fluoxetine combination (n = 82) (OFC, 6 and 25, 6 and 50, or 12 and 50 mg/d)." | 5.12 | Clinical relevance of depressive symptom improvement in bipolar I depressed patients. ( Ahl, J; Baker, RW; Brown, E; Perlis, RH; Tohen, M; Williamson, D, 2006) |
| "To examine the effects of fluoxetine and repetitive transcranial magnetic stimulation (rTMS) on regional cerebral blood flow (rCBF) using SPECT in patients with PD and depression." | 5.12 | Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. ( Barbosa, ER; Bermpohl, F; Buchpiguel, C; Fregni, F; Marcolin, MA; Ono, CR; Pascual-Leone, A; Santos, CM; Valente, KD, 2006) |
| "Brain structure and function were measured with MRI in 17 patients with major depression immediately before 8 weeks treatment with fluoxetine 20 mg/day." | 5.12 | Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. ( Bullmore, E; Chen, CH; Fu, CH; Merlo-Pich, E; Ridler, K; Suckling, J; Williams, S, 2007) |
| "WLC is effective in treating patients with poststroke depression and shows synergism with fluoxetine." | 5.12 | [Observation on effect of Wuling Capsule in treating poststroke depression]. ( Xu, B; Zhang, SJ; Zhou, WY, 2007) |
| "In this multicenter, double-blind study, outpatients with recurrent unipolar major depression were randomly assigned to receive venlafaxine ER (75-300 mg/day; n = 821) or fluoxetine (20-60 mg/day; n = 275)." | 5.12 | The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. ( Ahmed, S; Dunlop, BW; Dunner, DL; Ferguson, JM; Friedman, ES; Gelenberg, AJ; Hirschfeld, RM; Keller, MB; Kocsis, JH; Kornstein, SG; Nemeroff, CB; Ninan, PT; Pedersen, R; Rothschild, AJ; Schatzberg, AF; Schmidt, M; Shelton, RC; Thase, ME; Trivedi, MH; Yan, B; Zajecka, JM, 2007) |
| "Fluoxetine combined with CBT had greater efficacy than did placebo and CBT according to changes on the Childhood Depression Rating Scale-Revised (effect size, 0." | 5.12 | A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. ( Davies, RD; Klein, C; Lohman, M; Mikulich-Gilbertson, SK; Riggs, PD; Stover, SK, 2007) |
| "Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder." | 5.11 | Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. ( Borrelli, B; Cook, JW; Hitsman, B; Keuthen, NJ; Kristeller, J; McChargue, DE; Niaura, R; Spring, B, 2004) |
| "Fifty four patients suffered from the depression after acute cerebral infarction were randomly divided into three groups: depression control group, fluoxetine treated group and Jieyu Huoxue Decoction treated group." | 5.11 | [Influence of Jieyu Huoxue Decoction on rehabilitation of patients with depression after cerebral infarction]. ( Feng, BL; Li, ZY; Wang, QC, 2004) |
| "Stabilised MMPs scoring over 21 on the Beck Depression Inventory were randomised to receive fluoxetine or placebo over 12 weeks." | 5.10 | A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. ( Bell, J; Christie, MJ; Dean, AJ; Mascord, DJ; Parker, G, 2002) |
| " Moderate to severe depressed patients (determined by Hamilton Depression Scale (HDS) > 15, the Beck Depression Inventory (BDI) and the Clinical Global Impression (CGI) Scale) were randomized to receive either 20 mg/d fluoxetine or placebo for 3 months." | 5.10 | Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. ( Baumhackl, U; Fruehwald, S; Gatterbauer, E; Rehak, P, 2003) |
| "To determine whether fluoxetine improves overall quality of life (QOL) in advanced cancer patients with symptoms of depression revealed by a simple survey." | 5.10 | Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. ( Arquette, MA; Brames, MJ; Einhorn, LH; Fisch, MJ; Jung, SH; Kristeller, J; Loehrer, PJ; Passik, S; Shen, J, 2003) |
| "A total of 104 patients were randomly assigned to receive a 12-week double-blind course of nortriptyline, fluoxetine, or placebo early in the recovery period after a stroke." | 5.10 | Mortality and poststroke depression: a placebo-controlled trial of antidepressants. ( Arndt, S; Jorge, RE; Robinson, RG; Starkstein, S, 2003) |
| "In an ongoing study, perimenopausal women diagnosed with major depression were randomly assigned to one of three treatment conditions: (1) fluoxetine 10-20 mg alone, (2) estradiol patch 0." | 5.10 | Does estrogen enhance the antidepressant effects of fluoxetine? ( Parry, BL; Westlund Tam, L, 2003) |
| "To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression." | 5.10 | Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. ( Baker, RW; Beymer, K; Bowden, C; Breier, A; Calabrese, J; Centorrino, F; Dube, S; Evans, AR; Ketter, TA; Mitchell, PB; Risser, R; Sachs, G; Tohen, M; Tollefson, GD; Vieta, E, 2003) |
| "To evaluate the efficacy and feasibility of treating older people suffering from depression and/or phobic anxiety in the community with fluoxetine alone." | 5.09 | Drug treatment of older people with affective disorders in the community: lessons from an attempted clinical trial. ( Katona, C; Livingston, G; Manela, M; Stevens, T; Watkin, V, 1999) |
| "Adult smokers (N = 253) without clinically significant depression were randomized on a double-blind basis to receive fluoxetine (30 or 60 mg daily) or a placebo for 10 weeks in combination with cognitive-behavioral therapy (CBT)." | 5.09 | Antidepressant pharmacotherapy helps some cigarette smokers more than others. ( Hitsman, B; Kristeller, JL; Mahableshwarkar, A; Mizes, JS; Pingitore, R; Segraves, KA; Spring, B; Xu, W, 1999) |
| "Reduction in depression symptoms was significantly greater in patients treated with fluoxetine compared with those receiving placebo (BDI, -14." | 5.09 | Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. ( Clouse, RE; Freedland, KE; Griffith, LS; Lustman, PJ, 2000) |
| " Recent hemiplegic patients (<3 months) suffering from major depressive disorder (determined by International Classification of Diseases, 10th Revision, and Montgomery-Asberg Depression Rating Scale [MADRS] >19) were randomized to receive either 20 mg/d fluoxetine (FLX) or placebo for 6 weeks." | 5.09 | Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. ( Barat, M; Joseph, PA; Mazaux, JM; Petit, H; Wiart, L, 2000) |
| "It is postulated that the initial recovery of the HPA axis during the treatment of depression with fluoxetine is mediated via restoration of glucocorticoid negative feedback on ACTH levels." | 5.09 | Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. ( Donald, RA; Inder, WJ; Joyce, PR; Mulder, RT; Prickett, TC, 2001) |
| "Twenty-two female patients with anorexia nervosa, restricted type, 14-35 years old, were treated with a 4-month course of combined cognitive-behavioral therapy, nutritional counselling and antidepressant drugs (nortriptyline for 7, fluoxetine for 15)." | 5.08 | Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type. ( Brambilla, F; Brunetta, M; Draisci, A; Peirone, A, 1995) |
| "The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics." | 5.08 | Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. ( Black, A; Cornelius, JR; Cornelius, MD; Ehler, JG; Jarrett, PJ; Levin, RL; Mann, JJ; Perel, JM; Salloum, IM, 1995) |
| "Of 132 eligible patients with major depression, 111 were randomly assigned to treatment with fluoxetine (20 mg daily) and either placebo or pindolol (7." | 5.08 | Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. ( Alvarez, E; Artigas, F; Faries, D; Gilaberte, I; Pérez, V, 1997) |
| "Acute geriatric medical inpatients with depression, randomly assigned to an 8-week double-blind placebo-controlled trial of fluoxetine." | 5.08 | Treatment of depression in the elderly: effect of physical illness on response. ( Copeland, J; Evans, M; Hammond, M; Lye, M; Wilson, K, 1997) |
| "This study tested the effectiveness of fluoxetine as a treatment for depression in a population of methadone-maintained opioid addicts." | 5.08 | Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. ( Carroll, KM; Gordon, L; Kosten, T; Nich, C; Petrakis, I; Rounsaville, B, 1998) |
| " By the response of the patients to alprazolam (anxiolytic) and fluoketin (antidepressant) given by a special scheme, 3 types of comorbidity of obsessional-phobic and affective disturbances were recognized: 1) prevalent depression, 2) combination of dysthymia with marked obsessional-phobic disorders, 3) overcoming of obsessional-phobic and affective disorders." | 5.07 | [The psychopharmacotherapy of anxious-depressive states (the interrelationship of the structure of the comorbidity to the choice of drug therapy)]. ( Andriushchenko, AV; Koliutskaia, EV; Morkovkina, IV; Smulevich, AB; Tkhostov, ASh, 1994) |
| "To assess the possible efficacy of fluoxetine hydrochloride in severe PMS (premenstrual syndrome, luteal phase dysphoric disorder), an open trial of this medication was undertaken on women with severe PMS." | 5.07 | Open trial of fluoxetine therapy for premenstrual syndrome. ( Elks, ML, 1993) |
| "Amitriptyline reduces the pain caused by peripheral-nerve disease, but treatment is often limited by side effects related to the drug's many pharmacologic actions." | 5.07 | Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992) |
| "Mean ratings of positive and negative symptoms and depression significantly improved in nine treatment-resistant schizophrenic patients who completed a 6-week open trial of fluoxetine added to their neuroleptics." | 5.06 | Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. ( Brotman, AW; Goff, DC; McCormick, S; Waites, M, 1990) |
| "To determine whether fluoxetine is effective in the long-term treatment of obesity and whether it is particularly useful in the treatment of obese binge-eaters, the authors randomly assigned 45 obese subjects (22 with binge-eating problems and 23 without binge-eating) to fluoxetine (60 mg/day) or placebo in a 52-week double-blind trial." | 5.06 | A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. ( Ewing, L; Gooding, W; Kern, E; Marcus, MD; McDermott, M; Wing, RR, 1990) |
| "To investigate the safety of fluoxetine use during pregnancy, and to better understand the relationship between maternal fluoxetine use during the first trimester and congenital malformations in infants." | 4.95 | Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. ( Gao, SY; Ji, C; Liu, CX; Shen, ZQ; Wu, QJ; Xu, X; Zhang, TN; Zhao, YH, 2017) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 4.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| " Several treatments [monoamine oxidase inhibitors (MAOIs), ziprasidone, aripiprazole and risperidone] have limited or no therapeutic activity in bipolar depression." | 4.90 | Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. ( Cornelius, V; Smith, L; Taylor, DM; Young, AH, 2014) |
| " By chronically exposing pregnant/lactating mice to MeHg, we found persistent behavioural changes in the male offspring, which exhibited depression-like behaviour that could be reversed by chronic treatment with the antidepressant fluoxetine." | 4.89 | Long-lasting neurotoxic effects of exposure to methylmercury during development. ( Bose, R; Ceccatelli, S; Edoff, K; Onishchenko, N; Spulber, S, 2013) |
| "The apparent increased risk of fetal cardiac malformations associated with maternal use of fluoxetine has recently been shown also in depressed women who deferred SSRI therapy in pregnancy, and therefore most probably reflects an ascertainment bias." | 4.89 | The fetal safety of fluoxetine: a systematic review and meta-analysis. ( Frankel, Z; Koren, G; Moretti, M; Pupco, A; Riggin, L, 2013) |
| "During and following pregnancy, women are at high risk of experiencing depression, for which fluoxetine (FLX; brand names Prozac, Sarafem, Rapiflux) is the most commonly prescribed treatment." | 4.89 | Long-term outcomes of developmental exposure to fluoxetine: a review of the animal literature. ( Dyck, RH; Kiryanova, V; McAllister, BB, 2013) |
| "The selective serotonin reuptake inhibitor (SSRI) Prozac® (fluoxetine) is widely prescribed for the treatment of depression and anxiety-related disorders." | 4.87 | The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review. ( Arentsen, T; Blom, T; Homberg, JR; Olivier, JD, 2011) |
| "The recent clinical studies on hypericum extract support the present indications for its use in mild to moderate depression and depressive episodes." | 4.84 | [New developments in hypericum extracts: data on efficacy and interactions]. ( Kraft, K, 2007) |
| "Selective serotonin reuptake inhibitors such as fluoxetine that are widely used for the treatment of depression and anxiety disorders produce neuroadaptive change not only in the serotoninergic system but also in other neuromediator systems." | 4.84 | [Neuroadaptive changes in brain during selective serotonin reuptake inhibitors action]. ( Shishkina, GT, 2007) |
| " TRAZODONE: Studies conducted in patients with Alzheimer's disease, mixed type dementia, or fronto-temporal dementia have shown the efficacy of trazodone for diverse types of symptoms: sadness, emotional disorders, irritability, fear, psychomotor instability, delirant ideas." | 4.82 | [Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias]. ( Lebert, F, 2003) |
| "Fluoxetine was the first selective serotonin re-uptake inhibitor to be widely available for treatment of depression and numerous other neuropsychiatric disorders." | 4.82 | Safety and side effect profile of fluoxetine. ( Wernicke, JF, 2004) |
| "Fluoxetine has shown superior efficacy compared with placebo in the treatment of depression in patients with HIV/AIDS, diabetes mellitus or stroke; however, it has not significantly improved depressive symptoms versus placebo in patients with cancer." | 4.81 | Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. ( Cheer, SM; Goa, KL, 2001) |
| "After major depression was diagnosed in a 83-year-old woman, fluoxetine was prescribed." | 4.78 | Fluoxetine-induced SIADH: a geriatric occurrence? ( Hall, DL; Kazal, LA; Miller, LG; Noel, ML, 1993) |
| "Fluoxetine has been used as the first line for the therapy of depression." | 4.31 | Gap junction is essential for the antidepressant effects of fluoxetine. ( Chen, NH; Chu, SF; Jiang, H; Li, FF; Lou, YX; Ren, Q; Shao, QH; Wan, JF; Wang, ZZ; Xia, CY; Yan, X; Yang, PF; Zhang, NN; Zhang, XL; Zhang, Y; Zhang, YN; Zhu, HY, 2023) |
| "The salt-inducible kinase 1 (SIK1)-CREB-regulated transcription co-activator 1 (CRTC1) system in the paraventricular nucleus (PVN) of the hypothalamus has been demonstrated to participate in not only depression neurobiology but also the antidepressant mechanisms of fluoxetine, paroxetine, venlafaxine, and duloxetine." | 4.31 | The antidepressant-like effects of escitalopram in mice require salt-inducible kinase 1 and CREB-regulated transcription co-activator 1 in the paraventricular nucleus of the hypothalamus. ( Chen, YM; Guan, W; Huang, J; Jiang, B; Li, WY; Shi, TS; Xu, DW, 2023) |
| "Compare the effects of LAT and fluoxetine on depression-like behaviors in mice exposed to CSDS." | 4.31 | Isoalantolactone relieves depression-like behaviors in mice after chronic social defeat stress via the gut-brain axis. ( Cai, Q; Li, K; Ni, Z; Sun, Y; Wang, M; Wang, S; Wang, Y; Xu, L; Zhang, L, 2023) |
| "The treatment for adolescents with depression study (TADS) has influenced most international practice guidelines for treating children and adolescents with depression, supporting first-line prescription of fluoxetine in combination with cognitive behavioural therapy (CBT)." | 4.12 | Barriers to access to clinical trial data: Obstruction of a RIAT reanalysis of the treatment for adolescents with depression study. ( Aboustate, N; Jureidini, J, 2022) |
| "Selective serotonergic reuptake inhibitors, including fluoxetine (FLX), are the most commonly used for the treatment of major depression." | 4.12 | Galanin (1-15) Enhances the Behavioral Effects of Fluoxetine in the Olfactory Bulbectomy Rat, Suggesting a New Augmentation Strategy in Depression. ( Cantero-García, N; Díaz-Cabiale, Z; Flores-Burgess, A; Fuxe, K; Gago, B; García-Durán, L; Millón, C; Narváez, JA; Puigcerver, A; Santín, L, 2022) |
| "Cholecalciferol deficiency has been associated with stress-related psychiatric disorders, particularly depression." | 4.12 | Involvement of serotonergic neurotransmission in the antidepressant-like effect elicited by cholecalciferol in the chronic unpredictable stress model in mice. ( Camargo, A; Dafre, AL; de Almeida, GRL; de O Dalsenter, Y; Engel, WD; Moretti, M; Neis, VB; Platt, N; Rodrigues, ALS; Rosa, PB; Rosado, AF; Selhorst, I; Werle, I, 2022) |
| "A high-performance liquid chromatography-tandem mass spectrometry(LC-MS/MS) was developed for simultaneously determining the components(magnoflorine, jatrorrhizine, berberrubine, coptisine, berberine) of Jiaotai Pills and Fluoxetine in plasma of rats with chronic unpredictable mild stress(CUMS)-induced depression to investigate the pharmacokinetic herb-drug interaction of Jiaotai Pills and Fluoxetine in the rats." | 4.12 | [Pharmacokinetic interaction of Jiaotai Pills and Fluoxetine in rats with CUMS-induced depression]. ( Cao, Y; Chen, SS; Dai, GL; Ju, WZ; Li, FR; Li, Y; Liu, MC; Wang, YQ; Yang, XY, 2022) |
| " PPD rat models were prepared by withdrawing hormone‑simulated pregnancy (HSP), and subjects were treated with paeoniflorin and fluoxetine or plasmids." | 4.12 | Paeoniflorin exhibits antidepressant activity in rats with postpartum depression via the TSPO and BDNF‑mTOR pathways. ( Chen, J; Hu, L; Peng, H; Yang, K; Zeng, X; Zhu, W, 2022) |
| " Regular use of fluoxetine apparently prevented the onset of anxiety, depression, aggressiveness, and suicide ideation, even with the concurrent use of AAS." | 4.02 | Effective treatment and prevention of attempted suicide, anxiety, and aggressiveness with fluoxetine, despite proven use of androgenic anabolic steroids. ( Amaral, JMX; Aquino Neto, FR; Baker, JS; Chagas, SV; Cruz, MS; Mullen, C; Padilha, MC; Vieira Neto, L, 2021) |
| " This study aimed to evaluate the anti-depressant effect of Cerebrolysin (CBL) in Reserpine-induced depressed rats, its effect on oxidative stress, inflammation, regulatory cyclic AMP-dependent response element binding protein (CREB)/brain derived neurotropic factor (BDNF) signaling pathways, brain monoamines and histopathological changes was assessed." | 4.02 | Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Behavioral, biochemical, molecular and immunohistochemical evidence. ( Ahmed-Farid, OA; El Awdan, SA; El-Marasy, SA; Hassan, A; Ogaly, HA, 2021) |
| "Emerging evidence has shown that ursolic acid exerts antidepressant-like effects, however, its ability to elicit an antidepressant-like response in rodents subjected to stress model that mimics behavioral and neurochemical alterations found in depression remains to be determined." | 4.02 | Ursolic acid abrogates depressive-like behavior and hippocampal pro-apoptotic imbalance induced by chronic unpredictable stress. ( Camargo, A; Colla, ARS; Lieberknecht, V; Pazini, FL; Rodrigues, ALS, 2021) |
| " The C1 and fluoxetine co-administration produced additive effect on depression-like behaviors in stress-naïve mice." | 4.02 | Identification of the antidepressive properties of C1, a specific inhibitor of Skp2, in mice. ( Chen, J; Chen, Z; He, H; Huang, C; Li, F; Lu, X; Wang, D; Xiang, H; Yuan, X, 2021) |
| " A randomized controlled trial of simple acupuncture combined with fluoxetine in the treatment of poststroke depression will be selected." | 4.02 | Simple acupuncture combined with fluoxetine in the treatment of poststroke depression: A protocol for systematic review and meta-analysis. ( Bi, J; Gao, L; Gong, P; Ma, X, 2021) |
| "Fluoxetine (FLX) has become the first-line drug in the pharmacotherapy of patients with depression." | 4.02 | ( Marzouk, MA; Mohamed, OS; Osman, DA, 2021) |
| "Our results demonstrated that CUMS induced depression-like behaviors, which were reversed by fluoxetine treatment and swimming exercise." | 4.02 | The Role of Fgf9 in the Antidepressant Effects of Exercise and Fluoxetine in Chronic Unpredictable Mild Stress Mice. ( Liu, W; Qi, Z; Xia, J; Xue, X, 2021) |
| "Fluoxetine is often prescribed to treat depression during pregnancy." | 4.02 | Prenatal fluoxetine impairs non-hippocampal but not hippocampal memory in adult male rat offspring. ( Ampuero, E; de Vries, EF; Díaz-Galarce, R; Donoso-Ramos, JP; Doorduin, J; Linsambarth, S; Moraga-Amaro, R; Pacheco, R; Peña, F; Stehberg, J; Ugalde, V; Wyneken, U, 2021) |
| "The metformin treatment counteracted the development of depression-like behaviors in mice suffering SDS when administered alone and enhanced the anti-depressant effect of fluoxetine when combined with fluoxetine." | 3.96 | Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation. ( Chen, X; Dai, X; Fang, W; Hong, L; Huang, W; Ye, Q; Zhang, J, 2020) |
| "The study group included seven patients diagnosed with depression and treated with fluoxetine; 22 subjects were included as a control group." | 3.96 | Mesopic pupillary reflex in patients treated with fluoxetine. ( Arregui-Olaizola, C; Bonnin-Arias, C; Gutiérrez-Jorrín, S; López-Ibor, MI; Quezada-Sánchez, J; Rodríguez-Alonso, X; Rubio-Corgo, S; Sánchez-Ramos, C, 2020) |
| "We used a rat prenatal stress (PS) model of depression to explore the functional role of mGluR5 in ketamine's rapidly induced antidepressant activity." | 3.96 | mGluR5 mediates ketamine antidepressant response in susceptible rats exposed to prenatal stress. ( Cao, Y; Che, F; He, W; Sun, H; Wang, Y; Yao, Z; Zhang, H, 2020) |
| " Fluoxetine, a commonly used antidepressant for treatment of depression, is known to regulate several important structural and neurochemical aspects of hippocampal functions." | 3.96 | Fluoxetine increases hippocampal neural survival by improving axonal transport in stress-induced model of depression male rats. ( Nahavandi, A; Zavvari, F, 2020) |
| " In this regard, we chronically treated normal female mice with different dosages (0, 10, and 20 mg/kg) of fluoxetine (FLU) for 2 weeks before mating them with drug-free male mice and then tested the offspring for anxiety/depression-like behaviors with the elevated plus maze and the tail-suspension test after exposing to acute or chronic stress in adult period." | 3.91 | Chronic exposure to fluoxetine of female mice before mating causes impaired stress resilience in female offspring. ( Li, J; Si, J; Suo, L; Yang, C; Zhang, Y, 2019) |
| "The study was designed to find out the effect of thymoquinone (TQ) alone and combination of TQ + fluoxetine in depression of type-2 diabetic rats." | 3.91 | Thymoquinone and fluoxetine alleviate depression via attenuating oxidative damage and inflammatory markers in type-2 diabetic rats. ( Alam, MF; Anwer, T; Khan, G; Masmali, AUM; Qumayri, HM; Safhi, MM; Siddiqui, R, 2019) |
| "The objective of this study is to investigate the possible mechanism of the effect of resveratrol on depression." | 3.91 | Resveratrol exerts a protective effect in chronic unpredictable mild stress-induced depressive-like behavior: involvement of the AKT/GSK3β signaling pathway in hippocampus. ( Qu, C; Shen, J; Sun, H; Xu, L; Zhang, J, 2019) |
| "To explore the pathogenesis of depression and the possible mechanism of the effects of selective serotonin reuptake inhibitors (SSRIs) on the myelinated fibers and myelin sheaths in the white matter during the antidepressant action of fluoxetine." | 3.91 | Changes in white matter and the effects of fluoxetine on such changes in the CUS rat model of depression. ( Chao, FL; Chen, LM; Du, L; Gao, Y; Huang, CX; Liang, X; Luo, YM; Ma, J; Qi, YQ; Tang, J; Tang, Y; Wang, SR; Xiao, Q; Yao, Y; Zhang, L; Zhang, Y, 2019) |
| "Although depression and cardiovascular diseases are related, the role of antidepressants such as fluoxetine (increasing serotonin levels) within cardiac regulation remains unclear." | 3.91 | Fluoxetine oral treatment discloses 5-HT ( García-Domingo, M; García-Pedraza, JÁ; Gómez-Roso, M; López, C; Martín, ML; Morán, A, 2019) |
| " This study investigated antidepressant-like effects and possible underlying mechanisms of Lactobacillus paracasei PS23 (PS23), live or heat-killed, in a mouse model of corticosterone-induced depression using fluoxetine as standard drug." | 3.91 | Antidepressant-like activities of live and heat-killed Lactobacillus paracasei PS23 in chronic corticosterone-treated mice and possible mechanisms. ( Cheng, YF; Hsu, CC; Liao, CL; Tsai, YC; Wang, S; Wei, CL; Wu, CC; Yen, JT, 2019) |
| "The aim of this study was to determine the effects of maternal fluoxetine treatment on anxiety-like and depressive-like behaviours in adolescent offspring as well as associated glutamatergic markers, using a clinically relevant rodent model of depression." | 3.91 | Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviours and alters glutamatergic markers in the prefrontal cortex and hippocampus of male adolescent rats: A comparison between Sprague-Dawley rats and the Wistar-Kyoto rat model o ( Fernandez, F; Lum, JS; Millard, SJ; Newell, KA; Weston-Green, K, 2019) |
| " The influences of N-acetylcysteine (NAC) on neuroinflammation associated depression-like behavior have not been investigated yet, and associated biochemical changes are currently unclear." | 3.91 | N-acetylcysteine attenuates neuroinflammation associated depressive behavior induced by chronic unpredictable mild stress in rat. ( Fernandes, J; Gupta, GL, 2019) |
| "In this item-based, patient-level, post-hoc analysis, we pooled data from all completed, acute-phase, placebo-controlled, industry-sponsored, HDRS-based trials of the SSRIs citalopram, paroxetine, or sertraline in adult major depression." | 3.91 | Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. ( Eriksson, E; Hieronymus, F; Lisinski, A; Nilsson, S, 2019) |
| "Recent studies demonstrated beneficial effects of zileuton, a 5-lipoxygenase (5LO) inhibitor, on some brain diseases in animal models, but the role of zileuton in the depression remains unknown." | 3.88 | Antidepressant-like effect of zileuton is accompanied by hippocampal neuroinflammation reduction and CREB/BDNF upregulation in lipopolysaccharide-challenged mice. ( Du, YF; Hong, H; Hu, M; Li, DD; Long, Y; Reed, MN; Suppiramaniam, V; Tang, SS; Xie, H, 2018) |
| "The antidepression and anti-anxiety drug fluoxetine reduced TPA-induced skin lesions and increased expression of BDNF and TrkB in K5." | 3.88 | Depression- and anxiety-like behaviour is related to BDNF/TrkB signalling in a mouse model of psoriasis. ( Hong, S; JiaWen, W; Jing, L; ShengXiang, X, 2018) |
| "Our goal was to find out the impact of two antidepressant drugs with various mechanisms of action - imipramine and fluoxetine, on the frontal cortex mitochondria-enriched fraction in an animal model of depression based on the prenatal stress procedure." | 3.88 | Mitochondrial proteomics investigation of frontal cortex in an animal model of depression: Focus on chronic antidepressant drugs treatment. ( Basta-Kaim, A; Chamera, K; Głombik, K; Kotarska, K; Olszanecki, R; Ślusarczyk, J; Stachowicz, A; Suski, M; Trojan, E, 2018) |
| "We evaluated the effect of the co-administration of fluoxetine (5 mg/kg) and flurbiprofen (5 mg/kg) or fluoxetine (5 mg/kg) and celecoxib (5 mg/kg) in the chronic escape deficit (CED) model of depression after 7 days of treatment." | 3.88 | Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression. ( Alboni, S; Benatti, C; Brunello, N; Capone, G; Tascedda, F, 2018) |
| " Fluoxetine (FLX) is the first selective serotonin reuptake inhibitor to be widely available for the treatment of depression." | 3.88 | Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression. ( Liu, J; Pan, SJ; Tan, YL; Xin, Y; Xiong, J; Yang, X; Yao, SW, 2018) |
| " The current study investigates possible effects of SSRIs, fluoxetine, and paroxetine on SB in patients with anxiety and depression." | 3.85 | BiteStrip analysis of the effect of fluoxetine and paroxetine on sleep bruxism. ( Aksoy, S; Atıcı, M; Erdogan, MS; Ertaş, ET; Isa Kara, M; Kelebek, S; Ozen, E, 2017) |
| " We carried out a study to compare the behavioural effects of fluoxetine (FLX) in a model of depression in two mice strains: C57BL6/J and BALB/c." | 3.85 | Fluoxetine induces paradoxical effects in C57BL6/J mice: comparison with BALB/c mice. ( Belzung, C; Brizard, B; Gosselin, T; Hommet, C; Le Guisquet, AM; Minier, F, 2017) |
| "To further explore the underlying antidepressant mechanism of ginseng total saponins (GTS), this study observed the effects on hippocampal astrocyte structural plasticity and hippocampal volume in the corticosterone-induced mouse depression model." | 3.85 | Preventive Effects of Ginseng Total Saponins on Chronic Corticosterone-Induced Impairment in Astrocyte Structural Plasticity and Hippocampal Atrophy. ( Chen, L; Dai, JG; Huang, YF; Lin, ZX; Wang, X; Zhao, YN, 2017) |
| " Interrupted time series analyses measured changes due to the warning in levels and trends, by race/ethnicity, of three outcomes: antidepressant prescription fills, depression treatment visits, and incident fluoxetine prescription fills." | 3.85 | A decline in depression treatment following FDA antidepressant warnings largely explains racial/ethnic disparities in prescription fills. ( Carson, NJ; Cook, BL; Progovac, AM; Wang, Y, 2017) |
| "Administration of leonurine (60 mg/kg) for 4 weeks significantly alleviated depression-like behaviors of chronic mild stress mice, including increased sucrose preference and reduced immobility time in forced swimming test and tail suspension test." | 3.85 | Leonurine Exerts Antidepressant-Like Effects in the Chronic Mild Stress-Induced Depression Model in Mice by Inhibiting Neuroinflammation. ( Chen, M; Ding, J; Ding, X; Du, R; Hu, G; Jia, M; Li, C; Lu, M; Zheng, Y, 2017) |
| "This study evaluated the chronic effects of fluoxetine, a commonly prescribed SSRI antidepressant, on the peripheral and central levels of inflammatory cytokines including IL-1β, IL-6, TNF-α and IL-17 over a 4-interval in a rat model of chronic mild stress (CMS) which resembles the human experience of depression." | 3.85 | Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression. ( Chua, AN; Ho, CS; Ho, RC; Liu, X; Lu, Y; McIntyre, RS; Wang, W, 2017) |
| "Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepressants, has been thought to be effective for treating post-stroke depression (PSD)." | 3.85 | Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression. ( He, QW; Hu, B; Jin, HJ; Li, M; Li, YN; Mao, L; Pei, L; Wan, Y; Xia, YP; Yang, S; Yue, ZY; Zheng, H, 2017) |
| "To observe the depression in patients with malignant tumor and influencing factors of the disease, as well as to investigate the effects of fluoxetine on depressive symptoms in cancer patients and the immune function." | 3.85 | Study of prevalence and influencing factors of depression in tumor patients and the therapeutic effects of fluoxetine. ( Dai, J; Liao, N; Shi, J; Tao, JQ, 2017) |
| " However, vital safety and efficacy issues related to combined therapy with temozolomide, the first-line cytostatic in patients diagnosed with glioblastoma multiforme, and antidepressant drugs have yet to be addressed." | 3.85 | Antidepressant drugs can modify cytotoxic action of temozolomide. ( Bielecka, AM; Obuchowicz, E, 2017) |
| "The benefits of creatine supplementation have been reported in a broad range of central nervous system diseases, including depression, although the mechanisms underlying these effects remain to be understood." | 3.85 | Creatine Prevents Corticosterone-Induced Reduction in Hippocampal Proliferation and Differentiation: Possible Implication for Its Antidepressant Effect. ( Azevedo, D; Brocardo, PS; Colla, A; Cunha, MP; de Oliveira, J; Gil-Mohapel, J; Pazini, FL; Ramos-Hryb, AB; Rodrigues, ALS; Rosa, JM, 2017) |
| " Using a genetic animal model of depression, this study investigated the long-term effects of pre-pubertal administration of fluoxetine (FLX) on depressive-like behaviour in early adulthood, as well as on central monoaminergic response to an acute stressor." | 3.85 | Long-term effects of pre-pubertal fluoxetine on behaviour and monoaminergic stress response in stress-sensitive rats. ( Badenhorst, NJ; Brand, L; Brink, CB; Ellis, SM; Harvey, BH, 2017) |
| "The present study was undertaken to examine whether brexpiprazole could augment antidepressant effects of the SSRI fluoxetine in an inflammation model of depression." | 3.85 | Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation. ( Dong, C; Futamura, T; Hashimoto, K; Ma, M; Ohgi, Y; Ren, Q; Yang, C; Yao, W; Zhang, JC, 2017) |
| " The aim of this study was to investigate whether anxiety or depression-like behavior can be found in rat strains with different susceptibility to audiogenic seizures (AS) and whether chronic fluoxetine treatment affects this co-morbidity." | 3.85 | Genetic background contributes to the co-morbidity of anxiety and depression with audiogenic seizure propensity and responses to fluoxetine treatment. ( Fedotova, IB; Kostina, ZA; Nikolaev, GM; Perepelkina, OV; Poletaeva, II; Sarkisova, KY; Surina, NM, 2017) |
| "After 1 month treatment, vortioxetine improved visuospatial memory and reduced depression-like behavior." | 3.85 | Distinct Antidepressant-Like and Cognitive Effects of Antidepressants with Different Mechanisms of Action in Middle-Aged Female Mice. ( Gulinello, M; Li, Y; Sanchez, C, 2017) |
| "Ketamine has emerged as a novel strategy to treat refractory depression, producing rapid remission, but elicits some side effects that limit its use." | 3.83 | Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway. ( Colla, AR; Cunha, MP; Lieberknecht, V; Oliveira, Á; Pazini, FL; Rodrigues, AL; Rosa, JM, 2016) |
| " Here we used a rodent model of anxiety/depression-like states, which is based on chronic CORT administration and studied the effects of the antidepressant fluoxetine (FLX) on behavior, olfaction, and adult neurogenesis in the dentate gyrus (DG), olfactory bulb (OB), and the olfactory epithelium (OE)." | 3.83 | Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice. ( de Chaumont, F; Denizet, M; Gabellec, MM; Guilloux, JP; Lazarini, F; Lledo, PM; Olivo-Marin, JC; Siopi, E, 2016) |
| "The current study assessed whether antidepressant and/or antinociceptive drugs, duloxetine, fluoxetine as well as (±)-8-hydroxy-2-[di-n-propylamino] tetralin (8-OH-DPAT), are able to reverse depression-like behaviour in animals with chronic neuropathic pain." | 3.83 | Duloxetine and 8-OH-DPAT, but not fluoxetine, reduce depression-like behaviour in an animal model of chronic neuropathic pain. ( Ceci, A; Doods, H; Hu, B; Treede, RD, 2016) |
| "A new (aryloxyalkyl)adenine derivative Adeprophen (9-[2-(4-isopropylphenoxy)ethyl]adenine, VMA-99-82) has a strong antidepressant effect on the model of reserpine-induced depression in rats (single dose 4 mg/kg, intraperitoneally)." | 3.83 | Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats. ( Bagmetova, VV; Chernysheva, YV; Ozerov, AA; Tyurenkov, IN, 2016) |
| " We report a patient with persistent congenital hyperinsulinism (CHI) who developed recurrent hypoglycaemia following fluoxetine therapy." | 3.83 | Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy. ( Didi, M; Giri, D; Price, V; Senniappan, S; Yung, Z, 2016) |
| "The effect of chronic treatment with antidepressant drugs fluoxetine (20 mg/kg) and imipramine (25 mg/kg) on the number of antibody-producing cells and the main T cell subpopulations in ASC mice characterized by genetic predisposition to depression-like states was studied at the peak of the SE-induced immune response (5×10(8))." | 3.83 | Effect of Antidepressants on Immunological Reactivity in ASC Mice with Genetically Determined Depression-Like State. ( Al'perina, EL; Gevorgyan, MM; Idova, GV; Kulikov, AV; Tikhonova, MA, 2016) |
| "The aim of this study was to compare the effects of treatment with fluoxetine and 1-methyl-L-tryptophan (1-MT) on Bacillus Calmette-Guerin (BCG)-induced inflammatory model of depression in mice." | 3.83 | Comparison of fluoxetine and 1-methyl-L-tryptophan in treatment of depression-like illness in Bacillus Calmette-Guerin-induced inflammatory model of depression in mice. ( Banerjee, BD; Bhattacharya, SK; Deshmukh, P; Jain, S; Mediratta, PK; Rana, P; Sharma, AK, 2016) |
| "We demonstrated that confronting mice to the Unpredictable Chronic Mild Stress (UCMS) procedure-a validated model of stress-induced depression-results in behavioural alterations and biochemical changes in the kynurenine pathway (KP), suspected to modify the glutamatergic neurotransmission through the imbalance between downstream metabolites such as 3-hydroxykynurenine, quinolinic and kynurenic acids." | 3.83 | Chronic Treatment with the IDO1 Inhibitor 1-Methyl-D-Tryptophan Minimizes the Behavioural and Biochemical Abnormalities Induced by Unpredictable Chronic Mild Stress in Mice - Comparison with Fluoxetine. ( Barone, PR; Belzung, C; Callebert, J; Guillemin, GJ; Laugeray, A; Launay, JM; Mutlu, O, 2016) |
| "The present study was carried out to determine the role of thymoquinone (TQ) in modulating the levels of neurotransmitter and reducing the oxidative stress in animal models of depression." | 3.81 | Antidepressant Effect of Thymoquinone in Animal Models of Depression. ( Akhtar, M; Aquib, M; Najmi, AK, 2015) |
| "Major depression is diagnosed in 18% of patients following myocardial infarction (MI), and the antidepressant fluoxetine is shown to effectively decrease depressive symptoms and improve coronary heart disease prognosis." | 3.81 | Effect and mechanism of fluoxetine on electrophysiology in vivo in a rat model of postmyocardial infarction depression. ( Chen, J; Chen, Y; Hu, D; Liang, J; Qu, C; Shi, S; Wang, F; Yang, B; Yuan, X, 2015) |
| " We found that chronic treatment of a mouse model of anxiety/depression (CORT model) with a selective serotonin reuptake inhibitor (SSRI, fluoxetine, 18mg/kg/day) reversed CORT-induced anxiety/depression-like behavior in mice." | 3.81 | Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression. ( Ali, ZE; Damiens, MH; David, DJ; Gardier, AM; Kerdine-Römer, S; Mendez-David, I; Pallardy, M; Tritschler, L, 2015) |
| " The purpose of our study was to determine if antidepressants improve depression via the NO pathway using an acute depressive rat model induced by L-arginine (AR)." | 3.81 | Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin. ( Abe, M; Mori, Y; Nakata, S; Ochi, S; Ueno, S; Yamazaki, K; Yoshino, Y, 2015) |
| " We compared the effects of chronic treatment with the preferential nNOS inhibitor 7-nitroindazole (7-NI) with those evoked by the conventional antidepressant fluoxetine on alterations that are considered as markers of depression (immobility in the forced swimming test, FST, decreased body weight gain and increased plasma corticosterone concentration) and cardiovascular changes caused by CVS." | 3.81 | Effects of nitric oxide synthesis inhibitor or fluoxetine treatment on depression-like state and cardiovascular changes induced by chronic variable stress in rats. ( Almeida, J; Crestani, CC; Duarte, JO; Oliveira, LA, 2015) |
| " At 12 months, but not earlier, DEX-exposed mice displayed depression-like behavior and impaired hippocampal neurogenesis, not reversible by the antidepressant fluoxetine (FLX)." | 3.81 | Alterations in circadian entrainment precede the onset of depression-like behavior that does not respond to fluoxetine. ( Bose, R; Ceccatelli, S; Conti, M; DuPont, C; Onishchenko, N; Raciti, M; Spulber, S, 2015) |
| "Postnatal treatment with the selective serotonin reuptake inhibitor fluoxetine, evokes anxiety and depressive behavior in rodent models in adulthood." | 3.80 | Postnatal fluoxetine-evoked anxiety is prevented by concomitant 5-HT2A/C receptor blockade and mimicked by postnatal 5-HT2A/C receptor stimulation. ( Chachra, P; Sarkar, A; Vaidya, VA, 2014) |
| "Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are the most common form of medication treatment for major depression." | 3.80 | Global state measures of the dentate gyrus gene expression system predict antidepressant-sensitive behaviors. ( Alter, M; Dranovsky, A; Hen, R; Leonardo, ED; McCurdy, RD; Nesbitt, AM; Samuels, BA; Williams, A; Wong, E, 2014) |
| "Several epidemiological studies have reported an association between arsenic exposure and increased rates of psychiatric disorders, including depression, in exposed populations." | 3.80 | Fluoxetine treatment ameliorates depression induced by perinatal arsenic exposure via a neurogenic mechanism. ( Allan, AM; Solomon, BR; Tyler, CR; Ulibarri, AL, 2014) |
| "After 6 months, in the group receiving fluoxetine, the reduction of the level of anxiety was obtained from 22." | 3.80 | [The effect of fluoxetine and tianeptine on emotional and eating disorders in postmenopausal women]. ( Chojnacki, J; Jałocha, W; Klupińska, G; Tomaszewska-Warda, K; Walecka-Kapica, E, 2014) |
| " In this study, we investigated the antidepressant effect of GTS on the corticosterone-induced mouse depression model and explored the underlying mechanism." | 3.80 | The antidepressant effects of ginseng total saponins in male C57BL/6N mice by enhancing hippocampal inhibitory phosphorylation of GSK-3β. ( Chen, L; Dai, J; Huang, Y; Wang, Z; Zhang, H; Zhao, Y, 2014) |
| " Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes." | 3.80 | Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| " Magnolol is the main constituent identified in the bark of Magnolia officinalis, which has been used for the treatment of mental disorders, including depression, in Asian countries." | 3.79 | Magnolol treatment reversed the glial pathology in an unpredictable chronic mild stress-induced rat model of depression. ( Li, LF; Ma, SP; Qu, R; Yang, J, 2013) |
| "To observe the effect of hesperidin on behavior and hypothalamic-pituitary-adrenal (HPA) axis of ratmodel of chronic stress-induced depression." | 3.79 | [Effect of hesperidin on behavior and HPA axis of rat model of chronic stress-induced depression]. ( Cai, L; Li, R; Wu, QQ; Wu, TN, 2013) |
| " A possible mechanism was explored in the tests of antagonism of reserpine-induced ptosis and hypothermia, and 5-HTP induced head twitch response in mice." | 3.79 | Antidepressant-like effect of ethanol extract from Zuojin Pill, containing two herbal drugs of Rhizoma Coptidis and Fructus Evodiae, is explained by modulating the monoaminergic neurotransmitter system in mice. ( Cui, YL; Ding, SL; Mao, HP; Qi, XJ; Wang, QS, 2013) |
| "To investigate the effects of Sini San and fluoxetine on the levels of central and peripheral 5-HT in a rat model of depression, and provide new insight into the treatment of depression with integrated Chinese-Western Medicine." | 3.79 | Effects of Sini San used alone and in combination with fluoxetine on central and peripheral 5-HT levels in a rat model of depression. ( Chen, J; Guo, S; Li, Y; Ma, X; Ouyang, Y; Sun, Y; Wang, W; Wu, Z; Xue, X; Zhang, W, 2013) |
| "Because selective serotonin reuptake inhibitors (SSRIs) are the first-line pharmacological treatment for depression, we investigated the effect of chronic treatment with the SSRI fluoxetine on long-term changes in CRF/CRF1 signaling in animals showing a depressive-like behavior." | 3.79 | Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm. ( Cassanelli, PM; Cladouchos, ML; Fernández Macedo, GV; Sifonios, L; Wikinski, S, 2013) |
| " To test this hypothesis, we administered the AChE inhibitor physostigmine to mice and demonstrated an increase in anxiety- and depression-like behaviors that was reversed by administration of nicotinic or muscarinic antagonists." | 3.79 | Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. ( Calarco, CA; Fote, GM; Li, AM; Mineur, YS; Obayemi, A; Picciotto, MR; Wigestrand, MB, 2013) |
| "Several clinical reports have postulated a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants in treatment-resistant depression." | 3.78 | Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. ( Gądek-Michalska, A; Kabziński, M; Rachwalska, P; Rogóż, Z; Sadaj, W, 2012) |
| " This study aimed to examine the antidepressant-like effect and the possible mechanisms of total glycosides of peony (TGP) in the CORT-induced depression model in rats." | 3.78 | Peony glycosides reverse the effects of corticosterone on behavior and brain BDNF expression in rats. ( Che, CT; Huang, Z; Ip, SP; Mao, QQ; Xian, YF, 2012) |
| "Exposure to CUMS for four weeks caused depression-like behaviour in rats, as indicated by significant decreases in weight gain, sucrose consumption and locomotor activity." | 3.78 | Anti-depressant effects of Xiaoyaosan on rat model of chronic unpredictable mild stress: a plasma metabonomics study based on NMR spectroscopy. ( Cui, J; Du, GH; Gao, XX; Li, ZF; Li, ZY; Liu, XJ; Qin, XM; Sun, HF; Zhang, LZ; Zhou, YZ, 2012) |
| "The potential role of metabolic impairments in the pathophysiology of depression is motivating researchers to evaluate the treatment efficacy of creatine, a naturally occurring energetic and neuroprotective compound found in brain and muscle tissues." | 3.78 | Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats. ( Allen, PJ; D'Anci, KE; Kanarek, RB; Renshaw, PF, 2012) |
| " In the present study, pain sensitivity was assessed in a mouse model of anxiety/depression on the basis of chronic corticosterone (CORT) administration through the drinking water (CORT model)." | 3.78 | Antinociceptive effects of fluoxetine in a mouse model of anxiety/depression. ( Coudoré, F; David, DJ; Gardier, AM; Guiard, BP; Hache, G; Le Dantec, Y; Orvoën, S, 2012) |
| " Here we investigate changes in cell proliferation and neurogenesis along the septo-temporal axis of the hippocampus induced by the Unpredictable Chronic Mild Stress model of depression (UCMS), chronic fluoxetine treatment and enriched environment." | 3.78 | Differential environmental regulation of neurogenesis along the septo-temporal axis of the hippocampus. ( Belzung, C; Minier, F; Rainer, Q; Surget, A; Tanti, A, 2012) |
| "To evaluate the ability of Rosmarinus officinalis hydroalcoholic extract (ROHE), as compared to the positive control fluoxetine, to reverse behavioral (hyperactivity, anhedonic behavior and learning deficit in water maze) and biochemical alterations (serum glucose level and acetylcholinesterase, AChE, activity) induced by an animal model of depression, the olfactory bulbectomy (OB) in mice." | 3.78 | Rosmarinus officinalis L. hydroalcoholic extract, similar to fluoxetine, reverses depressive-like behavior without altering learning deficit in olfactory bulbectomized mice. ( Balen, GO; Bettio, LE; Brocardo, PS; Colla, AR; Cunha, MP; Dalmarco, JB; Grando, J; Machado, DG; Neis, VB; Pizzolatti, MG; Prediger, RD; Rial, D; Rodrigues, AL, 2012) |
| "Immunity inflammation and autoimmune reaction exist in CUMS depression model rats, and fluoxetine treatment can improve these immune response." | 3.78 | [Concentration increase in Hcy and anti-CCP antibody in the serum of depression rat model induced by chronic unpredictable mild stress]. ( Chen, R; Liu, Y; Qin, L; Tang, Y; Zhang, R, 2012) |
| " The present study was undertaken to investigate effects of chronic administration of tianeptine or olanzapine on unpredictable chronic mild stress (UCMS)-induced depression-like behavior in mice compared to a widely used SSRI antidepressant, fluoxetine." | 3.78 | Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice. ( Akar, F; Celikyurt, IK; Erden, F; Gumuslu, E; Kır, HM; Kokturk, S; Mutlu, O; Ulak, G, 2012) |
| "In C6 glioma cells, we studied acute administration of SSRI antidepressants - fluoxetine, sertraline and citalopram." | 3.78 | Effect of fluoxetine and adenosine receptor NECA agonist on G alpha q/11 protein of C6 glioma cells. ( Kováru, F; Kovárů, H; Lisá, V, 2012) |
| "The selective serotonin reuptake inhibitor (SSRI) Prozac® (fluoxetine) is the only registered antidepressant to treat depression in children and adolescents." | 3.77 | Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. ( Arentsen, T; Blom, T; Homberg, JR; Korte-Bouws, G; Olivier, JD; Reneman, L; Schipper, P; van Brunschot, C; van Luijtelaar, G, 2011) |
| " During adulthood, SFR and IMS mice received chronic treatment (∼3 weeks) with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (18 mg/kg/day), and were assessed for anxiety- and depression-related behavior in the light/dark test and forced swim tests (FST), respectively." | 3.77 | Infant maternal separation impairs adult cognitive performance in BALB/cJ mice. ( Dulawa, SC; Jiao, J; Wang, L, 2011) |
| "Weight gain during olanzapine/fluoxetine combination (OFC) therapy is very common." | 3.77 | Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. ( Case, M; Degenhardt, EK; Jamal, HH; Tormey, S, 2011) |
| "The current study established whether vomiting bulimic and/or non-bulimic depressive patients, both treated with a serotonin reuptake inhibitor (fluoxetine), have changes in their whole salivary secretion and inorganic components: Na(+), K(+), Ca(2+)." | 3.77 | Flow rates and inorganic composition of whole saliva in purging bulimic patients treated with a fluoxetine. ( Linden, RW; Paszynska, E; Rajewski, A; Slopien, A, 2011) |
| "Clinical studies have reported that adjunctive acetylsalicylic acid (aspirin) therapy is beneficial for patients with treatment resistant depression (TRD)." | 3.77 | Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. ( Gao, F; Jiang, W; Liu, YF; Wang, Y; Yang, F, 2011) |
| "Dissection of the styloid process via an extraoral approach is simple and reliable; dissection of the styloid process combined with antidepressants (fluoxetine) is preferred for treating Eagle's syndrome." | 3.77 | Eagle's syndrome treated with dissection of the styloid process via an extraoral approach combined with antidepressants. ( Chen, WL; Pan, JY; Peng, GG; Wu, JW, 2011) |
| " This study investigated the effects of agomelatine and fluoxetine in a genetic model of depression called H/Rouen mice Male and female H/Rouen (helpless line) and NH/Rouen (nonhelpless line) mice, received once daily for 3 weeks agomelatine (10 and 50 mg/kgi." | 3.77 | Chronic agomelatine and fluoxetine induce antidepressant-like effects in H/Rouen mice, a genetic mouse model of depression. ( Dubois, M; El Yacoubi, M; Gabriel, C; Mocaër, E; Vaugeois, JM, 2011) |
| "Changes in gene expression of beta1- and beta2-adrenoceptors (beta1 - and beta2-AR) in right and left atria and ventricles after fluoxetine treatment in stress-induced depression of adult rat males were studied." | 3.77 | Flouxetine treatment acts selectively increasing myocardial beta1-adrenoceptor mRNA expression in stress-induced depression. ( Dronjak, S; Gavrilovic, L; Jovanovic, P; Spasojevic, N, 2011) |
| "The study demonstrated that tianeptine is as effective as fluoxetine in the treatment of PTSD, with even stronger effect on anxiety and equal tolerance." | 3.77 | Tianeptine in the combined treatment of combat related posttraumatic stress disorder. ( Frančišković, T; Janović, S; Letica-Crepulja, M; Nemčić-Moro, I; Rončević-Gržeta, I; Stevanović, A; Suković, Z, 2011) |
| "Status epilepticus was induced in the rats by administration of pilocarpine 350 mg/kg i." | 3.77 | Piperine protects epilepsy associated depression: a study on role of monoamines. ( Nayak, S; Pal, A; Sahu, PK; Swain, T, 2011) |
| " Experiment 2 showed that fluoxetine treatment administered via drinking water attenuated depressive-like behaviour in the FST and TST in individually housed female C57BL/6J mice, but had no effect on anxiety-like behaviour." | 3.76 | The lonely mouse: verification of a separation-induced model of depression in female mice. ( Brown, RE; Martin, AL, 2010) |
| " We investigated here whether the BLA modulates the effects of the SSRI antidepressant fluoxetine on hippocampal cell proliferation and survival in relation to a behavioral index of depression-like behavior (forced swim test)." | 3.76 | Role of the amygdala in antidepressant effects on hippocampal cell proliferation and survival and on depression-like behavior in the rat. ( Castro, JE; Cordero, MI; Márquez, C; Poirier, G; Sandi, C; Varea, E, 2010) |
| "Neonatal treatment with clomipramine (CMI) in rats induces multiple behavioral alterations during adulthood that resemble certain symptoms of human depression, such as impairments of pleasure-seeking behaviors." | 3.76 | Circadian activity of corticosterone in an animal model of depression: response to muscarinic cholinergic stimulation. ( Arteaga-Silva, M; Bonilla-Jaime, H; Hernández-González, M; Retana-Márquez, S; Vázquez-Palacios, G, 2010) |
| " A possible mechanism was explored in the test of antagonism of reserpine-induced ptosis and hypothermia in mice." | 3.76 | Antidepressant-like effect of genipin in mice. ( Chi, W; Cui, YL; Dong, TJ; Gao, S; Hu, LM; Liu, LP; Tian, JS, 2010) |
| " Here, we attempt to expand upon and replicate these results by (i) resequencing the exonic and putatively regulatory regions of five serotonin-related candidate genes (HTR1A, HTR2A, TPH1, TPH2, and MAOA) in our fluoxetine-treated sample to uncover novel variants; (ii) selecting tagging single nucleotide polymorphisms (SNPs) for these genes from the resequencing data; and (iii) evaluating these tagging SNPs for association with response to the selective serotonin reuptake inhibitor citalopram in an independent sample of participants who are enrolled in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) clinical study (N=1953)." | 3.75 | Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. ( Garriock, HA; Hamilton, SP; Jenkins, GD; Kraft, JB; McGrath, PJ; Peters, EJ; Reinalda, MS; Shyn, SI; Slager, SL, 2009) |
| "The aim of this study was to investigate the relationship between plasma glutamate, glutamine and gamma-aminobutyric acid (GABA) levels in female patients with major depression treated with S-citalopram or fluoxetine." | 3.75 | The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. ( Calişkan, M; Gören, MZ; Kaplan, OK; Küçükibrahimoğlu, E; Saygin, MZ; Unsal, C, 2009) |
| " Here we describe a mouse model of an anxiety/depressive-like state induced by chronic corticosterone treatment." | 3.75 | Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. ( Antonijevic, IA; Artymyshyn, RP; Craig, DA; David, DJ; Drew, M; Gardier, AM; Gerald, C; Guiard, BP; Guilloux, JP; Hen, R; Leonardo, ED; Marsteller, D; Mendez, I; Rainer, Q; Samuels, BA; Wang, JW, 2009) |
| " First, by determining the requirement for VEGF in the actions of a 5-HT selective reuptake inhibitor (SSRI), fluoxetine in behavioral models of depression/antidepressant response; and second, by examining the role of the 5-HT1A receptor subtype in the regulation of VEGF, and the cellular localization of antidepressant regulation of VEGF expression." | 3.75 | Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. ( Banasr, M; Duman, RS; Greene, J; Lee, B; Warner-Schmidt, J, 2009) |
| "(1) When an antidepressant is considered a necessary addition to psychological support in treating patients with depression, the first-line drug is a tricyclic such as clomipramine or a selective serotonin reuptake inhibitor (SSRI) such as paroxetine; (2) Agomelatine, a melatonin receptor agonist, is approved in the European Union for the treatment of depression; (3) Available evaluation does not include any clinical trials designed to compare the efficacy of agomelatine with that of a tricyclic or a selective serotonin reuptake inhibitor." | 3.75 | Agomelatine: new drug. Adverse effects and no proven efficacy. ( , 2009) |
| " Data from a clinical trial comparing fluoxetine to a placebo for treating depression is used to illustrate this methodology." | 3.75 | Predicting potential placebo effect in drug treated subjects. ( Govindarajulu, U; Petkova, E; Tarpey, T, 2009) |
| " We report a case of recurrent priapism that was treated with Fluoxetine and low dose Perphenazine." | 3.74 | Treatment of idiopathic recurrent priapism with fluoxetine and low dose Perphenazine. ( Ahmadi, A; Khazaie, H; Moradi, M; Tahmasian, M, 2008) |
| " Male Wistar rats were subjected to LiCl and pilocarpine status epilepticus (SE)." | 3.74 | Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. ( Baldwin, RA; Caplan, R; Mazarati, A; Sankar, R; Shin, D; Siddarth, P, 2008) |
| "Clinical studies have reported the beneficial outcome of addition of lower doses of risperidone to antidepressant therapy specifically with selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depression." | 3.74 | Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. ( Dhir, A; Kulkarni, SK, 2008) |
| "Mice injected with anti-P developed depression-like behavior, which improved significantly upon treatment with fluoxetine." | 3.74 | Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS -SLE (depression). ( Ben-Ziv, T; Blank, M; Chapman, J; Katzav, A; Reichlin, M; Shoenfeld, Y, 2008) |
| "To investigate the effects of fluoxetine on depression-induced changes of mast cell morphology and protease-1 (rMCP-1) expression in rats." | 3.74 | Effects of fluoxetine on mast cell morphology and protease-1 expression in gastric antrum in a rat model of depression. ( Chen, JH; Chen, ZH; Huang, YL; Luo, HS; Wang, GH; Wang, XP; Xiao, L, 2008) |
| "Familial Mediterranean Fever (FMF) is characterized by recurrent acute attacks of fever and serositis, and colchicine is the primary treatment." | 3.74 | Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever. ( Calgüneri, M; Ertenli, I; Kaymak, SU; Kiraz, S; Onat, AM; Ozçakar, L; Oztürk, MA; Ureten, K, 2007) |
| " The behavioral and neuroendocrinological effects of icariin, a major constituent of flavonoids isolated from Epimedium brevicornum, were investigated in the CMS model of depression in male Wistar rats." | 3.74 | Icariin from Epimedium brevicornum attenuates chronic mild stress-induced behavioral and neuroendocrinological alterations in male Wistar rats. ( Jiang, FX; Kong, LD; Kung, HF; Li, YC; Pan, Y; Xia, X, 2007) |
| " The aim of this study was to investigate the effects of the SSRIs citalopram and fluoxetine, on the corticocerebral blood flow (cCBF) in rabbits with unilateral carotid occlusion induced cerebral ischemia." | 3.74 | Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits. ( Csete, K; Papp, JG; Sas, K; Sztriha, L; Vécseil, L; Vezekényi, Z, 2007) |
| " We describe the case of a 53-year-old woman that was started on fluoxetine 20 mg/day for depression and nine days later was found to have fluoxetine-induced syndrome of inappropriate secretion of antidiuretic hormone." | 3.74 | Pontine and extrapontine osmotic myelinolysis after the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report. ( Bertolucci, CB; Gracia, Cde M; Twardowschy, CA, 2007) |
| "To investigate changes in vasoactive intestinal polypeptide (VIP) and corticotrophin releasing factor (CRF) in the plasma and duodenum of chronic stress-induced depressed rats and the effects of fluoxetine hydrochloride (fluoxetine) treatment on depression-induced changes in VIP and CRF." | 3.74 | Effect of fluoxetine on depression-induced changes in the expression of vasoactive intestinal polypeptide and corticotrophin releasing factor in rat duodenum. ( Chen, ZH; Huang, YL; Wang, GH; Wang, Q; Xiao, L; Yu, JP, 2007) |
| "Clinical studies have shown that folic acid plays a role in the pathophysiology of depression." | 3.74 | Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems. ( Brocardo, PS; Budni, J; Kaster, MP; Rodrigues, AL; Santos, AR, 2008) |
| "A dysregulated hypothalamic-pituitary-adrenal axis (HPA) has been implicated in major depressive disorder and most commonly used animal models of depression have been shown to elevate circulating levels of plasma corticosterone." | 3.74 | Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. ( Hutson, PH; Murray, F; Smith, DW, 2008) |
| "The effects of acute and chronic fluoxetine treatment in intact and anxiety-depressive male and female inbred mice of the C57BL/6J strain were studied." | 3.74 | [Effects of acute and chronic introduction of fluoxetine on anxiety-depressive condition of male and female mice]. ( Avgustinovich, DF; Kovalenko, IL; Tolstikova, TG, 2007) |
| " In this study, we report that the depression-like behavior in MeHg-exposed male mice is reversed by chronic treatment with the antidepressant fluoxetine." | 3.74 | Long-lasting depression-like behavior and epigenetic changes of BDNF gene expression induced by perinatal exposure to methylmercury. ( Castrén, E; Ceccatelli, S; Karpova, N; Onishchenko, N; Sabri, F, 2008) |
| "These experiments aimed to investigate the effects of the cannabinoid CB1 receptor antagonist rimonabant (SR141716) in animal models measuring aspects of emotional reactivity and depression." | 3.73 | Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. ( Griebel, G; Scatton, B; Stemmelin, J, 2005) |
| "Fluoxetine, citalopram, paroxetine and venlafaxine have been widely used in the treatment of depression." | 3.73 | Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ( Huande, L; Juan, H; Zhiling, Z, 2005) |
| " We describe a case of a 53-year-old woman that was started on fluoxetine 20 mg/day for depression." | 3.73 | Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report. ( Bertolucci, CB; Brandão, MA; Gracia, Cde M; Twardowschy, CA, 2006) |
| " The present study aimed at determining whether the CRF(1) receptor antagonist SSR125543A, the V(1b) receptor antagonist SSR149415, and the clinically effective antidepressant fluoxetine may influence newborn cell proliferation and differentiation in the dentate gyrus of mice subjected to the chronic mild stress (CMS) procedure, a model of depression with predictive validity." | 3.72 | Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. ( Alonso, R; Griebel, G; Le Fur, G; Pavone, G; Soubrié, P; Stemmelin, J, 2004) |
| " We initially assessed four inbred mouse strains for their behavioral response to chronic treatment with the selective-serotonin reuptake inhibitor fluoxetine (0, 5, 10 mg/kg/day in drinking water), which is used for the treatment of mood and anxiety disorders." | 3.72 | Effects of chronic fluoxetine in animal models of anxiety and depression. ( Dulawa, SC; Gundersen, B; Hen, R; Holick, KA, 2004) |
| "In a 59-year-old man with a swallowing problem and loss of weight, who used fluoxetine because of depression, gastroscopy revealed a black hairy structure on the dorsum of the tongue, known as black hairy tongue." | 3.72 | [Diagnostic image (189). A man with a tongue disorder. Black hairy tongue]. ( Hommes, M; Hoskam, JA, 2004) |
| "The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder." | 3.71 | Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. ( Ancione, M; Avenoso, A; Gatti, G; Madia, A; Perucca, E; Scordo, MG; Spina, E, 2002) |
| "The water decoction of Rhizoma acori tatarinowii and Fluoxetine significantly shortened motionless time of rat forced swimming and despair time of mouse tail suspension in the two behavioural despair animal models of depression." | 3.71 | [Antidepressant effect of water decoction of Rhizoma acori tatarinowii in the behavioural despair animal models of depression]. ( Chen, H; Li, M, 2001) |
| "The symptom of "diminished interest or pleasure" in rewarding stimuli is an affective symptom of nicotine and amphetamine withdrawal, and a core symptom of depression." | 3.71 | Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. ( Harrison, AA; Liem, YT; Markou, A, 2001) |
| "We report a case of a 32-year-old woman who developed paroxysmal episodes of right hemidystonia 2 days after taking fluoxetine." | 3.71 | Acute paroxysmal dystonia induced by fluoxetine. ( Callejo, JM; Domínguez-Morán, JA; Fernández-Ruiz, LC; Martínez-Castrillo, JC, 2001) |
| "Fluoxetine (Prozac) is the most widely prescribed medication for the treatment of depression." | 3.71 | Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). ( Fienberg, AA; Greengard, P; Nomikos, GG; Svenningsson, P; Tzavara, ET; Witkin, JM, 2002) |
| "We present a 15-year-old girl with depression, an obsessive compulsive disorder and conduct disorder, who developed EPS (torticollis, bradykinesia and cogwheel rigidity) while on fluoxetine." | 3.71 | Fluoxetine-induced extrapyramidal symptoms in an adolescent: a case report. ( Avci, A; Diler, RS; Yolga, AY, 2002) |
| "Efficiency of fluoxetine (one of the selective serotonin reuptake inhibitors) was examined in the course of treatment of 24 patients with atypical depressions that were characterized by prevalence of either negative (12 patients) or positive (12 patients) affectivity." | 3.70 | [Effectiveness of fluoxetine (portal) in atypical depressions]. ( Andriushchenko, AV, 1998) |
| "Previously, we observed specific alterations of neuropeptide Y (NPY) and Y1 receptor mRNA expression in discrete regions of the Flinders Sensitive Line rats (FSL), an animal model of depression." | 3.70 | Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression. ( Caberlotto, L; Fuxe, K; Hurd, YL; Jimenez, P; Mathé, AA; Overstreet, DH, 1999) |
| " We give an example of its utility on a clinical trial of fluoxetine in depression." | 3.70 | Bootstrap methods for adaptive designs. ( Hu, F; Rosenberger, WF, 1999) |
| " In addition, hypericum extracts, as well as standard antidepressants such as the tricyclic, impramine, and the selective serotonin reuptake inhibitor, fluoxetine, have been reported to be of therapeutic benefit in the treatment of alcoholism, as these compounds may reduce alcohol craving and/or intake in particular subgroups of patients." | 3.70 | Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. ( de Beun, R; De Vry, J; Jentzsch, KR; Maurel, S; Schreiber, R, 1999) |
| "A 17-year-old boy with type 1 diabetes mellitus developed new loss of hypoglycemia awareness while being treated with fluoxetine hydrochloride for depression." | 3.70 | Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. ( Burgart, V; Sawka, AM; Zimmerman, D, 2000) |
| "This study modelled the economic impact of mirtazapine, compared to amitriptyline and fluoxetine, in the management of moderate and severe depression in the UK, as well as the costs related to discontinuation of antidepressant treatment." | 3.70 | Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. ( Borghi, J; Guest, JF, 2000) |
| "Fluoxetine is a selective serotonin reuptake inhibitor that often is associated with a modest weight loss when used for the treatment of depression, although it also has been reported to have the opposite effects of weight gain and hyperphagia in some patients." | 3.69 | Hyperphagia and weight loss during fluoxetine treatment. ( Braun, BG; Fichtner, CG, 1994) |
| "We studied the sensitivity in detecting changes of the 6-item version of the original 17-item Hamilton Depression Rating Scale (HAM-D) and compared it with the more widely used versions among 164 depressed outpatients with and without atypical features before and after treatment with fluoxetine." | 3.69 | Sensitivity of the six-item Hamilton Depression Rating Scale. ( Agustin, C; Baer, L; Fava, M; O'Sullivan, RL; Rosenbaum, JF, 1997) |
| "To describe two cases of stomatitis related to fluoxetine given for the treatment of depression that were detected in the hospital emergency department." | 3.69 | Fluoxetine-associated stomatitis. ( Martínez-Mir, I; Morales-Olivas, FJ; Palop, V; Sancho, A, 1997) |
| " We here report a case of interferon-alpha-induced depression in a 40-yr-old man with hepatitis C successfully treated with the antidepressant fluoxetine, which allowed completion of interferon treatment." | 3.68 | Fluoxetine treatment of depression caused by interferon-alpha. ( Fallon, HJ; Levenson, JL, 1993) |
| "Two women being treated for depression with fluoxetine developed psoriasis after 6 and 12 months' exposure." | 3.68 | Fluoxetine-induced psoriasis. ( Hemlock, C; Rosenthal, JS; Winston, A, 1992) |
| "Fluoxetine (Prozac) is a nontricyclic serotonin (5-hydroxytryptamine) reuptake inhibitor commonly prescribed for the treatment of depression." | 3.68 | Fluoxetine and the bleeding time. ( Humphries, JE; VandenBerg, SR; Wheby, MS, 1990) |
| "A 12-week open trial of fluoxetine in 61 obsessive-compulsive disorder patients significantly improved depressive and obsessive-compulsive symptoms." | 3.67 | Open trial of fluoxetine in obsessive-compulsive disorder. ( Baer, L; Buttolph, L; Holland, A; Jenike, MA; Ricciardi, J, 1989) |
| "Rats working on a food-reinforced operant schedule and exhibiting behavioral depression following administration of D,L-5-hydroxytryptophan (5-HTP) were pretreated with one of three drugs: methysergide, fluoxetine, or amitriptyline." | 3.66 | Pre- and postsynaptic serotonergic manipulations in an animal model of depression. ( Aprison, MH; Hingtgen, JN; Nagayama, H, 1980) |
| "Adolescent major depressive disorder (MDD) is a prevalent mental health problem with low treatment success rates." | 3.30 | Sequenced treatment alternatives to relieve adolescent depression (STAR-AD): a multicentre open-label randomized controlled trial protocol. ( Chen, F; Gan, X; He, Y; Huang, Y; Lei, T; Li, J; Li, X; Liu, R; Ouyang, X; Teng, T; Wang, T; Xie, Y; Zhou, X, 2023) |
| "Adults with major depressive disorder (MDD) often experience reduced quality of life (QOL)." | 3.01 | Quality of life after response to acute-phase cognitive therapy for recurrent depression. ( Jarrett, RB; Jha, MK; Minhajuddin, A; Thase, ME; Vittengl, JR, 2021) |
| "Effective treatment of depression is a key target for suicide prevention strategies." | 3.01 | Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people. ( Berk, M; Chanen, A; Cotton, S; Davey, CG; Dean, O; Hetrick, S; Madsen, T; McGorry, PD; Witt, K, 2021) |
| "Poststroke depression is a serious and common complication of stroke, especially the ischemic poststroke depression." | 2.90 | Efficacy and mechanism of acupuncture for ischemic poststroke depression: Study protocol for a multicenter single-blinded randomized sham-controlled trial. ( Bai, W; Ding, S; Gan, Y; Li, M; Li, P; Lu, H; Meng, L; Meng, Z; Ren, X; Wang, F; Wang, L; Wang, Z; Zhang, B; Zhang, C; Zhang, Z; Zhao, H, 2019) |
| "Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear." | 2.90 | The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. ( Amminger, GP; Berk, M; Catania, L; Chanen, AM; Cotton, SM; Davey, CG; Dean, OM; Harrison, BJ; Hetrick, SE; Kazantzis, N; Kerr, M; Koutsogiannis, J; McGorry, PD; Mullen, E; Parker, AG; Phelan, M; Quinn, AL; Ratheesh, A; Rice, S; Weller, A, 2019) |
| "Depression is a common affective disorder or mood disorder, which seriously affects people's physical and mental health and the quality of life." | 2.87 | Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation. ( Xiaoling, Z; Yingdong, L; Yunping, H, 2018) |
| "Fluoxetine was not different from placebo in Greene Climacteric Scale." | 2.80 | Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial. ( Aguilar-Faisal, L; Asbun-Bojalil, J; Llanes-González, L; Macías-Cortés, Edel C, 2015) |
| "Twenty-one patients with major depressive disorder and without other Axis I or Axis II diagnoses were scanned before treatment and 2 and 6 months into treatment at the university's functional magnetic resonance imaging facility." | 2.78 | Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months. ( Davidson, RJ; Heller, AS; Johnstone, T; Kalin, NH; Kolden, GG; Peterson, MJ, 2013) |
| "Fluoxetine has a better analgesic effect than a placebo in treating persistent somatoform pain disorder, and is considered a safe treatment; its analgesic effect may be related to an antidepressant effect." | 2.74 | A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder. ( Li, CB; Li, QW; Lu, Z; Luo, YL; Wu, WY; Zhang, MY, 2009) |
| "Successful treatment of depression in three groups was fluoxetine group 50%, CBT 79." | 2.73 | Is psychotherapy a reliable alternative to pharmacotherapy to promote the mental health of infertile women? A randomized clinical trial. ( Alipour, A; Esmaelzadeh, S; Faramarzi, M; Hjiahmadi, M; Kheirkhah, F; Rahnama, J, 2008) |
| "Depression is one of the most common neuropsychiatric conditions, with a lifetime prevalence approaching 17%." | 2.73 | Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. ( Abbasi, SH; Akhondzadeh Basti, A; Akhondzadeh, S; Jamshidi, AH; Moshiri, E; Noorbala, AA, 2007) |
| "Eighty-eight PTSD subjects diagnosed according to DSM-IV criteria were randomly assigned to EMDR, fluoxetine, or pill placebo." | 2.73 | A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. ( Blaustein, ME; Hopper, EK; Hopper, JW; Korn, DL; Simpson, WB; Spinazzola, J; van der Kolk, BA, 2007) |
| "Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state." | 2.73 | Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. ( Brenner, MC; Navari, RM; Wilson, MN, 2008) |
| "Machado-Joseph Disease (MJD/SCA3) is an autosomal dominant spinocerebellar degeneration that evolves to disability and death." | 2.71 | Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. ( Ferro, A; Jardim, LB; Monte, TL; Pereira, ML; Rieder, CR; Rockenback, I; Sequeiros, J; Silveira, I; Tort, AB, 2003) |
| "Treatment with fluoxetine and citalopram reversed these biochemical parameters." | 2.71 | Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. ( Dakhale, GN; Khanzode, SD; Khanzode, SS; Palasodkar, R; Saoji, A, 2003) |
| "At the end of the treatment, EDSS, fatigue and depression scores were further evaluated." | 2.71 | Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. ( Alfonsi, E; Bergamaschi, R; Callieco, R; Candeloro, E; Cosi, V; Romani, A, 2004) |
| "Patients with depression are often excluded from studies on the treatment of social anxiety disorder (SAD), leaving gaps in our knowledge about the impact of depressive affect on treatment for SAD." | 2.71 | Impact of depressive symptoms on the treatment of generalized social anxiety disorder. ( Davidson, JR; Foa, EB; Huppert, JD; Keefe, FJ; Ledley, DR; Potts, NL, 2005) |
| "Patients with major depressive disorder remain at risk for relapse following remission and often continue to experience subthreshold symptoms." | 2.70 | Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. ( Alpert, JE; Buchin, J; Fava, M; Matthews, JD; Nierenberg, AA; Pava, J; Perlis, RH; Sickinger, AH, 2002) |
| "The Clinician-Administered PTSD Scale, the 21-item Hamilton Rating Scale for Depression, and the Clinical Global Impressions-Severity of Illness scale were administered every 2 weeks, and self-assessments were performed with a 100 mm visual analog mood scale." | 2.70 | Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. ( Agid, O; Lerer, B; Shalev, AY, 2001) |
| "Fluoxetine treatment resulted in decreased symptoms of depression and increased serum concentrations of fluoxetine and norfluoxetine." | 2.69 | Antidepressants augment natural killer cell activity: in vivo and in vitro. ( Burke, WJ; Frank, MG; Hendricks, SE; Johnson, DR; Wieseler, JL, 1999) |
| "Fluoxetine is an efficacious, nonsedative antidepressant, but its selective efficacy on symptoms of insomnia has not been thoroughly explored." | 2.68 | The effects of fluoxetine on symptoms of insomnia in depressed patients. ( Faries, D; Satterlee, WG, 1995) |
| " Outpatients at a Veterans Affairs mental health clinic who were being treated with fluoxetine were randomly assigned to receive either 50 or 75 mg of sertraline hydrochloride for every 20 mg of fluoxetine (as the hydrochloride salt) or to continue to receive their current dosage of fluoxetine." | 2.68 | Clinical effect of converting antidepressant therapy from fluoxetine to sertraline. ( Christenson, JL; Cushing, AG; Haider, A; Miller, DR; Station, RD, 1995) |
| "Treatment with fluoxetine at a dose of 20 mg per day reduces the potential for side effects while maximizing therapeutic efficacy." | 2.68 | Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. ( Berger, C; Carter, D; Grover, D; Reid, R; Steinberg, S; Steiner, M; Stewart, D; Streiner, D, 1995) |
| " As indicated by the significant decrease in the Hamilton Depression scale and the Montgomery Asberg Depression scale, fluoxetine showed similar antidepressant effects to amitriptyline with significantly fewer adverse effects." | 2.67 | Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables. ( Czarka, M; de Maertelaer, V; Kerkhofs, M; Linkowski, P; Mendlewicz, J; Rielaert, C, 1990) |
| "Recent meta-analyses on dose-response relationships of SSRIs are largely based on indirect evidence." | 2.66 | In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis. ( Adams, A; Baethge, C; Braun, C; Bschor, T; Kuhr, K; Rink, L, 2020) |
| "Stroke is a major cause of adult disability." | 2.61 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. ( Barugh, A; Dennis, M; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Legg, LA; Lundström, E; Mead, GE; Rudberg, AS; Soleimani, B; Tilney, R; Wu, S, 2019) |
| "Guidelines suggest treatment of depression in dialysis patients with pharmacological therapy, preferably a selective serotonin reuptake inhibitor." | 2.53 | Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis. ( Craig, JC; Natale, P; Palmer, SC; Rabindranath, KS; Ruospo, M; Saglimbene, VM; Strippoli, GF, 2016) |
| "The efficiency of EA treatment for depression and the mechanism of it were discussed, to shed light on new ideas and new fronts for the further research on depression in clinical or pre-clinical fields." | 2.50 | Progress of animal research on electro-acupuncture treatment for depression(△). ( Li, ZG; Mo, YP; Song, HT; Tang, YS; Xu, AP; Yao, HJ, 2014) |
| "Providing an accurate and timely bipolar depression diagnosis is critical for the proper treatment of the patient." | 2.50 | Acute and maintenance treatments for bipolar depression. ( Ketter, TA, 2014) |
| "Duloxetine hydrochloride is a dual reuptake inhibitor of serotonin and norepinephrine and has been licensed by the Food and Drug Administration in the US for major depressive disorder (MDD), generalised anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain." | 2.48 | Duloxetine versus other anti-depressive agents for depression. ( Barbui, C; Cipriani, A; Furukawa, TA; Koesters, M; Nosè, M; Omori, IM; Purgato, M; Trespidi, C, 2012) |
| "Stroke is the major cause of adult disability." | 2.48 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. ( Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE, 2012) |
| "Depression may affect 2-8% of children and adolescents, with a peak incidence around puberty." | 2.45 | Depression in children and adolescents. ( Hazell, P, 2009) |
| "Depression has a female sex predilection with 2 to 3% of the pregnant women population presently requiring treatment with selective serotonin reuptake inhibitors (SSRI)." | 2.44 | Fetal and neonatal effects of maternal drug treatment for depression. ( Belik, J, 2008) |
| "The association of migraine and depression has been confirmed in numerous studies and it has been suggested that both diseases influence each other in a bidirectional way." | 2.44 | [A clinical challenge. Pragmatic treatment of migraine and concomitant depression]. ( Jürgens, TP; Koch, HJ; Leinisch, E, 2008) |
| "Emphasis is given to the treatment of depression and how the potential of one pure enantiomer-escitalopram, the S-enantiomer of the selective serotonin reuptake inhibitor citalopram-appears to be fulfilling its preclinical promise in the clinic." | 2.41 | Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. ( Baumann, P; Eap, CB; Zullino, DF, 2002) |
| "Direct costs for treating depression, i." | 2.41 | [Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective]. ( Häggström, L; Nordling, S; Norinder, A, 2000) |
| " In particular, patients beginning therapy with fluoxetine are more likely to receive treatment regimens that meet minimum recommended guidelines for dosage and duration and are less likely to require treatment switching/augmentation than those receiving tricyclic antidepressants or other SSRIs as initial therapy." | 2.40 | Fluoxetine. A pharmacoeconomic review of its use in depression. ( Benfield, P; Wilde, MI, 1998) |
| "Depression is a highly prevalent concomitant of dementia." | 2.40 | Depression and dementia: comorbidities, identification, and treatment. ( Meyers, BS, 1998) |
| "Fluoxetine was developed as an antidepressant drug." | 2.39 | Fluoxetine. ( Gram, L, 1994) |
| " Although fluoxetine has been promoted as a safe antidepressant, a recent literature search revealed a number of case reports of adverse effects and drug interactions attributed to its use." | 2.38 | Adverse effects and drug interactions associated with fluoxetine therapy. ( Fuller, DK; Levinson, ML; Lipsy, RJ, 1991) |
| "Fluoxetine is a new, chemically unique antidepressant." | 2.38 | An overview of fluoxetine, a new serotonin-specific antidepressant. ( Boyer, WF; Feighner, JP, 1989) |
| "The concomitant use of MPHs and SSRIs showed generally safe profiles in adolescent ADHD patients with depression." | 1.91 | Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression: ( Alhambra, DP; Kim, C; Kim, SJ; Lee, DY; Lee, J; Lee, S; Lee, YH; Park, J; Park, RW; Shin, Y; Tan, EH; Yang, SJ, 2023) |
| " Health workers should be mindful of dosing to minimise side effects and considerate of the additional pill burden." | 1.91 | The acceptability of antidepressant treatment in people living with HIV in Malawi: A patient perspective. ( Gaynes, BN; Hosseinipour, MC; Kulisewa, K; Minnick, CE; Mphonda, S; Pence, BW; Sansbury, G; Stockton, MA; Udedi, MM, 2023) |
| "Depression is a major mental disease worldwide, causing dysfunction of Lateral Habenular (LHb)." | 1.91 | The effects of acupuncture on depression by regulating BDNF-related balance via lateral habenular nucleus BDNF/TrkB/CREB signaling pathway in rats. ( Chen, W; Chen, Y; Cheng, W; Gulizhaerkezi, T; Hao, C; Li, J; Li, Y; Meng, X; Shen, J; Tong, T; Yan, S; Zeng, J, 2023) |
| "ZZCT has been used for the treatment of depression for centuries." | 1.91 | 14-3-3ζ Plays a key role in the modulation of neuroplasticity underlying the antidepressant-like effects of Zhi-Zi-Chi-Tang. ( Chen, G; Cheng, X; Hu, Y; Qi, M; Tao, W; Xu, C; Yao, G; Yu, Y; Yue, Q; Zhao, M; Zhao, T, 2023) |
| "Gabapentin is a commonly prescribed antiepileptic agent for seizures, which is also used for pain and addiction management." | 1.91 | Effect of Gabapentin-Fluoxetine Derivative GBP1F in a Murine Model of Depression, Anxiety and Cognition. ( Ali, G; Alkahramaan, YMSA; Arif, M; Gohar, A; Khan, MS; Rashid, U; Rauf, K; Sewell, RDE, 2023) |
| "Pretreatment with guanosine was able to prevent LPS- induced depressive-like behaviors in the TST and FST." | 1.91 | Guanosine treatment prevents lipopolysaccharide-induced depressive-like behavior in mice. ( da Silva Buss, Z; de Arruda, CM; de Lima Reis, SR; de Lima, E; de Matos, YAV; Doneda, DL; Dos Santos, RAL; Gibbert, PC; Rios Santos, F; Vandresen-Filho, S; Viola, GG, 2023) |
| " Mianserin and mirtazapine (separately) induced dose-dependent antinociception, each one yielding a biphasic dose-response curve, and they were antagonized by naloxone." | 1.91 | Treatment-Resistant Depression (TRD): Is the Opioid System Involved? ( Keidan, L; Pick, CG; Schreiber, S, 2023) |
| "Metformin has antidepressant and antiparkinsonian potential due to anti-inflammatory neurogenic, and neuroplasticity-inducing effects when combined with fluoxetine." | 1.72 | Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity. ( Costa, BLDSAD; Duarte-Silva, EP; Melo, MG; Mendonça, IP; Oliveira, WH; Paiva, IHR; Peixoto, CA; Silva, RSD, 2022) |
| "Depression is a psychiatric disorder that affects about 10% of the world's population and is accompanied by anxiety." | 1.72 | Alpha2-antiplasmin deficiency affects depression and anxiety-like behavior and apoptosis induced by stress in mice. ( Asahi, S; Hori, K; Kanno, Y; Maruyama, C; Matsuo, O; Ozaki, KI; Teramura, H; Tsuchida, K, 2022) |
| "Depression is a mood disorder with a high prevalence rate globally, which is associated with abnormalities in 5-hydroxytryptamine (5-HT) metabolism." | 1.72 | Oral administration of ( Chen, C; Chen, S; Farzi, A; Gao, K; Ke, X; Li, Y; Wang, H; Yu, T; Yu, Y, 2022) |
| "Fluoxetine treatment showed protective effect against SI, AD and prevents exacerbation of CVD." | 1.72 | Fluoxetine ameliorates Alzheimer's disease progression and prevents the exacerbation of cardiovascular dysfunction of socially isolated depressed rats through activation of Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome signaling pathway. ( Aboutaleb, AS; Abu-Elfotuh, K; Al-Najjar, AH; Badawi, GA; Mohammed, AA, 2022) |
| "To compare opioid overdose rates in patients initiating oxycodone while taking SSRIs that are potent inhibitors of the cytochrome-P450 2D6 enzyme (CYP2D6) vs SSRIs that are not." | 1.72 | Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. ( Bykov, K; Gagne, JJ; Yoshida, K; Yunusa, I, 2022) |
| "Major depression is a leading contributor to the global burden of disease." | 1.72 | Lower antidepressant response to fluoxetine is associated with anxiety-like behavior, hippocampal oxidative imbalance, and increase on peripheral IL-17 and IFN-γ levels. ( Becker, G; Bochi, GV; Camargo, LFM; da Silva Carlotto, M; Dos Santos, BM; Fialho, MFP; Oliveira, SM; Pereira, GC; Pillat, MM; Piton, E; Ramanzini, LG; Trevisan, G; Zanchet, EM, 2022) |
| "Fluoxetine group was administered with fluoxetine (2." | 1.72 | Anti-depressant effects of acupuncture: The insights from NLRP3 mediated pyroptosis and inflammation. ( Chen, W; Chen, Y; Cheng, W; Hao, C; He, T; Huang, S; Huang, Z; Li, P; Meng, X; Shen, J; Tong, T; Yan, S, 2022) |
| "Fluoxetine is a highly prescribed selective serotonin reuptake inhibitor (SSRI) in the treatment of depression and is reported to be a risk factor for fractures." | 1.72 | Fluoxetine improves bone microarchitecture and mechanical properties in rodents undergoing chronic mild stress - an animal model of depression. ( Chua, AN; Ho, CS; Ho, RC; Kumarsing, RA; Lam, RW; McIntyre, RS; Wong, HK, 2022) |
| "Depression is a mental disease involving complex pathophysiological mechanisms, and there are many ways to establish depressive mouse models." | 1.72 | Comparison of LPS and MS-induced depressive mouse model: behavior, inflammation and biochemical changes. ( Dong, Y; Liu, L; Liu, S; Yao, H; Yu, X; Zhang, X, 2022) |
| "Fluoxetine treatment was applied in chronic variable mild stress (CVMS)-exposed (environmental hit) CD1 mice carrying one mutated allele of pituitary adenylate cyclase-activating polypeptide gene (genetic hit) that were previously exposed to maternal deprivation (epigenetic hit) vs." | 1.72 | Fluoxetine treatment supports predictive validity of the three hit model of depression in male PACAP heterozygous mice and underpins the impact of early life adversity on therapeutic efficacy. ( Berta, G; Csernus, V; Farkas, J; Füredi, N; Gaszner, B; Gaszner, T; Hashimoto, H; Kormos, V; Kovács, LÁ; Kun, D; Reglődi, D; Ujvári, B, 2022) |
| "Fluoxetine treatment was applied to test the predictive validity of our model." | 1.72 | Epigenetic and Neuronal Activity Markers Suggest the Recruitment of the Prefrontal Cortex and Hippocampus in the Three-Hit Model of Depression in Male PACAP Heterozygous Mice. ( Farkas, J; Füredi, N; Gaszner, B; Gaszner, T; Hashimoto, H; Kormos, V; Kovács, LÁ; Kun, D; Reglődi, D; Ujvári, B, 2022) |
| "We conclude that screening for and treating depression among PLHIV in SSA with fluoxetine would be effective in improving HIV treatment outcomes and would be highly cost-effective." | 1.62 | Health outcomes and cost-effectiveness of treating depression in people with HIV in Sub-Saharan Africa: a model-based analysis. ( Arjmand, IK; Bendavid, E; Brandeau, ML; Zhong, H, 2021) |
| "Fluoxetine treatment exhibited antidepressant effects and ameliorated the molecular changes induced by LPS." | 1.62 | Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression. ( Ali, T; He, K; Li, N; Li, S; Li, W; Liu, Z; Rahman, SU; Ren, Q; Shah, FA; Yu, ZJ; Zheng, C, 2021) |
| "Depression is a disabling psychiatric disorder affecting millions of people all around the world." | 1.62 | SAHA Improves Depressive Symptoms, Cognitive Impairment and Oxidative Stress: Rise of a New Antidepressant Class. ( Amini-Khoei, H; Dehpour, AR; Ershadi, ASB; Hosseini, MJ, 2021) |
| "Fluoxetine (Fx) is an FDA-approved anti-depressant agent and one of the selective serotonin reuptake inhibitor drugs (SSRI), used in neurological disorder treatment." | 1.62 | Modulation of the Nitric Oxide/BH4 Pathway Protects Against Irradiation-Induced Neuronal Damage. ( Abdel-Rafei, MK; Moustafa, EM; Rashed, ER; Thabet, NM, 2021) |
| "Depression is the most common psychiatric comorbidity of epilepsy." | 1.62 | Chronically altered NMDAR signaling in epilepsy mediates comorbid depression. ( Dehpour, AR; Hemmati, S; Mohammadi, S; Sadeghi, MA; Vafaei, A; Yousefi-Manesh, H; Zare, M, 2021) |
| "Depression is a psychiatric disorder with several comorbidities that has a complicated pathophysiology." | 1.62 | Exercise and fluoxetine treatment during adolescence protect against early life stress-induced behavioral abnormalities in adult rats. ( Amiri, S; Gauvin, E; Peeri, M; Pirri, F; Zolfaghari, FS, 2021) |
| "Depression is responsible for 800 000 deaths worldwide, a number that will rise significantly due to the COVID-19 pandemic." | 1.62 | Withanone Ameliorates Stress Symptoms in Caenorhabditis Elegans by Acting through Serotonin Receptors. ( Efferth, T; Naß, J, 2021) |
| "Stroke is the leading neurologic cause of burden operationalized in terms of disability-adjusted life-years." | 1.62 | Fluoxetine for Stroke: A Mixed Bag of Outcomes. ( Andrade, C, 2021) |
| "Depression was induced via six weeks of CUMS in male ICR mice, and drug therapy was given simultaneously for the last three weeks." | 1.62 | Baicalin ameliorates chronic unpredictable mild stress-induced depression through the BDNF/ERK/CREB signaling pathway. ( Cao, Z; Chen, Y; Chu, L; Jia, Z; Lu, Y; Pei, L; Yang, J; Zhang, J; Zhang, S; Zhao, J, 2021) |
| "The body weight was determined, and behavior tests, including sucrose preference test, forced swimming test and open field test were performed." | 1.56 | Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive-like behavior in a depressive-like adult male rat model. ( Wang, G; Wang, H; Xiao, L, 2020) |
| "Inflammation has been associated with the progression of many neurological diseases." | 1.56 | Inflammation-induced behavioral changes is driven by alterations in Nrf2-dependent apoptosis and autophagy in mouse hippocampus: Role of fluoxetine. ( Adhikary, A; Chattopadhyay, S; Choudhury, S; Chowdhury, O; Das, A; Ghosh, S; Gupta, P; Mukherjee, S; Sain, A, 2020) |
| "Treatment with 5-hydroxytryptophan restores the levels of 5-HT and its precursors in the HpC, improves HpC neurogenesis, and alleviates despair-like symptoms." | 1.56 | Changes in Gut Microbiota by Chronic Stress Impair the Efficacy of Fluoxetine. ( Bigot, M; Chevalier, G; Eberl, G; Katsimpardi, L; Lledo, PM; Moigneu, C; Saha, S; Siopi, E, 2020) |
| "Fluoxetine (FLX) has been considered as an effective anti-depressant drug." | 1.56 | Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period. ( Amin, N; Botchway, BOA; Chen, Y; Fang, M; Hu, S; Hu, Z; Ma, Y; Ren, Q; Tan, X; Xie, S, 2020) |
| "Depression is one of the most common forms of mental illness and also a leading cause of disability worldwide." | 1.56 | LIMK1/2 in the mPFC Plays a Role in Chronic Stress-Induced Depressive-Like Effects in Mice. ( Chen, TT; Gao, TT; Guan, W; Jiang, B; Liu, L; Wang, JL; Wang, Y; Wang, YJ; Zhao, J, 2020) |
| " Serotonin dosage shows that fluoxetine at 10 nM blocks serotonin reuptake in 1C11ND but slows down its release when cells are differentiated through a decrease of 5HT1b receptors density." | 1.56 | First Evidence of Kv3.1b Potassium Channel Subtype Expression during Neuronal Serotonergic 1C11 Cell Line Development. ( Ayeb, ME; Bendahhou, S; Benkhalifa, R; Cheikh, A; Maatoug, S; Tabka, H, 2020) |
| "Depression is one of the most common associated diseases, which aggravates psoriatic skin lesions and affects the life quality of patients." | 1.56 | Depressive-like behaviors in mice with Imiquimod-induced psoriasis. ( Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J, 2020) |
| " Conversely, acute chemogenetic inhibition of mossy cells using Gi-DREADD impairs behavioral and neurogenic responses to chronic administration of SSRI." | 1.56 | Hippocampal mossy cell involvement in behavioral and neurogenic responses to chronic antidepressant treatment. ( Arace, J; Cheng, J; Greengard, P; Jang, JH; Jeong, M; Jin, J; Oh, SJ; Oh, YS; Park, J; Shin, CH, 2020) |
| "The etiology of major depressive disorder (MDD), the leading cause of worldwide disability, is unknown." | 1.51 | Activating newborn neurons suppresses depression and anxiety-like behaviors. ( Contractor, A; Dunlop, SR; Kessler, JA; Peng, CY; Tunc-Ozcan, E; Zhu, Y, 2019) |
| " Results showed that TUDCA pretreatment (once daily for 7 consecutive days) at the dosage of 200 and 400 mg/kg, but not 100 mg/kg, markedly attenuated LPS (0." | 1.51 | Tauroursodeoxycholic Acid Ameliorates Lipopolysaccharide-Induced Depression Like Behavior in Mice via the Inhibition of Neuroinflammation and Oxido-Nitrosative Stress. ( Chen, Z; Cheng, L; Huang, C, 2019) |
| "Treatment with atorvastatin (1 or 10 mg/kg/day) or fluoxetine prevented LPS-induced increase in lipid peroxidation and the reduction of glutathione levels in the hippocampus and prefrontal cortex." | 1.51 | Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice. ( Buss, ZS; Doneda, DL; Ferreira, YS; Fraga-Junior, EB; Lima, E; Lopes, L; Rios-Santos, F; Stupp, IJV; Taniguti, EH; Vandresen-Filho, S; Viola, GG, 2019) |
| "Depression is highly prevalent among patients with chronic obstructive pulmonary disease (COPD)." | 1.51 | Glucocorticoid receptor dysfunction orchestrates inflammasome effects on chronic obstructive pulmonary disease-induced depression: A potential mechanism underlying the cross talk between lung and brain. ( Deng, X; Fu, J; Guo, Q; Ji, Z; Ma, S; Song, Y; Xu, B, 2019) |
| "Depression is a neuropsychiatry medical condition with high prevalence, in which the hypothalamic-pituitary-adrenal axis dysfunction has been postulated as the main cause." | 1.51 | Lutein prevents corticosterone-induced depressive-like behavior in mice with the involvement of antioxidant and neuroprotective activities. ( Camargo, A; Dalmagro, AP; Zeni, ALB, 2019) |
| "Nonsudden cardiac death was treated as a competing event." | 1.51 | Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis. ( Assimon, MM; Brookhart, MA; Flythe, JE, 2019) |
| " We also investigated the effects of dosing time on the pharmacological activity of several antidepressants acting on serotonergic, noradrenergic, and/or dopaminergic neurons." | 1.51 | Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice. ( Ishibashi, T; Iwadate, R; Kawai, H; Kawashima, Y; Kudo, N; Mitsumoto, A, 2019) |
| "Depression is a serious medical condition, typically treated by antidepressants." | 1.51 | Neuronal life or death linked to depression treatment: the interplay between drugs and their stress-related outcomes relate to single or combined drug therapies. ( Badura, J; Chelminiak, Z; Cuprys, M; Fraczek, J; Koszla, O; Koziorowski, M; Mytych, J; Solek, P; Tabecka-Lonczynska, A, 2019) |
| "Depression is a common mental disorder affecting around 350 million people worldwide." | 1.48 | A novel 5HT3 receptor-IGF1 mechanism distinct from SSRI-induced antidepressant effects. ( Kondo, M; Koyama, Y; Nakamura, Y; Shimada, S, 2018) |
| "Fluoxetine treatment reversed learned helplessness-induced changes in many long noncoding RNAs and target genes." | 1.48 | Long Noncoding RNA-Associated Transcriptomic Changes in Resiliency or Susceptibility to Depression and Response to Antidepressant Treatment. ( Dwivedi, Y; Roy, B; Wang, Q, 2018) |
| "Fluoxetine is a clinically successful antidepressant." | 1.48 | (R)-fluoxetine enhances cognitive flexibility and hippocampal cell proliferation in mice. ( Dawe, GS; Marwari, S, 2018) |
| "Depression is a common psychiatric disorder with heavy economic and social burdens." | 1.48 | Tauroursodeoxycholic acid produces antidepressant-like effects in a chronic unpredictable stress model of depression via attenuation of neuroinflammation, oxido-nitrosative stress, and endoplasmic reticulum stress. ( Gao, MH; Gong, Y; Hu, WF; Huang, C; Lu, X; Wang, P; Wu, Y; Yang, RR; Zhang, JL, 2018) |
| " We hypothesize that early intervention with TREK1 blockers can fully reverse depressive-like behaviors, that the chronic administration of TREK1 blockers has a more pronounced effect than the SSRI fluoxetine, and that its long-term therapeutic effects may be mediated by improvement of impaired neurogenesis." | 1.48 | Comparison of Therapeutic Effects of TREK1 Blockers and Fluoxetine on Chronic Unpredicted Mild Stress Sensitive Rats. ( Qi, X; Wang, L; Xu, H; Zhang, Z, 2018) |
| "Depression is one of the most frequent neuropsychiatric diseases in the western world and its physiological causes are not yet fully understood." | 1.48 | Cholecalciferol counteracts depressive-like behavior and oxidative stress induced by repeated corticosterone treatment in mice. ( Camargo, A; da Silva, EB; Dalmagro, AP; Rikel, L; Simão da Silva, KAB; Zeni, ALB, 2018) |
| "Agmatine is a neuromodulator that has been proposed as a therapeutic strategy for the treatment of major depressive disorder (MDD)." | 1.48 | Single administration of agmatine reverses the depressive-like behavior induced by corticosterone in mice: Comparison with ketamine and fluoxetine. ( Bettio, LB; Fraga, DB; Freitas, AE; Gonçalves, FM; Heinrich, IA; Leal, RB; Lopes, MW; Moretti, M; Neis, VB; Olescowicz, G; Rodrigues, ALS; Rosa, PB, 2018) |
| "Depression is very common in asthmatic patients and may increases risk for morbidity and mortality." | 1.48 | Fluoxetine protects against OVA induced bronchial asthma and depression in rats. ( Abo-Youssef, AM; Ismaiel, IE; Salama, AAA; Sherkawy, MM, 2018) |
| "Depression is associated with uncontrolled diabetes, which indicates a lack of insulin effect, yet the role of the insulin receptor in mediating depression is not clearly established because insulin receptors are not required for glucose entry into the brain." | 1.48 | Antidepressant-like effects of insulin and IGF-1 are mediated by IGF-1 receptors in the brain. ( Hajnal, A; Mueller, PL; Pritchett, CE; Wiechman, TN; Zharikov, A, 2018) |
| "Chronic stress and depression are challenging conditions to treat, owing to their complexity and lack of clinically available and effective therapeutic agents." | 1.46 | Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. ( Liu, H; Sun, Y; Zhang, C; Zhu, X, 2017) |
| "Fluoxetine (Flx) is a first-line treatment for depression; however, its downstream mechanisms of action beyond serotonergic signaling remain ill-defined." | 1.46 | Fluoxetine reverses behavior changes in socially isolated rats: role of the hippocampal GSH-dependent defense system and proinflammatory cytokines. ( Filipović, D; Gass, P; Perić, I; Stanisavljević, A, 2017) |
| " On the other hand, little is known about the impact of chronic administration of various antidepressant drugs on the brain mitochondria, as a target for the pharmacotherapy of depression." | 1.46 | Evaluation of the effectiveness of chronic antidepressant drug treatments in the hippocampal mitochondria - A proteomic study in an animal model of depression. ( Basta-Kaim, A; Budziszewska, B; Chamera, K; Głombik, K; Lasoń, W; Olszanecki, R; Ślusarczyk, J; Stachowicz, A; Suski, M; Trojan, E, 2017) |
| "Fluoxetine and melatonin treatments decreased TBARS in both cortices." | 1.46 | The antidepressant effect of melatonin and fluoxetine in diabetic rats is associated with a reduction of the oxidative stress in the prefrontal and hippocampal cortices. ( Boudah, A; Jasmin, L; Rebai, R, 2017) |
| "Recently, depression has been envisioned as more than an alteration in neurotransmitters centered around receptor signaling pathways." | 1.46 | Fluoxetine coupled with zinc in a chronic mild stress model of depression: Providing a reservoir for optimum zinc signaling and neuronal remodeling. ( Omar, NN; Tash, RF, 2017) |
| "Effects of enriched environment (EE) combined with fluoxetine in a chronic unpredictable stress (CUS) rat model were examined in our study." | 1.46 | Enriched environment combined with fluoxetine ameliorates depression-like behaviors and hippocampal SYP expression in a rat CUS model. ( Feng, YY; Gu, JY; Han, JH; Li, Y; Liu, C; Lv, TT; Shao, QJ; Wang, CH; Yan, FL; Zhang, XY; Zhao, LQ, 2017) |
| "Depression is one of the leading causes of disability in developing countries including Pakistan." | 1.46 | Depressive symptoms, monoamines levels, MAO-B activity and effect of treatment in a subset of depressed individuals from government sector hospital at Karachi. ( Farooq, AD; Naqvi, S; Rahman, R; Zeb, F, 2017) |
| " Here we investigated the effects of chronic administration of caffeine (5mg/kg, twice daily for 14days) and its withdrawal on day 15th on the activity of per se ineffective doses of fluoxetine (5mg/kg) and escitalopram (2mg/kg) given on day 15th." | 1.46 | Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression. ( Doboszewska, U; Dudka, J; Herbet, M; Kanadys, A; Korga, A; Ostrowska, M; Poleszak, E; Serefko, A; Świąder, K; Szopa, A; Terlecka, J; Wlaź, A; Wlaź, P; Wośko, S; Wróbel, A; Wyska, E, 2017) |
| "Objectives Depression is tightly associated with cardiovascular comorbidity and accounts for high financial and social burden worldwide." | 1.46 | Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine. ( Amiri, S; Anoush, M; Bergen, H; Haj-Mirzaian, A; Hosseini, MJ; Jafarian, I; Rahimi-Balaei, M; Sonei, N, 2017) |
| "Depression has become a common public health problem that is showing increasing prevalence." | 1.46 | Evaluation of the antidepressant-like effect of musk in an animal model of depression: how it works. ( Ayuob, NN, 2017) |
| "To develop drug therapies for the treatment of depression, it is necessary to use animal models of depression to screen drug candidates that exhibit anti-depressive effects." | 1.46 | The acute social defeat stress and nest-building test paradigm: A potential new method to screen drugs for depressive-like symptoms. ( Goto, T; Kohari, D; Okayama, T; Otabi, H; Toyoda, A, 2017) |
| "Ferulic acid is a hydroxycinnamic acid that widely presents in plant cell wall components." | 1.46 | Elevation of synaptic protein is associated with the antidepressant-like effects of ferulic acid in a chronic model of depression. ( Hu, CY; Li, YC; Liu, YM; Shen, JD; Wu, SH; Yi, LT, 2017) |
| "Juvenile depression is of great concern with only limited treatment currently approved." | 1.46 | Long-lasting effects of fluoxetine and/or exercise augmentation on bio-behavioural markers of depression in pre-pubertal stress sensitive rats. ( Brink, CB; Harvey, BH; Schoeman, JC; Steyn, SF, 2017) |
| "Ferulic acid is a hydroxycinnamic acid that widely presents in plant cell wall components." | 1.46 | Ferulic acid inhibits neuro-inflammation in mice exposed to chronic unpredictable mild stress. ( Li, HB; Li, YC; Liu, YM; Shen, JD; Xu, LP; Yi, LT, 2017) |
| "The pharmacological treatment of major depression is mainly based on drugs elevating serotonergic (5-HT) activity." | 1.46 | Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression. ( Borroto-Escuela, DO; Díaz-Cabiale, Z; Flores-Burgess, A; Fuxe, K; Gago, B; Mengod, G; Millón, C; Narváez, JA; Narváez, M; Santín, L, 2017) |
| "Using a depression comorbidity of chronic pain rat model induced by spinal nerve ligation (SNL), we investigated the potency of T10 for the treatment of comorbid depression in comparison with a widely used antidepressant, fluoxetine (FLX)." | 1.46 | The novel and potent anti-depressive action of triptolide and its influences on hippocampal neuroinflammation in a rat model of depression comorbidity of chronic pain. ( Dong, Y; Hu, X; Jin, X; Li, J; Shi, J; Zhang, C; Zhang, T; Zhao, J, 2017) |
| "Depression is a common mental illness and a leading cause of disability." | 1.43 | Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse. ( Blakely, RD; McMeekin, AM; Moussa-Tooks, AB; Nackenoff, AG; Veenstra-VanderWeele, J, 2016) |
| " Food and Drug Administration (FDA) on the risk of suicidality among children associated with use of antidepressants, but the warning's effect on dosing of antidepressants has not been evaluated." | 1.43 | Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning. ( Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A, 2016) |
| "Fluoxetine treatment blocked stress-induced up-regulation of HMGB1 and subsequent NF-κB activation, whereas TDZD-8 administration attenuated NF-κB activation downstream of HMGB1." | 1.43 | Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. ( Armini, RS; Beurel, E; Cheng, Y; Jope, RS; Martinez, A; Mouhsine, H; Pardo, M; Zagury, JF, 2016) |
| "Treatment with fluoxetine attenuated the expression of Htr2B mRNA, stimulated post-stroke neurogenesis in the subventricular zone and was associated with an improved anhedonic behavior and an increased activity in the forced swim test in aged animals." | 1.43 | Up-regulation of serotonin receptor 2B mRNA and protein in the peri-infarcted area of aged rats and stroke patients. ( Bădescu, GM; Bogdan, C; Buga, AM; Ciobanu, O; Di Napoli, M; Popa-Wagner, A; Slevin, M; Weston, R, 2016) |
| "Takotsubo cardiomyopathy is an acute coronary syndrome that is believed to be brought on by stress." | 1.43 | The Use of Fluoxetine in a Patient With Takotsubo Cardiomyopathy. ( Catalano, G; Catalano, MC; Conrad, SK, 2016) |
| "Fluoxetine treatment exerted antidepressant effect in all rat lines irrespective of its effect on AS." | 1.43 | Effect of chronic fluoxetine treatment on audiogenic epilepsy, symptoms of anxiety and depression in rats of four lines. ( Fedotova, IB; Nikolaev, GM; Perepelkina, OV; Poletaeva, II; Sarkissova, KY; Surina, NM, 2016) |
| "Considering that depression is involved in monoamine reduction, this study evaluated the antidepressant-like effects of gypenosides in mice exposed to chronic unpredictable mild stress (CUMS)." | 1.43 | Antidepressant-like effects of standardized gypenosides: involvement of brain-derived neurotrophic factor signaling in hippocampus. ( Chen, SM; Chen, XM; Fang, XY; Li, CF; Li, YC; Liu, Q; Mu, RH; Wang, SS; Yi, LT, 2016) |
| "Chrysin is a natural flavonoid which is found in bee propolis, honey and various plants, and antidepressant-like effect of chrysin in chronically stressed mice was previously demonstrated by our group." | 1.43 | Chrysin promotes attenuation of depressive-like behavior and hippocampal dysfunction resulting from olfactory bulbectomy in mice. ( Boeira, SP; Del Fabbro, L; Donato, F; Filho, CB; Gomes de Gomes, M; Jesse, CR; Rossito Goes, AT; Souza, LC, 2016) |
| "Laquinimod is a novel oral immunomodulatory drug for the treatment of multiple sclerosis (MS)." | 1.42 | Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models. ( Amit, BH; Gil-Ad, I; Gueta, RU; Hayardeni, L; Taler, M; Tarasenko, I; Weizman, A, 2015) |
| "Treatment with fluoxetine had no effect on tumor growth, muscle wasting, fatigue behavior, or cytokine expression in the brain." | 1.42 | Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue. ( Bicer, S; Devine, R; Godbout, JP; Jing, R; McCarthy, DO; Norden, DM; Reiser, PJ; Wold, LE, 2015) |
| "Depression is a complex psychiatric disorder, and its etiology and pathophysiology are not completely understood." | 1.42 | Differential proteomic analysis of the anti-depressive effects of oleamide in a rat chronic mild stress model of depression. ( Ge, L; Shen, J; Tian, HF; Wang, F; Wu, CF; Yang, JY; Zhang, JH; Zhang, R; Zhu, MM, 2015) |
| "A sample of 236 patients with chronic periodontitis and clinical depression were assessed for clinical parameters of periodontal disease." | 1.42 | Effect of Fluoxetine on Periodontal Status in Patients With Depression: A Cross-Sectional Observational Study. ( Bhatia, A; Khurana, H; Narula, SC; Sharma, RK; Tewari, S, 2015) |
| " Here we examined the effects of chronic administration of a selective serotonin reuptake inhibitor, fluoxetine (FLX), on behavioral and biochemical alterations (within NMDAR signaling pathway) induced by zinc deficiency." | 1.42 | Antidepressant activity of fluoxetine in the zinc deficiency model in rats involves the NMDA receptor complex. ( Doboszewska, U; Lankosz, M; Młyniec, K; Nowak, G; Ostachowicz, B; Rafało, A; Sowa-Kućma, M; Szewczyk, B, 2015) |
| "Ketamine is an anesthetic with antidepressant properties." | 1.42 | The positive effect on ketamine as a priming adjuvant in antidepressant treatment. ( Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP, 2015) |
| "Ketamine (Ketalar®) is a non-competitive glutamatergic antagonist classically used to induce sedation." | 1.42 | Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine. ( Hylton, A; Pittman, J, 2015) |
| "Fluoxetine was the most frequently prescribed anti-depressant and rates increased between 2002 and 2011." | 1.42 | Antidepressant prescribing in Irish children: secular trends and international comparison in the context of a safety warning. ( Bennett, K; Boland, F; Fahey, T; Kelly, D; Motterlini, N; O'Sullivan, K; Reulbach, U, 2015) |
| " The novel 5-HT7R antagonist 1-8 exhibited an antidepressant effect at a dose of 25mg/kg in the forced swimming test in mice and showed a U-shaped dose-response curve which typically appears in 5-HT7R antagonists such as SB-269970 and lurasidone." | 1.40 | Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression. ( Cho, H; Choo, H; Choo, IH; Keum, G; Kim, Y; Lee, K; Park, WK; Rhim, H; Tae, J, 2014) |
| "Major depression is one of the most prevalent mental disorders in the population." | 1.40 | Prenatal lipopolysaccharide exposure increases depression-like behaviors and reduces hippocampal neurogenesis in adult rats. ( Lin, YL; Wang, S, 2014) |
| " On the other hand, chronic administration of ketamine significantly elicited an increase in immobility score as well as reversed the reduction induced by fluoxetine." | 1.40 | Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test. ( Adeyemi, OI; Akanmu, MA; Owolabi, RA, 2014) |
| " The present study indicates that already a moderate lesion of dopaminergic neurons induces "depressive-like" behaviour in animals which is reversed by chronic administration of the antiparkinsonian drug, pramipexole." | 1.40 | Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease. ( Berghauzen-Maciejewska, K; Dziubina, A; Głowacka, U; Kolasiewicz, W; Kuter, K; Ossowska, K; Wardas, J, 2014) |
| "Fluoxetine was the reference treatment option in the medication models." | 1.39 | Influence of body mass index on the choice of therapy for depression and follow-up care. ( Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E, 2013) |
| "CD-1 mice were dosed with Bacille Calmette-Guérin (BCG) and measures of body weight, locomotor activity, and immobility in the tail suspension test (TST) were made." | 1.39 | A depressive phenotype induced by Bacille Calmette Guérin in 'susceptible' animals: sensitivity to antidepressants. ( Clark, JA; Klee, N; Nizami, M; Platt, B; Schulenberg, J, 2013) |
| "Treatment with fluoxetine for 3 weeks abolished the neurobehavioral effects of LPS." | 1.39 | A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months. ( Basta-Kaim, A; Budziszewska, B; Curzytek, K; Duda, W; Holan, V; Kubera, M; Lason, W; Leskiewicz, M; Maes, M; Roman, A; Szczesny, E; Zajicova, A, 2013) |
| "Depression is a major health problem worldwide." | 1.38 | Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. ( Alvarado, G; Artigas, F; Bortolozzi, A; Carmona, MC; Castañé, A; Cortés, R; Fernández, G; Ferrés-Coy, A; Montefeltro, A; Perales, JC; Santana, N; Semakova, J; Toth, M, 2012) |
| "In humans, depression is associated with altered rapid eye movement (REM) sleep." | 1.38 | Acute administration of fluoxetine normalizes rapid eye movement sleep abnormality, but not depressive behaviors in olfactory bulbectomized rats. ( Huang, ZL; Li, R; Qu, WM; Tu, ZC; Urade, Y; Wang, YQ; Xu, XY, 2012) |
| " Furthermore, we show that the serotonin transporter polyadenylation profile associated with the STPP risk allele is altered through the chronic administration of fluoxetine, a treatment that also facilitates retention of extinction learning." | 1.38 | Serotonin transporter polyadenylation polymorphism modulates the retention of fear extinction memory. ( Casey, BJ; Glatt, CE; Hartley, CA; Holmes, A; McKenna, MC; Phelps, EA; Salman, R, 2012) |
| " in acute, subchronic and chronic administration in the FST." | 1.38 | Alterations on the morphology, nitric oxide synthesis and activity of platelets reproduced in rats as possible biomarkers for depression are reversed by fluoxetine. ( Alvarado-Vásquez, N; Estrada-Camarena, E; González-Trujano, ME; López, G; Martínez-Mota, L; Mendoza-Sotelo, J; Moreno, J, 2012) |
| "Mice treated with fluoxetine and mice who exercised daily showed, not only similar antidepressant behavior, but also similar changes in gene expression and hippocampal neurons." | 1.38 | Neurogenomic evidence for a shared mechanism of the antidepressant effects of exercise and chronic fluoxetine in mice. ( Ben-David, E; Edwards, A; Flint, J; Huang, GJ; Shifman, S; Tort Piella, A, 2012) |
| "Methylphenidate (MPH) is a psychostimulant used in the treatment of attention-deficit/hyperactivity disorder in children and adults." | 1.38 | Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine. ( Brookshire, BR; Jones, SR, 2012) |
| "cruzi-induced depression is independent of active or prior CNS inflammation." | 1.38 | Trypanosoma cruzi-induced depressive-like behavior is independent of meningoencephalitis but responsive to parasiticide and TNF-targeted therapeutic interventions. ( de Almeida, LR; de Souza, AS; Lannes-Vieira, J; Moreira, OC; Pereira, IR; Rocha, MS; Silva, AA; Silva, RR; Vilar-Pereira, G, 2012) |
| "Depression is associated with increased risk of coronary heart diseases." | 1.38 | Chronic fluoxetine treatment affects gene expression of catecholamine enzymes in the heart of depression model rats. ( Dronjak, S; Jovanovic, P; Spasojevic, N, 2012) |
| "Icariin is a major constituent of flavonoids isolated from the herb Epimedium." | 1.37 | Icariin attenuates social defeat-induced down-regulation of glucocorticoid receptor in mice. ( Dong, J; Du, J; Le, J; Liu, B; Wu, J; Xu, C; Xu, Y, 2011) |
| "Depression is recognized as a predictor of increased cardiac morbidity and mortality." | 1.37 | Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging. ( Belzung, C; Camus, V; d'Audiffret, A; Isingrini, E, 2011) |
| "Depression is associated with hippocampus (HC) volume loss." | 1.37 | The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression. ( First, M; Gil-Ad, I; Novak, N; Taler, M; Tarasenko, I; Weizman, A, 2011) |
| "Despite recent success in pharmacologic treatment of depression, the inability to predict individual treatment response remains a liability." | 1.37 | Current source density measures of electroencephalographic alpha predict antidepressant treatment response. ( Alschuler, DM; Bruder, GE; Fekri, S; Kayser, J; Kroppmann, CJ; Manna, CG; McGrath, PJ; Schaller, JD; Stewart, JW; Tenke, CE, 2011) |
| "05-10 μg/mouse) produced antidepressant-like effect dose-dependently, whereas influenced the MBB in a biphasic manner (produced a U-shaped dose-response curve)." | 1.37 | Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. ( Jain, NS; Manna, SS; Umathe, SN, 2011) |
| " This was combined with two different doses of fluoxetine (10 and 20 mg/kg)." | 1.37 | Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats. ( Ghorpade, S; Manjrekar, N; Sonawane, D; Tripathi, R, 2011) |
| "The fluoxetine treatment reduced B(max) in all three rat strains when the saline and respective fluoxetine groups were compared (e." | 1.36 | Chronic fluoxetine treatment has a larger effect on the density of a serotonin transporter in the Flinders Sensitive Line (FSL) rat model of depression than in normal rats. ( Diksic, M; Kovacević, T; Skelin, I, 2010) |
| "The response frequency to mechanical allodynia in mice was measured with von Frey hairs." | 1.36 | Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. ( Jesse, CR; Nogueira, CW; Wilhelm, EA, 2010) |
| " Dose-response studies using two classes of anxiolytics (chlordiazepoxide: 2." | 1.35 | Modelling the anxiety-depression continuum in chicks. ( Acevedo, EO; Huang, CJ; Sufka, KJ; Warnick, JE, 2009) |
| "Fluoxetine treatment could reverse CMS-induced inhibition of PKA activity and ERK1/2 phosphorylation in both genotypes." | 1.35 | Requirement of AQP4 for antidepressive efficiency of fluoxetine: implication in adult hippocampal neurogenesis. ( Ding, JH; Fan, Y; Hu, G; Kong, H; Sha, LL; Wu, J; Xiao, M, 2009) |
| "Treatment with fluoxetine between postnatal days P4 and P21 resulted in a significant loss of body weight and long-lasting behavioural inhibition in adult mice in response to stressful events such as the light-dark or open field tests." | 1.35 | Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. ( Castrén, E; Karpova, NN; Lindholm, J; Pruunsild, P; Timmusk, T, 2009) |
| "Depression is experienced as a persistent low mood or anhedonia accompanied by behavioural and cognitive disturbances which impair day to day functioning." | 1.35 | Prognostic and diagnostic potential of the structural neuroanatomy of depression. ( Ashburner, J; Chu, C; Costafreda, SG; Fu, CH, 2009) |
| "The patient developed acute renal failure, and also had fever and unilateral ear inflammation." | 1.35 | Acute renal failure following detergent ingestion. ( Lim, YC, 2009) |
| "Dhat syndrome is a widely recognized clinical condition in the Indian subcontinent characterized by excessive preoccupation with semen loss as the main presenting complaint." | 1.35 | Depression in Dhat syndrome. ( Aggarwal, N; Dhikav, V; Gupta, S; Jadhavi, R; Singh, K, 2008) |
| "Curcumin is a major active component of C." | 1.35 | The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. ( Guo, JB; Li, XJ; Li, YB; Li, YH; Wang, R; Wu, HL; Xu, Y, 2008) |
| "Trazodone is a unique antidepressant, which blocks the postsynaptic serotonin (5-HT) receptors, 5-HT(2A) and 5-HT(2C), and weakly inhibits presynaptic 5-HT transporters." | 1.34 | Does trazodone have a role in palliating symptoms? ( Davis, MP, 2007) |
| "In this sample of children and adolescents with epilepsy and depressive disorders, we observed that SSRIs are a good therapeutic option, considering their efficacy in remission of depressive symptoms, their few adverse effects, and their maintenance of satisfactory seizure control." | 1.34 | Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. ( Kuczynski, E; Thomé-Souza, MS; Valente, KD, 2007) |
| "fluoxetine and cocaine), treatment schedule (i." | 1.33 | Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum. ( Ahmed, R; Akhisaroglu, M; Dirim Arslan, A; Imbesi, M; Kurtuncu, M; Manev, H; Uz, T, 2005) |
| "In fluoxetine-treated animals, blockade of terminal reuptake by local perfusion of fluoxetine increased 5-HT to the same level as it did in controls, suggesting normal terminal 5-HT release after chronic fluoxetine." | 1.32 | Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. ( Gartside, SE; Leitch, MM; Young, AH, 2003) |
| "Fluoxetine treatment also reversed the deficit in escape latency observed in animals exposed to IS." | 1.32 | Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. ( Duman, RS; Malberg, JE, 2003) |
| "Treatment with fluoxetine increased this enzyme activity and reversed the effect of stress." | 1.32 | Reduction of hippocampal Na+, K+-ATPase activity in rats subjected to an experimental model of depression. ( Dalmaz, C; Gamaro, GD; Matté, C; Prediger, ME; Streck, EL; Wyse, AT, 2003) |
| "Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test." | 1.32 | Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004) |
| "Depression is highly prevalent in diabetics and is associated with poor glucose regulation and increased risk of diabetic complications." | 1.32 | Antidepressant activity of quercetin, a bioflavonoid, in streptozotocin-induced diabetic mice. ( Anjaneyulu, M; Chopra, K; Kaur, I, 2003) |
| " In the present study, we analyzed the effects of the administration of NIC, fluoxetine (FLX), and the combination of both drugs given acutely, subchronically, and chronically as well as 7 days after chronic administration of these drugs on the forced swim test." | 1.32 | Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine [correction of flouxetine]. ( Bonilla-Jaime, H; Vázquez-Palacios, G; Velázquez-Moctezuma, J, 2004) |
| "Depression was induced by two models, (i) 60 days social isolation of litter; and ii) by applying chronic unpredictable mild stress for 21 days." | 1.32 | Evaluation of cognitive function of fluoxetine, sertraline and tianeptine in isolation and chronic unpredictable mild stress-induced depressive Wistar rats. ( Kumar, SN; Ramanathan, M; Suresh, B, 2003) |
| "Depression is associated with a dysfunctional serotonin (5-hydroxytryptamine; 5-HT) system." | 1.32 | Nelumbinis Semen reverses a decrease in 5-HT1A receptor binding induced by chronic mild stress, a depression-like symptom. ( Bae, H; Cho, JH; Hong, M; Jang, CG; Kang, M; Kim, H; Lee, J; Lee, SB; Park, S; Park, SK; Shim, IS; Shin, MK, 2004) |
| " A significant correlation was found between the concentrations of each enantiomer and the prescribed daily dosage (r = 0." | 1.31 | Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. ( Gatti, G; Guarneri, L; Jannuzzi, G; Magni, P; Pacifici, R; Perucca, E; Spina, E; Torta, R; Zuccaro, P, 2002) |
| "Helping oncologists to identify and treat depression is an important step in improving the overall care of people with cancer." | 1.31 | Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients. A demonstration project. ( Donaghy, K; Dugan, W; Edgerton, S; Holtsclaw, E; Kirsh, KL; Passik, SD; Theobald, D, 2002) |
| " Male and female Long-Evans rats received either a regimen of chronic administration of melatonin or the control condition for 14 days via the drinking water." | 1.31 | Sex differences in forced-swim and open-field test behaviours after chronic administration of melatonin. ( Barr, AM; Brotto, LA; Gorzalka, BB, 2000) |
| "A continuing challenge in the treatment of depression is how to determine whether an effective drug has been selected for a particular patient, given that individuals will respond to some antidepressants but not others." | 1.31 | Prefrontal changes and treatment response prediction in depression. ( Cook, IA; Leuchter, AF, 2001) |
| " Our hypothesis was that subchronic intake should cause changes qualitatively different from the single dose and that such changes could be sufficiently long-lived to suggest the possibility of a dosing in intervals of several days." | 1.31 | Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. ( Berger, M; Dittmann, R; Feige, B; Hohagen, F; Riemann, D; Voderholzer, U, 2002) |
| "Pretreatment with seganserin, a 5-HT(2) receptor antagonist (2 mg/kg, i." | 1.31 | Evidence for serotonergic modulation of progesterone-induced hyperphagia, depression and algesia in female mice. ( Kaur, G; Kulkarni, SK, 2002) |
| " The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition." | 1.30 | Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? ( Meier, E; Sánchez, C, 1997) |
| "Major depression and migraine are commonly comorbid." | 1.30 | Co-administration of fluoxetine and sumatriptan: the Canadian experience. ( Joffe, RT; Sokolov, ST, 1997) |
| "Pretreatment with buspirone (0." | 1.30 | Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. ( Bourin, M; Redrobe, JP, 1998) |
| "The treatment of fluoxetine significantly correlated with body mass index (T1: p < 0." | 1.30 | [The combined effect of psychotherapy and fluoxetine on obesity]. ( Haász, P; Jákó, P; Resch, M; Sidó, Z, 1999) |
| "Fluoxetine was discontinued in 6 (15%) cases because of adverse side effects." | 1.29 | Fluoxetine in family practice patients. ( Pritchard, DC; Taylor, AT; Tollison, JW; Wagner, PJ, 1994) |
| " Moreover, long term administration of both imipramine or SKF 38393 down regulated D1 dopamine receptor number in the prefrontal cortex, while the association of the two drugs resulted in a receptor density similar to that of control rats." | 1.29 | Desensitization of the D1 dopamine receptors in rats reproduces a model of escape deficit reverted by imipramine, fluoxetine and clomipramine. ( Gambarana, C; Ghiglieri, O; Graziella de Montis, M, 1995) |
| " Each patient manually collected 3 to 6 milk samples throughout a dosing interval." | 1.29 | Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. ( Ito, S; Koren, G; Taddio, A, 1996) |
| "Fluoxetine was the most frequently prescribed SSRI, accounting for 63." | 1.29 | An investigation into the prescribing patterns of selective serotonin re-uptake inhibitors in South Africa. ( Kotze, TJ; Truter, I, 1996) |
| " An antidepressant drug utilization review study performed in two different HMO models revealed important variations among available SSRI therapies in terms of dosage escalation and discontinuation, as well as concomitant medication costs associated with treating side effects." | 1.29 | Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings. ( Navarro, R; Spangler, M; Valler, WE, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (0.50) | 18.7374 |
| 1990's | 130 (12.91) | 18.2507 |
| 2000's | 273 (27.11) | 29.6817 |
| 2010's | 440 (43.69) | 24.3611 |
| 2020's | 159 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Na, YH | 1 |
| Hong, SH | 1 |
| Lee, JH | 2 |
| Park, WK | 2 |
| Baek, DJ | 1 |
| Koh, HY | 1 |
| Cho, YS | 1 |
| Choo, H | 2 |
| Pae, AN | 1 |
| Mittal, M | 1 |
| Goel, RK | 1 |
| Bhargava, G | 1 |
| Mahajan, MP | 1 |
| Gillman, KW | 1 |
| Parker, MF | 1 |
| Silva, M | 1 |
| Degnan, AP | 1 |
| Tora, GO | 1 |
| Lodge, NJ | 1 |
| Li, YW | 1 |
| Lelas, S | 1 |
| Taber, M | 1 |
| Krause, RG | 1 |
| Bertekap, RL | 1 |
| Newton, AE | 1 |
| Pieschl, RL | 1 |
| Lengyel, KD | 1 |
| Johnson, KA | 1 |
| Taylor, SJ | 1 |
| Bronson, JJ | 1 |
| Macor, JE | 1 |
| Sharma, H | 1 |
| Santra, S | 1 |
| Debnath, J | 1 |
| Antonio, T | 1 |
| Reith, M | 1 |
| Dutta, A | 1 |
| Kim, Y | 1 |
| Tae, J | 1 |
| Lee, K | 1 |
| Rhim, H | 1 |
| Choo, IH | 1 |
| Cho, H | 1 |
| Keum, G | 1 |
| Sashidhara, KV | 2 |
| Rao, KB | 1 |
| Singh, S | 5 |
| Modukuri, RK | 2 |
| Aruna Teja, G | 2 |
| Chandasana, H | 1 |
| Shukla, S | 3 |
| Bhatta, RS | 1 |
| Bhaskara Rao, K | 1 |
| Gupta, S | 4 |
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Pandey, D | 1 |
| Mandalapu, D | 1 |
| Sharma, V | 2 |
| Shukla, M | 1 |
| Singh, N | 1 |
| Yadav, SK | 1 |
| Tanpula, DK | 1 |
| Maikhuri, JP | 1 |
| Lal, J | 1 |
| Siddiqi, MI | 1 |
| Gupta, G | 1 |
| Sharma, VL | 1 |
| Yang, TH | 1 |
| Ma, YB | 1 |
| Geng, CA | 1 |
| Yan, DX | 1 |
| Huang, XY | 1 |
| Li, TZ | 1 |
| Zhang, XM | 1 |
| Chen, JJ | 2 |
| Huang, Z | 3 |
| Yin, L | 1 |
| Guan, L | 2 |
| Li, Z | 2 |
| Tan, C | 1 |
| Lundström, E | 3 |
| Isaksson, E | 1 |
| Greilert Norin, N | 1 |
| Näsman, P | 1 |
| Wester, P | 1 |
| Mårtensson, B | 2 |
| Norrving, B | 1 |
| Wallén, H | 1 |
| Borg, J | 1 |
| Hankey, GJ | 6 |
| Hackett, ML | 4 |
| Mead, GE | 3 |
| Dennis, MS | 1 |
| Sunnerhagen, KS | 1 |
| Sagahón-Azúa, J | 1 |
| Medellín-Garibay, SE | 1 |
| Chávez-Castillo, CE | 1 |
| González-Salinas, CG | 1 |
| Milán-Segovia, RDC | 1 |
| Romano-Moreno, S | 1 |
| Shu, Y | 1 |
| Wu, G | 1 |
| Bi, B | 1 |
| Liu, J | 3 |
| Xiong, J | 5 |
| Kuang, L | 1 |
| Liang, Z | 2 |
| Jia, Y | 2 |
| Zhao, L | 2 |
| Zhu, R | 1 |
| He, X | 1 |
| Tong, B | 1 |
| Yang, F | 2 |
| Hao, L | 1 |
| Cui, P | 1 |
| Yuan, J | 1 |
| Ambati, M | 1 |
| Apicella, I | 1 |
| Wang, SB | 1 |
| Narendran, S | 1 |
| Leung, H | 1 |
| Pereira, F | 1 |
| Nagasaka, Y | 1 |
| Huang, P | 1 |
| Varshney, A | 1 |
| Baker, KL | 1 |
| Marion, KM | 1 |
| Shadmehr, M | 1 |
| Stains, CI | 1 |
| Werner, BC | 1 |
| Sadda, SR | 1 |
| Taylor, EW | 1 |
| Sutton, SS | 1 |
| Magagnoli, J | 1 |
| Gelfand, BD | 1 |
| Aboustate, N | 1 |
| Jureidini, J | 1 |
| Rice, DR | 1 |
| Okeng'o, K | 1 |
| Massawe, E | 1 |
| Ismail, S | 1 |
| Mworia, NA | 1 |
| Chiwanga, F | 1 |
| Kapina, B | 1 |
| Wasserman, M | 1 |
| Mateen, FJ | 1 |
| Leussis, MP | 1 |
| Thanos, JM | 1 |
| Powers, A | 1 |
| Peterson, E | 1 |
| Head, JP | 1 |
| McGovern, NJ | 1 |
| Malarkey, FJ | 1 |
| Drake, A | 1 |
| Yuan, QF | 1 |
| He, J | 1 |
| Xu, ZZ | 1 |
| Lin, DD | 1 |
| Zhu, JJ | 1 |
| Wen, CY | 1 |
| Duan, HZ | 1 |
| Wang, WQ | 1 |
| Kadil, Y | 1 |
| Tabyaoui, I | 1 |
| Badre, L | 1 |
| Jouti, NT | 1 |
| Filali, H | 1 |
| García-García, ML | 1 |
| Tovilla-Zárate, CA | 1 |
| Villar-Soto, M | 1 |
| Juárez-Rojop, IE | 1 |
| González-Castro, TB | 1 |
| Genis-Mendoza, AD | 1 |
| Ramos-Méndez, MÁ | 1 |
| López-Nárvaez, ML | 1 |
| Saucedo-Osti, AS | 1 |
| Ruiz-Quiñones, JA | 1 |
| Martinez-Magaña, JJ | 1 |
| Mendonça, IP | 1 |
| Paiva, IHR | 1 |
| Duarte-Silva, EP | 1 |
| Melo, MG | 1 |
| Silva, RSD | 1 |
| Oliveira, WH | 1 |
| Costa, BLDSAD | 1 |
| Peixoto, CA | 1 |
| Flores-Burgess, A | 2 |
| Millón, C | 2 |
| Gago, B | 2 |
| García-Durán, L | 1 |
| Cantero-García, N | 1 |
| Puigcerver, A | 1 |
| Narváez, JA | 2 |
| Fuxe, K | 4 |
| Santín, L | 2 |
| Díaz-Cabiale, Z | 2 |
| Kanno, Y | 1 |
| Tsuchida, K | 1 |
| Maruyama, C | 1 |
| Hori, K | 1 |
| Teramura, H | 1 |
| Asahi, S | 1 |
| Matsuo, O | 1 |
| Ozaki, KI | 1 |
| Bhatt, S | 3 |
| Behl, T | 1 |
| Sehgal, A | 1 |
| Sharma, N | 1 |
| Chigurupati, S | 1 |
| Ahmed, AS | 1 |
| Gari, SBV | 1 |
| Gao, K | 2 |
| Farzi, A | 1 |
| Ke, X | 1 |
| Yu, Y | 2 |
| Chen, C | 2 |
| Chen, S | 3 |
| Yu, T | 1 |
| Wang, H | 10 |
| Li, Y | 14 |
| Misztak, P | 1 |
| Sowa-Kućma, M | 2 |
| Pańczyszyn-Trzewik, P | 1 |
| Szewczyk, B | 4 |
| Nowak, G | 5 |
| Abu-Elfotuh, K | 1 |
| Al-Najjar, AH | 1 |
| Mohammed, AA | 1 |
| Aboutaleb, AS | 1 |
| Badawi, GA | 1 |
| Almeida, OP | 5 |
| Ford, AH | 1 |
| Etherton-Beer, C | 2 |
| Flicker, L | 2 |
| Abdullina, AA | 1 |
| Vasileva, EV | 1 |
| Kulikova, EA | 1 |
| Naumenko, VS | 1 |
| Plyusnina, AV | 1 |
| Gudasheva, TA | 1 |
| Kovalev, GI | 1 |
| Seredenin, SB | 1 |
| Yunusa, I | 1 |
| Gagne, JJ | 1 |
| Yoshida, K | 1 |
| Bykov, K | 1 |
| Dos Santos, BM | 1 |
| Pereira, GC | 1 |
| Piton, E | 1 |
| Fialho, MFP | 1 |
| Becker, G | 1 |
| da Silva Carlotto, M | 1 |
| Camargo, LFM | 1 |
| Ramanzini, LG | 1 |
| Oliveira, SM | 1 |
| Trevisan, G | 1 |
| Zanchet, EM | 1 |
| Pillat, MM | 1 |
| Bochi, GV | 1 |
| Neis, VB | 3 |
| Werle, I | 1 |
| Moretti, M | 5 |
| Rosa, PB | 2 |
| Camargo, A | 7 |
| de O Dalsenter, Y | 1 |
| Platt, N | 2 |
| Rosado, AF | 1 |
| Engel, WD | 1 |
| de Almeida, GRL | 1 |
| Selhorst, I | 1 |
| Dafre, AL | 1 |
| Rodrigues, ALS | 5 |
| Liang, X | 3 |
| Tang, J | 2 |
| Qi, YQ | 2 |
| Luo, YM | 2 |
| Yang, CM | 1 |
| Dou, XY | 1 |
| Jiang, L | 1 |
| Xiao, Q | 3 |
| Zhang, L | 7 |
| Chao, FL | 2 |
| Zhou, CN | 1 |
| Tang, Y | 4 |
| Li, Q | 2 |
| Zhao, B | 2 |
| Li, W | 3 |
| He, Y | 4 |
| Tang, X | 2 |
| Zhang, T | 5 |
| Zhong, Z | 2 |
| Pan, Q | 1 |
| Zhang, Y | 6 |
| Masi, G | 1 |
| Liang, L | 1 |
| Hu, Y | 3 |
| Bian, H | 1 |
| Xiao, L | 4 |
| Wang, G | 5 |
| Gøtzsche, PC | 1 |
| Healy, D | 1 |
| Chen, Y | 10 |
| Hao, C | 2 |
| Chen, W | 6 |
| Cheng, W | 4 |
| Li, P | 5 |
| Shen, J | 6 |
| Tong, T | 3 |
| Yan, S | 2 |
| Huang, S | 2 |
| He, T | 1 |
| Meng, X | 5 |
| Hermanns, T | 1 |
| Graf-Boxhorn, S | 1 |
| Poeck, B | 1 |
| Strauss, R | 1 |
| Filipović, D | 7 |
| Novak, B | 1 |
| Xiao, J | 1 |
| Yan, Y | 2 |
| Yeoh, K | 1 |
| Turck, CW | 1 |
| Lam, RW | 1 |
| Wong, HK | 1 |
| Kumarsing, RA | 1 |
| Chua, AN | 2 |
| Ho, RC | 2 |
| McIntyre, RS | 2 |
| Ho, CS | 2 |
| Tay, J | 1 |
| Markus, HS | 1 |
| de Melo Martins, GM | 1 |
| Petersen, BD | 1 |
| Rübensam, G | 1 |
| da Silva, JMK | 1 |
| Gaspary, KV | 1 |
| Wiprich, MT | 1 |
| Altenhofen, S | 1 |
| Bonan, CD | 1 |
| Yu, X | 1 |
| Yao, H | 1 |
| Zhang, X | 5 |
| Liu, L | 3 |
| Liu, S | 3 |
| Dong, Y | 4 |
| Silveira, KM | 1 |
| Sartim, AG | 1 |
| Vieira, L | 1 |
| Lisboa, SF | 1 |
| Wegener, G | 1 |
| Joca, SRL | 1 |
| Deng, D | 1 |
| Cui, Y | 1 |
| Gan, S | 1 |
| Xie, Z | 1 |
| Cui, S | 1 |
| Cao, K | 2 |
| Wang, S | 7 |
| Shi, G | 1 |
| Yang, L | 3 |
| Bai, S | 1 |
| Shi, Y | 2 |
| Liu, Z | 3 |
| Zhao, J | 8 |
| Zhang, R | 3 |
| Chen, Z | 5 |
| Gu, J | 1 |
| Lin, S | 2 |
| Xu, Z | 2 |
| Xu, H | 3 |
| Feng, P | 1 |
| Tao, Y | 1 |
| Wang, P | 2 |
| Kryst, J | 1 |
| Majcher-Maślanka, I | 1 |
| Chocyk, A | 1 |
| Yang, XY | 1 |
| Dai, GL | 1 |
| Chen, SS | 1 |
| Liu, MC | 1 |
| Li, FR | 1 |
| Cao, Y | 3 |
| Wang, YQ | 2 |
| Ju, WZ | 1 |
| Chi, X | 1 |
| Xue, X | 4 |
| Pan, J | 1 |
| Wu, J | 5 |
| Shi, H | 1 |
| Wang, Y | 14 |
| Lu, Y | 5 |
| Zhang, Z | 4 |
| Ma, K | 1 |
| Gaszner, T | 2 |
| Farkas, J | 2 |
| Kun, D | 2 |
| Ujvári, B | 2 |
| Berta, G | 1 |
| Csernus, V | 1 |
| Füredi, N | 2 |
| Kovács, LÁ | 2 |
| Hashimoto, H | 2 |
| Reglődi, D | 2 |
| Kormos, V | 2 |
| Gaszner, B | 2 |
| Chen, J | 6 |
| Zhu, W | 2 |
| Zeng, X | 1 |
| Yang, K | 1 |
| Peng, H | 1 |
| Hu, L | 1 |
| Wang, Z | 8 |
| Cheng, YT | 1 |
| Sun, GQ | 1 |
| Pei, L | 3 |
| Logue, TC | 1 |
| Wen, T | 1 |
| Huang, Y | 6 |
| Wright, JD | 1 |
| D'Alton, ME | 1 |
| Friedman, AM | 1 |
| Adongo, DW | 1 |
| Mante, PK | 1 |
| Kukuia, KKE | 1 |
| Benneh, CK | 1 |
| Biney, RP | 1 |
| Boakye-Gyasi, E | 1 |
| Amekyeh, H | 1 |
| Harley, BK | 1 |
| Tandoh, A | 1 |
| Okyere, PD | 1 |
| Woode, E | 1 |
| Zeng, D | 1 |
| Li, S | 3 |
| Xu, F | 1 |
| Li, H | 2 |
| He, S | 1 |
| Yuan, Q | 1 |
| Kim, C | 1 |
| Lee, DY | 1 |
| Park, J | 2 |
| Yang, SJ | 1 |
| Tan, EH | 1 |
| Alhambra, DP | 1 |
| Lee, YH | 1 |
| Lee, S | 1 |
| Kim, SJ | 1 |
| Lee, J | 2 |
| Park, RW | 1 |
| Shin, Y | 1 |
| Song, W | 1 |
| Qin, Y | 1 |
| Todd, N | 1 |
| Gao, M | 1 |
| Xia, CY | 1 |
| Zhang, NN | 1 |
| Jiang, H | 4 |
| Lou, YX | 1 |
| Ren, Q | 5 |
| Zhang, XL | 3 |
| Yang, PF | 1 |
| Shao, QH | 1 |
| Zhu, HY | 1 |
| Wan, JF | 1 |
| Zhang, YN | 1 |
| Li, FF | 1 |
| Yan, X | 1 |
| Chu, SF | 1 |
| Wang, ZZ | 1 |
| Chen, NH | 1 |
| Sedighi, F | 1 |
| Zarghami, M | 1 |
| Alizadeh Arimi, F | 1 |
| Moosazadeh, M | 1 |
| Ala, S | 1 |
| Ghasemian, R | 1 |
| Mehravaran, H | 1 |
| Elyasi, F | 1 |
| Yu, H | 1 |
| Tian, Y | 1 |
| Chen, X | 3 |
| Ren, Y | 4 |
| Gong, X | 1 |
| Cheng, K | 1 |
| Liu, X | 5 |
| Zhong, L | 1 |
| Guo, Y | 2 |
| Xie, P | 1 |
| Parasuraman, R | 1 |
| Jayamurali, D | 1 |
| Manoharan, N | 1 |
| Govindarajulu, SN | 1 |
| Kulisewa, K | 1 |
| Minnick, CE | 1 |
| Stockton, MA | 1 |
| Gaynes, BN | 1 |
| Hosseinipour, MC | 1 |
| Mphonda, S | 1 |
| Sansbury, G | 1 |
| Udedi, MM | 1 |
| Pence, BW | 1 |
| Huang, CY | 1 |
| Chen, NN | 1 |
| Zhou, F | 1 |
| Zhang, HM | 1 |
| Yang, XR | 1 |
| Huang, W | 3 |
| Aslam, MS | 1 |
| Wu, X | 2 |
| Rao, Y | 1 |
| Yang, R | 1 |
| Cao, Q | 1 |
| Li, J | 5 |
| Gulizhaerkezi, T | 1 |
| Zeng, J | 1 |
| Tao, W | 1 |
| Yao, G | 1 |
| Yue, Q | 1 |
| Xu, C | 3 |
| Cheng, X | 1 |
| Zhao, T | 1 |
| Qi, M | 2 |
| Chen, G | 1 |
| Zhao, M | 2 |
| Shi, TS | 1 |
| Li, WY | 1 |
| Chen, YM | 1 |
| Huang, J | 1 |
| Guan, W | 2 |
| Xu, DW | 1 |
| Jiang, B | 4 |
| Joo, MK | 2 |
| Kim, DH | 3 |
| Gohar, A | 1 |
| Ali, G | 1 |
| Rashid, U | 1 |
| Rauf, K | 2 |
| Arif, M | 1 |
| Khan, MS | 1 |
| Alkahramaan, YMSA | 1 |
| Sewell, RDE | 1 |
| Haridas, NJ | 1 |
| Balan, S | 1 |
| Ravindren, RK | 1 |
| Dos Santos, RAL | 1 |
| de Lima Reis, SR | 1 |
| Gibbert, PC | 1 |
| de Arruda, CM | 1 |
| Doneda, DL | 2 |
| de Matos, YAV | 1 |
| Viola, GG | 2 |
| Rios Santos, F | 1 |
| de Lima, E | 1 |
| da Silva Buss, Z | 1 |
| Vandresen-Filho, S | 2 |
| Tseng, PT | 1 |
| Chiu, HJ | 1 |
| Suen, MW | 1 |
| Zeng, BS | 1 |
| Wu, MK | 1 |
| Tu, YK | 1 |
| Hung, KC | 1 |
| Wu, YC | 1 |
| Su, KP | 2 |
| Li, DJ | 1 |
| Chen, TY | 1 |
| Stubbs, B | 1 |
| Carvalho, AF | 1 |
| Solmi, M | 2 |
| Thompson, T | 1 |
| Caruso, MG | 1 |
| Matsuoka, YJ | 1 |
| Chen, YW | 2 |
| Lin, PY | 1 |
| Sun, CK | 1 |
| Cheng, YS | 1 |
| Shiue, YL | 1 |
| Cai, Q | 1 |
| Xu, L | 4 |
| Sun, Y | 5 |
| Wang, M | 1 |
| Li, K | 2 |
| Ni, Z | 1 |
| Jin, H | 2 |
| Xu, G | 1 |
| Niu, C | 1 |
| Kan, T | 1 |
| Cao, J | 1 |
| Yang, X | 3 |
| Cheng, Q | 2 |
| Zhang, J | 7 |
| Dong, J | 3 |
| Inderhees, J | 1 |
| Korda, A | 1 |
| Tadić, P | 1 |
| Schwaninger, M | 1 |
| Inta, D | 2 |
| Borgwardt, S | 2 |
| Schreiber, S | 1 |
| Keidan, L | 1 |
| Pick, CG | 2 |
| Yildiz, A | 1 |
| Siafis, S | 1 |
| Mavridis, D | 1 |
| Vieta, E | 2 |
| Leucht, S | 1 |
| Ma, J | 3 |
| Guo, CY | 1 |
| Li, HB | 2 |
| Wu, SH | 2 |
| Li, GL | 1 |
| Shin, YJ | 1 |
| Gan, X | 1 |
| Li, X | 3 |
| Wang, T | 1 |
| Lei, T | 1 |
| Liu, R | 1 |
| Chen, F | 1 |
| Teng, T | 1 |
| Xie, Y | 2 |
| Ouyang, X | 1 |
| Zhou, X | 2 |
| Rodrigues, ACC | 1 |
| Moreira, CVL | 1 |
| Prado, CC | 1 |
| Silva, LSB | 1 |
| Costa, RF | 1 |
| Arikawe, AP | 1 |
| Pedrino, GR | 1 |
| Costa, EA | 1 |
| Silva, ON | 1 |
| Napolitano, HB | 1 |
| Oliveira-Silva, I | 1 |
| Fajemiroye, JO | 1 |
| Zhou, YF | 1 |
| Feng, L | 2 |
| Liu, XM | 1 |
| Tao, X | 2 |
| Wang, LS | 1 |
| Zhang, MD | 1 |
| Chen, SG | 1 |
| Chang, Q | 2 |
| Tunc-Ozcan, E | 1 |
| Peng, CY | 2 |
| Zhu, Y | 2 |
| Dunlop, SR | 1 |
| Contractor, A | 1 |
| Kessler, JA | 2 |
| Sell, SL | 1 |
| Boone, DR | 1 |
| Weisz, HA | 1 |
| Cardenas, C | 1 |
| Willey, HE | 1 |
| Bolding, IJ | 1 |
| Micci, MA | 1 |
| Falduto, MT | 1 |
| Torres, KEO | 1 |
| DeWitt, DS | 1 |
| Prough, DS | 1 |
| Hellmich, HL | 1 |
| Zhou, Y | 3 |
| Wang, L | 8 |
| Pan, R | 1 |
| Liao, Y | 1 |
| Yang, C | 4 |
| Si, J | 1 |
| Suo, L | 1 |
| Fang, W | 1 |
| Hong, L | 1 |
| Dai, X | 1 |
| Ye, Q | 1 |
| Orrico-Sanchez, A | 1 |
| Chausset-Boissarie, L | 1 |
| Alves de Sousa, R | 1 |
| Coutens, B | 1 |
| Rezai Amin, S | 1 |
| Vialou, V | 2 |
| Louis, F | 1 |
| Hessani, A | 1 |
| Dansette, PM | 1 |
| Zornoza, T | 1 |
| Gruszczynski, C | 1 |
| Giros, B | 3 |
| Guiard, BP | 5 |
| Acher, F | 1 |
| Pietrancosta, N | 1 |
| Gautron, S | 1 |
| Dolatshahi, M | 1 |
| Davoudi, S | 1 |
| Paridar, Y | 1 |
| Naserzadeh, R | 2 |
| Ghorbanzadeh, B | 2 |
| Tian, P | 1 |
| Zou, R | 1 |
| Song, L | 2 |
| Lee, YK | 1 |
| Zhang, H | 8 |
| Zavvari, F | 2 |
| Nahavandi, A | 2 |
| Goudarzi, M | 1 |
| Legg, LA | 1 |
| Tilney, R | 1 |
| Hsieh, CF | 2 |
| Wu, S | 1 |
| Rudberg, AS | 1 |
| Kutlubaev, MA | 2 |
| Dennis, M | 1 |
| Soleimani, B | 1 |
| Barugh, A | 1 |
| Jin, L | 1 |
| Hu, P | 1 |
| Wu, L | 2 |
| Qin, K | 1 |
| Cheng, H | 1 |
| Pan, B | 1 |
| Xin, H | 1 |
| Zhang, W | 4 |
| Wang, X | 6 |
| Hirshman, NA | 1 |
| Hughes, FM | 1 |
| Harrison, WT | 1 |
| White, SW | 1 |
| Doan, I | 1 |
| Harper, SN | 1 |
| Leidig, PD | 1 |
| Purves, JT | 1 |
| Ghosh, S | 1 |
| Choudhury, S | 1 |
| Chowdhury, O | 1 |
| Mukherjee, S | 1 |
| Das, A | 1 |
| Sain, A | 1 |
| Gupta, P | 1 |
| Adhikary, A | 1 |
| Chattopadhyay, S | 1 |
| Lukmanji, A | 1 |
| Pringsheim, T | 1 |
| Bulloch, AG | 1 |
| Stewart, DG | 1 |
| Chan, P | 1 |
| Tehrani, A | 1 |
| Patten, SB | 1 |
| Tuttle, JP | 1 |
| Zhang, K | 1 |
| Lin, W | 1 |
| Zhao, Y | 3 |
| Yohn, CN | 1 |
| Shifman, S | 2 |
| Garino, A | 1 |
| Diethorn, E | 1 |
| Bokka, L | 1 |
| Ashamalla, SA | 1 |
| Samuels, BA | 3 |
| Ramsteijn, AS | 2 |
| Jašarević, E | 1 |
| Houwing, DJ | 2 |
| Bale, TL | 1 |
| Olivier, JD | 3 |
| Zhong, H | 1 |
| Arjmand, IK | 1 |
| Brandeau, ML | 1 |
| Bendavid, E | 1 |
| Dalmagro, AP | 4 |
| Pedron, NB | 1 |
| Garcia, SAM | 1 |
| Zeni, ALB | 3 |
| Dai, J | 3 |
| Pan, JY | 2 |
| Liao, N | 2 |
| Shi, J | 3 |
| Zeng, Q | 1 |
| Huang, L | 3 |
| Chen, LP | 3 |
| Siopi, E | 2 |
| Chevalier, G | 1 |
| Katsimpardi, L | 1 |
| Saha, S | 1 |
| Bigot, M | 1 |
| Moigneu, C | 1 |
| Eberl, G | 1 |
| Lledo, PM | 3 |
| Lorenzo-Luaces, L | 1 |
| Rodriguez-Quintana, N | 1 |
| Riley, TN | 1 |
| Weisz, JR | 1 |
| Amin, N | 1 |
| Xie, S | 1 |
| Tan, X | 1 |
| Botchway, BOA | 1 |
| Hu, S | 1 |
| Ma, Y | 1 |
| Hu, Z | 1 |
| Fang, M | 1 |
| Szoke-Kovacs, Z | 1 |
| More, C | 1 |
| Szoke-Kovacs, R | 1 |
| Mathe, E | 1 |
| Frecska, E | 1 |
| Schuttel, K | 1 |
| Struik, EL | 1 |
| Arling, C | 1 |
| Heinla, I | 1 |
| Olivier, JDA | 1 |
| Peng, Y | 1 |
| Su, Y | 1 |
| Jiang, Y | 2 |
| Licinio, J | 2 |
| Wong, ML | 2 |
| Rodríguez-Alonso, X | 1 |
| Gutiérrez-Jorrín, S | 1 |
| Bonnin-Arias, C | 1 |
| Rubio-Corgo, S | 1 |
| Arregui-Olaizola, C | 1 |
| Quezada-Sánchez, J | 1 |
| López-Ibor, MI | 1 |
| Sánchez-Ramos, C | 1 |
| Tatay-Manteiga, A | 1 |
| You, Y | 1 |
| Shu, S | 1 |
| Qian, X | 1 |
| Zhou, S | 1 |
| Yao, F | 1 |
| He, W | 2 |
| Yao, Z | 1 |
| Che, F | 1 |
| Sun, H | 3 |
| Suresh, V | 1 |
| Mills, JA | 1 |
| Croarkin, PE | 1 |
| Strawn, JR | 1 |
| F Rosado, A | 1 |
| B Neis, V | 1 |
| B Zeni, AL | 1 |
| P Kaster, M | 1 |
| S Rodrigues, AL | 1 |
| Cao, C | 1 |
| Liu, M | 2 |
| Qu, S | 1 |
| Huang, R | 1 |
| Zhu, Z | 2 |
| Zheng, J | 1 |
| Han, Z | 1 |
| Huang, F | 1 |
| Duan, JA | 1 |
| Araj-Khodaei, M | 1 |
| Noorbala, AA | 2 |
| Yarani, R | 1 |
| Emadi, F | 1 |
| Emaratkar, E | 1 |
| Faghihzadeh, S | 1 |
| Parsian, Z | 1 |
| Alijaniha, F | 1 |
| Kamalinejad, M | 1 |
| Naseri, M | 1 |
| Christodoulos, IN | 1 |
| Chyou, TY | 1 |
| Nishtala, PS | 1 |
| Stanisavljević, A | 4 |
| Perić, I | 4 |
| Gass, P | 3 |
| Lang, UE | 1 |
| Vittengl, JR | 6 |
| Stutzman, S | 1 |
| Atluru, A | 1 |
| Jarrett, RB | 6 |
| Amaral, JMX | 1 |
| Padilha, MC | 1 |
| Chagas, SV | 1 |
| Baker, JS | 1 |
| Mullen, C | 1 |
| Vieira Neto, L | 1 |
| Aquino Neto, FR | 1 |
| Cruz, MS | 1 |
| Gao, TT | 1 |
| Wang, JL | 2 |
| Wang, YJ | 2 |
| Chen, TT | 1 |
| Komulainen, K | 1 |
| Airaksinen, J | 1 |
| Savelieva, K | 1 |
| Gluschkoff, K | 1 |
| García Velázquez, R | 1 |
| Elovainio, M | 1 |
| Jokela, M | 1 |
| Gunlicks-Stoessel, M | 1 |
| Klimes-Dougan, B | 1 |
| VanZomeren, A | 1 |
| Ma, S | 3 |
| Braun, C | 1 |
| Adams, A | 1 |
| Rink, L | 1 |
| Bschor, T | 1 |
| Kuhr, K | 1 |
| Baethge, C | 1 |
| Jha, MK | 1 |
| Minhajuddin, A | 1 |
| Thase, ME | 6 |
| Zahrai, A | 1 |
| Vahid-Ansari, F | 1 |
| Daigle, M | 1 |
| Albert, PR | 1 |
| Tabka, H | 1 |
| Cheikh, A | 1 |
| Maatoug, S | 1 |
| Ayeb, ME | 1 |
| Bendahhou, S | 1 |
| Benkhalifa, R | 1 |
| Si, Y | 1 |
| Feng, C | 1 |
| Zhang, S | 4 |
| Ma, H | 1 |
| Xie, L | 1 |
| Guo, J | 1 |
| Liu, Y | 4 |
| Guo, X | 3 |
| Meng, Y | 1 |
| Qi, C | 1 |
| Di, T | 1 |
| El-Marasy, SA | 2 |
| El Awdan, SA | 1 |
| Hassan, A | 1 |
| Ahmed-Farid, OA | 1 |
| Ogaly, HA | 1 |
| Deng, SL | 1 |
| Hu, ZL | 1 |
| Mao, L | 2 |
| Gao, B | 1 |
| Yang, Q | 1 |
| Wang, F | 5 |
| Chen, JG | 1 |
| Ajaman, M | 1 |
| Hu, W | 1 |
| Xie, G | 1 |
| Zhou, T | 1 |
| Tu, J | 1 |
| Lin, Z | 1 |
| Gao, L | 2 |
| Shen, D | 1 |
| Zhao, H | 4 |
| Gao, S | 2 |
| Bi, C | 1 |
| Zhou, Z | 2 |
| Yu, C | 1 |
| Colla, ARS | 1 |
| Pazini, FL | 3 |
| Lieberknecht, V | 2 |
| Li, F | 1 |
| Huang, C | 3 |
| Lu, X | 3 |
| Xiang, H | 1 |
| Wang, D | 1 |
| He, H | 1 |
| Yuan, X | 3 |
| Li, A | 1 |
| Tian, J | 1 |
| Yang, J | 8 |
| Ren, X | 2 |
| Zhou, W | 1 |
| Yuan, T | 1 |
| Liao, K | 1 |
| Ali, T | 1 |
| Zheng, C | 1 |
| He, K | 1 |
| Shah, FA | 1 |
| Rahman, SU | 1 |
| Li, N | 1 |
| Yu, ZJ | 1 |
| Li, CX | 1 |
| Zheng, Y | 2 |
| Zhu, H | 1 |
| Li, CW | 1 |
| He, Z | 1 |
| Wang, C | 1 |
| Ding, JH | 2 |
| Hu, G | 4 |
| Lu, M | 3 |
| Ershadi, ASB | 1 |
| Amini-Khoei, H | 1 |
| Hosseini, MJ | 5 |
| Dehpour, AR | 2 |
| Herbet, M | 2 |
| Szumełda, I | 1 |
| Piątkowska-Chmiel, I | 1 |
| Gawrońska-Grzywacz, M | 1 |
| Dudka, J | 3 |
| Witt, K | 1 |
| Madsen, T | 1 |
| Berk, M | 3 |
| Dean, O | 1 |
| Chanen, A | 1 |
| McGorry, PD | 2 |
| Cotton, S | 1 |
| Davey, CG | 2 |
| Hetrick, S | 1 |
| Gong, P | 1 |
| Ma, X | 2 |
| Bi, J | 1 |
| Thabet, NM | 1 |
| Rashed, ER | 1 |
| Abdel-Rafei, MK | 1 |
| Moustafa, EM | 1 |
| Sadeghi, MA | 1 |
| Hemmati, S | 1 |
| Mohammadi, S | 1 |
| Yousefi-Manesh, H | 1 |
| Vafaei, A | 1 |
| Zare, M | 1 |
| Poggini, S | 3 |
| Matte Bon, G | 1 |
| Golia, MT | 1 |
| Ciano Albanese, N | 1 |
| Viglione, A | 1 |
| Poleggi, A | 1 |
| Limatola, C | 3 |
| Maggi, L | 3 |
| Branchi, I | 4 |
| Marzouk, MA | 1 |
| Osman, DA | 1 |
| Mohamed, OS | 1 |
| Zolfaghari, FS | 1 |
| Pirri, F | 1 |
| Gauvin, E | 1 |
| Peeri, M | 4 |
| Amiri, S | 3 |
| Xia, J | 1 |
| Liu, W | 2 |
| Qi, Z | 1 |
| Fraga, DB | 2 |
| Olescowicz, G | 2 |
| Padilha, DA | 1 |
| Mina, F | 1 |
| Budni, J | 3 |
| Brocardo, PS | 4 |
| Naß, J | 1 |
| Efferth, T | 1 |
| Amigo, J | 2 |
| Garro-Martinez, E | 1 |
| Vidal Casado, R | 1 |
| Compan, V | 2 |
| Pilar-Cuéllar, F | 3 |
| Pazos, A | 4 |
| Díaz, A | 3 |
| Castro, E | 2 |
| Scarborough, J | 1 |
| Mueller, FS | 1 |
| Weber-Stadlbauer, U | 1 |
| Mattei, D | 1 |
| Opitz, L | 1 |
| Cattaneo, A | 1 |
| Richetto, J | 1 |
| Yan, YN | 1 |
| Chen, YP | 1 |
| Gao, Y | 3 |
| Lu, W | 1 |
| Xu, Y | 4 |
| O'Dor, SL | 1 |
| Washburn, J | 1 |
| Howard, KR | 1 |
| Reinecke, MA | 1 |
| Chmielarz, P | 1 |
| Kuśmierczyk, J | 2 |
| Rafa-Zabłocka, K | 1 |
| Chorązka, K | 1 |
| Kowalska, M | 1 |
| Satała, G | 1 |
| Nalepa, I | 3 |
| Andrade, C | 1 |
| Sadowsky, J | 1 |
| Jones, JS | 1 |
| Kimata, R | 1 |
| Chiu, YJ | 1 |
| Tu, HH | 1 |
| Kung, ML | 1 |
| Wu, HJ | 1 |
| Ding, H | 1 |
| Li, B | 1 |
| Wen, L | 2 |
| Xiong, W | 1 |
| Xu, Q | 1 |
| Fan, Y | 2 |
| Wei, G | 1 |
| Yin, Q | 1 |
| Yan, Z | 1 |
| Jia, Z | 1 |
| Cao, Z | 2 |
| Chu, L | 1 |
| Ford, A | 1 |
| Hackett, M | 1 |
| Moraga-Amaro, R | 1 |
| Díaz-Galarce, R | 1 |
| Donoso-Ramos, JP | 1 |
| Ugalde, V | 1 |
| Linsambarth, S | 1 |
| Doorduin, J | 1 |
| de Vries, EF | 1 |
| Ampuero, E | 1 |
| Peña, F | 1 |
| Pacheco, R | 1 |
| Wyneken, U | 1 |
| Stehberg, J | 1 |
| Yi, ES | 1 |
| Oh, S | 1 |
| Lee, JK | 1 |
| Leem, YH | 1 |
| Zhu, X | 1 |
| Zhang, C | 7 |
| Liu, H | 3 |
| Isa Kara, M | 1 |
| Ertaş, ET | 1 |
| Ozen, E | 1 |
| Atıcı, M | 1 |
| Aksoy, S | 1 |
| Erdogan, MS | 1 |
| Kelebek, S | 1 |
| Kondo, M | 1 |
| Koyama, Y | 1 |
| Nakamura, Y | 1 |
| Shimada, S | 1 |
| Gassó, P | 1 |
| Rodríguez, N | 1 |
| Boloc, D | 1 |
| Blázquez, A | 1 |
| Torres, T | 1 |
| Gortat, A | 1 |
| Plana, MT | 1 |
| Lafuente, A | 1 |
| Mas, S | 1 |
| Arnaiz, JA | 1 |
| Lázaro, L | 1 |
| Duda, W | 2 |
| Kubera, M | 2 |
| Kreiner, G | 1 |
| Curzytek, K | 2 |
| Detka, J | 1 |
| Głombik, K | 3 |
| Ślusarczyk, J | 3 |
| Basta-Kaim, A | 4 |
| Budziszewska, B | 3 |
| Lasoń, W | 3 |
| Regulska, M | 1 |
| Leśkiewicz, M | 2 |
| Roman, A | 3 |
| Zelek-Molik, A | 1 |
| Younus, I | 1 |
| Siddiq, AA | 1 |
| Schiavone, S | 1 |
| Tucci, P | 1 |
| Mhillaj, E | 1 |
| Bove, M | 1 |
| Trabace, L | 1 |
| Morgese, MG | 1 |
| Gao, SY | 1 |
| Wu, QJ | 1 |
| Zhang, TN | 1 |
| Shen, ZQ | 1 |
| Liu, CX | 1 |
| Xu, X | 2 |
| Ji, C | 1 |
| Zhao, YH | 1 |
| Yu, M | 1 |
| Xu, M | 2 |
| Yu, Q | 1 |
| Shi, P | 1 |
| Bao, T | 1 |
| Stachowicz, A | 2 |
| Trojan, E | 2 |
| Olszanecki, R | 2 |
| Suski, M | 2 |
| Chamera, K | 2 |
| Riad, M | 1 |
| Kobert, A | 1 |
| Descarries, L | 1 |
| Boye, S | 1 |
| Rompré, PP | 1 |
| Lacaille, JC | 2 |
| Benham, RS | 1 |
| Hewage, NB | 1 |
| Suckow, RF | 1 |
| Engin, E | 1 |
| Rudolph, U | 1 |
| Gosselin, T | 1 |
| Le Guisquet, AM | 1 |
| Brizard, B | 1 |
| Hommet, C | 1 |
| Minier, F | 2 |
| Belzung, C | 11 |
| Chen, L | 4 |
| Lin, ZX | 1 |
| Dai, JG | 1 |
| Huang, YF | 1 |
| Zhao, YN | 1 |
| Li, L | 2 |
| Zheng, Q | 1 |
| Gemmel, M | 2 |
| Hazlett, M | 1 |
| Bögi, E | 2 |
| De Lacalle, S | 1 |
| Hill, LA | 1 |
| Kokras, N | 3 |
| Hammond, GL | 1 |
| Dalla, C | 3 |
| Charlier, TD | 2 |
| Pawluski, JL | 5 |
| da Silva Leal, VM | 1 |
| Bonassoli, VT | 1 |
| Soares, LM | 1 |
| Milani, H | 1 |
| de Oliveira, RMW | 1 |
| Rebai, R | 1 |
| Jasmin, L | 1 |
| Boudah, A | 1 |
| Pauleti, NN | 1 |
| Mello, J | 1 |
| Siebert, DA | 1 |
| Micke, GA | 1 |
| de Albuquerque, CAC | 1 |
| Alberton, MD | 1 |
| Barauna, SC | 1 |
| Liang, Y | 1 |
| Jiao, Y | 1 |
| Lin, J | 3 |
| Qu, H | 1 |
| Xu, J | 2 |
| Zhao, C | 1 |
| Omar, NN | 1 |
| Tash, RF | 1 |
| Jin, ZL | 2 |
| Chen, XF | 1 |
| Ran, YH | 2 |
| Li, XR | 2 |
| Zheng, YY | 1 |
| Gao, NN | 1 |
| Li, YF | 3 |
| Dong, XZ | 1 |
| Wang, DX | 1 |
| Lu, YP | 1 |
| Yuan, S | 1 |
| Liu, P | 2 |
| Hu, XX | 1 |
| Wang, YL | 1 |
| Zhao, N | 1 |
| Zhang, LM | 1 |
| Liu, HX | 1 |
| Ayres, ASFSJ | 1 |
| Santos, WB | 1 |
| Junqueira-Ayres, DD | 1 |
| Costa, GM | 1 |
| Ramos, FA | 1 |
| Castellanos, L | 1 |
| Alves, JSF | 1 |
| Asth, L | 1 |
| Medeiros, IU | 1 |
| Zucolotto, SM | 1 |
| Gavioli, EC | 1 |
| Liu, C | 1 |
| Gu, JY | 1 |
| Han, JH | 1 |
| Yan, FL | 1 |
| Lv, TT | 1 |
| Zhao, LQ | 1 |
| Shao, QJ | 1 |
| Feng, YY | 1 |
| Zhang, XY | 1 |
| Wang, CH | 2 |
| Carson, NJ | 1 |
| Progovac, AM | 1 |
| Cook, BL | 1 |
| Clark, LA | 4 |
| Jia, M | 1 |
| Li, C | 2 |
| Ding, X | 1 |
| Chen, M | 1 |
| Ding, J | 2 |
| Du, R | 1 |
| Zeb, F | 1 |
| Naqvi, S | 1 |
| Rahman, R | 1 |
| Farooq, AD | 1 |
| Wang, W | 4 |
| Sahafi, E | 1 |
| Azarbayjani, MA | 2 |
| Kudryashov, NV | 1 |
| Kalinina, TS | 1 |
| Shimshirt, AA | 1 |
| Korolev, AO | 1 |
| Volkova, AV | 1 |
| Voronina, TA | 1 |
| Shen, S | 1 |
| Ji, YT | 1 |
| Li, XY | 1 |
| Zhang, LS | 1 |
| Wang, XD | 1 |
| Jin, HJ | 1 |
| Li, YN | 1 |
| Zheng, H | 1 |
| Yang, S | 2 |
| Wan, Y | 1 |
| Xia, YP | 1 |
| He, QW | 1 |
| Li, M | 4 |
| Yue, ZY | 1 |
| Hu, B | 2 |
| Szopa, A | 2 |
| Doboszewska, U | 2 |
| Wośko, S | 3 |
| Wyska, E | 2 |
| Świąder, K | 2 |
| Serefko, A | 4 |
| Korga, A | 1 |
| Wlaź, A | 2 |
| Wróbel, A | 3 |
| Ostrowska, M | 1 |
| Terlecka, J | 1 |
| Kanadys, A | 1 |
| Poleszak, E | 5 |
| Wlaź, P | 3 |
| Tao, JQ | 1 |
| Li, DD | 1 |
| Xie, H | 1 |
| Du, YF | 1 |
| Long, Y | 2 |
| Reed, MN | 1 |
| Hu, M | 3 |
| Suppiramaniam, V | 1 |
| Hong, H | 2 |
| Tang, SS | 2 |
| Pu, ZP | 1 |
| Xia, JM | 1 |
| Xie, W | 1 |
| He, JC | 1 |
| Koek, W | 1 |
| Sandoval, TL | 1 |
| Daws, LC | 1 |
| Adams, SC | 1 |
| Guyot, CM | 1 |
| Berry, KM | 1 |
| Wallack, ST | 1 |
| Loar, AS | 1 |
| Leblanc, M | 1 |
| Thakare, VN | 1 |
| Patil, RR | 1 |
| Oswal, RJ | 1 |
| Dhakane, VD | 1 |
| Aswar, MK | 1 |
| Patel, BM | 1 |
| JiaWen, W | 1 |
| Hong, S | 1 |
| ShengXiang, X | 1 |
| Jing, L | 1 |
| Roy, B | 1 |
| Wang, Q | 2 |
| Dwivedi, Y | 1 |
| Marwari, S | 1 |
| Dawe, GS | 1 |
| Kotarska, K | 1 |
| Safhi, MM | 1 |
| Qumayri, HM | 1 |
| Masmali, AUM | 1 |
| Siddiqui, R | 1 |
| Alam, MF | 1 |
| Khan, G | 1 |
| Anwer, T | 1 |
| Belovicová, K | 1 |
| Ujhazy, E | 1 |
| Mach, M | 1 |
| Koprdova, R | 1 |
| Zilava, L | 1 |
| Garafová, A | 1 |
| Jezova, D | 1 |
| Dubovicky, M | 1 |
| Zoric, B | 1 |
| Jankovic, L | 1 |
| Kuzmanovic Pficer, J | 1 |
| Zidverc-Trajkovic, J | 1 |
| Mijajlovic, M | 2 |
| Stanimirovic, D | 1 |
| Yang, RR | 1 |
| Zhang, JL | 1 |
| Gong, Y | 1 |
| Hu, WF | 1 |
| Wu, Y | 2 |
| Gao, MH | 1 |
| Costina, V | 1 |
| Findeisen, P | 1 |
| Dávila-Hernández, A | 1 |
| Zamudio, SR | 1 |
| Martínez-Mota, L | 3 |
| González-González, R | 1 |
| Ramírez-San Juan, E | 1 |
| Masrour, FF | 1 |
| Çelikkol, Ç | 1 |
| Bilgiç, A | 1 |
| Alboni, S | 4 |
| Benatti, C | 2 |
| Capone, G | 2 |
| Tascedda, F | 2 |
| Brunello, N | 4 |
| Ruiz, P | 1 |
| Calliari, A | 1 |
| Pautassi, RM | 1 |
| Wang, J | 2 |
| Eitzman, DT | 1 |
| Zhu, Q | 1 |
| Wu, F | 1 |
| Xiaoling, Z | 1 |
| Yunping, H | 1 |
| Yingdong, L | 1 |
| Song, Y | 2 |
| Sun, R | 1 |
| Ji, Z | 2 |
| Fu, Q | 1 |
| Kinoshita, M | 1 |
| Hirayama, Y | 1 |
| Fujishita, K | 1 |
| Shibata, K | 1 |
| Shinozaki, Y | 1 |
| Shigetomi, E | 1 |
| Takeda, A | 1 |
| Le, HPN | 1 |
| Hayashi, H | 1 |
| Hiasa, M | 1 |
| Moriyama, Y | 1 |
| Ikenaka, K | 1 |
| Tanaka, KF | 1 |
| Koizumi, S | 1 |
| Pereira, MM | 1 |
| de Morais, H | 2 |
| Dos Santos Silva, E | 1 |
| Corso, CR | 1 |
| Adami, ER | 1 |
| Carlos, RM | 1 |
| Acco, A | 1 |
| Zanoveli, JM | 2 |
| Aguilar-Valles, A | 1 |
| Haji, N | 1 |
| De Gregorio, D | 1 |
| Matta-Camacho, E | 1 |
| Eslamizade, MJ | 1 |
| Popic, J | 1 |
| Cao, R | 1 |
| Rummel, C | 1 |
| Tanti, A | 5 |
| Wiebe, S | 1 |
| Nuñez, N | 1 |
| Comai, S | 1 |
| Nadon, R | 1 |
| Luheshi, G | 1 |
| Mechawar, N | 1 |
| Turecki, G | 1 |
| Gobbi, G | 1 |
| Sonenberg, N | 1 |
| Qi, X | 1 |
| Kim, EJ | 1 |
| Felsovalyi, K | 1 |
| Young, LM | 1 |
| Shmelkov, SV | 1 |
| Grunebaum, MF | 1 |
| Cardozo, T | 1 |
| Rikel, L | 1 |
| da Silva, EB | 1 |
| Simão da Silva, KAB | 1 |
| Farooq, RK | 1 |
| Ainouche, S | 1 |
| Roger, S | 1 |
| Camus, V | 2 |
| Bansal, Y | 1 |
| Singh, R | 1 |
| Saroj, P | 1 |
| Sodhi, RK | 1 |
| Kuhad, A | 1 |
| Zhuang, X | 1 |
| Fang, Z | 1 |
| Xue, C | 1 |
| Hong, X | 1 |
| Bettio, LB | 1 |
| Gonçalves, FM | 1 |
| Freitas, AE | 1 |
| Heinrich, IA | 1 |
| Lopes, MW | 1 |
| Leal, RB | 1 |
| Sherkawy, MM | 1 |
| Abo-Youssef, AM | 1 |
| Salama, AAA | 1 |
| Ismaiel, IE | 1 |
| Pan, SJ | 1 |
| Tan, YL | 1 |
| Yao, SW | 1 |
| Xin, Y | 1 |
| Micheli, L | 1 |
| Ceccarelli, M | 1 |
| D'Andrea, G | 1 |
| Tirone, F | 1 |
| Mueller, PL | 1 |
| Pritchett, CE | 1 |
| Wiechman, TN | 1 |
| Zharikov, A | 1 |
| Hajnal, A | 1 |
| Qu, C | 2 |
| Yao, Y | 1 |
| Huang, CX | 1 |
| Chen, LM | 1 |
| Du, L | 2 |
| Wang, SR | 1 |
| Todorović, N | 1 |
| Mićić, B | 1 |
| Schwirtlich, M | 1 |
| Stevanović, M | 1 |
| López, C | 1 |
| Gómez-Roso, M | 1 |
| García-Pedraza, JÁ | 1 |
| Martín, ML | 1 |
| Morán, A | 1 |
| García-Domingo, M | 1 |
| Cheng, L | 1 |
| Mikhailenko, VA | 1 |
| Butkevich, IP | 1 |
| Pérez-Sánchez, G | 1 |
| Becerril-Villanueva, E | 1 |
| Arreola, R | 1 |
| Martínez-Levy, G | 1 |
| Hernández-Gutiérrez, ME | 1 |
| Velasco-Velásquez, MA | 1 |
| Alvarez-Herrera, S | 1 |
| Cruz-Fuentes, C | 1 |
| Palacios, L | 1 |
| de la Peña, F | 1 |
| Pavón, L | 1 |
| Wei, CL | 1 |
| Yen, JT | 1 |
| Cheng, YF | 1 |
| Liao, CL | 1 |
| Hsu, CC | 1 |
| Wu, CC | 1 |
| Tsai, YC | 1 |
| Taniguti, EH | 1 |
| Ferreira, YS | 1 |
| Stupp, IJV | 1 |
| Fraga-Junior, EB | 1 |
| Lopes, L | 1 |
| Rios-Santos, F | 1 |
| Lima, E | 1 |
| Buss, ZS | 1 |
| Millard, SJ | 1 |
| Lum, JS | 1 |
| Fernandez, F | 1 |
| Weston-Green, K | 1 |
| Newell, KA | 1 |
| Deng, X | 1 |
| Fu, J | 1 |
| Xu, B | 2 |
| Guo, Q | 1 |
| Lu, H | 1 |
| Zhang, B | 1 |
| Meng, L | 1 |
| Bai, W | 1 |
| Ding, S | 1 |
| Gan, Y | 1 |
| Meng, Z | 1 |
| Fernandes, J | 1 |
| Gupta, GL | 1 |
| Oh, SJ | 1 |
| Cheng, J | 1 |
| Jang, JH | 1 |
| Arace, J | 1 |
| Jeong, M | 1 |
| Shin, CH | 1 |
| Jin, J | 1 |
| Greengard, P | 2 |
| Oh, YS | 1 |
| Walden, J | 1 |
| Assimon, MM | 1 |
| Brookhart, MA | 1 |
| Flythe, JE | 1 |
| Ashraf, A | 1 |
| Mahmoud, PA | 1 |
| Reda, H | 1 |
| Mansour, S | 1 |
| Helal, MH | 1 |
| Michel, HE | 1 |
| Nasr, M | 1 |
| Grech, LB | 1 |
| Butler, E | 1 |
| Stuckey, S | 1 |
| Hester, R | 1 |
| Kin, K | 1 |
| Yasuhara, T | 1 |
| Kawauchi, S | 1 |
| Kameda, M | 1 |
| Hosomoto, K | 1 |
| Tomita, Y | 1 |
| Umakoshi, M | 1 |
| Kuwahara, K | 1 |
| Kin, I | 1 |
| Kidani, N | 1 |
| Morimoto, J | 1 |
| Sasaki, T | 1 |
| Date, I | 1 |
| Chai, HH | 1 |
| Fu, XC | 1 |
| Ma, L | 1 |
| Sun, HT | 1 |
| Chen, GZ | 1 |
| Song, MY | 1 |
| Chen, WX | 1 |
| Chen, YS | 2 |
| Tan, MX | 1 |
| Guo, YW | 1 |
| Li, SP | 1 |
| Hinckley, JD | 1 |
| Riggs, P | 1 |
| Zubair, UB | 1 |
| Mansoor, S | 1 |
| Duffy, L | 1 |
| Bacon, F | 1 |
| Clarke, CS | 1 |
| Donkor, Y | 1 |
| Freemantle, N | 1 |
| Gilbody, S | 1 |
| Hunter, R | 1 |
| Kendrick, T | 2 |
| Kessler, D | 1 |
| King, M | 1 |
| Lanham, P | 1 |
| Lewis, G | 2 |
| Mangin, D | 1 |
| Marston, L | 1 |
| Moore, M | 2 |
| Nazareth, I | 1 |
| Wiles, N | 1 |
| Kawai, H | 1 |
| Iwadate, R | 1 |
| Ishibashi, T | 1 |
| Kudo, N | 1 |
| Kawashima, Y | 1 |
| Mitsumoto, A | 1 |
| Pochwat, B | 1 |
| Muszyńska, B | 1 |
| Opoka, W | 1 |
| Krakowska, A | 1 |
| Rafało-Ulińska, A | 1 |
| Friedland, K | 1 |
| Xiao, WZ | 1 |
| Zhou, WH | 1 |
| Ma, Q | 1 |
| Cui, WG | 1 |
| Mei, QY | 1 |
| Zhao, X | 2 |
| Solek, P | 1 |
| Koszla, O | 1 |
| Mytych, J | 1 |
| Badura, J | 1 |
| Chelminiak, Z | 1 |
| Cuprys, M | 1 |
| Fraczek, J | 1 |
| Tabecka-Lonczynska, A | 1 |
| Koziorowski, M | 1 |
| Lu, Q | 2 |
| Mouri, A | 1 |
| Yang, Y | 1 |
| Kunisawa, K | 1 |
| Teshigawara, T | 1 |
| Hirakawa, M | 1 |
| Mori, Y | 2 |
| Yamamoto, Y | 1 |
| Libo, Z | 1 |
| Nabeshima, T | 1 |
| Saito, K | 1 |
| Hieronymus, F | 1 |
| Lisinski, A | 1 |
| Nilsson, S | 1 |
| Eriksson, E | 1 |
| Jin, Q | 1 |
| Fu, Z | 1 |
| Vitiello, B | 1 |
| Chanen, AM | 1 |
| Hetrick, SE | 2 |
| Cotton, SM | 1 |
| Ratheesh, A | 1 |
| Amminger, GP | 1 |
| Koutsogiannis, J | 1 |
| Phelan, M | 1 |
| Mullen, E | 1 |
| Harrison, BJ | 1 |
| Rice, S | 1 |
| Parker, AG | 1 |
| Dean, OM | 1 |
| Weller, A | 1 |
| Kerr, M | 1 |
| Quinn, AL | 1 |
| Catania, L | 1 |
| Kazantzis, N | 1 |
| Shu, X | 1 |
| Sun, X | 1 |
| Bian, Y | 1 |
| Shu, Z | 1 |
| Boudreau, DM | 1 |
| Arterburn, D | 1 |
| Bogart, A | 1 |
| Haneuse, S | 1 |
| Theis, MK | 1 |
| Westbrook, E | 1 |
| Simon, G | 1 |
| Klimek, E | 1 |
| Rogóż, Z | 2 |
| Kabziński, M | 1 |
| Sadaj, W | 1 |
| Rachwalska, P | 1 |
| Gądek-Michalska, A | 1 |
| Kostić, V | 1 |
| Dzoljić, E | 1 |
| Todorović, Z | 1 |
| Svetel, M | 1 |
| Stefanova, E | 1 |
| Dragasević, N | 1 |
| Petrović, I | 1 |
| Milosević, M | 1 |
| Kovacević, I | 1 |
| Miljković, B | 1 |
| Pokrajac, M | 1 |
| Prostran, M | 1 |
| Knaepen, L | 1 |
| Rayen, I | 3 |
| Fillet, M | 1 |
| Houbart, V | 1 |
| van Kleef, M | 1 |
| Steinbusch, HW | 3 |
| Patijn, J | 1 |
| Tibboel, D | 1 |
| Joosten, EA | 1 |
| Souza, LC | 3 |
| Filho, CB | 3 |
| Fabbro, LD | 1 |
| de Gomes, MG | 2 |
| Goes, AT | 2 |
| Jesse, CR | 4 |
| Dzirasa, K | 1 |
| Kumar, S | 2 |
| Sachs, BD | 1 |
| Caron, MG | 1 |
| Nicolelis, MA | 1 |
| Aswar, UM | 1 |
| Kalshetti, PP | 1 |
| Shelke, SM | 1 |
| Bhosale, SH | 1 |
| Bodhankar, SL | 1 |
| Ceccatelli, S | 3 |
| Bose, R | 2 |
| Edoff, K | 1 |
| Onishchenko, N | 3 |
| Spulber, S | 2 |
| Li, LF | 1 |
| Ma, SP | 1 |
| Qu, R | 1 |
| Quesseveur, G | 2 |
| David, DJ | 7 |
| Gaillard, MC | 1 |
| Pla, P | 1 |
| Wu, MV | 1 |
| Nguyen, HT | 2 |
| Nicolas, V | 1 |
| Auregan, G | 1 |
| David, I | 1 |
| Dranovsky, A | 2 |
| Hantraye, P | 1 |
| Hen, R | 8 |
| Gardier, AM | 7 |
| Déglon, N | 1 |
| Ma, C | 1 |
| Bao, F | 1 |
| Wang, DH | 1 |
| Zhang, YX | 1 |
| Morozova, AY | 1 |
| Zubkov, EA | 1 |
| Storozheva, ZI | 1 |
| Kekelidze, ZI | 1 |
| Chekhonin, VP | 1 |
| Riggin, L | 1 |
| Frankel, Z | 1 |
| Pupco, A | 1 |
| Koren, G | 4 |
| Cai, L | 1 |
| Li, R | 3 |
| Wu, QQ | 1 |
| Wu, TN | 1 |
| Wang, QS | 1 |
| Ding, SL | 1 |
| Mao, HP | 1 |
| Cui, YL | 2 |
| Qi, XJ | 1 |
| Lapmanee, S | 1 |
| Charoenphandhu, J | 1 |
| Charoenphandhu, N | 1 |
| Zhuang, J | 1 |
| Wu, T | 1 |
| Kang, D | 1 |
| Macías-Cortés, Edel C | 2 |
| Aguilar-Faisal, L | 2 |
| Asbun-Bojalil, J | 2 |
| Cheng, Y | 2 |
| Gong, M | 1 |
| Liang, B | 2 |
| Zhang, M | 1 |
| Freund, N | 1 |
| Thompson, BS | 1 |
| Denormandie, J | 1 |
| Vaccarro, K | 1 |
| Andersen, SL | 1 |
| Piras, G | 3 |
| Piludu, MA | 1 |
| Giorgi, O | 3 |
| Corda, MG | 3 |
| Mahesh, R | 2 |
| Devadoss, T | 2 |
| Jindal, A | 2 |
| Tsai, AC | 1 |
| Mimiaga, MJ | 1 |
| Dilley, JW | 1 |
| Hammer, GP | 1 |
| Karasic, DH | 1 |
| Charlebois, ED | 1 |
| Sorensen, JL | 1 |
| Safren, SA | 1 |
| Bangsberg, DR | 1 |
| Fu, W | 1 |
| Du, J | 2 |
| Xi, H | 1 |
| Hou, J | 1 |
| Kangussu, LM | 1 |
| Almeida-Santos, AF | 1 |
| Bader, M | 1 |
| Alenina, N | 1 |
| Fontes, MA | 1 |
| Santos, RA | 1 |
| Aguiar, DC | 1 |
| Campagnole-Santos, MJ | 1 |
| Brown, RA | 1 |
| Abrantes, AM | 1 |
| Strong, DR | 1 |
| Niaura, R | 2 |
| Kahler, CW | 1 |
| Miller, IW | 1 |
| Price, LH | 1 |
| Purslow, C | 1 |
| Naudet, F | 1 |
| Millet, B | 1 |
| Charlier, P | 1 |
| Reymann, JM | 1 |
| Maria, AS | 1 |
| Falissard, B | 1 |
| Miller, MC | 1 |
| Heller, AS | 1 |
| Johnstone, T | 1 |
| Peterson, MJ | 1 |
| Kolden, GG | 1 |
| Kalin, NH | 1 |
| Davidson, RJ | 1 |
| Lin, YL | 1 |
| Hu, JF | 1 |
| Chen, CJ | 1 |
| Bi, XL | 1 |
| Yu, ZH | 1 |
| Yang, PQ | 1 |
| Fan, ZJ | 1 |
| Liu, TF | 1 |
| Liu, BF | 1 |
| Zhang, G | 1 |
| Kiryanova, V | 1 |
| McAllister, BB | 1 |
| Dyck, RH | 1 |
| Friedman, GD | 1 |
| Schwalbe, J | 1 |
| Achacoso, N | 1 |
| Meng, MV | 1 |
| Kroenke, CH | 1 |
| Habel, LA | 1 |
| Shahmansouri, N | 1 |
| Farokhnia, M | 1 |
| Abbasi, SH | 2 |
| Kassaian, SE | 1 |
| Noorbala Tafti, AA | 1 |
| Gougol, A | 1 |
| Yekehtaz, H | 1 |
| Forghani, S | 1 |
| Mahmoodian, M | 1 |
| Saroukhani, S | 1 |
| Arjmandi-Beglar, A | 1 |
| Akhondzadeh, S | 2 |
| Sarkar, A | 1 |
| Chachra, P | 1 |
| Vaidya, VA | 1 |
| Magni, LR | 1 |
| Purgato, M | 2 |
| Gastaldon, C | 1 |
| Papola, D | 1 |
| Furukawa, TA | 2 |
| Cipriani, A | 3 |
| Barbui, C | 4 |
| Gómez, ML | 1 |
| Estrada-Camarena, E | 4 |
| Fernández-Guasti, A | 3 |
| Iñiguez, SD | 3 |
| Alcantara, LF | 3 |
| Warren, BL | 3 |
| Riggs, LM | 1 |
| Parise, EM | 2 |
| Wright, KN | 2 |
| Dayrit, G | 1 |
| Nieto, SJ | 1 |
| Wilkinson, MB | 1 |
| Lobo, MK | 1 |
| Neve, RL | 1 |
| Nestler, EJ | 4 |
| Bolaños-Guzmán, CA | 3 |
| Leonardo, ED | 3 |
| Williams, A | 1 |
| Wong, E | 1 |
| Nesbitt, AM | 1 |
| McCurdy, RD | 1 |
| Alter, M | 1 |
| Qiu, J | 1 |
| Hu, SY | 2 |
| Zhang, CH | 1 |
| Shi, GQ | 1 |
| Wang, SE | 1 |
| Xiang, T | 1 |
| Owolabi, RA | 1 |
| Akanmu, MA | 1 |
| Adeyemi, OI | 1 |
| Luedtke, K | 1 |
| Bouchard, SM | 1 |
| Woller, SA | 1 |
| Funk, MK | 1 |
| Aceves, M | 1 |
| Hook, MA | 1 |
| Gao, N | 1 |
| Zhang, JR | 1 |
| Chen, HX | 1 |
| Dhingra, D | 3 |
| Valecha, R | 1 |
| Wang, GH | 3 |
| Wang, HL | 1 |
| Liu, ZC | 1 |
| Zhu, ZX | 1 |
| Ngoupaye, GT | 1 |
| Bum, EN | 1 |
| Taiwe, GS | 1 |
| Moto, FC | 1 |
| Talla, E | 1 |
| Wu, Z | 1 |
| Ouyang, Y | 1 |
| Guo, S | 1 |
| Mo, YP | 1 |
| Yao, HJ | 1 |
| Song, HT | 1 |
| Xu, AP | 1 |
| Tang, YS | 1 |
| Li, ZG | 1 |
| Ko, MC | 1 |
| Lee, LJ | 2 |
| Ketter, TA | 2 |
| Jin, Y | 1 |
| Sun, S | 1 |
| Cheng, S | 1 |
| Svenningsson, P | 2 |
| Rincón-Cortés, M | 1 |
| Macoveanu, J | 1 |
| Fisher, PM | 1 |
| Haahr, ME | 1 |
| Frokjaer, VG | 1 |
| Knudsen, GM | 1 |
| Siebner, HR | 1 |
| Bourke, CH | 1 |
| Glasper, ER | 1 |
| Neigh, GN | 2 |
| Lutz, PE | 1 |
| Ayranci, G | 1 |
| Chu-Sin-Chung, P | 1 |
| Matifas, A | 1 |
| Koebel, P | 1 |
| Filliol, D | 1 |
| Befort, K | 1 |
| Ouagazzal, AM | 2 |
| Kieffer, BL | 1 |
| Jedynak, P | 1 |
| Kos, T | 1 |
| Sandi, C | 3 |
| Kaczmarek, L | 1 |
| Filipkowski, RK | 1 |
| Tyler, CR | 1 |
| Solomon, BR | 1 |
| Ulibarri, AL | 1 |
| Allan, AM | 1 |
| Berghauzen-Maciejewska, K | 1 |
| Kuter, K | 1 |
| Kolasiewicz, W | 1 |
| Głowacka, U | 1 |
| Dziubina, A | 1 |
| Ossowska, K | 1 |
| Wardas, J | 1 |
| Anderson, ST | 1 |
| Commins, S | 1 |
| Moynagh, PN | 1 |
| Coogan, AN | 1 |
| Gil-Ad, I | 2 |
| Amit, BH | 1 |
| Hayardeni, L | 1 |
| Tarasenko, I | 2 |
| Taler, M | 2 |
| Gueta, RU | 1 |
| Weizman, A | 2 |
| Thibodeau, MA | 1 |
| Quilty, LC | 1 |
| De Fruyt, F | 1 |
| De Bolle, M | 1 |
| Rouillon, F | 1 |
| Bagby, RM | 1 |
| Saleh, LA | 1 |
| Hamza, M | 1 |
| El Gayar, NH | 1 |
| Abd El-Samad, AA | 1 |
| Nasr, EA | 1 |
| Masoud, SI | 1 |
| Ishola, IO | 1 |
| Olayemi, SO | 1 |
| Yemitan, OK | 1 |
| Akinseye, K | 1 |
| Jałocha, W | 1 |
| Walecka-Kapica, E | 2 |
| Tomaszewska-Warda, K | 1 |
| Chojnacki, J | 2 |
| Klupińska, G | 2 |
| Aquib, M | 1 |
| Najmi, AK | 1 |
| Akhtar, M | 1 |
| Gao, X | 1 |
| Sun, P | 1 |
| Qiao, M | 1 |
| Wei, S | 1 |
| Xue, L | 1 |
| Taylor, DM | 1 |
| Cornelius, V | 1 |
| Smith, L | 2 |
| Young, AH | 2 |
| Gupta, D | 2 |
| Radhakrishnan, M | 2 |
| Kurhe, Y | 2 |
| Manna, SS | 3 |
| Umathe, SN | 3 |
| Abdallah, HM | 1 |
| El-Shenawy, SM | 1 |
| El-Khatib, AS | 1 |
| El-Shabrawy, OA | 1 |
| Kenawy, SA | 1 |
| Wang, GD | 1 |
| Wang, XK | 1 |
| Ning, QF | 1 |
| Thangaraj, D | 1 |
| Prabhakar, V | 1 |
| Kanade, P | 1 |
| Kasperek, R | 1 |
| Tan, L | 1 |
| Zhou, J | 1 |
| Lei, F | 1 |
| Li, T | 1 |
| McEwen, BS | 1 |
| Norden, DM | 1 |
| Devine, R | 1 |
| Bicer, S | 1 |
| Jing, R | 1 |
| Reiser, PJ | 1 |
| Wold, LE | 1 |
| Godbout, JP | 1 |
| McCarthy, DO | 1 |
| Ge, L | 2 |
| Zhu, MM | 1 |
| Yang, JY | 1 |
| Zhang, JH | 1 |
| Tian, HF | 1 |
| Wu, CF | 1 |
| Xiao, W | 1 |
| Zhang, XB | 1 |
| Hu, HX | 1 |
| Guo, XL | 1 |
| Liang, J | 1 |
| Shi, S | 1 |
| Hu, D | 1 |
| Yang, B | 2 |
| Ruan, CS | 1 |
| Zhou, FH | 1 |
| He, ZY | 1 |
| Wang, SF | 1 |
| Yang, CR | 1 |
| Shen, YJ | 1 |
| Zhao, HB | 1 |
| Liu, D | 1 |
| Baune, BT | 1 |
| Xiao, ZC | 1 |
| Zhou, XF | 1 |
| Llanes-González, L | 1 |
| Bhatia, A | 1 |
| Sharma, RK | 1 |
| Tewari, S | 1 |
| Khurana, H | 1 |
| Narula, SC | 1 |
| Młyniec, K | 2 |
| Rafało, A | 1 |
| Ostachowicz, B | 1 |
| Lankosz, M | 1 |
| Jin, P | 1 |
| Yu, HL | 2 |
| Zhang, F | 1 |
| Quan, ZS | 2 |
| Mendez-David, I | 1 |
| Tritschler, L | 1 |
| Ali, ZE | 1 |
| Damiens, MH | 1 |
| Pallardy, M | 1 |
| Kerdine-Römer, S | 1 |
| Wolak, M | 1 |
| Siwek, A | 1 |
| Bystrowska, B | 1 |
| Moniczewski, A | 1 |
| Rutkowska, A | 1 |
| Yoshino, Y | 1 |
| Ochi, S | 1 |
| Yamazaki, K | 1 |
| Nakata, S | 1 |
| Abe, M | 1 |
| Ueno, S | 1 |
| Almeida, J | 1 |
| Duarte, JO | 1 |
| Oliveira, LA | 1 |
| Crestani, CC | 1 |
| Xiong, Z | 1 |
| Zheng, S | 1 |
| Su, G | 1 |
| Wu, C | 1 |
| Melo, A | 1 |
| Ferreira, C | 1 |
| Ventura-Silva, AP | 1 |
| Sousa, N | 4 |
| Pêgo, JM | 1 |
| Siddique, J | 1 |
| Reiter, JP | 1 |
| Brincks, A | 1 |
| Gibbons, RD | 1 |
| Crespi, CM | 1 |
| Brown, CH | 1 |
| Ferrés-Coy, A | 2 |
| Galofré, M | 1 |
| Vidal, R | 2 |
| Paz, V | 1 |
| Ruiz-Bronchal, E | 1 |
| Campa, L | 1 |
| Caso, JR | 1 |
| Leza, JC | 1 |
| Alvarado, G | 2 |
| Montefeltro, A | 2 |
| Valdizán, EM | 1 |
| Artigas, F | 4 |
| Bortolozzi, A | 2 |
| Castelhano-Carlos, M | 1 |
| Costa, PS | 1 |
| Russig, H | 1 |
| Zada, W | 1 |
| Zeeshan, S | 1 |
| Bhatti, HA | 1 |
| Mahmood, W | 1 |
| Abbas, G | 1 |
| Conti, M | 1 |
| DuPont, C | 1 |
| Raciti, M | 1 |
| Pittman, J | 1 |
| Hylton, A | 1 |
| Brown, GK | 1 |
| Borman, PD | 1 |
| Sakr, HF | 1 |
| Abbas, AM | 1 |
| Elsamanoudy, AZ | 1 |
| Ghoneim, FM | 1 |
| O'Sullivan, K | 1 |
| Boland, F | 1 |
| Reulbach, U | 1 |
| Motterlini, N | 1 |
| Kelly, D | 1 |
| Bennett, K | 1 |
| Fahey, T | 1 |
| Zhu, C | 1 |
| Zheng, R | 1 |
| Cao, H | 1 |
| Yun, HM | 1 |
| Park, KR | 1 |
| Kim, EC | 1 |
| Kim, S | 3 |
| Hong, JT | 1 |
| Roni, MA | 1 |
| Rahman, S | 1 |
| Nackenoff, AG | 1 |
| Moussa-Tooks, AB | 1 |
| McMeekin, AM | 1 |
| Veenstra-VanderWeele, J | 1 |
| Blakely, RD | 1 |
| Liu, XL | 1 |
| Luo, L | 2 |
| Mu, RH | 2 |
| Liu, BB | 1 |
| Geng, D | 1 |
| Liu, Q | 2 |
| Yi, LT | 6 |
| Wainwright, SR | 1 |
| Barha, CK | 1 |
| Hamson, DK | 1 |
| Epp, JR | 1 |
| Chow, C | 1 |
| Lieblich, SE | 1 |
| Rutishauser, U | 1 |
| Galea, LA | 1 |
| Yu, XB | 1 |
| Dong, RR | 1 |
| Lin, JR | 1 |
| An, YQ | 1 |
| Du, Y | 1 |
| Sun, HB | 1 |
| Kong, LY | 1 |
| Bushnell, GA | 1 |
| Stürmer, T | 1 |
| Swanson, SA | 1 |
| White, A | 1 |
| Azrael, D | 1 |
| Pate, V | 1 |
| Miller, M | 1 |
| Chojnacki, C | 1 |
| Pawlowicz, M | 1 |
| Blonska, A | 1 |
| Al-Samhari, MM | 1 |
| Al-Rasheed, NM | 2 |
| Al-Rejaie, S | 1 |
| Hasan, IH | 1 |
| Mahmoud, AM | 1 |
| Dzimiri, N | 1 |
| van Dijk, RM | 1 |
| Milior, G | 2 |
| Perrotta, M | 1 |
| Drenth, T | 1 |
| Wolfer, DP | 2 |
| Amrein, I | 1 |
| Cirulli, F | 2 |
| Cunha, MP | 3 |
| Rosa, JM | 2 |
| Colla, AR | 3 |
| Oliveira, Á | 1 |
| Rodrigues, AL | 6 |
| da Silva Dias, IC | 1 |
| Carabelli, B | 1 |
| Ishii, DK | 1 |
| de Carvalho, MC | 1 |
| Rizzo de Souza, LE | 1 |
| Zanata, SM | 1 |
| Brandão, ML | 1 |
| Cunha, TM | 1 |
| Ferraz, AC | 1 |
| Cunha, JM | 1 |
| Khalid, A | 1 |
| Jeong, Y | 1 |
| Jeong, B | 1 |
| Lee, ST | 1 |
| Jung, KH | 1 |
| Chu, K | 1 |
| Lee, SK | 2 |
| Jeon, D | 1 |
| Manosso, LM | 1 |
| Ribeiro, CM | 1 |
| Dal-Cim, T | 1 |
| Tasca, CI | 1 |
| Denizet, M | 1 |
| Gabellec, MM | 1 |
| de Chaumont, F | 1 |
| Olivo-Marin, JC | 1 |
| Guilloux, JP | 3 |
| Lazarini, F | 1 |
| Pardo, M | 1 |
| Armini, RS | 1 |
| Martinez, A | 1 |
| Mouhsine, H | 1 |
| Zagury, JF | 1 |
| Jope, RS | 1 |
| Beurel, E | 1 |
| Nemeth, CL | 1 |
| Miller, AH | 1 |
| Tansey, MG | 1 |
| Cravero, C | 1 |
| Guinchat, V | 1 |
| Barete, S | 1 |
| Consoli, A | 1 |
| Boulle, F | 1 |
| Homberg, JR | 3 |
| Machiels, B | 1 |
| Kroeze, Y | 1 |
| Kumar, N | 1 |
| Steinbusch, HWM | 1 |
| Kenis, G | 1 |
| van den Hove, DLA | 1 |
| Darcet, F | 1 |
| Bardet, R | 1 |
| Moreno, JP | 1 |
| Rodriguez, T | 1 |
| Trémeau, AL | 1 |
| Hernandez, É | 1 |
| Bolot, AL | 1 |
| Isa, A | 1 |
| Bernstein, I | 1 |
| Trivedi, M | 2 |
| Mayes, T | 2 |
| Kennard, B | 1 |
| Emslie, G | 1 |
| Stasiuk, W | 1 |
| Oniszczuk, A | 1 |
| Sumaya, IC | 1 |
| Bailey, D | 1 |
| Catlett, SL | 1 |
| Shen, F | 1 |
| Doods, H | 1 |
| Treede, RD | 1 |
| Ceci, A | 2 |
| Haj-Mirzaian, A | 3 |
| Kordjazy, N | 1 |
| Ostadhadi, S | 1 |
| Dehpour, A | 1 |
| Buga, AM | 1 |
| Ciobanu, O | 1 |
| Bădescu, GM | 1 |
| Bogdan, C | 1 |
| Weston, R | 1 |
| Slevin, M | 1 |
| Di Napoli, M | 1 |
| Popa-Wagner, A | 1 |
| Ozerov, AA | 1 |
| Bagmetova, VV | 1 |
| Chernysheva, YV | 1 |
| Tyurenkov, IN | 1 |
| Sonei, N | 1 |
| Jafarian, I | 1 |
| Anoush, M | 1 |
| Rahimi-Balaei, M | 1 |
| Bergen, H | 1 |
| van Donkelaar, E | 1 |
| Loftus, T | 1 |
| Giri, D | 1 |
| Price, V | 1 |
| Yung, Z | 1 |
| Didi, M | 1 |
| Senniappan, S | 1 |
| Bozzatello, P | 1 |
| Bellino, S | 1 |
| Conrad, SK | 1 |
| Catalano, MC | 1 |
| Catalano, G | 1 |
| Rechberger, T | 1 |
| Chu, X | 1 |
| Lou, J | 1 |
| Deng, Q | 1 |
| Xie, J | 1 |
| Serdyuk, T | 1 |
| He, L | 1 |
| Sadeghi, M | 1 |
| Sarkissova, KY | 1 |
| Fedotova, IB | 2 |
| Surina, NM | 2 |
| Nikolaev, GM | 2 |
| Perepelkina, OV | 2 |
| Poletaeva, II | 2 |
| Palmer, SC | 1 |
| Natale, P | 1 |
| Ruospo, M | 1 |
| Saglimbene, VM | 1 |
| Rabindranath, KS | 1 |
| Craig, JC | 1 |
| Strippoli, GF | 1 |
| Yan, T | 1 |
| Wu, B | 1 |
| Liao, Z | 1 |
| Bi, K | 1 |
| Gevorgyan, MM | 1 |
| Idova, GV | 1 |
| Al'perina, EL | 1 |
| Tikhonova, MA | 1 |
| Kulikov, AV | 1 |
| Fang, XY | 2 |
| Wang, SS | 1 |
| Li, CF | 2 |
| Chen, SM | 1 |
| Chen, XM | 1 |
| Li, YC | 6 |
| Surget, A | 4 |
| Van Nieuwenhuijzen, PS | 1 |
| Heinzmann, JM | 1 |
| Knapman, A | 1 |
| McIlwrick, S | 1 |
| Westphal, WP | 1 |
| Touma, C | 2 |
| Ayuob, NN | 1 |
| Süleyman, A | 1 |
| Kurt, FS | 1 |
| Soyata, AZ | 1 |
| Kaya, I | 1 |
| Alyanak, B | 1 |
| Garofalo, S | 1 |
| El Hajj, H | 1 |
| Lecours, C | 1 |
| Girard, I | 1 |
| Gagnon, S | 1 |
| Boisjoly-Villeneuve, S | 1 |
| Tremblay, MÈ | 1 |
| Vahia, IV | 1 |
| Sewell, DD | 1 |
| Bielecka, AM | 1 |
| Obuchowicz, E | 1 |
| Rana, P | 1 |
| Sharma, AK | 1 |
| Jain, S | 2 |
| Deshmukh, P | 1 |
| Bhattacharya, SK | 1 |
| Banerjee, BD | 1 |
| Mediratta, PK | 1 |
| Martín, A | 1 |
| Zhou, L | 1 |
| Ma, SL | 1 |
| Yeung, PK | 1 |
| Wong, YH | 1 |
| Tsim, KW | 1 |
| So, KF | 1 |
| Lam, LC | 1 |
| Chung, SK | 1 |
| Zhou, WJ | 1 |
| Xu, N | 1 |
| Kong, L | 1 |
| Sun, SC | 1 |
| Xu, XF | 1 |
| Jia, MZ | 1 |
| Chen, ZY | 1 |
| Veronese, N | 1 |
| Zaninotto, L | 1 |
| van der Loos, ML | 1 |
| Schaffer, A | 1 |
| Reis, C | 1 |
| Normann, C | 1 |
| Anghelescu, IG | 1 |
| Correll, CU | 1 |
| Brooker, SM | 1 |
| Gobeske, KT | 1 |
| Pei, S | 1 |
| Shang, J | 2 |
| Azevedo, D | 1 |
| Colla, A | 2 |
| de Oliveira, J | 1 |
| Ramos-Hryb, AB | 1 |
| Gil-Mohapel, J | 1 |
| Liu, YM | 4 |
| Shen, JD | 3 |
| Pei, YY | 1 |
| Zhou, QG | 1 |
| Lee, D | 1 |
| Ro, EJ | 1 |
| Suh, H | 1 |
| Donato, F | 1 |
| Del Fabbro, L | 2 |
| Gomes de Gomes, M | 1 |
| Rossito Goes, AT | 1 |
| Boeira, SP | 2 |
| Badenhorst, NJ | 1 |
| Brand, L | 2 |
| Harvey, BH | 3 |
| Ellis, SM | 1 |
| Brink, CB | 3 |
| Zhang, JC | 2 |
| Yao, W | 2 |
| Dong, C | 2 |
| Ma, M | 2 |
| Hashimoto, K | 2 |
| Laugeray, A | 2 |
| Launay, JM | 2 |
| Callebert, J | 1 |
| Mutlu, O | 2 |
| Guillemin, GJ | 1 |
| Barone, PR | 1 |
| Ohgi, Y | 1 |
| Futamura, T | 1 |
| Otabi, H | 1 |
| Goto, T | 1 |
| Okayama, T | 1 |
| Kohari, D | 1 |
| Toyoda, A | 1 |
| Hu, CY | 1 |
| Sarkisova, KY | 1 |
| Kostina, ZA | 1 |
| Schoeman, JC | 1 |
| Steyn, SF | 1 |
| Sanchez, C | 2 |
| Gulinello, M | 1 |
| Aswar, U | 1 |
| Chepurwar, S | 1 |
| Shintre, S | 1 |
| Aswar, M | 1 |
| Xu, LP | 1 |
| Narváez, M | 1 |
| Borroto-Escuela, DO | 1 |
| Mengod, G | 1 |
| Widenlou Nordmark, A | 1 |
| Hu, X | 1 |
| Jin, X | 1 |
| Warnick, JE | 1 |
| Huang, CJ | 1 |
| Acevedo, EO | 1 |
| Sufka, KJ | 1 |
| Khazaie, H | 2 |
| Moradi, M | 1 |
| Tahmasian, M | 2 |
| Ahmadi, A | 1 |
| Mazarati, A | 1 |
| Siddarth, P | 1 |
| Baldwin, RA | 1 |
| Shin, D | 2 |
| Caplan, R | 1 |
| Sankar, R | 2 |
| Yalcin, I | 1 |
| Lenderking, WR | 1 |
| Tennen, H | 1 |
| Cappelleri, JC | 1 |
| Petrie, CD | 1 |
| Rush, AJ | 5 |
| Kelly, BD | 1 |
| Bespalov, AY | 1 |
| van Gaalen, MM | 1 |
| Sukhotina, IA | 1 |
| Wicke, K | 1 |
| Mezler, M | 1 |
| Schoemaker, H | 1 |
| Gross, G | 1 |
| Choi-Kwon, S | 3 |
| Choi, J | 2 |
| Kwon, SU | 3 |
| Kang, DW | 4 |
| Kim, JS | 3 |
| Sugimoto, Y | 1 |
| Kajiwara, Y | 1 |
| Hirano, K | 1 |
| Yamada, S | 1 |
| Tagawa, N | 1 |
| Kobayashi, Y | 1 |
| Hotta, Y | 1 |
| Yamada, J | 1 |
| Tassabehji, NM | 1 |
| Corniola, RS | 1 |
| Alshingiti, A | 1 |
| Levenson, CW | 1 |
| Stone, EA | 1 |
| Lin, Y | 1 |
| Quartermain, D | 1 |
| Dodd, S | 1 |
| Dhir, A | 1 |
| Kulkarni, SK | 3 |
| Guadarrama-Cruz, G | 1 |
| Alarcon-Aguilar, FJ | 1 |
| Lezama-Velasco, R | 1 |
| Vazquez-Palacios, G | 3 |
| Bonilla-Jaime, H | 3 |
| Bot, ST | 1 |
| Faramarzi, M | 1 |
| Kheirkhah, F | 1 |
| Esmaelzadeh, S | 1 |
| Alipour, A | 1 |
| Hjiahmadi, M | 1 |
| Rahnama, J | 1 |
| Kong, H | 1 |
| Sha, LL | 1 |
| Xiao, M | 1 |
| Oh, W | 1 |
| Sedin, G | 1 |
| Belik, J | 1 |
| Katzav, A | 2 |
| Ben-Ziv, T | 1 |
| Chapman, J | 2 |
| Blank, M | 2 |
| Reichlin, M | 2 |
| Shoenfeld, Y | 2 |
| Karpova, NN | 1 |
| Lindholm, J | 1 |
| Pruunsild, P | 1 |
| Timmusk, T | 1 |
| Castrén, E | 2 |
| Bessa, JM | 2 |
| Ferreira, D | 1 |
| Melo, I | 1 |
| Marques, F | 1 |
| Cerqueira, JJ | 1 |
| Palha, JA | 1 |
| Almeida, OF | 2 |
| Lekakis, J | 1 |
| Ikonomidis, I | 1 |
| Papoutsi, Z | 1 |
| Moutsatsou, P | 1 |
| Nikolaou, M | 1 |
| Parissis, J | 1 |
| Kremastinos, DT | 1 |
| Mackay, GM | 1 |
| Forrest, CM | 1 |
| Christofides, J | 1 |
| Bridel, MA | 1 |
| Mitchell, S | 1 |
| Cowlard, R | 1 |
| Stone, TW | 1 |
| Darlington, LG | 1 |
| Renshaw, PF | 4 |
| Parsegian, A | 2 |
| Yang, CK | 1 |
| Novero, A | 1 |
| Yoon, SJ | 1 |
| Lyoo, IK | 1 |
| Cohen, BM | 3 |
| Carlezon, WA | 2 |
| Chen, ZH | 2 |
| Chen, JH | 1 |
| Luo, HS | 1 |
| Huang, YL | 2 |
| Wang, XP | 1 |
| Peters, EJ | 1 |
| Slager, SL | 1 |
| Jenkins, GD | 1 |
| Reinalda, MS | 1 |
| Garriock, HA | 1 |
| Shyn, SI | 1 |
| Kraft, JB | 1 |
| McGrath, PJ | 2 |
| Hamilton, SP | 1 |
| Schuh, B | 1 |
| Maffeo, ML | 1 |
| Manojlovic, Z | 1 |
| Bao, L | 1 |
| Lin, Q | 1 |
| Yao, XS | 1 |
| Hiroshi, K | 1 |
| Rodríguez-Gaztelumendi, A | 1 |
| Rojo, ML | 1 |
| Serrano-Blanco, A | 1 |
| Suárez, D | 1 |
| Pinto-Meza, A | 1 |
| Peñarrubia, MT | 1 |
| Haro, JM | 1 |
| Küçükibrahimoğlu, E | 1 |
| Saygin, MZ | 1 |
| Calişkan, M | 1 |
| Kaplan, OK | 1 |
| Unsal, C | 1 |
| Gören, MZ | 1 |
| Qi, H | 1 |
| Peng, L | 1 |
| Chen, HZ | 1 |
| Esposito, D | 1 |
| Wahl, P | 1 |
| Daniel, G | 1 |
| Stoto, MA | 1 |
| Erder, MH | 1 |
| Croghan, TW | 1 |
| Chatwin, J | 1 |
| Dowrick, C | 1 |
| Tylee, A | 1 |
| Morriss, R | 1 |
| Peveler, R | 1 |
| Leese, M | 1 |
| McCrone, P | 1 |
| Harris, T | 1 |
| Byng, R | 1 |
| Brown, G | 1 |
| Barthel, S | 1 |
| Mander, H | 1 |
| Ring, A | 1 |
| Kelly, V | 1 |
| Wallace, V | 1 |
| Gabbay, M | 1 |
| Craig, T | 1 |
| Mann, A | 1 |
| Portella, MJ | 1 |
| de Diego-Adeliño, J | 1 |
| Puigdemont, D | 1 |
| Pérez-Egea, R | 1 |
| Alvarez, E | 2 |
| Pérez, V | 2 |
| Hazell, P | 1 |
| Studd, J | 2 |
| Rainer, Q | 5 |
| Wang, JW | 1 |
| Marsteller, D | 1 |
| Mendez, I | 1 |
| Drew, M | 1 |
| Craig, DA | 1 |
| Artymyshyn, RP | 1 |
| Gerald, C | 1 |
| Antonijevic, IA | 1 |
| Korb, AS | 1 |
| Hunter, AM | 1 |
| Cook, IA | 2 |
| Leuchter, AF | 2 |
| Greene, J | 1 |
| Banasr, M | 1 |
| Lee, B | 2 |
| Warner-Schmidt, J | 1 |
| Duman, RS | 3 |
| Lee, JS | 1 |
| Jang, DJ | 1 |
| Lee, N | 1 |
| Ko, HG | 1 |
| Kim, H | 2 |
| Kim, YS | 1 |
| Kim, B | 1 |
| Son, J | 1 |
| Kim, SH | 1 |
| Chung, H | 1 |
| Lee, MY | 1 |
| Kim, WR | 1 |
| Sun, W | 1 |
| Zhuo, M | 1 |
| Abel, T | 1 |
| Kaang, BK | 1 |
| Son, H | 1 |
| León, LA | 1 |
| Landeira-Fernandez, J | 1 |
| Cardenas, FP | 1 |
| Costafreda, SG | 1 |
| Chu, C | 1 |
| Ashburner, J | 1 |
| Fu, CH | 2 |
| Lim, YC | 1 |
| Mowla, A | 1 |
| Dastgheib, SA | 1 |
| Ebrahimi, AA | 1 |
| Pani, A | 1 |
| Luo, YL | 1 |
| Zhang, MY | 1 |
| Wu, WY | 1 |
| Li, CB | 1 |
| Lu, Z | 1 |
| Li, QW | 1 |
| Covington, HE | 1 |
| Maze, I | 1 |
| LaPlant, QC | 1 |
| Vialou, VF | 2 |
| Ohnishi, YN | 1 |
| Berton, O | 2 |
| Fass, DM | 1 |
| Renthal, W | 2 |
| Wu, EY | 1 |
| Ghose, S | 1 |
| Krishnan, V | 2 |
| Russo, SJ | 2 |
| Tamminga, C | 1 |
| Haggarty, SJ | 1 |
| Martin, AL | 1 |
| Brown, RE | 1 |
| Simmons, MB | 1 |
| Willet, MR | 1 |
| Eitan, R | 1 |
| Landshut, G | 1 |
| Lifschytz, T | 2 |
| Einstein, O | 1 |
| Ben-Hur, T | 1 |
| Lerer, B | 3 |
| Duan, DM | 3 |
| Tu, Y | 3 |
| Wu, ZJ | 1 |
| Houston, JP | 1 |
| Fijal, B | 1 |
| Heinloth, AN | 1 |
| Adams, DH | 1 |
| Kovacević, T | 1 |
| Skelin, I | 1 |
| Diksic, M | 1 |
| Kwon, S | 1 |
| Kim, M | 1 |
| Lee, H | 1 |
| Park, HJ | 1 |
| Hahm, DH | 1 |
| Chen, PJ | 1 |
| Hsieh, CL | 1 |
| Hou, YC | 1 |
| Chiang, HM | 1 |
| Sheen, LY | 1 |
| D'Andrea, I | 1 |
| Lipp, HP | 1 |
| Alleva, E | 1 |
| Farley, S | 1 |
| Apazoglou, K | 1 |
| Witkin, JM | 2 |
| Tzavara, ET | 2 |
| Castro, JE | 2 |
| Varea, E | 2 |
| Márquez, C | 1 |
| Cordero, MI | 1 |
| Poirier, G | 1 |
| Liu, LY | 1 |
| Wang, LL | 1 |
| Conboy, L | 1 |
| Sakouhi-Ouertatani, H | 1 |
| Calandra, T | 1 |
| Lashuel, HA | 1 |
| Retana-Márquez, S | 1 |
| Arteaga-Silva, M | 1 |
| Hernández-González, M | 1 |
| Sas, K | 2 |
| Bobo, WV | 1 |
| Shelton, RC | 2 |
| Jiang, Z | 1 |
| Paslakis, G | 1 |
| Heuser, I | 1 |
| Schweiger, U | 1 |
| Deuschle, M | 1 |
| McCall, WV | 1 |
| Liebenberg, N | 1 |
| Tian, JS | 1 |
| Hu, LM | 1 |
| Chi, W | 1 |
| Dong, TJ | 1 |
| Liu, LP | 1 |
| Horder, J | 1 |
| Matthews, P | 1 |
| Waldmann, R | 1 |
| Thomas, KL | 1 |
| Ellingrod, VL | 1 |
| Bishop, JR | 1 |
| Keiser, MJ | 1 |
| Zhan, X | 2 |
| Cui, CC | 2 |
| Xiao, F | 1 |
| Zhou, LP | 2 |
| Drugan, RC | 1 |
| Macomber, H | 1 |
| Warner, TA | 1 |
| Tuccori, M | 1 |
| Montagnani, S | 1 |
| Testi, A | 1 |
| Ruggiero, E | 1 |
| Mantarro, S | 1 |
| Scollo, C | 1 |
| Pergola, A | 1 |
| Fornai, M | 1 |
| Antonioli, L | 1 |
| Colucci, R | 1 |
| Corona, T | 1 |
| Blandizzi, C | 1 |
| Wilhelm, EA | 1 |
| Nogueira, CW | 1 |
| Hodes, GE | 1 |
| Hill-Smith, TE | 1 |
| Lucki, I | 3 |
| Hsuchou, H | 1 |
| Kastin, AJ | 1 |
| Khan, RS | 1 |
| Stone, KP | 1 |
| Cash, MS | 1 |
| Pan, W | 1 |
| Christiansen, SH | 1 |
| Olesen, MV | 1 |
| Wörtwein, G | 1 |
| Woldbye, DP | 1 |
| Baudry, A | 1 |
| Mouillet-Richard, S | 1 |
| Schneider, B | 1 |
| Kellermann, O | 1 |
| Blom, T | 2 |
| Arentsen, T | 2 |
| Jungke, P | 1 |
| Ostrow, G | 1 |
| Li, JL | 1 |
| Norton, S | 1 |
| Nieber, K | 1 |
| Kelber, O | 1 |
| Butterweck, V | 1 |
| Lin, KW | 1 |
| Lam, C | 1 |
| Xu, HL | 1 |
| Feng, J | 2 |
| Mezadri, TJ | 1 |
| Batista, GM | 1 |
| Portes, AC | 1 |
| Marino-Neto, J | 1 |
| Lino-de-Oliveira, C | 1 |
| Rahimi, M | 1 |
| Tatari, F | 1 |
| Rezaei, M | 1 |
| Najafi, F | 1 |
| Robinson, RG | 3 |
| Adams, HP | 1 |
| Le, J | 1 |
| Liu, B | 1 |
| van Brunschot, C | 1 |
| Schipper, P | 1 |
| Korte-Bouws, G | 1 |
| van Luijtelaar, G | 1 |
| Reneman, L | 1 |
| Jiao, J | 1 |
| Dulawa, SC | 4 |
| Bougarel, L | 1 |
| Guitton, J | 1 |
| Zimmer, L | 1 |
| Vaugeois, JM | 3 |
| El Yacoubi, M | 3 |
| Jiao, S | 1 |
| Qin, W | 1 |
| Kobayashi, K | 1 |
| Ikeda, Y | 1 |
| Suzuki, H | 1 |
| Mitchell, JE | 1 |
| Agras, S | 1 |
| Crow, S | 1 |
| Halmi, K | 1 |
| Fairburn, CG | 1 |
| Bryson, S | 1 |
| Kraemer, H | 1 |
| Isingrini, E | 1 |
| d'Audiffret, A | 1 |
| Matatiashvili, TTs | 1 |
| Domianidze, TR | 1 |
| Chichinadze, KN | 1 |
| Pantsulaia, IN | 1 |
| Khananashvili, MM | 1 |
| First, M | 1 |
| Novak, N | 1 |
| Tenke, CE | 1 |
| Kayser, J | 1 |
| Manna, CG | 1 |
| Fekri, S | 1 |
| Kroppmann, CJ | 1 |
| Schaller, JD | 1 |
| Alschuler, DM | 1 |
| Stewart, JW | 1 |
| Bruder, GE | 1 |
| Degenhardt, EK | 1 |
| Jamal, HH | 1 |
| Tormey, S | 1 |
| Case, M | 1 |
| Chau, DT | 1 |
| Rada, PV | 2 |
| Kim, K | 1 |
| Kosloff, RA | 2 |
| Hoebel, BG | 2 |
| Palme, R | 1 |
| Griebel, G | 7 |
| Ibarguen-Vargas, Y | 1 |
| Bhatia, MS | 1 |
| Jhanjee, A | 1 |
| Srivastava, S | 1 |
| Kumar, P | 1 |
| Jain, NS | 1 |
| Paszynska, E | 1 |
| Linden, RW | 1 |
| Slopien, A | 1 |
| Rajewski, A | 1 |
| Petkova, E | 1 |
| Tarpey, T | 1 |
| Govindarajulu, U | 1 |
| Rong, H | 1 |
| Liu, T | 1 |
| Wan, Q | 1 |
| Weng, S | 1 |
| Hansen, F | 1 |
| de Oliveira, DL | 1 |
| Amaral, FU | 1 |
| Guedes, FS | 1 |
| Schneider, TJ | 1 |
| Tumelero, AC | 1 |
| Hansel, G | 1 |
| Schmidt, KH | 1 |
| Giacomini, AC | 1 |
| Torres, FV | 1 |
| Liu, YF | 2 |
| Gao, F | 2 |
| Jiang, W | 2 |
| Kim, NH | 1 |
| Kim, KY | 1 |
| Jeong, HJ | 1 |
| Kim, HM | 1 |
| Brown, RW | 1 |
| Noel, DM | 1 |
| Smith, JJ | 1 |
| Smith, ML | 1 |
| Huggins, KN | 1 |
| Szebeni, K | 1 |
| Szebeni, A | 1 |
| Duffourc, M | 1 |
| Chandley, M | 1 |
| Ordway, GA | 1 |
| Peng, GG | 1 |
| Chen, WL | 1 |
| Wu, JW | 1 |
| Crespi, F | 1 |
| Cui, XL | 1 |
| Wei, D | 1 |
| Li, XW | 1 |
| Wang, HN | 1 |
| Tan, QR | 1 |
| Castañé, A | 1 |
| Semakova, J | 1 |
| Santana, N | 1 |
| Cortés, R | 1 |
| Fernández, G | 1 |
| Carmona, MC | 1 |
| Toth, M | 1 |
| Perales, JC | 1 |
| Molenaar, PJ | 1 |
| Boom, Y | 1 |
| Peen, J | 1 |
| Schoevers, RA | 1 |
| Van, R | 1 |
| Dekker, JJ | 1 |
| Cuestas, ME | 1 |
| Cuestas, E | 1 |
| Dubois, M | 1 |
| Gabriel, C | 1 |
| Mocaër, E | 1 |
| Deng, XQ | 1 |
| Li, YJ | 1 |
| Sun, XY | 1 |
| Gotter, AL | 1 |
| Santarelli, VP | 1 |
| Doran, SM | 1 |
| Tannenbaum, PL | 1 |
| Kraus, RL | 1 |
| Rosahl, TW | 1 |
| Meziane, H | 1 |
| Montial, M | 1 |
| Reiss, DR | 1 |
| Wessner, K | 1 |
| McCampbell, A | 1 |
| Stevens, J | 1 |
| Brunner, JI | 1 |
| Fox, SV | 1 |
| Uebele, VN | 1 |
| Bayliss, DA | 1 |
| Winrow, CJ | 1 |
| Renger, JJ | 1 |
| Spasojevic, N | 2 |
| Gavrilovic, L | 1 |
| Jovanovic, P | 2 |
| Dronjak, S | 2 |
| Saddichha, S | 1 |
| Kumar, R | 1 |
| Babu, GN | 1 |
| Chandra, P | 1 |
| van den Hove, DL | 1 |
| Prickaerts, J | 1 |
| Frančišković, T | 1 |
| Suković, Z | 1 |
| Janović, S | 1 |
| Stevanović, A | 1 |
| Nemčić-Moro, I | 1 |
| Rončević-Gržeta, I | 1 |
| Letica-Crepulja, M | 1 |
| Feng, Y | 1 |
| Wang, XY | 1 |
| Li, SD | 1 |
| Wang, HM | 1 |
| Ye, YF | 1 |
| Djordjevic, A | 1 |
| Djordjevic, J | 1 |
| Elaković, I | 1 |
| Adzic, M | 1 |
| Matić, G | 1 |
| Radojcic, MB | 1 |
| Tu, ZC | 1 |
| Xu, XY | 1 |
| Qu, WM | 1 |
| Urade, Y | 1 |
| Huang, ZL | 1 |
| Pechnick, RN | 1 |
| Zonis, S | 1 |
| Wawrowsky, K | 1 |
| Cosgayon, R | 1 |
| Farrokhi, C | 1 |
| Lacayo, L | 1 |
| Chesnokova, V | 1 |
| Grøholt, B | 1 |
| Fertuck, EA | 1 |
| Keilp, J | 1 |
| Song, I | 1 |
| Morris, MC | 1 |
| Wilson, ST | 1 |
| Brodsky, BS | 1 |
| Stanley, B | 1 |
| Mao, QQ | 1 |
| Ip, SP | 1 |
| Xian, YF | 1 |
| Che, CT | 1 |
| Zhou, XJ | 1 |
| Yan, JJ | 1 |
| de Oliveira Balen, G | 1 |
| dos Santos, DB | 1 |
| de Freitas, AE | 1 |
| Farina, M | 1 |
| Severo Rodrigues, AL | 1 |
| Domianidze, T | 1 |
| Matitaishvili, T | 1 |
| Chichinadze, K | 1 |
| Labadze, I | 1 |
| Khananashvili, M | 1 |
| Rickards, H | 1 |
| Cavanna, AE | 1 |
| Worrall, R | 1 |
| Pal, A | 1 |
| Nayak, S | 1 |
| Sahu, PK | 1 |
| Swain, T | 1 |
| Rosania, K | 1 |
| Grilo, CM | 1 |
| Masheb, RM | 1 |
| Crosby, RD | 1 |
| Parabiaghi, A | 1 |
| Franchi, C | 1 |
| Tettamanti, M | 1 |
| Barbato, A | 1 |
| D'Avanzo, B | 1 |
| Fortino, I | 1 |
| Bortolotti, A | 1 |
| Merlino, L | 1 |
| Nobili, A | 1 |
| Devi, S | 1 |
| Liu, XJ | 1 |
| Zhou, YZ | 1 |
| Li, ZF | 1 |
| Cui, J | 1 |
| Li, ZY | 2 |
| Gao, XX | 1 |
| Sun, HF | 1 |
| Zhang, LZ | 1 |
| Du, GH | 1 |
| Qin, XM | 1 |
| Pineda, EA | 1 |
| Hensler, JG | 1 |
| Burke, TF | 1 |
| Mazarati, AM | 1 |
| Allen, PJ | 1 |
| D'Anci, KE | 1 |
| Kanarek, RB | 1 |
| Hartley, CA | 1 |
| McKenna, MC | 1 |
| Salman, R | 1 |
| Holmes, A | 3 |
| Casey, BJ | 1 |
| Phelps, EA | 1 |
| Glatt, CE | 1 |
| Chhillar, R | 1 |
| González-Trujano, ME | 1 |
| Alvarado-Vásquez, N | 1 |
| Mendoza-Sotelo, J | 1 |
| López, G | 1 |
| Moreno, J | 1 |
| Lesemann, A | 1 |
| Reinel, C | 1 |
| Hühnchen, P | 1 |
| Pilhatsch, M | 1 |
| Hellweg, R | 1 |
| Klaissle, P | 1 |
| Winter, C | 1 |
| Steiner, B | 1 |
| Hache, G | 1 |
| Le Dantec, Y | 1 |
| Orvoën, S | 1 |
| Coudoré, F | 1 |
| Huang, GJ | 1 |
| Ben-David, E | 1 |
| Tort Piella, A | 1 |
| Edwards, A | 1 |
| Flint, J | 1 |
| Brookshire, BR | 1 |
| Jones, SR | 1 |
| Récamier-Carballo, S | 1 |
| Reyes, R | 1 |
| Venzala, E | 1 |
| García-García, AL | 1 |
| Elizalde, N | 1 |
| Delagrange, P | 1 |
| Tordera, RM | 1 |
| Nollet, M | 1 |
| Gaillard, P | 1 |
| Girault, V | 1 |
| Leman, S | 1 |
| Machado, DG | 2 |
| Balen, GO | 1 |
| Grando, J | 1 |
| Bettio, LE | 1 |
| Dalmarco, JB | 1 |
| Rial, D | 1 |
| Prediger, RD | 1 |
| Pizzolatti, MG | 2 |
| Kennedy, PJ | 1 |
| Laplant, Q | 1 |
| Shen, L | 1 |
| Cohn, DW | 1 |
| Kinoshita, D | 1 |
| Palermo-Neto, J | 1 |
| Vilar-Pereira, G | 1 |
| Silva, AA | 1 |
| Pereira, IR | 1 |
| Silva, RR | 1 |
| Moreira, OC | 1 |
| de Almeida, LR | 1 |
| de Souza, AS | 1 |
| Rocha, MS | 1 |
| Lannes-Vieira, J | 1 |
| Ghorpade, S | 1 |
| Tripathi, R | 1 |
| Sonawane, D | 1 |
| Manjrekar, N | 1 |
| Qin, L | 1 |
| Chen, R | 1 |
| Fernández Macedo, GV | 1 |
| Cladouchos, ML | 1 |
| Sifonios, L | 1 |
| Cassanelli, PM | 1 |
| Wikinski, S | 1 |
| Yoo, SB | 1 |
| Kim, BT | 1 |
| Kim, JY | 1 |
| Ryu, V | 1 |
| Jahng, JW | 1 |
| Fournet, V | 1 |
| de Lavilléon, G | 1 |
| Schweitzer, A | 1 |
| Andrieux, A | 1 |
| Martres, MP | 1 |
| Sah, A | 1 |
| Schmuckermair, C | 1 |
| Sartori, SB | 1 |
| Gaburro, S | 1 |
| Kandasamy, M | 1 |
| Irschick, R | 1 |
| Klimaschewski, L | 1 |
| Landgraf, R | 1 |
| Aigner, L | 1 |
| Singewald, N | 1 |
| Gumuslu, E | 1 |
| Ulak, G | 1 |
| Celikyurt, IK | 1 |
| Kokturk, S | 1 |
| Kır, HM | 1 |
| Akar, F | 1 |
| Erden, F | 1 |
| Koesters, M | 1 |
| Nosè, M | 1 |
| Omori, IM | 1 |
| Trespidi, C | 1 |
| LeGates, TA | 1 |
| Altimus, CM | 1 |
| Lee, HK | 1 |
| Kirkwood, A | 1 |
| Weber, ET | 1 |
| Hattar, S | 1 |
| Lee, R | 1 |
| Claxton, A | 1 |
| Kovárů, H | 1 |
| Kováru, F | 1 |
| Lisá, V | 1 |
| Platt, B | 1 |
| Schulenberg, J | 1 |
| Klee, N | 1 |
| Nizami, M | 1 |
| Clark, JA | 1 |
| Ledo, JH | 1 |
| Azevedo, EP | 1 |
| Clarke, JR | 1 |
| Ribeiro, FC | 1 |
| Figueiredo, CP | 1 |
| Foguel, D | 1 |
| De Felice, FG | 1 |
| Ferreira, ST | 1 |
| Jang, MH | 1 |
| Kitabatake, Y | 1 |
| Kang, E | 1 |
| Jun, H | 1 |
| Pletnikov, MV | 1 |
| Christian, KM | 2 |
| Lucae, S | 1 |
| Binder, EB | 1 |
| Song, H | 1 |
| Ming, GI | 1 |
| Miguelez, C | 1 |
| Berrocoso, E | 1 |
| Mico, JA | 1 |
| Ugedo, L | 1 |
| Sukoff Rizzo, SJ | 1 |
| Neal, SJ | 1 |
| Hughes, ZA | 1 |
| Beyna, M | 1 |
| Rosenzweig-Lipson, S | 1 |
| Moss, SJ | 1 |
| Brandon, NJ | 1 |
| Doosti, MH | 1 |
| Bakhtiari, A | 1 |
| Zare, P | 1 |
| Amani, M | 1 |
| Majidi-Zolbanin, N | 1 |
| Babri, S | 1 |
| Salari, AA | 1 |
| Burgdorf, J | 1 |
| Nicholson, KL | 1 |
| Balster, RL | 1 |
| Leander, JD | 2 |
| Stanton, PK | 1 |
| Gross, AL | 1 |
| Kroes, RA | 1 |
| Moskal, JR | 1 |
| Zajicova, A | 1 |
| Holan, V | 1 |
| Szczesny, E | 1 |
| Maes, M | 1 |
| Mateus-Pinheiro, A | 1 |
| Pinto, L | 1 |
| Morais, M | 1 |
| Alves, ND | 1 |
| Monteiro, S | 1 |
| Patrício, P | 1 |
| Kuo, JR | 1 |
| Cheng, YH | 1 |
| Chio, CC | 1 |
| Gean, PW | 1 |
| Dournes, C | 1 |
| Beeské, S | 1 |
| Mineur, YS | 1 |
| Obayemi, A | 1 |
| Wigestrand, MB | 1 |
| Fote, GM | 1 |
| Calarco, CA | 1 |
| Li, AM | 1 |
| Picciotto, MR | 1 |
| Spina, E | 4 |
| Avenoso, A | 3 |
| Scordo, MG | 1 |
| Ancione, M | 1 |
| Madia, A | 1 |
| Gatti, G | 2 |
| Perucca, E | 3 |
| Dean, AJ | 1 |
| Bell, J | 1 |
| Mascord, DJ | 1 |
| Parker, G | 1 |
| Christie, MJ | 1 |
| Baumann, P | 1 |
| Zullino, DF | 1 |
| Eap, CB | 1 |
| Fava, M | 5 |
| Farabaugh, AH | 1 |
| Sickinger, AH | 2 |
| Wright, E | 1 |
| Alpert, JE | 2 |
| Sonawalla, S | 1 |
| Nierenberg, AA | 4 |
| Worthington, JJ | 2 |
| Hotopf, M | 2 |
| Garattini, S | 1 |
| Perlis, RH | 2 |
| Pava, J | 1 |
| Matthews, JD | 1 |
| Buchin, J | 1 |
| Jannuzzi, G | 1 |
| Magni, P | 1 |
| Pacifici, R | 1 |
| Zuccaro, P | 1 |
| Torta, R | 1 |
| Guarneri, L | 1 |
| Roca, CA | 1 |
| Schmidt, PJ | 1 |
| Smith, MJ | 1 |
| Danaceau, MA | 1 |
| Murphy, DL | 1 |
| Rubinow, DR | 1 |
| Yu, ZF | 1 |
| Kong, LD | 3 |
| Rénéric, JP | 2 |
| Bouvard, M | 2 |
| Stinus, L | 2 |
| Passik, SD | 1 |
| Kirsh, KL | 1 |
| Theobald, D | 1 |
| Donaghy, K | 1 |
| Holtsclaw, E | 1 |
| Edgerton, S | 1 |
| Dugan, W | 1 |
| Mendes-da-Silva, C | 1 |
| de Souza, SL | 1 |
| Barreto-Medeiros, JM | 1 |
| de Freitas-Silva, SR | 1 |
| Antunes, DE | 1 |
| Cunha, AD | 1 |
| Ribas, VR | 1 |
| de França, MF | 1 |
| Nogueira, MI | 1 |
| Manhães-de-Castro, R | 1 |
| Monte, TL | 1 |
| Rieder, CR | 1 |
| Tort, AB | 1 |
| Rockenback, I | 1 |
| Pereira, ML | 1 |
| Silveira, I | 1 |
| Ferro, A | 1 |
| Sequeiros, J | 1 |
| Jardim, LB | 1 |
| Fruehwald, S | 1 |
| Gatterbauer, E | 1 |
| Rehak, P | 1 |
| Baumhackl, U | 1 |
| Schilder, M | 1 |
| Fisch, MJ | 1 |
| Loehrer, PJ | 1 |
| Kristeller, J | 2 |
| Passik, S | 1 |
| Jung, SH | 1 |
| Arquette, MA | 1 |
| Brames, MJ | 1 |
| Einhorn, LH | 1 |
| Gartside, SE | 1 |
| Leitch, MM | 1 |
| Ducottet, C | 1 |
| Malberg, JE | 1 |
| Strik, JJ | 1 |
| van Praag, HM | 1 |
| Honig, A | 1 |
| Lecca, D | 1 |
| Hansson, S | 1 |
| Driscoll, P | 1 |
| Vogel, G | 1 |
| Gamaro, GD | 1 |
| Streck, EL | 1 |
| Matté, C | 1 |
| Prediger, ME | 1 |
| Wyse, AT | 1 |
| Dalmaz, C | 1 |
| Rosa, AO | 1 |
| Calixto, JB | 2 |
| Santos, AR | 4 |
| Lebert, F | 1 |
| Jorge, RE | 1 |
| Arndt, S | 2 |
| Starkstein, S | 1 |
| Westlund Tam, L | 1 |
| Parry, BL | 1 |
| Kordon, A | 1 |
| Broocks, A | 1 |
| Hohagen, F | 2 |
| Boerner, RJ | 1 |
| Tohen, M | 2 |
| Calabrese, J | 1 |
| Sachs, G | 1 |
| Bowden, C | 1 |
| Mitchell, PB | 1 |
| Centorrino, F | 1 |
| Risser, R | 1 |
| Baker, RW | 2 |
| Evans, AR | 1 |
| Beymer, K | 1 |
| Dube, S | 1 |
| Tollefson, GD | 1 |
| Breier, A | 1 |
| Thompson, MR | 1 |
| Li, KM | 1 |
| Clemens, KJ | 1 |
| Gurtman, CG | 1 |
| Hunt, GE | 1 |
| Cornish, JL | 1 |
| McGregor, IS | 1 |
| Condon, J | 1 |
| Alonso, R | 1 |
| Pavone, G | 1 |
| Stemmelin, J | 2 |
| Le Fur, G | 1 |
| Soubrié, P | 2 |
| Alliot, C | 1 |
| Cook, JW | 1 |
| Spring, B | 2 |
| McChargue, DE | 1 |
| Borrelli, B | 1 |
| Hitsman, B | 2 |
| Keuthen, NJ | 1 |
| Rex, A | 1 |
| Schickert, R | 1 |
| Fink, H | 1 |
| Check, E | 2 |
| Anjaneyulu, M | 1 |
| Chopra, K | 1 |
| Kaur, I | 1 |
| Khanzode, SD | 1 |
| Dakhale, GN | 1 |
| Khanzode, SS | 1 |
| Saoji, A | 1 |
| Palasodkar, R | 1 |
| Overstreet, DH | 5 |
| Hlavka, J | 1 |
| Feighner, JP | 2 |
| Nicolau, G | 1 |
| Freed, JS | 1 |
| Greenslit, N | 2 |
| Roberts, NJ | 1 |
| Bowskill, RJ | 1 |
| Rafferty, PG | 1 |
| Holick, KA | 1 |
| Gundersen, B | 1 |
| Cryan, JF | 1 |
| O'Leary, OF | 1 |
| Jin, SH | 1 |
| Friedland, JC | 1 |
| Ouyang, M | 1 |
| Hirsch, BR | 1 |
| Page, ME | 1 |
| Dalvi, A | 1 |
| Thomas, SA | 1 |
| Velázquez-Moctezuma, J | 1 |
| Flores, DL | 1 |
| Alvarado, I | 1 |
| Flockhart, D | 1 |
| Hommes, M | 1 |
| Hoskam, JA | 1 |
| Norman, TR | 1 |
| Olver, JS | 1 |
| Lee, HS | 1 |
| Lee, TB | 1 |
| Koo, JR | 1 |
| Kim, YK | 1 |
| Son, BK | 1 |
| Fountoulakis, KN | 1 |
| Kaprinis, S | 1 |
| Iacovides, A | 1 |
| Fotiou, F | 1 |
| Kaprinis, G | 1 |
| Thomas, CR | 1 |
| Rosenberg, M | 1 |
| Blythe, V | 1 |
| Meyer, WJ | 1 |
| Bano, S | 1 |
| Akhter, S | 1 |
| Afridi, MI | 1 |
| Emery, M | 1 |
| Senn, A | 1 |
| Wisard, M | 1 |
| Germond, M | 1 |
| OZdel, O | 1 |
| Oğuzhanoğlu, A | 1 |
| Oğuzhanoğlu, NK | 1 |
| Karadağ, F | 1 |
| CUlha Atecí, F | 1 |
| Aybek, Z | 1 |
| Waern, M | 1 |
| Agren, H | 1 |
| Hägglöf, B | 1 |
| Lundin, B | 1 |
| Romani, A | 1 |
| Bergamaschi, R | 1 |
| Candeloro, E | 1 |
| Alfonsi, E | 1 |
| Callieco, R | 1 |
| Cosi, V | 1 |
| Ramanathan, M | 1 |
| Kumar, SN | 1 |
| Suresh, B | 1 |
| Wernicke, JF | 2 |
| Feng, BL | 1 |
| Wang, QC | 1 |
| Rüedi-Bettschen, D | 1 |
| Feldon, J | 1 |
| Pryce, CR | 1 |
| Koenig, EA | 1 |
| Gold, E | 1 |
| Stephenson, D | 1 |
| Yang, RJ | 1 |
| Dreiling, J | 1 |
| Sullivan, T | 1 |
| Crawley, JN | 2 |
| Dias Elpo Zomkowski, A | 1 |
| Oscar Rosa, A | 1 |
| Lúcia Severo Rodrigues, A | 1 |
| Bjerkenstedt, L | 1 |
| Edman, GV | 1 |
| Alken, RG | 1 |
| Mannel, M | 1 |
| Jang, CG | 1 |
| Kang, M | 1 |
| Cho, JH | 1 |
| Lee, SB | 1 |
| Park, S | 1 |
| Park, SK | 1 |
| Hong, M | 1 |
| Shin, MK | 1 |
| Shim, IS | 1 |
| Bae, H | 1 |
| Bochkarev, VK | 1 |
| Avedisova, AS | 1 |
| Liupaeva, NV | 1 |
| Englander, MT | 1 |
| Bhansali, P | 1 |
| Schmauss, C | 2 |
| Jones, MD | 1 |
| Scatton, B | 2 |
| Rohan, ML | 1 |
| Mague, SD | 1 |
| Meloni, EG | 1 |
| Cayetano, K | 1 |
| Tomasiewicz, HC | 1 |
| Rouse, ED | 1 |
| Bjorklund, P | 1 |
| Cornelius, JR | 2 |
| Clark, DB | 1 |
| Bukstein, OG | 1 |
| Kelly, TM | 1 |
| Salloum, IM | 2 |
| Wood, DS | 1 |
| Juan, H | 1 |
| Zhiling, Z | 1 |
| Huande, L | 1 |
| Trivedi, JK | 1 |
| Sharma, S | 1 |
| Tandon, R | 1 |
| Dow, AL | 1 |
| Russell, DS | 1 |
| van Geffen, EC | 1 |
| Hugtenburg, JG | 1 |
| Heerdink, ER | 1 |
| van Hulten, RP | 1 |
| Egberts, AC | 1 |
| Nelson, JC | 2 |
| Portera, L | 2 |
| Leon, AC | 2 |
| Uz, T | 1 |
| Ahmed, R | 1 |
| Akhisaroglu, M | 1 |
| Kurtuncu, M | 1 |
| Imbesi, M | 1 |
| Dirim Arslan, A | 1 |
| Manev, H | 2 |
| Treffers, PD | 1 |
| Rinne-Albers, MA | 1 |
| Shalom, G | 1 |
| Newman, ME | 1 |
| Wong, DT | 2 |
| Perry, KW | 1 |
| Bymaster, FP | 1 |
| Gopal, KV | 1 |
| Briley, KA | 1 |
| Goodale, ES | 1 |
| Hendea, OM | 1 |
| Goldney, RD | 1 |
| Penttilä, J | 1 |
| Hietala, J | 1 |
| Ledley, DR | 1 |
| Huppert, JD | 1 |
| Foa, EB | 1 |
| Davidson, JR | 1 |
| Keefe, FJ | 1 |
| Potts, NL | 1 |
| Gueorguieva, RV | 1 |
| Sanacora, G | 1 |
| Brambilla, P | 1 |
| Furukawa, T | 1 |
| Geddes, J | 1 |
| Gregis, M | 1 |
| Malvini, L | 1 |
| Sumen-Secgin, G | 1 |
| Cimsit, M | 1 |
| Ozek, M | 1 |
| Eroglu, L | 1 |
| Morrison, JL | 2 |
| Riggs, KW | 2 |
| Rurak, DW | 1 |
| Han, SW | 1 |
| Choi, JM | 1 |
| Dopheide, JA | 1 |
| Sharma, A | 1 |
| McClung, CA | 1 |
| Dileone, RJ | 1 |
| Graham, D | 1 |
| Tsankova, NM | 1 |
| Bolanos, CA | 1 |
| Rios, M | 1 |
| Monteggia, LM | 1 |
| Self, DW | 1 |
| Williamson, D | 1 |
| Brown, E | 1 |
| Ahl, J | 1 |
| Twardowschy, CA | 2 |
| Bertolucci, CB | 2 |
| Gracia, Cde M | 2 |
| Brandão, MA | 1 |
| Blom, JM | 1 |
| Kriwin, P | 1 |
| Mendlewicz, J | 2 |
| Chan, KL | 1 |
| Campayo, A | 1 |
| Moser, DJ | 1 |
| Thompson, A | 1 |
| Nazir, S | 1 |
| Sorour, W | 1 |
| Baune, B | 1 |
| Hay, P | 1 |
| Fregni, F | 1 |
| Ono, CR | 1 |
| Santos, CM | 1 |
| Bermpohl, F | 1 |
| Buchpiguel, C | 1 |
| Barbosa, ER | 1 |
| Marcolin, MA | 1 |
| Pascual-Leone, A | 1 |
| Valente, KD | 2 |
| Manev, R | 1 |
| López-Rubalcava, C | 1 |
| Sokol, MS | 1 |
| Fujimoto, CK | 1 |
| Jackson, TK | 1 |
| Silberberg, PJ | 1 |
| Theleritis, CG | 1 |
| Papadimitriou, GN | 1 |
| Papageorgiou, CC | 1 |
| Dikeos, DG | 1 |
| Masdrakis, V | 1 |
| Kostoulas, C | 1 |
| Psarros, C | 1 |
| Soldatos, CR | 1 |
| Hockey, R | 1 |
| Reidak, A | 1 |
| Shahine, LK | 1 |
| Lathi, RB | 1 |
| Siegmund, A | 1 |
| Wotjak, CT | 1 |
| Lei, DL | 1 |
| Song, WX | 1 |
| Simon, NM | 1 |
| Zalta, AK | 1 |
| Hoge, EA | 1 |
| Stevens, JC | 1 |
| Pollack, MH | 1 |
| Himmerich, H | 1 |
| Ehrlinger, M | 1 |
| Hackenberg, M | 1 |
| Löhr, B | 1 |
| Nickel, T | 1 |
| Chan, CH | 1 |
| Liu, HC | 1 |
| Huang, MC | 1 |
| Davis, MP | 1 |
| Camargo, CA | 1 |
| Bloch, DA | 1 |
| Xia, X | 2 |
| Cheng, G | 1 |
| Pan, Y | 2 |
| Xia, ZH | 1 |
| Akhondzadeh Basti, A | 1 |
| Moshiri, E | 1 |
| Jamshidi, AH | 1 |
| Kaster, MP | 2 |
| Binfaré, RW | 1 |
| Dias, M | 1 |
| Brighente, IM | 1 |
| Onat, AM | 1 |
| Oztürk, MA | 1 |
| Ozçakar, L | 1 |
| Ureten, K | 1 |
| Kaymak, SU | 1 |
| Kiraz, S | 1 |
| Ertenli, I | 1 |
| Calgüneri, M | 1 |
| Chen, CH | 1 |
| Ridler, K | 1 |
| Suckling, J | 1 |
| Williams, S | 1 |
| Merlo-Pich, E | 1 |
| Bullmore, E | 1 |
| van der Kolk, BA | 1 |
| Spinazzola, J | 1 |
| Blaustein, ME | 1 |
| Hopper, JW | 1 |
| Hopper, EK | 1 |
| Korn, DL | 1 |
| Simpson, WB | 1 |
| Thomé-Souza, MS | 1 |
| Kuczynski, E | 1 |
| Solodeev, I | 1 |
| Brodsky, O | 1 |
| Dhikav, V | 1 |
| Aggarwal, N | 1 |
| Jadhavi, R | 1 |
| Singh, K | 1 |
| Kung, HF | 1 |
| Jiang, FX | 1 |
| Kraft, K | 1 |
| Carmody, TJ | 1 |
| Trivedi, MH | 2 |
| Hughes, C | 1 |
| Bernstein, IH | 1 |
| Morris, DW | 1 |
| Emslie, GJ | 4 |
| Waslick, B | 1 |
| Weller, EB | 1 |
| Kloos, A | 1 |
| Weller, RA | 1 |
| Kratochvil, CJ | 1 |
| Zhou, WY | 1 |
| Zhang, SJ | 1 |
| Keller, MB | 1 |
| Kornstein, SG | 1 |
| Nemeroff, CB | 1 |
| Friedman, ES | 1 |
| Gelenberg, AJ | 1 |
| Kocsis, JH | 1 |
| Dunner, DL | 1 |
| Dunlop, BW | 1 |
| Hirschfeld, RM | 1 |
| Rothschild, AJ | 2 |
| Ferguson, JM | 1 |
| Schatzberg, AF | 1 |
| Zajecka, JM | 1 |
| Pedersen, R | 1 |
| Yan, B | 1 |
| Ahmed, S | 1 |
| Schmidt, M | 1 |
| Ninan, PT | 1 |
| Csete, K | 1 |
| Vezekényi, Z | 1 |
| Sztriha, L | 1 |
| Vécseil, L | 1 |
| Papp, JG | 1 |
| Dokoupil, T | 1 |
| Shih, YC | 1 |
| Bekele, NB | 1 |
| Karlsson, RM | 1 |
| Choe, JS | 1 |
| Cameron, HA | 1 |
| Thorsell, A | 1 |
| Heilig, M | 1 |
| Santor, DA | 1 |
| Debrota, D | 1 |
| Engelhardt, N | 1 |
| Gelwicks, S | 1 |
| Wang, R | 1 |
| Wu, HL | 1 |
| Li, YB | 1 |
| Li, YH | 1 |
| Guo, JB | 1 |
| Li, XJ | 1 |
| Riggs, PD | 1 |
| Mikulich-Gilbertson, SK | 1 |
| Davies, RD | 1 |
| Lohman, M | 1 |
| Klein, C | 1 |
| Stover, SK | 1 |
| Yu, JP | 1 |
| Navari, RM | 1 |
| Brenner, MC | 1 |
| Wilson, MN | 1 |
| Shishkina, GT | 1 |
| Jürgens, TP | 1 |
| Leinisch, E | 1 |
| Koch, HJ | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| McLay, R | 1 |
| Klinski, A | 1 |
| Kramer, PD | 1 |
| Curzon, G | 1 |
| Hughes, E | 1 |
| Crews, F | 1 |
| Murray, F | 1 |
| Smith, DW | 1 |
| Hutson, PH | 1 |
| Kovalenko, IL | 1 |
| Avgustinovich, DF | 1 |
| Tolstikova, TG | 1 |
| Wei, XH | 1 |
| Cheng, XM | 1 |
| Shen, JS | 1 |
| Wang, ZT | 1 |
| Katz, LY | 1 |
| Kozyrskyj, AL | 1 |
| Prior, HJ | 1 |
| Enns, MW | 1 |
| Cox, BJ | 1 |
| Sareen, J | 1 |
| Kwon, P | 1 |
| Lefkowitz, W | 1 |
| Kennard, BD | 1 |
| Hughes, JL | 1 |
| Stewart, SM | 1 |
| Nightingale-Teresi, J | 1 |
| Tao, R | 1 |
| Carmody, T | 1 |
| Guirguis-Blake, J | 1 |
| Wright, A | 1 |
| Rich, J | 1 |
| Crawford, J | 1 |
| Karpova, N | 1 |
| Sabri, F | 1 |
| Nagayama, H | 1 |
| Hingtgen, JN | 1 |
| Aprison, MH | 1 |
| Brambilla, F | 2 |
| Draisci, A | 2 |
| Peirone, A | 2 |
| Brunetta, M | 2 |
| Reynaert, C | 1 |
| Janne, P | 1 |
| Vause, M | 1 |
| Zdanowicz, N | 1 |
| Lejeune, D | 1 |
| Worthington, J | 1 |
| Davidson, K | 1 |
| Alpert, J | 1 |
| Rosenbaum, JF | 5 |
| Satterlee, WG | 1 |
| Faries, D | 2 |
| Cornelius, MD | 1 |
| Perel, JM | 1 |
| Ehler, JG | 1 |
| Jarrett, PJ | 1 |
| Levin, RL | 1 |
| Black, A | 1 |
| Mann, JJ | 3 |
| Haider, A | 1 |
| Miller, DR | 1 |
| Christenson, JL | 1 |
| Cushing, AG | 1 |
| Station, RD | 1 |
| Mathews, J | 1 |
| Słuzewska, A | 1 |
| Rybakowski, JK | 1 |
| Laciak, M | 1 |
| Mackiewicz, A | 1 |
| Sobieska, M | 1 |
| Wiktorowicz, K | 1 |
| Jick, SS | 1 |
| Dean, AD | 1 |
| Jick, H | 1 |
| Fichtner, CG | 1 |
| Braun, BG | 1 |
| Steiner, M | 1 |
| Steinberg, S | 1 |
| Stewart, D | 1 |
| Carter, D | 1 |
| Berger, C | 1 |
| Reid, R | 1 |
| Grover, D | 1 |
| Streiner, D | 1 |
| Gagiano, CA | 1 |
| el-Yazigi, A | 1 |
| Chaleby, K | 1 |
| Gad, A | 1 |
| Raines, DA | 1 |
| Schleis, T | 1 |
| Vendittelli, F | 1 |
| Alain, J | 1 |
| Nouaille, Y | 1 |
| Brosset, A | 1 |
| Tabaste, JL | 1 |
| Armitage, R | 1 |
| Muilenburg, ND | 1 |
| Smulevich, AB | 1 |
| Andriushchenko, AV | 2 |
| Morkovkina, IV | 1 |
| Tkhostov, ASh | 1 |
| Koliutskaia, EV | 1 |
| Ogilvie, AD | 1 |
| Gram, L | 1 |
| Tejani-Butt, SM | 1 |
| Paré, WP | 1 |
| Wolfe, F | 1 |
| Cathey, MA | 1 |
| Hawley, DJ | 1 |
| Taylor, AT | 1 |
| Wagner, PJ | 1 |
| Pritchard, DC | 1 |
| Tollison, JW | 1 |
| Cesana, R | 1 |
| Ciprandi, C | 1 |
| Borsini, F | 1 |
| Castiella, A | 2 |
| Arenas, JI | 2 |
| Jackson, CW | 1 |
| Morton, WA | 1 |
| Lydiard, RB | 1 |
| Grégoire, J | 1 |
| de Leval, N | 1 |
| Mesters, P | 1 |
| Czarka, M | 2 |
| Lauterbach, EC | 1 |
| Pollicino, AM | 1 |
| Caputi, AP | 2 |
| Fazio, A | 1 |
| Pisani, F | 1 |
| Kazal, LA | 1 |
| Hall, DL | 1 |
| Miller, LG | 1 |
| Noel, ML | 1 |
| Levenson, JL | 1 |
| Fallon, HJ | 1 |
| Elks, ML | 1 |
| Pescatori, ES | 1 |
| Engelman, JC | 1 |
| Davis, G | 1 |
| Goldstein, I | 1 |
| Gambarana, C | 3 |
| Ghiglieri, O | 1 |
| Graziella de Montis, M | 1 |
| Cleare, AJ | 1 |
| Albukrek, D | 1 |
| Moran, DS | 1 |
| Epstein, Y | 1 |
| Nobler, MS | 1 |
| Devanand, DP | 1 |
| Kim, MK | 1 |
| Fitzsimons, LM | 1 |
| Singer, TM | 1 |
| Turret, N | 1 |
| Sackeim, HA | 1 |
| Roose, SP | 1 |
| Dam, M | 1 |
| Tonin, P | 1 |
| De Boni, A | 1 |
| Pizzolato, G | 1 |
| Casson, S | 1 |
| Ermani, M | 1 |
| Freo, U | 1 |
| Piron, L | 1 |
| Battistin, L | 1 |
| McGown, A | 1 |
| Whitbread, J | 1 |
| Patel, SV | 1 |
| Tariot, PN | 1 |
| Asnis, J | 1 |
| Deeg, MA | 1 |
| Lipkin, EW | 1 |
| Robert, E | 1 |
| Bushell, I | 1 |
| Newton, W | 1 |
| Boyeson, MG | 1 |
| Truter, I | 2 |
| Kotze, TJ | 2 |
| Cosme, A | 1 |
| Barrio, J | 1 |
| Lobo, C | 1 |
| Gil, I | 1 |
| Taddio, A | 1 |
| Ito, S | 1 |
| Rintelmann, JW | 1 |
| Varghese, T | 1 |
| Gullion, CM | 1 |
| Kowatch, RA | 1 |
| Hughes, CW | 1 |
| Johnson, GL | 1 |
| Meier, E | 1 |
| Lafer, B | 1 |
| Babb, SM | 1 |
| Stoll, AL | 2 |
| Christensen, JD | 1 |
| Moore, CM | 1 |
| Yurgelun-Todd, DA | 1 |
| Bonello, CM | 1 |
| Pillay, SS | 1 |
| Gilaberte, I | 1 |
| O'Sullivan, RL | 1 |
| Agustin, C | 1 |
| Baer, L | 2 |
| Joffe, RT | 1 |
| Sokolov, ST | 1 |
| Tamai, S | 1 |
| Bostic, JQ | 1 |
| Muriel, AC | 1 |
| Hack, S | 1 |
| Weinstein, S | 1 |
| Herzog, D | 1 |
| Palop, V | 1 |
| Sancho, A | 1 |
| Morales-Olivas, FJ | 1 |
| Martínez-Mir, I | 1 |
| Evans, M | 1 |
| Hammond, M | 1 |
| Wilson, K | 1 |
| Lye, M | 1 |
| Copeland, J | 1 |
| Bates, GD | 1 |
| Khin-Maung-Zaw, F | 1 |
| Hendrie, CA | 1 |
| Sairally, J | 1 |
| Starkey, N | 1 |
| Pazzagli, L | 1 |
| Banfi, R | 1 |
| Borselli, G | 1 |
| Semmola, MV | 1 |
| Petrakis, I | 1 |
| Carroll, KM | 1 |
| Nich, C | 1 |
| Gordon, L | 1 |
| Kosten, T | 1 |
| Rounsaville, B | 1 |
| Behnke, K | 1 |
| Facciolà, G | 1 |
| Fabrazzo, M | 1 |
| Monteleone, P | 1 |
| Maj, M | 1 |
| Benazzi, F | 1 |
| Redrobe, JP | 1 |
| Bourin, M | 1 |
| Caberlotto, L | 2 |
| Gerrard, P | 1 |
| Hurd, YL | 2 |
| Nerhood, RC | 1 |
| Posada, IJ | 1 |
| López-Valdés, E | 1 |
| Vallejo, AR | 1 |
| Portera, A | 1 |
| Bourgeois, JA | 1 |
| Thomas, D | 1 |
| Johansen, T | 1 |
| Walker, DM | 1 |
| Masand, PS | 1 |
| Rangwani, S | 1 |
| Frank, MG | 1 |
| Hendricks, SE | 1 |
| Johnson, DR | 1 |
| Wieseler, JL | 1 |
| Burke, WJ | 1 |
| Amsterdam, JD | 2 |
| Garcia-Espana, F | 1 |
| Fawcett, J | 2 |
| Quitkin, FM | 2 |
| Reimherr, FW | 2 |
| Beasley, C | 1 |
| Navarro, R | 1 |
| Valler, WE | 1 |
| Spangler, M | 1 |
| Wilde, MI | 1 |
| Benfield, P | 1 |
| File, SE | 1 |
| Gonzalez, LE | 1 |
| Meyers, BS | 1 |
| Jimenez, P | 1 |
| Mathé, AA | 1 |
| Stevens, T | 1 |
| Katona, C | 1 |
| Manela, M | 1 |
| Watkin, V | 1 |
| Livingston, G | 1 |
| Rosenberger, WF | 1 |
| Hu, F | 1 |
| Chau, D | 1 |
| Carli, P | 1 |
| Gisserot, O | 1 |
| Marlier, S | 1 |
| Paris, JF | 1 |
| Pingitore, R | 1 |
| Mahableshwarkar, A | 1 |
| Mizes, JS | 1 |
| Segraves, KA | 1 |
| Kristeller, JL | 1 |
| Xu, W | 1 |
| Boylan, LS | 1 |
| Resch, M | 1 |
| Jákó, P | 1 |
| Sidó, Z | 1 |
| Haász, P | 1 |
| Bridler, R | 1 |
| Rault, S | 1 |
| Grosieux-Dauger, C | 1 |
| Verraes, S | 1 |
| Bernardeau, K | 1 |
| Durlach, A | 1 |
| Bernard, P | 1 |
| De Vry, J | 1 |
| Maurel, S | 1 |
| Schreiber, R | 1 |
| de Beun, R | 1 |
| Jentzsch, KR | 1 |
| Sawka, AM | 1 |
| Burgart, V | 1 |
| Zimmerman, D | 1 |
| Norinder, A | 1 |
| Nordling, S | 1 |
| Häggström, L | 1 |
| Lustman, PJ | 1 |
| Freedland, KE | 1 |
| Griffith, LS | 1 |
| Clouse, RE | 1 |
| Rasmussen, K | 1 |
| Calligaro, DO | 1 |
| Czachura, JF | 1 |
| Dreshfield-Ahmad, LJ | 1 |
| Evans, DC | 1 |
| Hemrick-Luecke, SK | 1 |
| Kallman, MJ | 1 |
| Kendrick, WT | 1 |
| Nelson, DL | 1 |
| Overshiner, CD | 1 |
| Wainscott, DB | 1 |
| Wolff, MC | 1 |
| Branchek, TA | 1 |
| Zgombick, JM | 1 |
| Xu, YC | 1 |
| Tyra, JM | 1 |
| Greenawald, MH | 1 |
| Wiart, L | 1 |
| Petit, H | 1 |
| Joseph, PA | 1 |
| Mazaux, JM | 1 |
| Barat, M | 1 |
| Brotto, LA | 1 |
| Barr, AM | 1 |
| Gorzalka, BB | 1 |
| Borghi, J | 1 |
| Guest, JF | 1 |
| Ackerman, DL | 1 |
| Greenland, S | 1 |
| Bystritsky, A | 1 |
| Small, GW | 1 |
| Cyr, M | 2 |
| Charbonneau, C | 1 |
| Morissette, M | 2 |
| Rochford, J | 2 |
| Barden, N | 2 |
| Di Paolo, T | 2 |
| Oke, A | 1 |
| Adhiyaman, V | 1 |
| Aziz, K | 1 |
| Ross, A | 1 |
| Shad, MU | 1 |
| Marsh, C | 1 |
| Preskorn, SH | 1 |
| Cheer, SM | 1 |
| Goa, KL | 1 |
| Beaulieu, S | 1 |
| Varriale, P | 1 |
| Cole, MG | 1 |
| Elie, LM | 1 |
| McCusker, J | 1 |
| Bellavance, F | 1 |
| Mansour, A | 1 |
| Grimm, PJ | 1 |
| Scheggi, S | 1 |
| Tagliamonte, A | 1 |
| Tolu, P | 1 |
| De Montis, MG | 2 |
| Agid, O | 1 |
| Shalev, AY | 1 |
| Chen, H | 1 |
| Harrison, AA | 1 |
| Liem, YT | 1 |
| Markou, A | 1 |
| Schramm, NL | 1 |
| McDonald, MP | 1 |
| Limbird, LE | 1 |
| DeSilva, KE | 1 |
| Le Flore, DB | 1 |
| Marston, BJ | 1 |
| Rimland, D | 1 |
| Inder, WJ | 1 |
| Prickett, TC | 1 |
| Mulder, RT | 1 |
| Donald, RA | 1 |
| Joyce, PR | 1 |
| Darko, W | 1 |
| Guharoy, R | 1 |
| Rose, F | 1 |
| Lehman, D | 1 |
| Pappas, V | 1 |
| Domínguez-Morán, JA | 1 |
| Callejo, JM | 1 |
| Fernández-Ruiz, LC | 1 |
| Martínez-Castrillo, JC | 1 |
| Greene, MA | 1 |
| Tolu, PL | 1 |
| Masi, F | 1 |
| Rinaldi, M | 1 |
| Giachetti, D | 1 |
| Morazzoni, P | 1 |
| Käufeler, R | 1 |
| Meier, B | 1 |
| Brattström, A | 1 |
| Voznesenskaia, TG | 1 |
| Paolucci, S | 1 |
| Antonucci, G | 1 |
| Grasso, MG | 1 |
| Morelli, D | 1 |
| Troisi, E | 1 |
| Coiro, P | 1 |
| De Angelis, D | 1 |
| Rizzi, F | 1 |
| Bragoni, M | 1 |
| Madland, G | 1 |
| Feinmann, C | 1 |
| Tan, RX | 1 |
| Brunswick, DJ | 1 |
| Beasley, CM | 2 |
| Hale, TW | 1 |
| Shum, S | 1 |
| Grossberg, M | 1 |
| Feige, B | 1 |
| Voderholzer, U | 1 |
| Riemann, D | 1 |
| Dittmann, R | 1 |
| Berger, M | 1 |
| Fienberg, AA | 1 |
| Nomikos, GG | 1 |
| Weisberger, AM | 1 |
| Chien, C | 1 |
| Gruber, N | 1 |
| Rurak, D | 1 |
| Spinella, M | 1 |
| Eaton, LA | 1 |
| Simiand, J | 1 |
| Serradeil-Le Gal, C | 1 |
| Wagnon, J | 1 |
| Pascal, M | 1 |
| Maffrand, JP | 1 |
| Garlow, SJ | 1 |
| Gurevich, I | 1 |
| Tamir, H | 1 |
| Arango, V | 1 |
| Dwork, AJ | 1 |
| Naudon, L | 1 |
| Leroux-Nicollet, I | 1 |
| Costentin, J | 1 |
| Luque Ramírez, M | 1 |
| Bajo Martínez, A | 1 |
| Bernal Morell, E | 1 |
| Manzano Espinosa, L | 1 |
| Sammut, S | 1 |
| Bethus, I | 1 |
| Goodall, G | 1 |
| Muscat, R | 1 |
| Diler, RS | 1 |
| Yolga, AY | 1 |
| Avci, A | 1 |
| Kaur, G | 1 |
| Meltzer, HY | 1 |
| Young, M | 1 |
| Metz, J | 1 |
| Fang, VS | 1 |
| Schyve, PM | 1 |
| Arora, RC | 1 |
| Hamilton, MS | 1 |
| Opler, LA | 1 |
| Jermain, DM | 1 |
| Hughes, PL | 1 |
| Follender, AB | 1 |
| Cohen, LJ | 1 |
| Grothe, DR | 1 |
| Shuster, JL | 1 |
| Stern, TA | 1 |
| Greenberg, DB | 1 |
| Hemlock, C | 1 |
| Rosenthal, JS | 1 |
| Winston, A | 1 |
| Burch, KJ | 1 |
| Wells, BG | 1 |
| Max, MB | 1 |
| Lynch, SA | 1 |
| Muir, J | 1 |
| Shoaf, SE | 1 |
| Smoller, B | 1 |
| Dubner, R | 1 |
| Jansen, EN | 1 |
| Kölling, P | 1 |
| Baldwin, D | 1 |
| Müller, N | 1 |
| Brockmöller, J | 1 |
| Roots, I | 1 |
| McGrath, BJ | 1 |
| Stoukides, CA | 1 |
| Levinson, ML | 1 |
| Lipsy, RJ | 1 |
| Fuller, DK | 1 |
| Holden, C | 1 |
| Goff, DC | 1 |
| Brotman, AW | 1 |
| Waites, M | 1 |
| McCormick, S | 1 |
| Vaz, FJ | 1 |
| Salcedo, MS | 1 |
| Mars, F | 1 |
| Dumas de la Roque, G | 1 |
| Goissen, P | 1 |
| Ooi, TK | 1 |
| Sayler, ME | 1 |
| Bosomworth, JC | 1 |
| Pope, HG | 1 |
| McElroy, SL | 1 |
| Kerkhofs, M | 1 |
| Rielaert, C | 1 |
| de Maertelaer, V | 1 |
| Linkowski, P | 1 |
| Westwick, F | 1 |
| Marcus, MD | 1 |
| Wing, RR | 1 |
| Ewing, L | 1 |
| Kern, E | 1 |
| McDermott, M | 1 |
| Gooding, W | 1 |
| Metz, A | 2 |
| Shader, RI | 1 |
| Orzack, MH | 1 |
| Friedman, LM | 1 |
| Marby, DW | 1 |
| Simeon, JG | 1 |
| Dinicola, VF | 1 |
| Ferguson, HB | 1 |
| Copping, W | 1 |
| Wong, SH | 1 |
| Dellafera, SS | 1 |
| Fernandes, R | 1 |
| Kranzler, H | 1 |
| Humphries, JE | 1 |
| Wheby, MS | 1 |
| VandenBerg, SR | 1 |
| Boyer, WF | 1 |
| Corne, SJ | 1 |
| Hall, JR | 1 |
| Jenike, MA | 1 |
| Buttolph, L | 1 |
| Ricciardi, J | 1 |
| Holland, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke[NCT02683213] | Phase 3 | 1,500 participants (Actual) | Interventional | 2014-10-20 | Completed | ||
| Influence of Oxycodone on Individuals Taking an SSRI[NCT05730062] | Phase 1 | 55 participants (Anticipated) | Interventional | 2023-03-15 | Not yet recruiting | ||
| Study to Investigate Melissa Officinalis L. Supplementation for Emotional Health and Sleep Disturbance: A Perspective, Randomized, Double-blinded, Placebo-controlled, Parallel-group Clinical Trial[NCT05602688] | 102 participants (Actual) | Interventional | 2023-01-03 | Completed | |||
| A Randomised Double-blind Placebo-controlled Trial on Encapsulated Lemon Balm Efficacy and Tolerance on Sleep Quality Changes, and Mood and Wellbeing Effects Using Objective and Subjective Measures[NCT05422599] | 99 participants (Actual) | Interventional | 2022-05-05 | Completed | |||
| Clinical Professor[NCT05138887] | Phase 2 | 366 participants (Anticipated) | Interventional | 2022-03-01 | Recruiting | ||
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| Efficacy of Individualized Homeopathic Treatment for Moderate to Severe Depression in Peri- and Postmenopausal Women: a Randomized Placebo-controlled, Double-blind, Double-dummy, Study Protocol[NCT01635218] | Phase 2 | 133 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Non-Invasive Brain Imaging Techniques That Predict Antidepressant Responsiveness and Provide Insights Into the Mechanism of Action of Venlafaxine ER vs. Fluoxetine[NCT00909155] | 50 participants (Actual) | Interventional | 2002-07-31 | Completed | |||
| Placebo-controlled, Dose-response Study of Ibuprofen Effects on Brain Function[NCT02507219] | Phase 2/Phase 3 | 24 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of a Weight Management Program on Body Weight in Individuals Who Are Overweight and Otherwise Healthy[NCT04107155] | 54 participants (Actual) | Interventional | 2019-07-23 | Completed | |||
| A Randomized Controlled Trial to Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain in Overweight But Generally Healthy Adults Over the Winter Holiday Period[NCT03372109] | 23 participants (Actual) | Interventional | 2017-11-14 | Completed | |||
| Prophylactic Cognitive Therapy for Depression.[NCT00118404] | Phase 3 | 523 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544] | Phase 2 | 236 participants (Anticipated) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Stepped Care vs Best Available Care for Bulimia Nervosa[NCT00733525] | 293 participants (Actual) | Interventional | 2000-09-30 | Completed | |||
| Mood Disorder Cohort Research Consortium (MDCRC) in Korea[NCT03088657] | 500 participants (Anticipated) | Observational [Patient Registry] | 2015-09-30 | Recruiting | |||
| Creatine Augmentation in Female & Male Veterans With Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder[NCT01175616] | Phase 4 | 0 participants (Actual) | Interventional | 2012-09-30 | Withdrawn (stopped due to Study withdrawn from ClinicalTrials.gov.) | ||
| Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder: An Open-Label Trial[NCT02660528] | Phase 2 | 3 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to Study staff change.) | ||
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [NCT00113737] | 0 participants | Interventional | 1998-02-28 | Completed | |||
| [NCT00265291] | Phase 2 | 700 participants (Actual) | Interventional | 1999-11-30 | Completed | ||
| Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.[NCT02280096] | Phase 2 | 24 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device[NCT00578383] | 107 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| Low Field Magnetic Stimulation in Bipolar Depression[NCT00217217] | Phase 3 | 13 participants (Actual) | Interventional | 2004-09-30 | Terminated (stopped due to Study was terminated for lack of recruitment.) | ||
| Low Field Magnetic Stimulation in Mood Disorders in Six Visits[NCT01557192] | Phase 1 | 200 participants (Anticipated) | Interventional | 2010-05-31 | Suspended (stopped due to on hold indefinitely due to lack of funding) | ||
| Preliminary Studies for Whole Genome Association Study (WGAS) in Acute Perioperative Pain[NCT01557751] | 156 participants (Actual) | Interventional | 2010-02-28 | Completed | |||
| Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics[NCT04780152] | Phase 2/Phase 3 | 172 participants (Anticipated) | Interventional | 2021-10-31 | Recruiting | ||
| Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) Plus Broad Form of Enhanced Cognitive Behavioural Therapy (CBT-Eb) in Patients With Eating Disorders. A Randomized Controlled Trial[NCT03156959] | 80 participants (Anticipated) | Interventional | 2017-06-19 | Recruiting | |||
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Substance Dependent Teens - Impact of Treating Depression Study 1[NCT00061113] | Phase 4 | 126 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Childhood Depression: Remission and Relapse[NCT00332787] | 200 participants | Interventional | 2000-06-30 | Completed | |||
| Comparative Effects of Aerobic Exercises and Yoga on Pain and Symptoms Severity in Premenstrual Syndrome[NCT05834127] | 36 participants (Actual) | Interventional | 2022-11-20 | Completed | |||
| Evaluation of the Efficiency of a Therapeutic Education Program in Standardized Thermal Cure for Fibromyalgia Patients[NCT02406313] | 152 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder[NCT01852383] | Phase 4 | 30 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial[NCT00657163] | Phase 2 | 100 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475] | Phase 4 | 39 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)[NCT00271596] | Phase 2 | 33 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Cortex Motor Function Reorganization in Stroke Patients: A Longitudinal fMRI Study[NCT04794673] | 36 participants (Actual) | Observational | 2020-01-12 | Completed | |||
| Program ACTIVE: Implementing a Cognitive Behavioral Therapy and Physical Activity Program for Black Men With Comorbid Diabetes and Depression[NCT04369001] | 0 participants (Actual) | Interventional | 2020-12-31 | Withdrawn (stopped due to Due to covid-19 and social distancing, this study was terminated.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17-item Hamilton Rating Scale for Depression (HRSD) is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in HRSD was assessed at baseline and after six weeks of treatment. For this study the change was calculated as the later time point (total score in 17- HRSD at 6 weeks) minus the earlier time point (total score at baseline). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks
| Intervention | Units in Hamilton Scale (Mean) |
|---|---|
| Individualized Homeopathic Treatment | 9.9 |
| Fluoxetine | 11.7 |
| Placebo | 15 |
Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory that assess severity of depression. A total score range was assessed at baseline and after six weeks of treatment. A score 0 (without depression) up to 63 (most severe depression). For this study the change was calculated as the later time point (total score in BDI at 6 weeks) minus the earlier time point (total score in BDI at baseline). A score 0 - 8 is considered normal, 9 - 18 (mild to moderate depression), 19 - 28 (moderate to severe depression), > 29 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks
| Intervention | Units in Beck Depression Inventory (Mean) |
|---|---|
| Individualized Homeopathic Treatment | 12 |
| Fluoxetine | 14.2 |
| Placebo | 15.5 |
Greene Climacteric Scale (GS) is intended to be a standard measure of core climacteric symptoms. For this study a total range was assessed at baseline and after six weeks of treatment. A total score 0 (without climacteric symptoms) up to 63 (most severe climacteric symptoms). The change was calculated as the later time point (total score in GS at 6 weeks) minus the earlier time point (total score at baseline).The scale measures four separate sub-scales (anxiety, depression, somatic symptoms and sexual function). The score of the four sub-scales was summed. A total score of 0 -10 is considered without symptoms, 11 - 29 (mild symptoms), 30 - 49 (moderate symptoms) and > 50 (severe symptoms). (NCT01635218)
Timeframe: Baseline and 6 weeks
| Intervention | Units in Green Scale (Mean) |
|---|---|
| Individualized Homeopathic Treatment | 18.1 |
| Fluoxetine | 23.1 |
| Placebo | 26.8 |
17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Remission rate definition: 17-item Hamilton Rating Scale for Depression score < 7 points after 6 weeks of treatment. (NCT01635218)
Timeframe: 6 weeks
| Intervention | participants with a score of < 7 in HS (Number) |
|---|---|
| Individualized Homeopathic Treatment | 7 |
| Fluoxetine | 7 |
| Placebo | 2 |
17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Responder rate definition: a decrease of 50% or more from baseline score using 17-item Hamilton Rating Scale for Depression after six weeks treatment. (NCT01635218)
Timeframe: 6 weeks
| Intervention | participants with a decrease >50% in HS (Number) |
|---|---|
| Individualized Homeopathic Treatment | 24 |
| Fluoxetine | 19 |
| Placebo | 5 |
"Depressed participants were scanned while viewing a sequence of positive and negative images; they were instructed to enhance or supress their emotional response to the image or to continue to attend. To examine brain function when regulating negative affect, we created contrast maps for each participant at all 3 time points by subtracting the attend condition from the suppress condition in response to negative stimuli. Data from all 3 scan sessions were used to assess treatment-induced change in brain activity when regulating emotion. Analyses examining change using difference scores (end vs. starting points), we subtracted initial HAMD score from final HAMD score. For fMRI analyses, in a voxelwise manner, we subtracted initial negative suppress vs attend from final negative suppress vs attend.~Control subjects were not depressed, repeat scans to assess change were not completed.~Reported results are from BA10, one of our areas of interest." (NCT00909155)
Timeframe: At study entry, 2 months and end of study (6 months)
| Intervention | fMRI signal change (Mean) |
|---|---|
| Depressed; Venlafaxine Treatment | -0.042666667 |
| Depressed; Fluoxetine Treatment | 0.0414 |
"Hamilton Depression rating scale is a clinician assessment tool to measure severity of depression symptoms. Minimum score is 0 (no symptoms); maximum score is 52 (severe symptoms of depression).~Hamilton Anxiety rating scale is a clinician assessment tool to measure severity of anxiety symptoms. Minimum score is 0 (no symptoms); maximum score is 56 (severe symptoms of anxiety)." (NCT00909155)
Timeframe: Study entry, 2 months, and at end of study (6 mos)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| HAMD T0 | HAMA T0 | HAMD 2months | HAMA 2months | HAMD 6months | HAMA 6months | |
| Control (Non-psychiatric Subjects) | 1 | NA | 1.25 | NA | 1.64 | NA |
| Currently Depressed Subjects: Fluoxetine | 21.36 | 15.57 | 10.15 | 8.54 | 7.33 | 5.89 |
| Currently Depressed Subjects: Venlafaxine | 20.07 | 14.07 | 8.86 | 7.5 | 5 | 4.25 |
Change in amygdala activation following administration of placebo, 200mg of ibuprofen or 600mg of ibuprofen (NCT02507219)
Timeframe: 3-6 weeks
| Intervention | percent signal change (Mean) | |
|---|---|---|
| Left amygdala | Right amygdala | |
| Ibuprofen, 200mg | 0.21 | 0.23 |
| Ibuprofen, 600mg | 0.23 | 0.17 |
| Placebo | 0.20 | 0.23 |
"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring major depressive disorder) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~The relapse rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)" (NCT00118404)
Timeframe: Measured at month 8
| Intervention | % patients who relapsed (Number) |
|---|---|
| Continuation Phase Fluoxetine | 18 |
| Continuation Phase Cognitive Therapy | 18.3 |
| Continuation Phase Pill Placebo | 32.7 |
"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~Relapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)." (NCT00118404)
Timeframe: Measured at month 32
| Intervention | % patients who relapsed/recurred (Number) |
|---|---|
| Continuation Phase Fluoxetine | 41.1 |
| Continuation Phase Cognitive Therapy | 45.2 |
| Continuation Phase Pill Placebo | 56.3 |
"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~Relapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)" (NCT00118404)
Timeframe: Measured at month 20
| Intervention | % patients who relapsed/recurred (Number) |
|---|---|
| Continuation Phase Fluoxetine | 35.1 |
| Continuation Phase Cognitive Therapy | 35.0 |
| Continuation Phase Pill Placebo | 42.7 |
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
Measure sustained attention. The CTT uses numbered coloured circles and universal sign language symbols. The circles are printed with vivid pink or yellow backgrounds that are perceptible to colourblind individuals. For the Colour Trails 1 trial, the respondent uses a pencil to rapidly connect circles numbered 1 through 25 in sequence. Less time indicates better performance (min=10, max= 240). (NCT02280096)
Timeframe: 5-8 minutes
| Intervention | units on a scale (seconds) (Mean) |
|---|---|
| 4-aminopyridine | 68.91 |
| Placebo | 67.3 |
The Fatigue Severity Scale (FSS) is one of the most frequently used inventories for measuring fatigue in people with chronic illnesses. The FSS questionnaire is comprised of nine statements inquiring about the examinee's sleep habits over the preceding week. Ratings are on a 7-point Likert scale, where higher scores indicate how strongly the patient agrees with the nine statements.Scale. Scoring using a bimodal response system or a Likert score with weights assigned to each response choice. Likert or bimodal rating scales with 4 response options. For the Likert Scale: better than usual= 0, no more than usual= 1, worse than usual= 2, much worse than usual= 3. For the bimodal scale: better than usual= 0, no more than usual= 0, worse than usual= 1, much worse than usual= 1. Sum all items for a total score. Score range. Range is 0 -11 for bimodal response format. Interpretation of scores. Higher score indicates more fatigue. Self report scale (NCT02280096)
Timeframe: 10 minutes
| Intervention | score on a scale (Mean) |
|---|---|
| 4-aminopirydine | 4.3 |
| Placebo | 3.3 |
The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with MS. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. The first levels 1.0 to 4.5 refers to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refers to the loss of ambulatory ability. It also provides eight subscale measurements called Functional System (FS) scores. The levels of function within each category refer to the eight FS affected by MS: The FS are scored on a scale of 0 (low level of problems) to 5 (high level of problems) to best reflect the level of disability observed clinically. (NCT02280096)
Timeframe: 15-20 minutes
| Intervention | score on a scale (Mean) |
|---|---|
| 4-aminopyridine Treatment | 4.6 |
| Placebo | 4.04 |
Integrated Program of Neuropsychological Exploration Test Barcelona: Digit Span Forward (DSF), (attention spam and improved scoring metrics significantly enhance the precision of DSF assessments of short-term verbal memory). Digit sequences are presented beginning with a length of two digits and two trials are presented at each increasing list length. Max score 8 and min score 0 digits. Higher scores indicate a better cognitive performance. (NCT02280096)
Timeframe: 7-10 min
| Intervention | correct numbers recalled (Mean) |
|---|---|
| 4-aminopyridine | 6.1 |
| Placebo | 5 |
The purpose of this test is to assess visual-spatial constructional ability and visual memory. The time required to copy the drawing is recorded. Less time indicates a better performance and more time indicates a worse outcome (min score 60 and max score 300 seconds). (NCT02280096)
Timeframe: 10-15 minutes
| Intervention | units on a scale (seconds) (Mean) |
|---|---|
| 4-aminopyridine | 208.6 |
| Placebo | 231.2 |
Neuropsychological tests to assess: verbal fluency. Participants have to say as many words as possible from a category in a given time 60 Sec (F, A, S) Max score 72 and min score 19 words. Higher scores indicate a better cognitive performance. (NCT02280096)
Timeframe: 10-15 minutes
| Intervention | Correct words (Mean) |
|---|---|
| 4-aminopyridine | 42.09 |
| Placebo | 35.5 |
Timed 25 Foot Walk Test (T25-FW). The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. TIME LIMIT PER TRIAL (2) 3 minutes (180 seconds) per trial. (NCT02280096)
Timeframe: 5-10 minutes
| Intervention | seconds (Mean) |
|---|---|
| 4-aminopyridine | 15.2 |
| Placebo | 10.4 |
"Is used primarily to assess perseveration and abstract thinking, allows the clinician to assess the following 'frontal' lobe functions: strategic planning, organised searching, utilising environmental feedback to shift cognitive sets, directing behaviour toward achieving a goal. WCST measures abstract reasoning and ability to alter problem solving strategies. Patients are given 128 response cards and 4 stimulus cards and asked to match each stimulus card to 1 pile of response cards. The patient is not told how to match the cards, only right or wrong to each placement. The examiner may change matching rules during the test. Perseveration errors occur when subject repeats the same error no matter how many times they are told the placement is wrong. Higher scores indicate a worse cognitive performance (min=0-3, max=58-126)" (NCT02280096)
Timeframe: 10-15 minutes
| Intervention | score on a scale (Mean) |
|---|---|
| 4-aminopyridine | 19.8 |
| Placebo | 22.8 |
Processing speed information (which includes reading, count, and alternation speed). Cards with a different number of stimuli are shown to the patient, who has to read, count, and respond to a change of instructions (alternation). Reading speed (min 12, max 31+ seconds), counting speed (min 14, max 28+ seconds), and alternation speed (min 26, max 56+ seconds) are recorded. Less speed corresponds to a better outcome. (NCT02280096)
Timeframe: 8-10 min
| Intervention | seconds (Mean) | ||
|---|---|---|---|
| Reading speed | Count speed | Alternation speed | |
| 4-aminopirydine | 28 | 30.5 | 60.3 |
| Placebo | 29.6 | 34.2 | 58.8 |
Safety surveillance will be done every two weeks from the beginning of the study, intentionally searching for adverse events (AE). EEG (Diffuse or focal cerebral dysfunction through demonstration of background slowing or presence of epileptiform activity assessed by a neurophysiologist) and laboratory tests (Presence of values higher of the normal value established by local laboratory and related to the administration of treatments), blood and urine samples: creatinine, blood urea nitrogen, total cholesterol, triglycerides, total direct, and indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, creatinine kinase, lactic acid dehydrogenase, amylase and lipase. A complete blood cell count with differentials and a routine urinalysis and urine culture also obtained at each visit, will be done before the patients take 40, 50 and 60 mg/day. The number of participants with abnormal studies were reported. (NCT02280096)
Timeframe: 22 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Number of participants with abnormal lab results | Number of participants with abnormal EEG | |
| 4-aminopyridine Treatment | 1 | 0 |
| Placebo | 0 | 0 |
Measures higher-order problem-solving ability. The information it provides is not only useful when assessing frontal lobe damage, but also when evaluating attention disorders and executive functioning difficulties. The administrator arranges red, green, and blue beads on a peg board to match the configuration in the diagram. The patient is asked to replicate the configuration on a second peg board. Scores are calculated for Total Execution Time (since the patient performs the first move until he ends the test), Total Problem-Solving Time (the sum of planning and execution times). Total execution time higher scores indicate a worse outcome (min= 0-78, max=564+ seconds), Total problem-solving time higher scores indicate a worse outcome (min= 0-56, max=500+ seconds). (NCT02280096)
Timeframe: 25-30 minutes
| Intervention | seconds (Mean) | |
|---|---|---|
| Total execution time | Total problem-solving time | |
| 4-aminopyridine | 296.2 | 363.3 |
| Placebo | 367.9 | 426.8 |
Measures higher order problem-solving ability. The information it provides is not only useful when assessing frontal lobe damage, but also when evaluating attention disorders and executive functioning difficulties. The administrator arranges red, green, and blue beads on a peg board to match the configuration in the diagram. The patient is asked to replicate the configuration on a second peg board. Scores are calculated for Total Correct Moves and Total Moves. Total moves: higher scores indicate a worse cognitive performance (min= 0, max=58+); Total correct higher scores indicate a better cognitive performance (min=0, max=10). (NCT02280096)
Timeframe: 25-30 minutes
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Total moves | Correct moves | |
| 4-aminopyridine | 42.7 | 4 |
| Placebo | 50.8 | 3 |
A multiple choice questionnaire used to rate depression severity. Mean change from pretreatment score. 17 items reflecting depression symptoms are scored on scale of severity; 9 items are scored 0 = Absent 1 = Trivial 2 = Mild 3 = Moderate 4 = Severe 8 items are scored 0 = Absent 1 = Mild 2 = Severe. Items are summed; minimum score is 0, maximum score is 52. Higher scores represent more severe depression. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Major Depressive Disorder Active LFMS Treatment | -7.19 |
| Major Depressive Disorder Sham LFMS Treatment | -4.02 |
A multiple choice questionnaire used to rate depression severity. Mean change from pretreatment score. 17 items reflecting depression symptoms are scored on scale of severity; 9 items are scored 0 = Absent 1 = Trivial 2 = Mild 3 = Moderate 4 = Severe 8 items are scored 0 = Absent 1 = Mild 2 = Severe. Items are summed; minimum score is 0, maximum score is 52. Higher scores represent more severe depression. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Bipolar Disorder Active LFMS Treatment | -8.3 |
| Bipolar Disorder Sham LFMS Treatment | -5.79 |
A multiple choice questionnaire used to rate depression severity. Mean change from pretreatment score. 17 items reflecting depression symptoms are scored on scale of severity; 9 items are scored 0 = Absent 1 = Trivial 2 = Mild 3 = Moderate 4 = Severe 8 items are scored 0 = Absent 1 = Mild 2 = Severe. Items are summed; minimum score is 0, maximum score is 52. Higher scores represent more severe depression. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Combined Group Active LFMS Treatment | -8.13 |
| Combined Group Sham LFMS Treatment | -5.02 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: once pre and once post LFMS treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Bipolar Disorder Active LFMS Treatment | -7.66 |
| Bipolar Disorder Sham LFMS Treatment | -6.31 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: once pre and once post LFMS treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Major Depressive Disorder Active LFMS Treatment | -5.28 |
| Major Depressive Disorder Sham LFMS Treatment | -3.04 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: once pre and once post LFMS treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Combined Groups Active LFMS Treatment | -7.00 |
| Combined Groups Sham LFMS Treatment | -5.00 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Bipolar Disorder Active LFMS Treatment | 4.18 |
| Bipolar Disorder Sham LFMS Treatment | -0.79 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Major Depressive Disorder Active LFMS Treatment | 1.05 |
| Major Depressive Disorder Sham LFMS Treatment | -0.63 |
20 item list of words that describe different feelings and emotions with positive and negative valences (10 each), which the subject scores on a 1-5 scale: 1 = very slightly or not at all 2 = a little 3 = moderate 4 = quite a bit 5 = extremely. Positive and Negative scores are calculated and reported separately and range from 10-50. Higher positive score reflects stronger positive affect and higher negative score reflects stronger negative affect. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Combined Groups Active LFMS Treatment | 3.16 |
| Combined Groups Sham LFMS Treatment | -0.94 |
Eleven point Likert scales indicating immediate depression state. Mean change from pretreatment score. Participant marks an 'X' on a numbered line anchored by 0 = no depression and 10 = most depressed ever been. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Bipolar Disorder Active LFMS Treatment | -1.18 |
| Bipolar Disorder Sham LFMS Treatment | -1.05 |
Eleven point Likert scales indicating immediate depression state. Mean change from pretreatment score. Participant marks an 'X' on a numbered line anchored by 0 = no depression and 10 = most depressed ever been. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Major Depressive Disorder Active LFMS Treatment | -1.33 |
| Major Depressive Disorder Sham LFMS Treatment | 0.25 |
Eleven point Likert scales indicating immediate depression state. Mean change from pretreatment score. Participant marks an 'X' on a numbered line anchored by 0 = no depression and 10 = most depressed ever been. (NCT00578383)
Timeframe: Once just before and once just after treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Combined Group Active LFMS Treatment | -1.66 |
| Combined Groups Sham LFMS Treatment | -0.60 |
"The primary endpoint is the pain reported by subjects, using the NRS-Pain with movement on the second day after surgery.The assumption behind this study is that certain genetic variants (e.g. single-nucleotide polymorphism (SNP) are responsible for part of total variation of certain clinical phenotypes (e.g. post-operative pain here).~Numeric Rating Score Pain Assessment (0-10 scale where 0 indicates no pain at all and 10 indicates the worst pain imaginable) on Post Op Day 2, Pain with Movement" (NCT01557751)
Timeframe: Postoperative day (POD) 2
| Intervention | units on a scale (Mean) |
|---|---|
| Total Knee Arthroplasty Subjects Who Are Genotyped | 2.83 |
Cornell Dysthymia Rating Scale scores from range 0-64. Lower or decreasing scores represent decreased severity and a better outcome, while higher or increasing scores represent more severe depression and a worse outcome. The change score was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: Week 0 and 12
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 28.8 |
The research rater completed the 24-item Hamilton Rating Scale for Depression (HAM-D) and documented the scores on each visit. Hamilton Rating Scale for Depression scores range from 0-50 with low scores or decreasing scores representing decreased severity and better outcome, and higher scores or increasing scores representing more severe depressive symptoms and a worse outcome. The change score was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: Screen (0) and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 8 |
The Treatment Emergent Symptom Scale (TESS) documents the presence of common side effects. There are 26 items and the total score range is 0-26. Low scores or decrease in scores represent less side effects and high scores or increase in scores represent more side effects. The change in side effect severity scores was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: 0 and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 5.2 |
Maximum duloxetine oral dose (NCT01852383)
Timeframe: Week 0, 1, 2, 4, 6, 8, 10, 12
| Intervention | mg (Mean) |
|---|---|
| Duloxetine | 101 |
Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.005 |
| Placebo | 0.172 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.67 |
| Placebo | 1.23 |
Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.113 |
| Placebo | 0.225 |
Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) & 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.386 |
| Placebo | 0.664 |
"Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say red to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.256 |
| Placebo | -0.046 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.10 |
| Placebo | 1.50 |
Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.227 |
| Placebo | -0.170 |
Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.54 |
| Placebo | -0.06 |
"Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to connect-the-dots of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.087 |
| Placebo | 0.405 |
Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.140 |
| Placebo | 0.071 |
75 reviews available for fluoxetine and Depression
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis.
Topics: Cytokines; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Interleukin-1beta; Interleuki | 2022 |
Controversies in the Pharmacotherapy of Adolescent Depression.
Topics: Adolescent; Adult; Antidepressive Agents; Depression; Depressive Disorder; Fluoxetine; Humans; Suici | 2022 |
Restoring the two pivotal fluoxetine trials in children and adolescents with depression.
Topics: Adolescent; Child; Depression; Fluoxetine; Humans; Psychiatric Status Rating Scales; Treatment Outco | 2022 |
Effects of chronic fluoxetine treatment on anxiety- and depressive-like behaviors in adolescent rodents - systematic review and meta-analysis.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Fluoxetine; Plastics; Rodenti | 2022 |
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Dul | 2022 |
Stroke, depression, and self-harm in later life.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Stroke; Su | 2023 |
Pharmacological interventions and hormonal therapies for depressive symptoms in peri- and post-menopausal women: a network meta-analysis of randomized controlled trials.
Topics: Depression; Female; Fluoxetine; Humans; Middle Aged; Network Meta-Analysis; Postmenopause; Randomize | 2023 |
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Topics: Adult; Bipolar Disorder; Depression; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxe | 2023 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Fluoxetine; Humans; Quality of Life; Randomized | 2019 |
In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis.
Topics: Depression; Dose-Response Relationship, Drug; Fluoxetine; Humans; Network Meta-Analysis; Paroxetine; | 2020 |
Meta-analysis of the clinical effectiveness of combined acupuncture and Western Medicine to treat post-stroke depression.
Topics: Activities of Daily Living; Acupuncture Therapy; Antidepressive Agents; Combined Modality Therapy; D | 2021 |
Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis.
Topics: Citalopram; Depression; Fluoxetine; Fractures, Bone; Humans; Selective Serotonin Reuptake Inhibitors | 2021 |
Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetin | 2017 |
Depression and adult neurogenesis: Positive effects of the antidepressant fluoxetine and of physical exercise.
Topics: Adult; Animals; Antidepressive Agents; Anxiety; Cell Differentiation; Cell Proliferation; Dentate Gy | 2018 |
Integrated Treatment of Adolescents with Co-occurring Depression and Substance Use Disorder.
Topics: Adolescent; Cognitive Behavioral Therapy; Delivery of Health Care, Integrated; Depression; Fluoxetin | 2019 |
Long-lasting neurotoxic effects of exposure to methylmercury during development.
Topics: Animals; Antidepressive Agents, Second-Generation; Cell Proliferation; Cellular Senescence; Depressi | 2013 |
The fetal safety of fluoxetine: a systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Case-Control Studies; Cohort Studies; Depression; Female; Fluoxetine; H | 2013 |
Antidepressants for polycystic ovary syndrome.
Topics: Antidepressive Agents; Cyclobutanes; Depression; Female; Fluoxetine; Humans; Polycystic Ovary Syndro | 2013 |
Which placebo to cure depression? A thought-provoking network meta-analysis.
Topics: Antidepressive Agents; Biomedical Research; Clinical Trials as Topic; Cyclohexanols; Depression; Flu | 2013 |
Long-term outcomes of developmental exposure to fluoxetine: a review of the animal literature.
Topics: Animals; Anxiety; Brain; Depression; Female; Fluoxetine; Humans; Pregnancy; Prenatal Exposure Delaye | 2013 |
Fluoxetine versus other types of pharmacotherapy for depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; D | 2013 |
Progress of animal research on electro-acupuncture treatment for depression(△).
Topics: Animal Experimentation; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Combine | 2014 |
Acute and maintenance treatments for bipolar depression.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depression; Dibenzothiazepin | 2014 |
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; | 2014 |
Biomarkers for assessing population and individual health and disease related to stress and adaptation.
Topics: Adaptation, Psychological; Allostasis; Animals; Antidepressive Agents, Second-Generation; Anxiety; A | 2015 |
Comparison between herbal medicine and fluoxetine for depression: a systematic review of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depression; Drugs, Chinese Herbal; Female; Fl | 2015 |
Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Fluoxetine; Humans; Kidney Failure, Chronic; P | 2016 |
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip | 2016 |
Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility.
Topics: Benzodiazepines; Depression; Drug Combinations; Fluoxetine; Humans; Olanzapine; Randomized Controlle | 2008 |
Antenatal depression: guidelines for when to use pharmacotherapy.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Female; Fluoxetine; Humans; Inf | 2008 |
Fetal and neonatal effects of maternal drug treatment for depression.
Topics: Animals; Depression; Female; Fetal Diseases; Fluoxetine; Gastrointestinal Diseases; Humans; Hyperten | 2008 |
Depression in children and adolescents.
Topics: Adolescent; Child; Depression; Depressive Disorder; Fluoxetine; Humans; Incidence; Psychotherapy, Ps | 2009 |
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.
Topics: Adult; Age Factors; Antidepressive Agents; Benzodiazepines; Depression; Drug Combinations; Drug Inte | 2010 |
Placebo, prozac and PLoS: significant lessons for psychopharmacology.
Topics: Antidepressive Agents, Second-Generation; Controlled Clinical Trials as Topic; Depression; Fluoxetin | 2011 |
Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.
Topics: Abnormalities, Drug-Induced; Cardiovascular Abnormalities; Citalopram; Depression; Female; Fluoxetin | 2010 |
The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review.
Topics: Age Factors; Animals; Anxiety; Behavior, Animal; Depression; Disease Models, Animal; Fluoxetine; Hum | 2011 |
'PROFOX'--the post HRT nightmare.
Topics: Alendronate; Depression; Estrogen Replacement Therapy; Estrogens; Female; Fluoxetine; Humans; Osteop | 2011 |
Duloxetine versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Desvenlafaxine Succinate; Dibenzothiaz | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Fluoxetine; Humans; Menta | 2002 |
Fluoxetine dose and outcome in antidepressant drug trials.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bias; Depression; Fluoxe | 2002 |
[Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias].
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Tri | 2003 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2003 |
[Panic attacks and panic disorder. Checklist for the diagnosis].
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2003 |
New formulations of existing antidepressants: advantages in the management of depression.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2004 |
Safety and side effect profile of fluoxetine.
Topics: Adolescent; Adult; Biotransformation; Bipolar Disorder; Cardiovascular Diseases; Child; Comorbidity; | 2004 |
Can there be a 'cosmetic' psychopharmacology? Prozac unplugged: the search for an ontologically distinct cosmetic psychopharmacology.
Topics: Affect; Antidepressive Agents; Cosmetics; Depression; Depressive Disorder; Drug Utilization; Existen | 2005 |
Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, | 2005 |
Case history: the discovery of fluoxetine hydrochloride (Prozac).
Topics: Depression; Drug Approval; Drug Design; Drug Industry; Fluoxetine; History, 20th Century; Humans | 2005 |
Fluoxetine versus other types of pharmacotherapy for depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; D | 2005 |
Fluoxetine during pregnancy: impact on fetal development.
Topics: Animals; Antidepressive Agents, Second-Generation; Circadian Rhythm; Depression; Disease Models, Ani | 2005 |
[New developments in hypericum extracts: data on efficacy and interactions].
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bridg | 2007 |
[Neuroadaptive changes in brain during selective serotonin reuptake inhibitors action].
Topics: Adaptation, Physiological; Animals; Anxiety Disorders; Depression; Fluoxetine; Humans; Selective Ser | 2007 |
[A clinical challenge. Pragmatic treatment of migraine and concomitant depression].
Topics: Amitriptyline; Analgesics, Non-Narcotic; Antidepressive Agents, Second-Generation; Antidepressive Ag | 2008 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
Clinical inquiries. Which drugs are most effective for moderate to severe depression in adolescents?
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Fluoxetine; Humans; | 2008 |
Fluoxetine.
Topics: Depression; Drug Interactions; Drug Tolerance; Fluoxetine; Humans | 1994 |
Fluoxetine-induced SIADH: a geriatric occurrence?
Topics: Age Factors; Aged; Aged, 80 and over; Depression; Female; Fluoxetine; Humans; Inappropriate ADH Synd | 1993 |
Out of control! the most effective way to help the binge-eating patient.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Bulimia; Cognitive Behavioral Therapy; D | 1996 |
Selective serotonin reuptake inhibitors in pregnancy and lactation.
Topics: Animals; Breast Feeding; Depression; Depression, Postpartum; Female; Fluoxetine; Humans; Pregnancy; | 1998 |
Fluoxetine. A pharmacoeconomic review of its use in depression.
Topics: Antidepressive Agents, Tricyclic; Depression; Fluoxetine; Health Care Costs; Humans; Piperazines; Qu | 1998 |
Depression and dementia: comorbidities, identification, and treatment.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Benzamides; Citalopram; Clomipramine; Cog | 1998 |
[Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective].
Topics: Adrenergic alpha-Agonists; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive A | 2000 |
Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.
Topics: Acquired Immunodeficiency Syndrome; Antidepressive Agents; Clinical Trials as Topic; Cytochrome P-45 | 2001 |
Feasibility and effectiveness of treatments for depression in elderly medical inpatients: a systematic review.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Central Nervous System Stimulants; Contra | 2000 |
Efficacy and tolerability of Ze 117 St. John's wort extract in comparison with placebo, imipramine and fluoxetine for the treatment of mild to moderate depression according to ICD-10. An overview.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; D | 2001 |
Chronic facial pain: a multidisciplinary problem.
Topics: Cognitive Behavioral Therapy; Combined Modality Therapy; Counseling; Depression; Diagnosis, Differen | 2001 |
Akathisia, suicidality, and fluoxetine.
Topics: Akathisia, Drug-Induced; Basal Ganglia Diseases; Depression; Fluoxetine; Humans; Models, Neurologica | 1992 |
Major depression: its recognition and treatment. Part 2. Second-generation and newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Clomipramine; Depression; Female; Fluoxetine; Humans; Male; Maprot | 1992 |
Pros and cons of fluoxetine for the depressed cancer patient.
Topics: Antidepressive Agents; Depression; Fluoxetine; Half-Life; Humans; Neoplasms | 1992 |
Fluoxetine and suicidal ideation.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depression; Female; Fluoxetine; Humans; Male; Middle | 1991 |
Adverse effects and drug interactions associated with fluoxetine therapy.
Topics: Adult; Aged; Depression; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Suicide | 1991 |
Depression and selective serotonin reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depression; Fluoxetine; Humans; Imipramine; Meta-Ana | 1990 |
An overview of fluoxetine, a new serotonin-specific antidepressant.
Topics: Depression; Fluoxetine; Humans | 1989 |
138 trials available for fluoxetine and Depression
| Article | Year |
|---|---|
Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial.
Topics: Affect; Aged; Aged, 80 and over; Depression; Double-Blind Method; Fatigue; Female; Fluoxetine; Healt | 2021 |
Changes of functional connectivity of the subgenual anterior cingulate cortex and precuneus after cognitive behavioral therapy combined with fluoxetine in young depressed patients with suicide attempt.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain; Cognitive Behavioral Therapy; Depression; Fe | 2022 |
Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
Topics: Acetamides; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Depression; Diabetes Melli | 2021 |
Efficacy of Fluoxetine for Post-Ischemic Stroke Depression in Tanzania.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; Ische | 2022 |
Measures Associated With Early, Late, and Persistent Clinically Significant Symptoms of Depression 1 Year After Stroke in the AFFINITY Trial.
Topics: Australia; Cohort Studies; Depression; Female; Fluoxetine; Humans; Infant; Male; Middle Aged; Stroke | 2022 |
Does fluoxetine reduce apathetic and depressive symptoms after stroke? An analysis of the Efficacy oF Fluoxetine-a randomized Controlled Trial in Stroke trial data set.
Topics: Apathy; Depression; Double-Blind Method; Fluoxetine; Humans; Stroke; Treatment Outcome | 2023 |
Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial.
Topics: Antidepressive Agents, Second-Generation; Anxiety; C-Reactive Protein; COVID-19; Depression; Double- | 2023 |
Sequenced treatment alternatives to relieve adolescent depression (STAR-AD): a multicentre open-label randomized controlled trial protocol.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Depressive D | 2023 |
A placebo prognostic index (PI) as a moderator of outcomes in the treatment of adolescent depression: Could it inform risk-stratification in treatment with cognitive-behavioral therapy, fluoxetine, or their combination?
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Depressive Disorder | 2021 |
Wrist-ankle acupuncture and Fluoxetine in the treatment of post-stroke depression: a randomized controlled clinical trial.
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Aged; Ankle; Antidepressive Agents; Combined Modalit | 2020 |
A double-blind, randomized pilot study for comparison of Melissa officinalis L. and Lavandula angustifolia Mill. with Fluoxetine for the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Comb | 2020 |
A double-blind, randomized pilot study for comparison of Melissa officinalis L. and Lavandula angustifolia Mill. with Fluoxetine for the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Comb | 2020 |
A double-blind, randomized pilot study for comparison of Melissa officinalis L. and Lavandula angustifolia Mill. with Fluoxetine for the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Comb | 2020 |
A double-blind, randomized pilot study for comparison of Melissa officinalis L. and Lavandula angustifolia Mill. with Fluoxetine for the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Comb | 2020 |
Network dynamics of depressive symptoms in antidepressant medication treatment: secondary analysis of eight clinical trials.
Topics: Antidepressive Agents; Depression; Fluoxetine; Humans; Paroxetine; Prospective Studies | 2021 |
Quality of life after response to acute-phase cognitive therapy for recurrent depression.
Topics: Adult; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxetine; Follow-Up S | 2021 |
Clinical serum metabolomics study on fluoxetine hydrochloride for depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Biomarkers; Chromatography, High | 2021 |
Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people.
Topics: Adolescent; Australia; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxet | 2021 |
Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Female; Fluoxetine; | 2021 |
Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine.
Topics: Adolescent; Antidepressive Agents; Child; Depression; Female; Fluoxetine; Gene Frequency; Genotype; | 2017 |
The efficacy of fluoxetine in BMS-A cross-over study.
Topics: Aged; Anxiety; Burning Mouth Syndrome; Cross-Over Studies; Depression; Female; Fluoxetine; Humans; M | 2018 |
Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cytokines; Depression; Female; Fluoxeti | 2018 |
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Metho | 2019 |
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Metho | 2019 |
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Metho | 2019 |
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Metho | 2019 |
Inflammatory Profiles in Depressed Adolescents Treated with Fluoxetine: An 8-Week Follow-up Open Study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cytokines; Depression; Depressive Disor | 2018 |
Efficacy and mechanism of acupuncture for ischemic poststroke depression: Study protocol for a multicenter single-blinded randomized sham-controlled trial.
Topics: Activities of Daily Living; Acupuncture Therapy; Adult; Aged; Antidepressive Agents; Brain; Cytokine | 2019 |
A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Depression; Double-Blind Meth | 2019 |
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
Topics: Adolescent; Adult; Anxiety; Australia; Cognitive Behavioral Therapy; Combined Modality Therapy; Como | 2019 |
Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine.
Topics: Activities of Daily Living; Affect; Antidepressive Agents, Second-Generation; Dementia; Depression; | 2012 |
Effects of electroacupuncture on depression and the production of glial cell line-derived neurotrophic factor compared with fluoxetine: a randomized controlled pilot study.
Topics: Adult; Biomarkers; Depression; Electroacupuncture; Enzyme-Linked Immunosorbent Assay; Female; Fluoxe | 2013 |
Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial.
Topics: Analysis of Variance; Antidepressive Agents, Second-Generation; Clinical Protocols; Depression; Doub | 2013 |
Does effective depression treatment alone reduce secondary HIV transmission risk? Equivocal findings from a randomized controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Comorbidity; Depression; Female; Fluoxetine; Follow | 2013 |
Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Behavior Therapy; Combined Modali | 2014 |
Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depression; De | 2013 |
[Effect of early intervention of liver-smoothing and blood-activating decoction combined with acupuncture on patients with post-stroke depression].
Topics: Acupuncture Therapy; Combined Modality Therapy; Depression; Drugs, Chinese Herbal; Early Interventio | 2013 |
A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients.
Topics: Antidepressive Agents; Crocus; Depression; Double-Blind Method; Female; Fluoxetine; Follow-Up Studie | 2014 |
Effects of selective serotonin reuptake inhibition on neural activity related to risky decisions and monetary rewards in healthy males.
Topics: Adult; Brain; Decision Making; Depression; Double-Blind Method; Fluoxetine; Gambling; Humans; Magnet | 2014 |
Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depres | 2014 |
Latent classes of nonresponders, rapid responders, and gradual responders in depressed outpatients receiving antidepressant medication and psychotherapy.
Topics: Adult; Aged; Antidepressive Agents; Bayes Theorem; Cognitive Behavioral Therapy; Combined Modality T | 2015 |
[Acupuncture and drug for subcortical ischemic vascular disease complicated with depression: a randomized controlled trial].
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Aged; Cerebral Infarction; Depression; Female; Fluox | 2014 |
Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxeti | 2015 |
Assessing cognitive therapy skills comprehension, acquisition, and use by means of an independent observer version of the Skills of Cognitive Therapy (SoCT-IO).
Topics: Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Comprehension; Depression; D | 2016 |
Effects of fluoxetine and melatonin on mood, sleep quality and body mass index in postmenopausal women.
Topics: Affect; Aged; Anxiety; Appetite; Body Mass Index; Depression; Double-Blind Method; Drug Therapy, Com | 2015 |
Understanding the Impact of Treatment on the Dimensions of Childhood Depression.
Topics: Adolescent; Child; Depression; Double-Blind Method; Female; Fluoxetine; Humans; Male; Principal Comp | 2017 |
Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: A two-years follow-up.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety; Borderline Personality Disorde | 2016 |
Daily process methodology for measuring earlier antidepressant response.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; Male; Middl | 2008 |
Fluoxetine improves the quality of life in patients with poststroke emotional disturbances.
Topics: Affective Symptoms; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; | 2008 |
Is psychotherapy a reliable alternative to pharmacotherapy to promote the mental health of infertile women? A randomized clinical trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depression; Female; F | 2008 |
Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules.
Topics: Adult; Aged; Aorta; Cell Adhesion; Cell Survival; Chronic Disease; Citalopram; Depression; Endotheli | 2010 |
Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling.
Topics: Adult; Antidepressive Agents; Biomarkers; Counseling; Depression; Drug Therapy, Combination; Female; | 2009 |
Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care?
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Costs and Cost An | 2009 |
Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care
Topics: Adolescent; Adult; Aged; Comorbidity; Cost-Benefit Analysis; Depression; Female; Fluoxetine; Humans; | 2009 |
Pindolol augmentation enhances response outcomes in first depressive episodes.
Topics: Adolescent; Adult; Antidepressive Agents; Depression; Double-Blind Method; Drug Therapy, Combination | 2009 |
Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Biomarkers; Brain Mapping; Cerebr | 2009 |
A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder.
Topics: Adolescent; Adult; Aged; Analgesics; Antidepressive Agents, Second-Generation; Depression; Double-Bl | 2009 |
Efficacy evaluation for depression with somatic symptoms treated by electroacupuncture combined with Fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depression; Dizziness; D | 2009 |
Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Depression; Dose-Response | 2010 |
Influence of electro-acupuncture on the side effects of fluoxetine on depression patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Drug-Related Side Effects and Adv | 2009 |
A single DEX/CRH test in male drug-free depressed patients is associated with the clinical response to treatment with fluoxetine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Area Under Curve; Corticotropin-Releasing Hor | 2010 |
Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram?
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Chi-Square Distribution; Cital | 2011 |
The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with Fluoxetine intervention - A randomized, controlled trial.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depression; Elec | 2011 |
Stepped care and cognitive-behavioural therapy for bulimia nervosa: randomised trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Bulimia Nervosa; Clinical Protocols; Cognitive Beha | 2011 |
Is there a dose-effect relationship between the number of psychotherapy sessions and improvement of social functioning?
Topics: Adolescent; Adult; Combined Modality Therapy; Depression; Dose-Response Relationship, Drug; Female; | 2011 |
Clinical research of acupuncture on malignant tumor patients for improving depression and sleep quality.
Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depression; | 2011 |
Higher executive control and visual memory performance predict treatment completion in borderline personality disorder.
Topics: Adult; Ambulatory Care; Attention; Behavior Therapy; Borderline Personality Disorder; Depression; Ex | 2012 |
Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder.
Topics: Adolescent; Adult; Affect; Binge-Eating Disorder; Body Image; Body Mass Index; Cognitive Behavioral | 2012 |
A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms.
Topics: Adult; Antidepressive Agents; Comorbidity; Depression; Female; Fluoxetine; Humans; Male; Methadone; | 2002 |
Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The | 2002 |
Effects of metergoline on symptoms in women with premenstrual dysphoric disorder.
Topics: Adult; Affect; Depression; Diphenhydramine; Double-Blind Method; Female; Fluoxetine; Humans; Metergo | 2002 |
Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study.
Topics: Adolescent; Adult; Cognition; Depression; Female; Fluoxetine; Humans; Machado-Joseph Disease; Male; | 2003 |
Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Topics: Activities of Daily Living; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind | 2003 |
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Female; | 2003 |
[Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment].
Topics: Antidepressive Agents, Second-Generation; Cohort Studies; Depression; Female; Fluoxetine; Follow-Up | 2003 |
Mortality and poststroke depression: a placebo-controlled trial of antidepressants.
Topics: Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2003 |
Does estrogen enhance the antidepressant effects of fluoxetine?
Topics: Climacteric; Depression; Drug Administration Schedule; Drug Synergism; Estradiol; Estrogen Replaceme | 2003 |
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Diso | 2003 |
Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Moda | 2004 |
Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors.
Topics: Adult; Antioxidants; Ascorbic Acid; Citalopram; Depression; Female; Fluoxetine; Humans; Lipid Peroxi | 2003 |
Biological markers and psychophysiological methods as long term response predictors to fluoxetine treatment.
Topics: Adrenal Cortex Hormones; Adult; Chronic Disease; Depression; Dexamethasone; Dexfenfluramine; Drug Ad | 2004 |
Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment.
Topics: 4-Aminopyridine; Adult; Antidepressive Agents, Second-Generation; Cognition; Depression; Disability | 2004 |
[Influence of Jieyu Huoxue Decoction on rehabilitation of patients with depression after cerebral infarction].
Topics: Aged; Antidepressive Agents, Second-Generation; Cerebral Infarction; Depression; Drugs, Chinese Herb | 2004 |
Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Depr | 2005 |
Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
Topics: Adrenergic Uptake Inhibitors; Adult; Depression; Double-Blind Method; Female; Fluoxetine; Humans; Ma | 2005 |
Selective serotonin reuptake inhibitors treatment effects on auditory measures in depressed female subjects.
Topics: Acoustic Impedance Tests; Adult; Brain; Depression; Dichotic Listening Tests; Evoked Potentials, Aud | 2005 |
Impact of depressive symptoms on the treatment of generalized social anxiety disorder.
Topics: Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depr | 2005 |
Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study.
Topics: Aged; Anger; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Female; Fluo | 2006 |
Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anxiety Disorders; Depression; Depressive Disorder; Double-Blin | 2005 |
Clinical relevance of depressive symptom improvement in bipolar I depressed patients.
Topics: Benzodiazepines; Bipolar Disorder; Depression; Diagnostic and Statistical Manual of Mental Disorders | 2006 |
Aggressive behavior in patients with stroke: association with psychopathology and results of antidepressant treatment on aggression.
Topics: Aged; Aggression; Analysis of Variance; Antidepressive Agents, Tricyclic; Depression; Double-Blind M | 2006 |
Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD.
Topics: Aged; Antidepressive Agents; Brain; Cerebrovascular Circulation; Combined Modality Therapy; Depressi | 2006 |
Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder.
Topics: Adult; Age of Onset; Anxiety Disorders; Comorbidity; Depression; Dysthymic Disorder; Female; Fluoxet | 2006 |
Fluoxetine is not effective in the treatment of post-stroke fatigue: a double-blind, placebo-controlled study.
Topics: Affective Symptoms; Anger; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method | 2007 |
Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Crocus; Depression; Double-Blind Method; Drug Ad | 2007 |
Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment.
Topics: Adult; Antidepressive Agents; Brain; Brain Mapping; Depression; Female; Fluoxetine; Humans; Image Pr | 2007 |
A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance.
Topics: Adult; Combined Modality Therapy; Depression; Desensitization, Psychologic; Double-Blind Method; Eye | 2007 |
A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children.
Topics: Child; Depression; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Psychometrics; Sele | 2007 |
[Observation on effect of Wuling Capsule in treating poststroke depression].
Topics: Aged; Antidepressive Agents, Second-Generation; Capsules; Depression; Drug Synergism; Drug Therapy, | 2007 |
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; De | 2007 |
Optimizing the ability of the Hamilton Depression Rating Scale to discriminate across levels of severity and between antidepressants and placebos.
Topics: Adult; Antidepressive Agents; Depression; Female; Fluoxetine; Humans; Male; Reproducibility of Resul | 2008 |
A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders.
Topics: Adolescent; Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depression; | 2007 |
Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Bre | 2008 |
Maternal depressive symptoms in pediatric major depressive disorder: relationship to acute treatment outcome.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Child; Child of Impaired Parent | 2008 |
[Assessment of effectiveness of electroacupuncture and fluoxetine for treatment of depression with physical symptoms].
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depression; Electroacupu | 2008 |
Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Antidepressive Agents | 1995 |
Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 2. Anorexia nervosa--binge-eating/purging type.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxie | 1995 |
Clinical trials of antidepressants: the hidden face: where locus of control appears to play a key role in depression outcome.
Topics: Adult; Antidepressive Agents; Depression; Fluoxetine; Humans; Internal-External Control; Maprotiline | 1995 |
Patterns of improvement in depressive symptoms with fluoxetine treatment.
Topics: Adolescent; Adult; Aged; Appetite; Cognition; Depression; Female; Fluoxetine; Follow-Up Studies; Hum | 1995 |
The effects of fluoxetine on symptoms of insomnia in depressed patients.
Topics: Adolescent; Adult; Depression; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; P | 1995 |
Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Depression; Double-Blind Method; Female; Fluoxetine | 1995 |
Clinical effect of converting antidepressant therapy from fluoxetine to sertraline.
Topics: 1-Naphthylamine; Ambulatory Care; Antidepressive Agents; Depression; Female; Fluoxetine; Humans; Mal | 1995 |
Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.
Topics: Adolescent; Adult; Depression; Double-Blind Method; Female; Fluoxetine; Humans; Middle Aged; Premens | 1995 |
Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone.
Topics: Adolescent; Adult; Amitriptyline; Bipolar Disorder; Chromatography, High Pressure Liquid; Depression | 1995 |
[The psychopharmacotherapy of anxious-depressive states (the interrelationship of the structure of the comorbidity to the choice of drug therapy)].
Topics: Adult; Alprazolam; Anxiety; Comorbidity; Depression; Double-Blind Method; Female; Fluoxetine; Humans | 1994 |
A double-blind placebo controlled trial of fluoxetine in fibromyalgia.
Topics: Adult; Aged; Anxiety; Depression; Double-Blind Method; Female; Fibromyalgia; Fluoxetine; Humans; Mid | 1994 |
Carbamazepine coadministration with fluoxetine or fluvoxamine.
Topics: Adult; Carbamazepine; Depression; Drug Interactions; Drug Therapy, Combination; Epilepsy, Complex Pa | 1993 |
Open trial of fluoxetine therapy for premenstrual syndrome.
Topics: Adult; Depression; Female; Fluoxetine; Humans; Premenstrual Syndrome | 1993 |
Fluoxetine treatment of dysthymia in the elderly.
Topics: Adult; Age Factors; Age of Onset; Aged; Depression; Depressive Disorder; Female; Fluoxetine; Humans; | 1996 |
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.
Topics: Activities of Daily Living; Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents, Second-Genera | 1996 |
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.
Topics: Activities of Daily Living; Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents, Second-Genera | 1996 |
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.
Topics: Activities of Daily Living; Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents, Second-Genera | 1996 |
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.
Topics: Activities of Daily Living; Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents, Second-Genera | 1996 |
The effects of extended evaluation on depressive symptoms in children and adolescents.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depression; Depressive Disorder; Double | 1996 |
Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study.
Topics: Adult; Antidepressive Agents, Second-Generation; Basal Ganglia; Choline; Depression; Female; Fluoxet | 1997 |
Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Comb | 1997 |
Treatment of depression in the elderly: effect of physical illness on response.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Chronic Disease; Depression; Doub | 1997 |
Self-medication with alcohol appears not to be an effective treatment for the control of depression.
Topics: Adult; Alcohol Drinking; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; H | 1998 |
Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior, Addictive; Cocaine; Cocaine-Related Disor | 1998 |
Antidepressants augment natural killer cell activity: in vivo and in vitro.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; Immunoassay | 1999 |
Blood pressure changes during short-term fluoxetine treatment.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Pressure; Depression; Doubl | 1999 |
Drug treatment of older people with affective disorders in the community: lessons from an attempted clinical trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety Disorders; Clinical Trial | 1999 |
Antidepressant pharmacotherapy helps some cigarette smokers more than others.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Com | 1999 |
[Optimal duration of fluoxetine administration for the successful treatment of depression].
Topics: Adolescent; Adult; Depression; Drug Administration Schedule; Fluoxetine; Humans; Middle Aged | 1999 |
Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Depression; Diabetes Mellitus, | 2000 |
Fluoxetine in early poststroke depression: a double-blind placebo-controlled study.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Female; Fluoxetine; | 2000 |
Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression.
Topics: Aged; Confidence Intervals; Depression; Female; Fluoxetine; Humans; Logistic Models; Male; Middle Ag | 2000 |
Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder.
Topics: Adult; Ambulatory Care; Depression; Drug Administration Schedule; Drug Therapy, Combination; Female; | 2001 |
Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Analysis of Variance; Arginine Vasopressin; Depressi | 2001 |
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Depression; Desipramine; Diabetic Neuropa | 1992 |
Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Depression; Drug Therapy, Combination; Female | 1990 |
High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression.
Topics: Adolescent; Adult; Aged; Depression; Drug Administration Schedule; Female; Fluoxetine; Humans; Hypno | 1991 |
Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables.
Topics: Adolescent; Adult; Amitriptyline; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Psychia | 1990 |
A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters.
Topics: Adolescent; Adult; Attitude to Health; Behavior Therapy; Bulimia; Clinical Trials as Topic; Combined | 1990 |
Weight changes on fluoxetine as a function of baseline weight in depressed outpatients.
Topics: Adult; Aged; Body Weight; Depression; Double-Blind Method; Doxepin; Female; Fluoxetine; Humans; Male | 1990 |
Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up.
Topics: Adolescent Psychiatry; Depression; Double-Blind Method; Fluoxetine; Follow-Up Studies; Humans; Place | 1990 |
A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general practice.
Topics: Adolescent; Adult; Aged; Body Weight; Clinical Trials as Topic; Depression; Dibenzothiepins; Dothiep | 1989 |
794 other studies available for fluoxetine and Depression
| Article | Year |
|---|---|
Novel quinazolinone derivatives as 5-HT7 receptor ligands.
Topics: Animals; Antidepressive Agents; Depression; Ligands; Mice; Molecular Structure; Neurotransmitter Age | 2008 |
PASS-assisted exploration of antidepressant activity of 1,3,4-trisubstituted-beta-lactam derivatives.
Topics: Animals; Antidepressive Agents; Chemistry, Pharmaceutical; Computational Biology; Crystallography, X | 2008 |
Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.
Topics: Animals; Depression; Disease Models, Animal; Drug Design; Gerbillinae; Inhibitory Concentration 50; | 2013 |
Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.
Topics: Antidepressive Agents; Biomimetics; Brain; Computational Biology; Depression; Membrane Transport Pro | 2014 |
Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression.
Topics: Amides; Animals; Antidepressive Agents; Depression; HEK293 Cells; Humans; Injections, Intraperitonea | 2014 |
Synthesis and evaluation of new 3-phenylcoumarin derivatives as potential antidepressant agents.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Coumarins; Depression; Dose-Response Relationship, | 2014 |
Design and synthesis of new series of coumarin-aminopyran derivatives possessing potential anti-depressant-like activity.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Coumarins; Depression; Dose-Response Relationship, | 2015 |
Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression.
Topics: Androgen Antagonists; Andropause; Animals; Cell Line; Depression; Down-Regulation; Humans; Male; Mol | 2017 |
Synthesis and biological evaluation of magnolol derivatives as melatonergic receptor agonists with potential use in depression.
Topics: Animals; Antidepressive Agents; Biphenyl Compounds; Brain; Depression; Female; HEK293 Cells; Hindlim | 2018 |
Novel piperazine-2,5-dione analogs bearing 1H-indole: Synthesis and biological effects.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Depression; Drug Discovery; In | 2020 |
Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
Topics: Adult; Antipsychotic Agents; Anxiety; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome | 2021 |
Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration.
Topics: Alu Elements; Animals; Antidepressive Agents, Second-Generation; Blindness; Cell Line; Cytokines; De | 2021 |
Barriers to access to clinical trial data: Obstruction of a RIAT reanalysis of the treatment for adolescents with depression study.
Topics: Adolescent; Cognitive Behavioral Therapy; Depression; Fluoxetine; Humans; Randomized Controlled Tria | 2022 |
Sex differences in long-term behavioral alterations, especially anxiety, following prenatal fluoxetine exposure in C57BL/6 mice.
Topics: Animals; Anxiety; Autism Spectrum Disorder; Behavior, Animal; Communication; Depression; Female; Flu | 2021 |
[Effects of repeated transcranial magnetic stimulation combined with low-dose fluoxetine on CUMS depression mice].
Topics: Animals; Brain-Derived Neurotrophic Factor; Depression; Fluoxetine; Mice; Stress, Psychological; Tra | 2021 |
Evaluation of the Antidepressant-like Effect of Chronic Administration of Nigella Fixed Oil Versus Fluoxetine in Rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Fluoxetine; Hippocampus; Humans; | 2022 |
Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity.
Topics: Animals; Antidepressive Agents, Second-Generation; Blotting, Western; Depression; Drug Therapy, Comb | 2022 |
Galanin (1-15) Enhances the Behavioral Effects of Fluoxetine in the Olfactory Bulbectomy Rat, Suggesting a New Augmentation Strategy in Depression.
Topics: Animals; Antidepressive Agents; Corticosterone; Depression; Fluoxetine; Galanin; Humans; Peptide Fra | 2022 |
Alpha2-antiplasmin deficiency affects depression and anxiety-like behavior and apoptosis induced by stress in mice.
Topics: alpha-2-Antiplasmin; Animals; Anxiety; Apoptosis; Behavior, Animal; Cytokines; Depression; Fibrinoly | 2022 |
Investigation of Cochlospermum religiosum leaves for antidepressant and anxiolytic activities and its synergistic effect with imipramine and fluoxetine.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Bixaceae; Depression; Fluoxet | 2022 |
Oral administration of
Topics: Administration, Oral; Animals; Anxiety; Cell Line; Depression; Feces; Fluoxetine; Lactococcus lactis | 2022 |
Antidepressant-like Effects of Combined Fluoxetine and Zinc Treatment in Mice Exposed to Chronic Restraint Stress Are Related to Modulation of Histone Deacetylase.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Depression; Disease Models, Animal; Dose-Re | 2021 |
Fluoxetine ameliorates Alzheimer's disease progression and prevents the exacerbation of cardiovascular dysfunction of socially isolated depressed rats through activation of Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome signaling pathway.
Topics: Alzheimer Disease; Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Biogenic Monoamin | 2022 |
The neuropeptide cycloprolylglycine produces antidepressant-like effect and enhances
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dis | 2022 |
Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
Topics: Adult; Aged; Analgesics, Opioid; Cohort Studies; Comorbidity; Depression; Emergency Medical Services | 2022 |
Lower antidepressant response to fluoxetine is associated with anxiety-like behavior, hippocampal oxidative imbalance, and increase on peripheral IL-17 and IFN-γ levels.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Corticosterone; Depression; Disease Model | 2022 |
Involvement of serotonergic neurotransmission in the antidepressant-like effect elicited by cholecalciferol in the chronic unpredictable stress model in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cholecalciferol; Depression; Female; Fluoxetine; H | 2022 |
Exercise more efficiently regulates the maturation of newborn neurons and synaptic plasticity than fluoxetine in a CUS-induced depression mouse model.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Fluoxetine; Hippocampus; Mice; N | 2022 |
Effects of repeated drug administration on behaviors in normal mice and fluoxetine efficacy in chronic unpredictable mild stress mice.
Topics: Animals; Anxiety; Behavior, Animal; Depression; Disease Models, Animal; Fluoxetine; Hippocampus; Hum | 2022 |
Oridonin relieves depressive-like behaviors by inhibiting neuroinflammation and autophagy impairment in rats subjected to chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Autophagy; Autophagy-Related Proteins; Cytokines; Depression; Depres | 2022 |
Anti-depressant effects of acupuncture: The insights from NLRP3 mediated pyroptosis and inflammation.
Topics: Acupuncture Therapy; Animals; Depression; Fluoxetine; Inflammasomes; Inflammation; NLR Family, Pyrin | 2022 |
Octopamine mediates sugar relief from a chronic-stress-induced depression-like state in Drosophila.
Topics: 5-Hydroxytryptophan; Animals; Depression; Depressive Disorder, Major; Dopaminergic Neurons; Drosophi | 2022 |
Chronic Fluoxetine Treatment of Socially Isolated Rats Modulates Prefrontal Cortex Proteome.
Topics: Animals; Antidepressive Agents; Calcium; Calcium-Binding Proteins; Cytochromes c; Depression; Depres | 2022 |
Fluoxetine improves bone microarchitecture and mechanical properties in rodents undergoing chronic mild stress - an animal model of depression.
Topics: Animals; Bone Density; Depression; Disease Models, Animal; Fluoxetine; Rats; Rodentia; Sucrose; X-Ra | 2022 |
Physical exercise prevents behavioral alterations in a reserpine-treated zebrafish: A putative depression model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Behavior, Animal; COVID-19; Depressi | 2022 |
Comparison of LPS and MS-induced depressive mouse model: behavior, inflammation and biochemical changes.
Topics: Animals; Depression; Disease Models, Animal; Fluoxetine; Hippocampus; Humans; Hypothalamo-Hypophysea | 2022 |
Decreased sensitivity to antidepressant drugs in Wistar Hannover rats submitted to two animal models of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Escitalopram; Fluoxetine; Imipramine; | 2023 |
Sinisan alleviates depression-like behaviors by regulating mitochondrial function and synaptic plasticity in maternal separation rats.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents; Depression; Drugs, Chinese Herbal; Fluoxetin | 2022 |
Saffron essential oil ameliorates CUMS-induced depression-like behavior in mice via the MAPK-CREB1-BDNF signaling pathway.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Crocus; Depress | 2023 |
[Pharmacokinetic interaction of Jiaotai Pills and Fluoxetine in rats with CUMS-induced depression].
Topics: Animals; Berberine; Chromatography, Liquid; Depression; Drugs, Chinese Herbal; Fluoxetine; Rats; Tan | 2022 |
Mechanism of lily bulb and Rehmannia decoction in the treatment of lipopolysaccharide-induced depression-like rats based on metabolomics study and network pharmacology.
Topics: Animals; Antidepressive Agents; Cytokines; Depression; Drugs, Chinese Herbal; Endocannabinoids; Fluo | 2022 |
Fluoxetine treatment supports predictive validity of the three hit model of depression in male PACAP heterozygous mice and underpins the impact of early life adversity on therapeutic efficacy.
Topics: Animals; Calcium Carbonate; Corticotropin-Releasing Hormone; Depression; Disease Models, Animal; Flu | 2022 |
Paeoniflorin exhibits antidepressant activity in rats with postpartum depression via the TSPO and BDNF‑mTOR pathways.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Carrier Proteins; Corticosterone; | 2022 |
Epigenetic and Neuronal Activity Markers Suggest the Recruitment of the Prefrontal Cortex and Hippocampus in the Three-Hit Model of Depression in Male PACAP Heterozygous Mice.
Topics: Animals; Depression; Epigenesis, Genetic; Fluoxetine; Hippocampus; Histones; Lysine; Male; Mice; Pit | 2022 |
Baicalin Ameliorates Corticosterone-Induced Depression by Promoting Neurodevelopment of Hippocampal via mTOR/GSK3β Pathway.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal | 2023 |
Continuation of psychiatric medications during pregnancy.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Depression; Female; Fluoxetine; Humans; Pharmaceutical P | 2023 |
Fast-onset effects of Pseudospondias microcarpa (A. Rich) Engl. (Anacardiaceae) hydroethanolic leaf extract on behavioral alterations induced by chronic mild stress in mice.
Topics: Anacardiaceae; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; | 2023 |
miR-124 Exacerbates depressive-like behavior by targeting Ezh2 to induce autophagy.
Topics: Animals; Antidepressive Agents; Autophagy; Depression; Disease Models, Animal; Fluoxetine; Hippocamp | 2023 |
Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression:
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort | 2023 |
Traxoprodil Produces Antidepressant-Like Behaviors in Chronic Unpredictable Mild Stress Mice through BDNF/ERK/CREB and AKT/FOXO/Bim Signaling Pathway.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Anima | 2023 |
Gap junction is essential for the antidepressant effects of fluoxetine.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Fluoxetine; Gap Junctions; Hindl | 2023 |
Protective effect of Nr4a2 (Nurr1) against LPS-induced depressive-like behaviors via regulating activity of microglia and CamkII neurons in anterior cingulate cortex.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Depression; Fluoxetine; Gyrus Cinguli; | 2023 |
Effect of Bromelain on Chronic Unpredictable Stress-induced Behavioral, Biochemical, and Monoamine Changes in Wistar Albino Rat Model of Depression.
Topics: Animals; Antidepressive Agents; Antioxidants; Bromelains; Depression; Disease Models, Animal; Fluoxe | 2023 |
The acceptability of antidepressant treatment in people living with HIV in Malawi: A patient perspective.
Topics: Amitriptyline; Antidepressive Agents; Depression; Fluoxetine; HIV Infections; Humans; Malawi; Pilot | 2023 |
[Effects of SIRT1 in amygdala on chronic restraint stress-induced depression-like behaviors in rats].
Topics: Amygdala; Animals; Depression; Fluoxetine; Male; Rats; Rats, Sprague-Dawley; Restraint, Physical; Si | 2022 |
Acupuncture Alleviates CUMS-Induced Depression-Like Behaviors by Restoring Prefrontal Cortex Neuroplasticity.
Topics: Acupuncture Therapy; Animals; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; | 2023 |
The effects of acupuncture on depression by regulating BDNF-related balance via lateral habenular nucleus BDNF/TrkB/CREB signaling pathway in rats.
Topics: Acupuncture Therapy; Animals; Brain-Derived Neurotrophic Factor; Depression; Fibronectins; Fluoxetin | 2023 |
14-3-3ζ Plays a key role in the modulation of neuroplasticity underlying the antidepressant-like effects of Zhi-Zi-Chi-Tang.
Topics: 14-3-3 Proteins; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclic AMP Respo | 2023 |
The antidepressant-like effects of escitalopram in mice require salt-inducible kinase 1 and CREB-regulated transcription co-activator 1 in the paraventricular nucleus of the hypothalamus.
Topics: Animals; Antidepressive Agents; Depression; Escitalopram; Fluoxetine; Humans; Mice; Paraventricular | 2023 |
Vagus nerve-dependent effects of fluoxetine on anxiety- and depression-like behaviors in mice.
Topics: Animals; Anxiety; Depression; Fluoxetine; Hippocampus; Mice; Serotonin; Vagus Nerve | 2023 |
Effect of Gabapentin-Fluoxetine Derivative GBP1F in a Murine Model of Depression, Anxiety and Cognition.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Ascorbic Acid; Behavior, Animal; Cogni | 2023 |
Fluoxetine-Induced Acute Urinary Retention in a Child With Depression.
Topics: Antidepressive Agents, Second-Generation; Child; Depression; Fluoxetine; Humans; Selective Serotonin | 2023 |
Guanosine treatment prevents lipopolysaccharide-induced depressive-like behavior in mice.
Topics: Animals; Behavior, Animal; Depression; Fluoxetine; Guanosine; Hippocampus; Lipopolysaccharides; Mice | 2023 |
Isoalantolactone relieves depression-like behaviors in mice after chronic social defeat stress via the gut-brain axis.
Topics: Animals; Antidepressive Agents; Brain-Gut Axis; Butyric Acid; Depression; Fluoxetine; Mice; Mice, In | 2023 |
Fluoxetine partially alleviates inflammation in the kidney of socially stressed male C57 BL/6 mice.
Topics: Animals; Antidepressive Agents; Depression; Fluoxetine; Inflammation; Kidney; Male; Mice | 2023 |
Metabolic Fingerprints of Effective Fluoxetine Treatment in the Prefrontal Cortex of Chronically Socially Isolated Rats: Marker Candidates and Predictive Metabolites.
Topics: Acetylcarnitine; Animals; Antidepressive Agents; Behavior, Animal; Biomarkers; Depression; Fluoxetin | 2023 |
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Fl | 2023 |
Prophylactic Effects of Hemp Seed Oil on Perimenopausal Depression: A Role of HPA Axis.
Topics: Adrenocorticotropic Hormone; Animals; Cannabis; Depression; Disease Models, Animal; Estrogen Recepto | 2023 |
Cefaclor causes vagus nerve-mediated depression-like symptoms with gut dysbiosis in mice.
Topics: Animals; Anti-Bacterial Agents; Cefaclor; Colitis; Depression; Dysbiosis; Fluoxetine; Mice; Serotoni | 2023 |
A comparative analysis of depressive-like behavior: Exploring sex-related differences and insights.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal | 2023 |
Urinary metabolic disturbance in the olfactory bulbectomized rats and the modulatory effects of fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; Fluoxetine; M | 2019 |
Activating newborn neurons suppresses depression and anxiety-like behaviors.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Dentate Gyrus; Depression; Depressive Dis | 2019 |
MicroRNA profiling identifies a novel compound with antidepressant properties.
Topics: Animals; Antidepressive Agents; Brain Injuries, Traumatic; Computational Biology; Depression; Diseas | 2019 |
Hippocampus Metabolic Disturbance and Autophagy Deficiency in Olfactory Bulbectomized Rats and the Modulatory Effect of Fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Autophagy; Depression; Disease Models, Animal; Fl | 2019 |
Chronic exposure to fluoxetine of female mice before mating causes impaired stress resilience in female offspring.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Depression; Disease Mo | 2019 |
Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation.
Topics: Acetylation; AMP-Activated Protein Kinases; Animals; Antidepressive Agents; Brain-Derived Neurotroph | 2020 |
Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Anxiety; Depression; Disease Models, Animal; Fluoxetine; | 2020 |
Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of simvastatin in mice: Without tolerance and withdrawal syndrome.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Behavior, Animal; Depression; Drug Tolerance; Fl | 2020 |
Ingestion of Bifidobacterium longum subspecies infantis strain CCFM687 regulated emotional behavior and the central BDNF pathway in chronic stress-induced depressive mice through reshaping the gut microbiota.
Topics: Animals; Bifidobacterium longum subspecies infantis; Brain-Derived Neurotrophic Factor; Depression; | 2019 |
Fluoxetine attenuates stress-induced depressive-like behavior through modulation of hippocampal GAP43 and neurogenesis in male rats.
Topics: Animals; Behavior, Animal; Corticosterone; Depression; Fluoxetine; GAP-43 Protein; Hippocampus; Inte | 2020 |
Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive-like behavior in a depressive-like adult male rat model.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Body Weight; Depression; Fluoxetine; Food | 2020 |
Fast-Acting Black-Phosphorus-Assisted Depression Therapy with Low Toxicity.
Topics: Animals; Behavior, Animal; Depression; Drug Carriers; Electrophysiological Phenomena; Fluoxetine; Ki | 2020 |
Cyclophosphamide-induced cystitis results in NLRP3-mediated inflammation in the hippocampus and symptoms of depression in rats.
Topics: Affect; Animals; Antidepressive Agents; Behavior, Animal; Blood-Brain Barrier; Caspase 1; Cyclophosp | 2020 |
Inflammation-induced behavioral changes is driven by alterations in Nrf2-dependent apoptosis and autophagy in mouse hippocampus: Role of fluoxetine.
Topics: Animals; Apoptosis; Autophagy; Behavior, Animal; Catalase; Depression; Fluoxetine; Glutathione; Hipp | 2020 |
Antidepressant Prescriptions, Including Tricyclics, Continue to Increase in Canadian Children.
Topics: Adolescent; Antidepressive Agents; Antidepressive Agents, Tricyclic; Canada; Child; Child, Preschool | 2020 |
Clinical Case Conference: A Woman with Alcohol Use Disorder and PTSD Case Report.
Topics: Adult; Alcohol-Induced Disorders; Antidepressive Agents; Depression; Female; Fluoxetine; Humans; Mid | 2019 |
Effect of Toll-like receptor 4 on depressive-like behaviors induced by chronic social defeat stress.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Cytokines; Depression; Disease | 2020 |
Fluoxetine effects on behavior and adult hippocampal neurogenesis in female C57BL/6J mice across the estrous cycle.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Estrous Cycle; Female; Fluoxetine; Hip | 2020 |
Antidepressant treatment with fluoxetine during pregnancy and lactation modulates the gut microbiome and metabolome in a rat model relevant to depression.
Topics: Amino Acids; Animals; Antidepressive Agents, Second-Generation; Bacteria; Depression; Feces; Female; | 2020 |
Health outcomes and cost-effectiveness of treating depression in people with HIV in Sub-Saharan Africa: a model-based analysis.
Topics: Adult; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Cost-Benefit Analysis; Depression; | 2021 |
Morus nigra leaves extract revokes the depressive-like behavior, oxidative stress, and hippocampal damage induced by corticosterone: a pivotal role of the phenolic syringic acid.
Topics: Animals; Antioxidants; Behavior, Animal; Cell Survival; Corticosterone; Depression; Fluoxetine; Gall | 2020 |
Influence of miR-155 on behaviors of depression mice through regulating Wnt/β-catenin signaling pathway.
Topics: Animals; Antidepressive Agents, Second-Generation; beta Catenin; Depression; Fluoxetine; Hippocampus | 2020 |
Changes in Gut Microbiota by Chronic Stress Impair the Efficacy of Fluoxetine.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Cell Differentiation; Chronic Disease; Depressi | 2020 |
Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Drug Therapy, Combination; Female; Fl | 2020 |
Selective Inhibition of the Serotonin Transporter in the Treatment of Depression: Sertraline, Fluoxetine and Citalopram.
Topics: Citalopram; Depression; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Serotonin Plasm | 2020 |
Perinatal fluoxetine treatment and dams' early life stress history alter affective behavior in rat offspring depending on serotonin transporter genotype and sex.
Topics: Affect; Animals; Animals, Newborn; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Anim | 2020 |
Effect of the warming and tonifying kidney- yang recipe on monoamine neurotransmitters and pathological morphology of hippocampus tissue in depression model rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Biogenic Monoamines; Body Weight; Depression; Dis | 2020 |
Advances in depression research: special issue, 2020, with three research articles by Paul Greengard.
Topics: Antidepressive Agents; Dentate Gyrus; Depression; Fluoxetine; Receptors, Dopamine D1; Serotonin | 2020 |
Mesopic pupillary reflex in patients treated with fluoxetine.
Topics: Accommodation, Ocular; Adult; Depression; Female; Fluoxetine; Humans; Male; Reflex, Pupillary; Selec | 2020 |
Pica: obsessive-compulsive spectrum disorder, recurrent depression or eating disorder?
Topics: Adult; Anemia, Iron-Deficiency; Depression; Feeding and Eating Disorders; Female; Fluoxetine; Humans | 2020 |
mGluR5 mediates ketamine antidepressant response in susceptible rats exposed to prenatal stress.
Topics: Animals; Antidepressive Agents; Depression; Fluoxetine; Imipramine; Ketamine; Rats | 2020 |
What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Bayes Theorem; Cyclohexanols; Depression; Depressive Disorder, Major; Fluoxetine; Humans | 2020 |
Cholecalciferol abolishes depressive-like behavior and hippocampal glucocorticoid receptor impairment induced by chronic corticosterone administration in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Beclin-1; Behavior, Animal; Cholecalciferol; Cort | 2020 |
Chinese medicine formula Kai-Xin-San ameliorates depression-like behaviours in chronic unpredictable mild stressed mice by regulating gut microbiota-inflammation-stress system.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Chronic Disease; Cytokines; Depression; Dis | 2020 |
Safety of fluoxetine use in children and adolescents: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Anxie | 2020 |
Fluoxetine modulates neuronal activity in stress-related limbic areas of adult rats subjected to the chronic social isolation.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Corpus Striatum; De | 2020 |
Do Cognitive Therapy Skills Neutralize Lifetime Stress to Improve Treatment Outcomes in Recurrent Depression?
Topics: Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Recurrence | 2020 |
Effective treatment and prevention of attempted suicide, anxiety, and aggressiveness with fluoxetine, despite proven use of androgenic anabolic steroids.
Topics: Adult; Aggression; Antidepressive Agents, Second-Generation; Anxiety; Depression; Fluoxetine; Humans | 2021 |
LIMK1/2 in the mPFC Plays a Role in Chronic Stress-Induced Depressive-Like Effects in Mice.
Topics: Animals; Behavior, Animal; Chronic Disease; Depression; Disease Models, Animal; Fluoxetine; Lim Kina | 2020 |
Fluoxetine increases hippocampal neural survival by improving axonal transport in stress-induced model of depression male rats.
Topics: Animals; Axonal Transport; Behavior, Animal; Depression; Disease Models, Animal; Fluoxetine; Hippoca | 2020 |
Developing a data-driven algorithm for guiding selection between cognitive behavioral therapy, fluoxetine, and combination treatment for adolescent depression.
Topics: Adolescent; Algorithms; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; | 2020 |
Fluoxetine-induced recovery of serotonin and norepinephrine projections in a mouse model of post-stroke depression.
Topics: Animals; Depression; Fluoxetine; Mice; Norepinephrine; Serotonin; Stroke | 2020 |
First Evidence of Kv3.1b Potassium Channel Subtype Expression during Neuronal Serotonergic 1C11 Cell Line Development.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; CHO Cells; Cricetulus; Depression; Fluoxetine; Gene | 2020 |
CRTC1 signaling involvement in depression-like behavior of prenatally stressed offspring rat.
Topics: Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Female; Fluoxetine; Male; | 2021 |
Depressive-like behaviors in mice with Imiquimod-induced psoriasis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; | 2020 |
Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Behavioral, biochemical, molecular and immunohistochemical evidence.
Topics: Amino Acids; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Cyc | 2021 |
The effects of Kctd12, an auxiliary subunit of GABA
Topics: Adaptor Proteins, Signal Transducing; Animals; Antidepressive Agents; Behavior, Animal; Dentate Gyru | 2021 |
Pharmacological evaluation of NO/cGMP/KATP channels pathway in the antidepressant-like effect of carbamazepine in mice.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Carbamazepine; Cyclic GMP; Depression; Disease Mode | 2021 |
Intranasal administration of white tea alleviates the olfactory function deficit induced by chronic unpredictable mild stress.
Topics: Administration, Intranasal; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Bra | 2020 |
Ursolic acid abrogates depressive-like behavior and hippocampal pro-apoptotic imbalance induced by chronic unpredictable stress.
Topics: Animals; Antidepressive Agents; Apoptosis; Behavior, Animal; Corticosterone; Depression; Fluoxetine; | 2021 |
Identification of the antidepressive properties of C1, a specific inhibitor of Skp2, in mice.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Response Relationship, Drug | 2021 |
Expression of fibroblast growth factor 9 and its receptors in the dentate gyrus of hippocampus in poststroke depression rats.
Topics: Animals; Dentate Gyrus; Depression; Depressive Disorder; Disease Models, Animal; Down-Regulation; Fi | 2021 |
Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Cell Line; Depression; Disease Models, Animal; El | 2021 |
β-arrestin 2 is essential for fluoxetine-mediated promotion of hippocampal neurogenesis in a mouse model of depression.
Topics: Animals; Antidepressive Agents; beta-Arrestin 2; Cell Proliferation; Dendritic Spines; Dentate Gyrus | 2021 |
SAHA Improves Depressive Symptoms, Cognitive Impairment and Oxidative Stress: Rise of a New Antidepressant Class.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cognitive Dysfunction; Depression; Female; Fluoxet | 2021 |
Beneficial effects of combined administration of fluoxetine and mitochondria-targeted antioxidant at in behavioural and molecular studies in mice model of depression.
Topics: Animals; Antioxidants; Behavior, Animal; Depression; Disease Models, Animal; Drug Therapy, Combinati | 2021 |
Simple acupuncture combined with fluoxetine in the treatment of poststroke depression: A protocol for systematic review and meta-analysis.
Topics: Activities of Daily Living; Acupuncture Therapy; Combined Modality Therapy; Depression; Fluoxetine; | 2021 |
Modulation of the Nitric Oxide/BH4 Pathway Protects Against Irradiation-Induced Neuronal Damage.
Topics: Animals; Antidepressive Agents, Second-Generation; Apoptosis; Biopterins; Brain; Brain Injuries; Cra | 2021 |
Chronically altered NMDAR signaling in epilepsy mediates comorbid depression.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Depression; Epilepsy; Fluoxetine; Indazoles; Male; | 2021 |
Selecting antidepressants according to a drug-by-environment interaction: A comparison of fluoxetine and minocycline effects in mice living either in enriched or stressful conditions.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Environment; F | 2021 |
Topics: Administration, Oral; Depression; Drug Compounding; Fluoxetine; Humans; Solubility; Tablets; Taste | 2021 |
Exercise and fluoxetine treatment during adolescence protect against early life stress-induced behavioral abnormalities in adult rats.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Cort | 2021 |
The Role of Fgf9 in the Antidepressant Effects of Exercise and Fluoxetine in Chronic Unpredictable Mild Stress Mice.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Anima | 2021 |
Ketamine, but not fluoxetine, rapidly rescues corticosterone-induced impairments on glucocorticoid receptor and dendritic branching in the hippocampus of mice.
Topics: Animals; Corticosterone; Depression; Fluoxetine; Hippocampus; Ketamine; Mice; Receptors, Glucocortic | 2021 |
Withanone Ameliorates Stress Symptoms in Caenorhabditis Elegans by Acting through Serotonin Receptors.
Topics: Animals; Animals, Genetically Modified; Antidepressive Agents; Caenorhabditis elegans; COVID-19; Dep | 2021 |
5-HT
Topics: Animals; Anxiety; Corticosterone; Depression; Fluoxetine; Hippocampus; Mice; Serotonin | 2021 |
A novel murine model to study the impact of maternal depression and antidepressant treatment on biobehavioral functions in the offspring.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Female; Fluoxetine; Mice; Pregna | 2021 |
Acupuncture Can Play an Antidepressant Role by Regulating the Intestinal Microbes and Neurotransmitters in a Rat Model of Depression.
Topics: Acupuncture Therapy; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression | 2021 |
Fluoxetine exerts subregion/layer specific effects on parvalbumin/GAD67 protein expression in the dorsal hippocampus of male rats showing social isolation-induced depressive-like behaviour.
Topics: Animals; Behavior, Animal; Depression; Fluoxetine; Glutamate Decarboxylase; Hippocampus; Male; Neuro | 2021 |
Moderators and Predictors of Response After 36 Weeks of Treatment in the Treatment for Adolescents with Depression Study (TADS).
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Depressive D | 2021 |
Antidepressants Differentially Regulate Intracellular Signaling from α1-Adrenergic Receptor Subtypes In Vitro.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Fluoxetine; Gene Expression Reg | 2021 |
Fluoxetine for Stroke: A Mixed Bag of Outcomes.
Topics: Depression; Fluoxetine; Humans; Outcome Assessment, Health Care; Selective Serotonin Reuptake Inhibi | 2021 |
Before and After Prozac: Psychiatry as Medicine, and the Historiography of Depression.
Topics: Depression; Fluoxetine; Historiography; Humans; Mental Disorders; Psychiatry | 2021 |
Fluoxetine ameliorates high-fat diet-induced metabolic abnormalities partially via reduced adipose triglyceride lipase-mediated adipocyte lipolysis.
Topics: Adipocytes; Adipose Tissue; Adipose Tissue, White; Animals; Behavior, Animal; Depression; Diet, High | 2021 |
Antidepressant effects of total iridoids of
Topics: Animals; Animals, Outbred Strains; Antidepressive Agents; Blood-Brain Barrier; Depression; Disease M | 2021 |
Baicalin ameliorates chronic unpredictable mild stress-induced depression through the BDNF/ERK/CREB signaling pathway.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognitive Dysfu | 2021 |
Prenatal fluoxetine impairs non-hippocampal but not hippocampal memory in adult male rat offspring.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Depression; Female; Fluoxetine; Food Pre | 2021 |
Chronic stress-induced dendritic reorganization and abundance of synaptosomal PKA-dependent CP-AMPA receptor in the basolateral amygdala in a mouse model of depression.
Topics: Adamantane; Animals; Antidepressive Agents; Basolateral Nuclear Complex; Cyclic AMP-Dependent Protei | 2017 |
Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays.
Topics: Animals; Behavior, Animal; Berberine; Bifidobacterium; Body Weight; Depression; Disease Models, Anim | 2017 |
BiteStrip analysis of the effect of fluoxetine and paroxetine on sleep bruxism.
Topics: Adult; Anxiety; Dental Devices, Home Care; Depression; Female; Fluoxetine; Humans; Male; Paroxetine; | 2017 |
A novel 5HT3 receptor-IGF1 mechanism distinct from SSRI-induced antidepressant effects.
Topics: Animals; Antidepressive Agents, Second-Generation; Dentate Gyrus; Depression; Depressive Disorder; D | 2018 |
Suppression of pro-inflammatory cytokine expression and lack of anti-depressant-like effect of fluoxetine in lipopolysaccharide-treated old female mice.
Topics: Aging; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Cytokines; Depres | 2017 |
Fluoxetine reverses behavior changes in socially isolated rats: role of the hippocampal GSH-dependent defense system and proinflammatory cytokines.
Topics: Animals; Anxiety; Behavior, Animal; Catalase; Depression; Disease Models, Animal; Fluoxetine; Glutat | 2017 |
BEHAVIORAL EVIDENCE OF ANTIDEPRESSANT-LIKE ACTIVITY OF
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Ethanol; Fluoxetine; Hindlimb Suspensi | 2017 |
Antidepressant drugs for beta amyloid-induced depression: A new standpoint?
Topics: Amyloid beta-Peptides; Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Dep | 2017 |
Mechanisms Underlying the Antidepressant Response of Acupuncture via PKA/CREB Signaling Pathway.
Topics: Acupuncture Therapy; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Cyclic AMP | 2017 |
Evaluation of the effectiveness of chronic antidepressant drug treatments in the hippocampal mitochondria - A proteomic study in an animal model of depression.
Topics: 14-3-3 Proteins; Animals; Antidepressive Agents; Cathepsin D; COP9 Signalosome Complex; Depression; | 2017 |
Chronic fluoxetine rescues changes in plasma membrane density of 5-HT1A autoreceptors and serotonin transporters in the olfactory bulbectomy rodent model of depression.
Topics: Animals; Antidepressive Agents; Autoreceptors; Cell Membrane; Depression; Fluoxetine; Male; Neurons; | 2017 |
Prodepressant- and anxiogenic-like effects of serotonin-selective, but not noradrenaline-selective, antidepressant agents in mice lacking α2-containing GABA
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Anxiety; Depression; Desipramine; Dose | 2017 |
Fluoxetine induces paradoxical effects in C57BL6/J mice: comparison with BALB/c mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder, Major; Disease Mo | 2017 |
Preventive Effects of Ginseng Total Saponins on Chronic Corticosterone-Induced Impairment in Astrocyte Structural Plasticity and Hippocampal Atrophy.
Topics: Animals; Antidepressive Agents; Astrocytes; Atrophy; Corticosterone; Depression; Disease Models, Ani | 2017 |
High Placebo Response Rates Hamper the Discovery of Antidepressants for Depression in Children and Adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Depression; Depressive Disorder; Fluoxetine; Humans | 2017 |
Perinatal fluoxetine effects on social play, the HPA system, and hippocampal plasticity in pre-adolescent male and female rats: Interactions with pre-gestational maternal stress.
Topics: Animals; Anxiety; Behavior, Animal; Depression; Female; Fluoxetine; Hippocampus; Hypothalamo-Hypophy | 2017 |
Depletion of 5 hydroxy-triptamine (5-HT) affects the antidepressant-like effect of neuronal nitric oxide synthase inhibitor in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Dose-Response Relationship, Drug; Drug | 2017 |
The antidepressant effect of melatonin and fluoxetine in diabetic rats is associated with a reduction of the oxidative stress in the prefrontal and hippocampal cortices.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Diabetes Mellitus, Experimental; Fluoxetine; Gl | 2017 |
Characterisation of phenolic compounds of the ethyl acetate fraction from Tabernaemontana catharinensis and its potential antidepressant-like effect.
Topics: Acetates; Animals; Antidepressive Agents; Coumaric Acids; Depression; Fluoxetine; Mice; Phenols; Pla | 2018 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depre | 2017 |
Fluoxetine coupled with zinc in a chronic mild stress model of depression: Providing a reservoir for optimum zinc signaling and neuronal remodeling.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Chronic Disease; Corticosterone; Depressio | 2017 |
Mouse strain differences in SSRI sensitivity correlate with serotonin transporter binding and function.
Topics: Animals; Citalopram; Depression; Fluoxetine; Hindlimb Suspension; Male; Mice, Inbred C57BL; Mice, In | 2017 |
Antidepressant effects of Kai-Xin-San in fluoxetine-resistant depression rats.
Topics: Animals; Antidepressive Agents; Cytokines; Depression; Disease Models, Animal; Drug Resistance; Drug | 2017 |
YL-0919, a dual 5-HT
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclic AMP; | 2018 |
Monoaminergic neurotransmission is mediating the antidepressant-like effects of Passiflora edulis Sims fo. edulis.
Topics: Acetates; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive A | 2017 |
Enriched environment combined with fluoxetine ameliorates depression-like behaviors and hippocampal SYP expression in a rat CUS model.
Topics: Animals; Behavior, Animal; Depression; Depressive Disorder; Disease Models, Animal; Environment; Flu | 2017 |
A decline in depression treatment following FDA antidepressant warnings largely explains racial/ethnic disparities in prescription fills.
Topics: Adolescent; Antidepressive Agents; Black or African American; Child; Child, Preschool; Depression; D | 2017 |
Patients' comprehension and skill usage as a putative mediator of change or an engaged target in cognitive therapy: Preliminary findings.
Topics: Adult; Cognitive Behavioral Therapy; Comprehension; Depression; Depressive Disorder, Major; Female; | 2018 |
Leonurine Exerts Antidepressant-Like Effects in the Chronic Mild Stress-Induced Depression Model in Mice by Inhibiting Neuroinflammation.
Topics: Animals; Antidepressive Agents; Calcium-Binding Proteins; Cytokines; Depression; Disease Models, Ani | 2017 |
Depressive symptoms, monoamines levels, MAO-B activity and effect of treatment in a subset of depressed individuals from government sector hospital at Karachi.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents, Second-Generation; Biomarkers; Case-Control | 2017 |
Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression.
Topics: Animals; Brain; Cytokines; Depression; Disease Models, Animal; Female; Fluoxetine; Inflammation Medi | 2017 |
Cardiac oxidative stress following maternal separation stress was mitigated following adolescent voluntary exercise in adult male rat.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Depression; Disease Models, Ani | 2018 |
Antidepressant-like effect of fluoxetine may depend on translocator protein activity and pretest session duration in forced swimming test in mice.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Disease Models, Animal; Fluoxetine; | 2018 |
Melatonin Augments the Effects of Fluoxetine on Depression-Like Behavior and Hippocampal BDNF-TrkB Signaling.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Dru | 2018 |
Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Depression; De | 2017 |
Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression.
Topics: Amino Acid Transport Systems, Neutral; Animals; Antidepressive Agents, Second-Generation; Behavior, | 2017 |
Study of prevalence and influencing factors of depression in tumor patients and the therapeutic effects of fluoxetine.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; Killer Cells | 2017 |
Antidepressant-like effect of zileuton is accompanied by hippocampal neuroinflammation reduction and CREB/BDNF upregulation in lipopolysaccharide-challenged mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cyclic AMP; Dep | 2018 |
[Exploring the clinical characters of Shugan Jieyu capsule through text mining].
Topics: Anxiety; Data Mining; Depression; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Fluoxeti | 2017 |
Effects of the antidepressants desipramine and fluvoxamine on latency to immobility and duration of immobility in the forced swim test in adult male C57BL/6J mice.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Depression; Desi | 2018 |
Hypercortisolemia and Depressive-like Behaviors in a Rhesus Macaque (
Topics: Adrenal Glands; Alopecia; Animals; Antidepressive Agents, Second-Generation; Creatinine; Cushing Syn | 2017 |
Therapeutic potential of silymarin in chronic unpredictable mild stress induced depressive-like behavior in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Corticosterone; Depression; Disea | 2018 |
Depression- and anxiety-like behaviour is related to BDNF/TrkB signalling in a mouse model of psoriasis.
Topics: Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Disease Models, A | 2018 |
Long Noncoding RNA-Associated Transcriptomic Changes in Resiliency or Susceptibility to Depression and Response to Antidepressant Treatment.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Disease Models, Ani | 2018 |
(R)-fluoxetine enhances cognitive flexibility and hippocampal cell proliferation in mice.
Topics: Animals; Antidepressive Agents; Cell Proliferation; Cognition; Depression; Disease Models, Animal; F | 2018 |
Mitochondrial proteomics investigation of frontal cortex in an animal model of depression: Focus on chronic antidepressant drugs treatment.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Disease Models, Animal; Female; Flu | 2018 |
Thymoquinone and fluoxetine alleviate depression via attenuating oxidative damage and inflammatory markers in type-2 diabetic rats.
Topics: Animals; Antioxidants; Behavior, Animal; Benzoquinones; Biomarkers; Cytokines; Depression; Diabetes | 2019 |
Perinatal exposure to venlafaxine leads to lower anxiety and depression-like behavior in the adult rat offspring.
Topics: Adrenal Cortex Hormones; Aldosterone; Animals; Animals, Newborn; Anxiety; Anxiety Disorders; Behavio | 2018 |
Tauroursodeoxycholic acid produces antidepressant-like effects in a chronic unpredictable stress model of depression via attenuation of neuroinflammation, oxido-nitrosative stress, and endoplasmic reticulum stress.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Endoplasmic Reticulum Stress; Fl | 2018 |
Proteomic characterization of hippocampus of chronically socially isolated rats treated with fluoxetine: Depression-like behaviour and fluoxetine mechanism of action.
Topics: Animals; Behavior, Animal; Depression; Fluoxetine; Hippocampus; Male; Mitochondria; Proteome; Proteo | 2018 |
Antidepressant effects of acupoint stimulation and fluoxetine by increasing dendritic arborization and spine density in CA1 hippocampal neurons of socially isolated rats.
Topics: Acupuncture Points; Animals; Antidepressive Agents, Second-Generation; CA1 Region, Hippocampal; Dend | 2018 |
Voluntary Exercise During Adolescence Mitigated Negative the Effects of Maternal Separation Stress on the Depressive-Like Behaviors of Adult Male Rats: Role of NMDA Receptors.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Hippocampu | 2018 |
Excessive Masturbation Successfully Treated with Fluoxetine in an Adolescent with Autism Spectrum Disorder and Coexisting Depression.
Topics: Adolescent; Autism Spectrum Disorder; Comorbidity; Depression; Female; Fluoxetine; Humans; Male; Mas | 2018 |
Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Celecoxib; Depression; D | 2018 |
Reserpine-induced depression is associated in female, but not in male, adolescent rats with heightened, fluoxetine-sensitive, ethanol consumption.
Topics: Alcohol Drinking; Animals; Depression; Dopamine; Ethanol; Female; Fluoxetine; Male; Rats; Rats, Wist | 2018 |
Do Selective Serotonin Reuptake Inhibitor Antidepressant Drugs Promote Atherosclerosis?
Topics: Antidepressive Agents; Atherosclerosis; Depression; Fluoxetine; Humans; Selective Serotonin Reuptake | 2018 |
Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice.
Topics: Animals; Antidepressive Agents; Depression; Female; Fluoxetine; Hippocampus; Male; Mice, Inbred C57B | 2018 |
Perilla aldehyde attenuates CUMS-induced depressive-like behaviors via regulating TXNIP/TRX/NLRP3 pathway in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Carrier Proteins; Caspase Inhibitors; Cell Cycle | 2018 |
Anti-Depressant Fluoxetine Reveals its Therapeutic Effect Via Astrocytes.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents; Astrocytes; Depression; Exocytosis; Fluoxeti | 2018 |
The antioxidant gallic acid induces anxiolytic-, but not antidepressant-like effect, in streptozotocin-induced diabetes.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antioxidants; Anxiety; Behavior, Animal; Depres | 2018 |
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depr | 2018 |
Comparison of Therapeutic Effects of TREK1 Blockers and Fluoxetine on Chronic Unpredicted Mild Stress Sensitive Rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Apoptosis; Behavior, Animal; Bridged Bicyclo Comp | 2018 |
Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Fluoxetine; Ganglia, Spinal; Humans | 2018 |
Cholecalciferol counteracts depressive-like behavior and oxidative stress induced by repeated corticosterone treatment in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cholecalciferol; Corticosterone; Depression; Disea | 2018 |
A P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Chronic Disease; Dentate Gyrus; Depression; Depres | 2018 |
Naringenin protects against oxido-inflammatory aberrations and altered tryptophan metabolism in olfactory bulbectomized-mice model of depression.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain Ch | 2018 |
Platelet serotonin and serotonin transporter as peripheral surrogates in depression and anxiety patients.
Topics: Adult; Anxiety; Blood Platelets; Depression; Dose-Response Relationship, Drug; Female; Fluoxetine; H | 2018 |
Single administration of agmatine reverses the depressive-like behavior induced by corticosterone in mice: Comparison with ketamine and fluoxetine.
Topics: Agmatine; Animals; Antidepressive Agents; Brain; Corticosterone; Depression; Disks Large Homolog 4 P | 2018 |
Fluoxetine protects against OVA induced bronchial asthma and depression in rats.
Topics: Animals; Asthma; Brain-Derived Neurotrophic Factor; Depression; Dexamethasone; Fluoxetine; Immunoglo | 2018 |
Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression.
Topics: Adult; Animals; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Cholesterol; Depression; Femal | 2018 |
Antidepressant-like effects of insulin and IGF-1 are mediated by IGF-1 receptors in the brain.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Depression; Depressive Disorder; Fluoxetine | 2018 |
Resveratrol exerts a protective effect in chronic unpredictable mild stress-induced depressive-like behavior: involvement of the AKT/GSK3β signaling pathway in hippocampus.
Topics: Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Cytokines; Depression; Fluoxetine; G | 2019 |
Changes in white matter and the effects of fluoxetine on such changes in the CUS rat model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; Fluoxetine; M | 2019 |
Subregion-specific Protective Effects of Fluoxetine and Clozapine on Parvalbumin Expression in Medial Prefrontal Cortex of Chronically Isolated Rats.
Topics: Animals; Caspase 3; Cell Count; Clozapine; Depression; Fluoxetine; Male; Neurons; Neuroprotective Ag | 2019 |
Fluoxetine oral treatment discloses 5-HT
Topics: Administration, Oral; Animals; Antidepressive Agents, Second-Generation; Bradycardia; Depression; Di | 2019 |
Tauroursodeoxycholic Acid Ameliorates Lipopolysaccharide-Induced Depression Like Behavior in Mice via the Inhibition of Neuroinflammation and Oxido-Nitrosative Stress.
Topics: Animals; Antidepressive Agents; Cytokines; Depression; Disease Models, Animal; Fluoxetine; Hippocamp | 2019 |
Prenatal Stimulation of 5-HT
Topics: Adaptation, Psychological; Animals; Animals, Newborn; Anxiety; Behavior, Animal; Buspirone; Depressi | 2019 |
Antidepressant-like activities of live and heat-killed Lactobacillus paracasei PS23 in chronic corticosterone-treated mice and possible mechanisms.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Animal; Brain; Corticosterone; | 2019 |
Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice.
Topics: Animals; Antidepressive Agents; Atorvastatin; Behavior, Animal; Brain-Derived Neurotrophic Factor; D | 2019 |
Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviours and alters glutamatergic markers in the prefrontal cortex and hippocampus of male adolescent rats: A comparison between Sprague-Dawley rats and the Wistar-Kyoto rat model o
Topics: Animals; Anxiety; Depression; Disease Models, Animal; Female; Fluoxetine; Hippocampus; Male; Prefron | 2019 |
Glucocorticoid receptor dysfunction orchestrates inflammasome effects on chronic obstructive pulmonary disease-induced depression: A potential mechanism underlying the cross talk between lung and brain.
Topics: Animals; Brain; Bronchoalveolar Lavage Fluid; Caspase 1; Cigarette Smoking; Cytokines; Depression; D | 2019 |
N-acetylcysteine attenuates neuroinflammation associated depressive behavior induced by chronic unpredictable mild stress in rat.
Topics: Acetylcysteine; Animals; Antidepressive Agents; Behavior, Animal; Cytokines; Depression; Depressive | 2019 |
Lutein prevents corticosterone-induced depressive-like behavior in mice with the involvement of antioxidant and neuroprotective activities.
Topics: Animals; Antioxidants; Behavior, Animal; Corticosterone; Depression; Fluoxetine; Lutein; Male; Mice; | 2019 |
Hippocampal mossy cell involvement in behavioral and neurogenic responses to chronic antidepressant treatment.
Topics: Animals; Antidepressive Agents; Cell Line; Depression; Fluoxetine; Mice; Mossy Fibers, Hippocampal; | 2020 |
Fear.
Topics: Anticonvulsants; Anxiety; Clonazepam; Depression; Family Practice; Fear; Female; Fluoxetine; Humans; | 2019 |
Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiac Conduction System Disease; Citalopram; Death, Sudden, | 2019 |
Silymarin and silymarin nanoparticles guard against chronic unpredictable mild stress induced depressive-like behavior in mice: involvement of neurogenesis and NLRP3 inflammasome.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Fluoxetine; Hippocampus; Inflammasomes | 2019 |
Neuroprotective Benefits of Antidepressants in Multiple Sclerosis: Are We Missing the Mark?
Topics: Animals; Antidepressive Agents; Depression; Fluoxetine; Humans; Multiple Sclerosis; Neuroprotective | 2019 |
Lithium counteracts depressive behavior and augments the treatment effect of selective serotonin reuptake inhibitor in treatment-resistant depressed rats.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Disease Models | 2019 |
The chemokine CXCL1 and its receptor CXCR2 contribute to chronic stress-induced depression in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Apoptosis; Brain-Derived Neurotrophic Factor; Che | 2019 |
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman.
Topics: Bipolar Disorder; Delusions; Depression; Depressive Disorder; Emotions; Female; Fluoxetine; Humans; | 2019 |
Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Circadian Rhythm; Depression; Dopamine; | 2019 |
Could Treatment Matching Patients' Beliefs About Depression Improve Outcomes?
Topics: Adult; Chronic Disease; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Female | 2019 |
Antidepressant-like activity of hyperforin and changes in BDNF and zinc levels in mice exposed to chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder; | 2019 |
Serotonergically dependent antidepressant-like activity on behavior and stress axis responsivity of acacetin.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Flavones; Fluoxetine; Hindlimb Suspens | 2019 |
Neuronal life or death linked to depression treatment: the interplay between drugs and their stress-related outcomes relate to single or combined drug therapies.
Topics: Amitriptyline; Animals; Antidepressive Agents; Cell Cycle Checkpoints; Depression; Fluoxetine; Hippo | 2019 |
Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression.
Topics: Animals; Aripiprazole; Behavior, Animal; Depression; Depressive Disorder, Major; Disease Models, Ani | 2019 |
Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Depressive Disorder, Major; | 2019 |
Syntheses of Benzo[
Topics: Animals; Antarctic Regions; Anticonvulsants; Antidepressive Agents; Aquatic Organisms; Benzothiazole | 2019 |
Youth depression: are two treatments better than one?
Topics: Adolescent; Cognitive Behavioral Therapy; Depression; Depressive Disorder; Double-Blind Method; Fluo | 2019 |
The effect of fluoxetine on astrocyte autophagy flux and injured mitochondria clearance in a mouse model of depression.
Topics: Animals; Antidepressive Agents; Astrocytes; Autophagosomes; Autophagy; Corticosterone; Depression; D | 2019 |
Influence of body mass index on the choice of therapy for depression and follow-up care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; De | 2013 |
Effects of co-administration of fluoxetine and risperidone on properties of peritoneal and pleural macrophages in rats subjected to the forced swimming test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Arginase; Behavior, Animal; | 2012 |
Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic A | 2012 |
Developmental fluoxetine exposure normalizes the long-term effects of maternal stress on post-operative pain in Sprague-Dawley rat offspring.
Topics: Age Factors; Animals; Animals, Newborn; Antidepressive Agents; Depression; Female; Fluoxetine; Hypot | 2013 |
Depressive-like behaviour induced by an intracerebroventricular injection of streptozotocin in mice: the protective effect of fluoxetine, antitumour necrosis factor-α and thalidomide therapies.
Topics: Animals; Antibodies, Neutralizing; Antidepressive Agents; Behavior, Animal; Depression; Dietary Sucr | 2013 |
Cortical-amygdalar circuit dysfunction in a genetic mouse model of serotonin deficiency.
Topics: Amygdala; Analysis of Variance; Animals; Arginine; Biological Clocks; Cerebral Cortex; Depression; D | 2013 |
Effect of newly synthesized 1,2,4-triazino[5,6-b]indole-3-thione derivatives on olfactory bulbectomy induced depression in rats.
Topics: Acetamides; Acetanilides; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Mode | 2012 |
Magnolol treatment reversed the glial pathology in an unpredictable chronic mild stress-induced rat model of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biphenyl Compounds; Depression; Disease Models, An | 2013 |
BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Second-Generation; Anxiety; | 2013 |
Effect of ultrasonic irradiation on the development of symptoms of depression and anxiety in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Disease Models, An | 2013 |
[Effect of hesperidin on behavior and HPA axis of rat model of chronic stress-induced depression].
Topics: Administration, Oral; Animals; Behavior, Animal; Corticosterone; Corticotropin-Releasing Hormone; De | 2013 |
Antidepressant-like effect of ethanol extract from Zuojin Pill, containing two herbal drugs of Rhizoma Coptidis and Fructus Evodiae, is explained by modulating the monoaminergic neurotransmitter system in mice.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Behavior, Animal; Coptis; Corpus Striatum; Depr | 2013 |
Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Cyclohexanols; Depression; Disease Mode | 2013 |
Systematic correlation between spine plasticity and the anxiety/depression-like phenotype induced by corticosterone in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; CA1 Region, Hippocampal; Corticosterone; Dendritic | 2013 |
Windows of vulnerability: maternal separation, age, and fluoxetine on adolescent depressive-like behavior in rats.
Topics: Age Factors; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Depression; Female | 2013 |
Effects of chronic antidepressant treatments in a putative genetic model of vulnerability (Roman low-avoidance rats) and resistance (Roman high-avoidance rats) to stress-induced depression.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Avoidance Learning; Behavior, Anim | 2014 |
Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Fluoxetine; Guinea Pigs; Mice | 2013 |
Depression in older patients with advanced colorectal cancer is closely connected with immunosuppressive acidic protein.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antigens, CD; Ant | 2014 |
Angiotensin-(1-7) attenuates the anxiety and depression-like behaviors in transgenic rats with low brain angiotensinogen.
Topics: Angiotensin I; Angiotensinogen; Animals; Anxiety; Brain; Depression; Disease Models, Animal; Drug Ad | 2013 |
Linking Clostridium difficile infection with depression.
Topics: Antidepressive Agents; Clostridioides difficile; Clostridium Infections; Depression; Fluoxetine; Hum | 2013 |
When depression doesn't lead with depression.
Topics: Anger; Bipolar Disorder; Cyclohexanols; Depression; Depressive Disorder, Major; Emotions; Female; Fl | 2013 |
Prenatal lipopolysaccharide exposure increases depression-like behaviors and reduces hippocampal neurogenesis in adult rats.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Cell Proliferation; Depression; Fema | 2014 |
Synthesis and evaluation of novel 2,3-dihydrobenzo[b][1,4]dioxin- and indolealkylamine derivatives as potential antidepressants.
Topics: Animals; Antidepressive Agents; Depression; Dioxins; Disease Models, Animal; Fluoxetine; Indoles; Mi | 2014 |
Antidepressants and testicular cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; California; Ca | 2014 |
Postnatal fluoxetine-evoked anxiety is prevented by concomitant 5-HT2A/C receptor blockade and mimicked by postnatal 5-HT2A/C receptor stimulation.
Topics: Animals; Anxiety; Depression; Fluoxetine; Gene Expression; Male; Motor Activity; Prefrontal Cortex; | 2014 |
Influence of the brain sexual differentiation process on despair and antidepressant-like effect of fluoxetine in the rat forced swim test.
Topics: Age Factors; Androgens; Animals; Antidepressive Agents, Second-Generation; Brain; Depression; Estrus | 2014 |
Fluoxetine exposure during adolescence alters responses to aversive stimuli in adulthood.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Avoidance Learning; Depression; Fluo | 2014 |
Global state measures of the dentate gyrus gene expression system predict antidepressant-sensitive behaviors.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Dentate Gyrus; Depression; Disease Models, Animal; | 2014 |
The effect of Chaihu-Shugan-San and its components on the expression of ERK5 in the hippocampus of depressed rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blotting, Western; Depression; Disease Models, Ani | 2014 |
Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Fluoxetine; Ketamin | 2014 |
Assessment of depression in a rodent model of spinal cord injury.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Disease Models, Ani | 2014 |
The discovery of Yuanzhi-1, a triterpenoid saponin derived from the traditional Chinese medicine, has antidepressant-like activity.
Topics: Animals; Antidepressive Agents; Citalopram; Cocaine; Depression; Disease Models, Animal; Female; Flu | 2014 |
Behavioural and neuroendocrine effects of aqueous extract of Boerhaavia diffusa Linn. in mice using tail suspension and forced swim tests--a preliminary study.
Topics: Animals; Antidepressive Agents; Depression; Fluoxetine; Hindlimb Suspension; Male; Mice; Monoamine O | 2014 |
Changes in tau phosphorylation levels in the hippocampus and frontal cortex following chronic stress.
Topics: Alzheimer Disease; Analysis of Variance; Anhedonia; Animals; Antidepressive Agents, Second-Generatio | 2014 |
Antidepressant properties of aqueous macerate from Gladiolus dalenii corms.
Topics: 2-Amino-5-phosphonovalerate; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Depressio | 2014 |
Effects of Sini San used alone and in combination with fluoxetine on central and peripheral 5-HT levels in a rat model of depression.
Topics: Animals; Central Nervous System; Depression; Disease Models, Animal; Drug Synergism; Drug Therapy, C | 2013 |
Long-term consequences of neonatal fluoxetine exposure in adult rats.
Topics: Animals; Animals, Newborn; Brain; Dendrites; Depression; Fluoxetine; Hydroxyindoleacetic Acid; Male; | 2014 |
Exercise prevents raphe nucleus mitochondrial overactivity in a rat depression model.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Bra | 2014 |
Adolescent Prozac administration exerts antidepressant-like effects in adulthood by reducing ERK2 signaling in the VTA.
Topics: Animals; Antidepressive Agents, Second-Generation; Avoidance Learning; Depression; Fluoxetine; Male | 2014 |
SSRI or CRF antagonism partially ameliorate depressive-like behavior after adolescent social defeat.
Topics: Aging; Animals; Behavior, Animal; Depression; Fluoxetine; Male; Methylcellulose; Rats; Rats, Wistar; | 2014 |
Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; Dorsal Raphe | 2014 |
Mice with ablated adult brain neurogenesis are not impaired in antidepressant response to chronic fluoxetine.
Topics: Animals; Antidepressive Agents; Bromodeoxyuridine; Chronic Disease; Cyclin D2; Depression; Explorato | 2014 |
Fluoxetine treatment ameliorates depression induced by perinatal arsenic exposure via a neurogenic mechanism.
Topics: Animals; Antidepressive Agents, Second-Generation; Arsenic; Depression; Female; Fluoxetine; Helpless | 2014 |
Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
Topics: Animals; Antidepressive Agents; Benzothiazoles; Depression; Disease Models, Animal; Dopamine Agonist | 2014 |
Lipopolysaccharide-induced sepsis induces long-lasting affective changes in the mouse.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cytoskeletal Proteins; Depression; Diseas | 2015 |
Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models.
Topics: Animals; Antidepressive Agents; Anxiety; Brain-Derived Neurotrophic Factor; Depression; Fluoxetine; | 2015 |
Ibuprofen suppresses depressive like behavior induced by BCG inoculation in mice: role of nitric oxide and prostaglandin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; BCG Vaccine; Brain Chemistry; Depression; Dinopros | 2014 |
Neuropharmacological effect of novel 5-HT3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) on chronic unpredictable mild stress-induced molecular and cellular response: Behavioural and biochemical evidences.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Catalase; Depression; Disease Models, Anima | 2014 |
Role for monoaminergic systems in the antidepressant and anxiolytic properties of the hydroethanolic leaf extract from Adenia cissampeloides.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Depression; Fluoxetine; Hindl | 2015 |
[The effect of fluoxetine and tianeptine on emotional and eating disorders in postmenopausal women].
Topics: Aged; Antidepressive Agents, Tricyclic; Anxiety; Body Mass Index; Depression; Drug Administration Sc | 2014 |
The antidepressant effects of ginseng total saponins in male C57BL/6N mice by enhancing hippocampal inhibitory phosphorylation of GSK-3β.
Topics: Animals; Antidepressive Agents; Corticosterone; Depression; Disease Models, Animal; Down-Regulation; | 2014 |
Antidepressant Effect of Thymoquinone in Animal Models of Depression.
Topics: Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Benzoquinones; Brain; Depression; Di | 2015 |
Shu‑Yu capsule, a Traditional Chinese Medicine formulation, attenuates premenstrual syndrome depression induced by chronic stress constraint.
Topics: Animals; Body Mass Index; Depression; Drugs, Chinese Herbal; Female; Fluoxetine; gamma-Aminobutyric | 2014 |
Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system.
Topics: Animals; Antidepressive Agents; Antiemetics; Anxiety; Behavior, Animal; Brain; Depression; Depressiv | 2014 |
Paracetamol potentiates the antidepressant-like and anticompulsive-like effects of fluoxetine.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arachidonic Acids; Compulsive Behavior; Depression | 2015 |
Anti-depressant effect of hesperidin in diabetic rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain-Derived Neurotrophic Fa | 2014 |
Anti-depressant effect of hesperidin in diabetic rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain-Derived Neurotrophic Fa | 2014 |
Anti-depressant effect of hesperidin in diabetic rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain-Derived Neurotrophic Fa | 2014 |
Anti-depressant effect of hesperidin in diabetic rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain-Derived Neurotrophic Fa | 2014 |
Role of hippocampus mitogen-activated protein kinase phosphatase-1 mRNA expression and DNA methylation in the depression of the rats with chronic unpredicted stress.
Topics: Animals; Body Weight; Chronic Disease; Depression; DNA Methylation; Dual Specificity Phosphatase 1; | 2015 |
Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression.
Topics: Acute Disease; Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Benzothiazoles; Bioma | 2014 |
The effects of ifenprodil on the activity of antidepressant drugs in the forced swim test in mice.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Synergism; Fluoxetine; Imip | 2014 |
A Case of Quetiapine-Induced Rapid Eye Movement Sleep Behavior Disorder.
Topics: Antipsychotic Agents; Anxiety; Depression; Female; Fluoxetine; Humans; Middle Aged; Polysomnography; | 2016 |
"Prozac Baby" - 25 years of motherisk research into SSRIs and alcohol in pregnancy.
Topics: Abnormalities, Drug-Induced; Alcohol Drinking; Antidepressive Agents, Second-Generation; Depression; | 2014 |
Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antidepressive Agents, Second-Generation; Brain; Colo | 2015 |
Differential proteomic analysis of the anti-depressive effects of oleamide in a rat chronic mild stress model of depression.
Topics: Animals; Antidepressive Agents; Biomarkers; Depression; Disease Models, Animal; Electrophoresis, Gel | 2015 |
Effect and mechanism of fluoxetine on electrophysiology in vivo in a rat model of postmyocardial infarction depression.
Topics: Animals; Cardiac Electrophysiology; Depression; Disease Models, Animal; Dose-Response Relationship, | 2015 |
Mice deficient for wild-type p53-induced phosphatase 1 display elevated anxiety- and depression-like behaviors.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Depression; Exploratory Behavior; Fluoxe | 2015 |
Effect of Fluoxetine on Periodontal Status in Patients With Depression: A Cross-Sectional Observational Study.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Periodontitis; Cross-Sectional Studies; Den | 2015 |
Antidepressant activity of fluoxetine in the zinc deficiency model in rats involves the NMDA receptor complex.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Cyclic AMP Res | 2015 |
Antidepressant-like effects of oleoylethanolamide in a mouse model of chronic unpredictable mild stress.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Antioxidants; Atrophy; Brain-Derived Ne | 2015 |
Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression.
Topics: Animals; Antidepressive Agents; Anxiety; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Cortico | 2015 |
Evaluation of the role of NMDA receptor function in antidepressant-like activity. A new study with citalopram and fluoxetine in the forced swim test in mice.
Topics: 2-Amino-5-phosphonovalerate; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generatio | 2015 |
Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Arginine; Cyclopropanes | 2015 |
Effects of nitric oxide synthesis inhibitor or fluoxetine treatment on depression-like state and cardiovascular changes induced by chronic variable stress in rats.
Topics: Animals; Antidepressive Agents; Autonomic Nervous System; Baroreflex; Behavior, Animal; Cardiovascul | 2015 |
Metabonomic Evaluation of Chronic Unpredictable Mild Stress-Induced Changes in Rats by Intervention of Fluoxetine by HILIC-UHPLC/MS.
Topics: Animals; Antidepressive Agents, Second-Generation; Biomarkers; Chromatography, High Pressure Liquid; | 2015 |
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depress | 2015 |
Multiple imputation for harmonizing longitudinal non-commensurate measures in individual participant data meta-analysis.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Calibration; Child; Depression; Female; Fluoxe | 2015 |
Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Arabidopsis Proteins; Brain; Corticoster | 2016 |
PhenoWorld: a new paradigm to screen rodent behavior.
Topics: Animal Husbandry; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Anim | 2014 |
Cinnamomum cassia: an implication of serotonin reuptake inhibition in animal models of depression.
Topics: Animals; Antidepressive Agents; Cinnamomum aromaticum; Depression; Disease Models, Animal; Fluoxetin | 2016 |
Alterations in circadian entrainment precede the onset of depression-like behavior that does not respond to fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Circadian Rhythm; Corticosteron | 2015 |
Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Brain; Depression; Dis | 2015 |
Effect of fluoxetine and resveratrol on testicular functions and oxidative stress in a rat model of chronic mild stress-induced depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Antioxidants; Body Weight; Depression; Fluoxetine | 2015 |
Antidepressant prescribing in Irish children: secular trends and international comparison in the context of a safety warning.
Topics: Adolescent; Age Factors; Antidepressive Agents; Child; Child, Preschool; Depression; Drug Prescripti | 2015 |
Serotonin 6 receptor controls Alzheimer's disease and depression.
Topics: Adaptor Proteins, Signal Transducing; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid Pre | 2015 |
Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression; Drug Synergism; Drug Therap | 2015 |
Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse.
Topics: Animals; Antidepressive Agents; Brain; Cell Proliferation; Cell Survival; Citalopram; Depression; Di | 2016 |
Fluoxetine regulates mTOR signalling in a region-dependent manner in depression-like mice.
Topics: Amygdala; Animals; Antidepressive Agents; Depression; Fluoxetine; Frontal Lobe; Hippocampus; Male; M | 2015 |
Enzymatic Depletion of the Polysialic Acid Moiety Associated with the Neural Cell Adhesion Molecule Inhibits Antidepressant Efficacy.
Topics: Animals; Antidepressive Agents, Second-Generation; Corticosterone; Depression; Disease Models, Anima | 2016 |
Knockdown of hippocampal cysteinyl leukotriene receptor 1 prevents depressive behavior and neuroinflammation induced by chronic mild stress in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Cytokines; Depression; Eating; Fluoxetin | 2016 |
Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Child, Preschool; Citalopram; Cohort Studies; Datab | 2016 |
Possible involvement of the JAK/STAT signaling pathway in N-acetylcysteine-mediated antidepressant-like effects.
Topics: Acetylcysteine; Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Depression; Disease | 2016 |
Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment.
Topics: Affect; Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; CA1 Region, Hippocampal | 2017 |
Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corticosterone; | 2016 |
Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Cytokines; Depression; Diabetes Mel | 2016 |
Rhythmical Photic Stimulation at Alpha Frequencies Produces Antidepressant-Like Effects in a Mouse Model of Depression.
Topics: Animals; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal; Fluoxetine; Male; Mic | 2016 |
Involvement of glutamatergic neurotransmission in the antidepressant-like effect of zinc in the chronic unpredictable stress model of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blotting, Western; Chlorides; Depression; Disease | 2016 |
Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Anxiety; Cell Prolifera | 2016 |
Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior.
Topics: Animals; Cytokines; Depression; Fluoxetine; Glycogen Synthase Kinase 3; Hippocampus; HMGB1 Protein; | 2016 |
Inflammatory mechanisms contribute to microembolism-induced anxiety-like and depressive-like behaviors.
Topics: Animals; Anxiety; B-Lymphocytes; Cyclooxygenase Inhibitors; Cytokines; Depression; Encephalitis; Flu | 2016 |
Cornelia de Lange and Ehlers-Danlos: comorbidity of two rare syndromes.
Topics: Adult; Anemia, Iron-Deficiency; Antidepressive Agents, Second-Generation; Cognitive Behavioral Thera | 2016 |
Developmental fluoxetine exposure increases behavioral despair and alters epigenetic regulation of the hippocampal BDNF gene in adult female offspring.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Epigenesis, | 2016 |
Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety/depression.
Topics: Aniline Compounds; Animals; Antidepressive Agents; Anxiety; Association Learning; Corticosterone; De | 2016 |
[A resistant diarrhea].
Topics: Aged, 80 and over; Anti-Ulcer Agents; Antidepressive Agents; Antidiarrheals; Colitis; Comorbidity; D | 2016 |
Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Ex | 2016 |
Differential effects of a short-term high-fat diet in an animal model of depression in rats treated with the 5-HT3 receptor antagonist, ondansetron, the 5-HT3 receptor agonist, 2-methyl-5-HT, and the SSRI, fluoxetine.
Topics: Animals; Depression; Diet, High-Fat; Disease Models, Animal; Fluoxetine; Male; Ondansetron; Rats; Ra | 2016 |
Depression-like behaviors in tree shrews and comparison of the effects of treatment with fluoxetine and carbetocin.
Topics: Anhedonia; Animals; Antidepressive Agents; Depression; Electroshock; Fluoxetine; Helplessness, Learn | 2016 |
Duloxetine and 8-OH-DPAT, but not fluoxetine, reduce depression-like behaviour in an animal model of chronic neuropathic pain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Neurons; Analgesics; Animals; Antidepressive Agen | 2016 |
Fluoxetine reverses the behavioral despair induced by neurogenic stress in mice: role of N-methyl-d-aspartate and opioid receptors.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Dizocilpine Maleate; Fluoxetine; Male | 2016 |
Up-regulation of serotonin receptor 2B mRNA and protein in the peri-infarcted area of aged rats and stroke patients.
Topics: Age Factors; Aged; Aged, 80 and over; Animals; Brain; Depression; Disease Models, Animal; Female; Fl | 2016 |
Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats.
Topics: Adenine; Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models | 2016 |
Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Cardiomyopathies; Depression; Disease Models, Animal; | 2017 |
Gestational stress and fluoxetine treatment differentially affect plasticity, methylation and serotonin levels in the PFC and hippocampus of rat dams.
Topics: Animals; Antidepressive Agents; Brain; Depression; Depressive Disorder; Female; Fluoxetine; Hippocam | 2016 |
Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Congenital Hyperinsulin | 2016 |
The Use of Fluoxetine in a Patient With Takotsubo Cardiomyopathy.
Topics: Depression; Female; Fluoxetine; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Takots | 2016 |
Fourteen-day administration of corticosterone may induce detrusor overactivity symptoms.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Corticosterone; Depression; Disease | 2016 |
Dental noise exposed mice display depressive-like phenotypes.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Choice Behavior; Dentistry; Depression; Fluoxetine | 2016 |
Adolescent voluntary exercise attenuated hippocampal innate immunity responses and depressive-like behaviors following maternal separation stress in male rats.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; | 2016 |
Effect of chronic fluoxetine treatment on audiogenic epilepsy, symptoms of anxiety and depression in rats of four lines.
Topics: Animals; Anxiety; Depression; Epilepsy, Reflex; Fluoxetine; Rats; Rats, Wistar; Species Specificity | 2016 |
The effect of Schisandra chinensis extracts on depression by noradrenergic, dopaminergic, GABAergic and glutamatergic systems in the forced swim test in mice.
Topics: Adrenergic Neurons; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dopaminergic | 2016 |
Effect of Antidepressants on Immunological Reactivity in ASC Mice with Genetically Determined Depression-Like State.
Topics: Adjuvants, Immunologic; Animals; Antidepressive Agents; Antigen-Presenting Cells; Depression; Drug E | 2016 |
Antidepressant-like effects of standardized gypenosides: involvement of brain-derived neurotrophic factor signaling in hippocampus.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Carbazoles; Depression; Disease M | 2016 |
Antidepressant treatment differentially affects the phenotype of high and low stress reactive mice.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Corticosterone; Depression; Fluoxetine; H | 2016 |
Evaluation of the antidepressant-like effect of musk in an animal model of depression: how it works.
Topics: Administration, Inhalation; Animals; Antidepressive Agents; Behavior; Brain-Derived Neurotrophic Fac | 2017 |
Henoch-Schönlein Purpura During Treatment with Fluoxetine.
Topics: Adolescent; Depression; Fluoxetine; Humans; IgA Vasculitis; Male; Selective Serotonin Reuptake Inhib | 2016 |
Fluoxetine treatment affects the inflammatory response and microglial function according to the quality of the living environment.
Topics: Animals; Cytokines; Depression; Encephalitis; Environment; Fluoxetine; Hippocampus; Inflammation Med | 2016 |
Late-Life Depression: A Role for Accelerometer Technology in Diagnosis and Management.
Topics: Actigraphy; Aged, 80 and over; Antidepressive Agents; Aripiprazole; Depression; Exercise; Fluoxetine | 2016 |
Antidepressant drugs can modify cytotoxic action of temozolomide.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; | 2017 |
Comparison of fluoxetine and 1-methyl-L-tryptophan in treatment of depression-like illness in Bacillus Calmette-Guerin-induced inflammatory model of depression in mice.
Topics: Animals; Antidepressive Agents; BCG Vaccine; Depression; Disease Models, Animal; Fluoxetine; Inflamm | 2016 |
The absence of 5-HT
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Anhedonia; Animals; Antidepressive Agents, Second-Generation | 2016 |
Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Animals; Anxiety; Asian People; Behavior, Animal | 2016 |
The antidepressant roles of Wnt2 and Wnt3 in stress-induced depression-like behaviors.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Cyclic AMP Response Element-Bin | 2016 |
Hippocampal bone morphogenetic protein signaling mediates behavioral effects of antidepressant treatment.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Bone Morphogenetic Protein 4; Bone Mor | 2017 |
Risk of prenatal depression and stress treatment: alteration on serotonin system of offspring through exposure to Fluoxetine.
Topics: Animals; Depression; Fluoxetine; Humans; Induced Pluripotent Stem Cells; Serotonin; Stress, Psycholo | 2016 |
Creatine Prevents Corticosterone-Induced Reduction in Hippocampal Proliferation and Differentiation: Possible Implication for Its Antidepressant Effect.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cell Differentiation; Cell Proliferation; Corticos | 2017 |
Resveratrol Ameliorates the Depressive-Like Behaviors and Metabolic Abnormalities Induced by Chronic Corticosterone Injection.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Body Weight; Corticosterone; Depres | 2016 |
Regional-specific effect of fluoxetine on rapidly dividing progenitors along the dorsoventral axis of the hippocampus.
Topics: Animals; Antidepressive Agents; Cell Proliferation; Cells, Cultured; Cognition; Depression; Disease | 2016 |
Chrysin promotes attenuation of depressive-like behavior and hippocampal dysfunction resulting from olfactory bulbectomy in mice.
Topics: Animals; Behavior, Animal; Biomarkers; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Fla | 2016 |
Long-term effects of pre-pubertal fluoxetine on behaviour and monoaminergic stress response in stress-sensitive rats.
Topics: Age Factors; Animals; Behavior, Animal; Depression; Disease Models, Animal; Fluoxetine; Hydroxyindol | 2017 |
Depression-like phenotype by deletion of α7 nicotinic acetylcholine receptor: Role of BDNF-TrkB in nucleus accumbens.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antidepressive Agents; Azepines; Behavior, Animal; | 2016 |
Chronic Treatment with the IDO1 Inhibitor 1-Methyl-D-Tryptophan Minimizes the Behavioural and Biochemical Abnormalities Induced by Unpredictable Chronic Mild Stress in Mice - Comparison with Fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Cytokines; Depression; Fluoxetin | 2016 |
Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Brain-Derived Neurotrophic F | 2017 |
The acute social defeat stress and nest-building test paradigm: A potential new method to screen drugs for depressive-like symptoms.
Topics: Animals; Depression; Disease Models, Animal; Dominance-Subordination; Fluorobenzenes; Fluoxetine; Ma | 2017 |
Elevation of synaptic protein is associated with the antidepressant-like effects of ferulic acid in a chronic model of depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Coum | 2017 |
Genetic background contributes to the co-morbidity of anxiety and depression with audiogenic seizure propensity and responses to fluoxetine treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Disease Models, Animal; Epilepsy, Reflex; Fluox | 2017 |
Long-lasting effects of fluoxetine and/or exercise augmentation on bio-behavioural markers of depression in pre-pubertal stress sensitive rats.
Topics: Animals; Biomarkers; Brain-Derived Neurotrophic Factor; Depression; Fluoxetine; Male; Malondialdehyd | 2017 |
Distinct Antidepressant-Like and Cognitive Effects of Antidepressants with Different Mechanisms of Action in Middle-Aged Female Mice.
Topics: Aging; Animals; Antidepressive Agents; Cognition; Cohort Studies; Depression; Duloxetine Hydrochlori | 2017 |
Telmisartan attenuates diabetes induced depression in rats.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzimidazoles; Benzoates; Brain; Depress | 2017 |
Ferulic acid inhibits neuro-inflammation in mice exposed to chronic unpredictable mild stress.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Coumaric Acids; Cytokines; Depression; Flu | 2017 |
Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression.
Topics: Animals; Antidepressive Agents; Autoradiography; Cyclohexanes; Depression; Disease Models, Animal; D | 2017 |
Topics: Adolescent; Adolescent Psychiatry; Child; Depression; Depressive Disorder; Fluoxetine; Humans; Selec | 2017 |
The novel and potent anti-depressive action of triptolide and its influences on hippocampal neuroinflammation in a rat model of depression comorbidity of chronic pain.
Topics: Analgesics; Animals; Antidepressive Agents; Behavior, Animal; Chronic Pain; Depression; Disease Mode | 2017 |
Modelling the anxiety-depression continuum in chicks.
Topics: Animals; Animals, Newborn; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Chickens; Chlordiaze | 2009 |
Treatment of idiopathic recurrent priapism with fluoxetine and low dose Perphenazine.
Topics: Adult; Antipsychotic Agents; Anxiety; Depression; Fluoxetine; Humans; Male; Perphenazine; Priapism; | 2008 |
Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine.
Topics: Animals; Behavior, Animal; Depression; Epilepsy, Temporal Lobe; Fluoxetine; Hippocampus; Lithium Chl | 2008 |
Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey.
Topics: Animals; Animals, Outbred Strains; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2008 |
Do new-generation antidepressants work?
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; | 2008 |
Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
Topics: Amino Acids; Amphetamine; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; An | 2008 |
Mouse strain differences in immobility and sensitivity to fluvoxamine and desipramine in the forced swimming test: analysis of serotonin and noradrenaline transporter binding.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depression; Des | 2008 |
Zinc deficiency induces depression-like symptoms in adult rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Body Weig | 2008 |
Evaluation of the repeated open-space swim model of depression in the mouse.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2008 |
Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal | 2008 |
Antidepressant-like effects of Tagetes lucida Cav. in the forced swimming test.
Topics: Administration, Oral; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, | 2008 |
Requirement of AQP4 for antidepressive efficiency of fluoxetine: implication in adult hippocampal neurogenesis.
Topics: Adult Stem Cells; Animals; Antidepressive Agents, Second-Generation; Aquaporin 4; Calcium-Calmodulin | 2009 |
Maternal depression is a common complication among pregnant women occurring approximately 2-3% of this population. Introduction.
Topics: Brain Diseases; Depression; Female; Fluoxetine; Humans; Infant, Newborn; Infant, Premature; Infant, | 2008 |
Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS -SLE (depression).
Topics: Animals; Antidepressive Agents, Second-Generation; Autoantibodies; Cerebral Ventricles; Depression; | 2008 |
Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice.
Topics: Animals; Animals, Newborn; Anxiety; Behavior, Animal; Body Weight; Brain Chemistry; Brain-Derived Ne | 2009 |
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.
Topics: Affect; Analysis of Variance; Animals; Antidepressive Agents; Antidiuretic Hormone Receptor Antagoni | 2009 |
Lovastatin potentiates the antidepressant efficacy of fluoxetine in rats.
Topics: Animals; Antidepressive Agents; Depression; Diet; Drug Synergism; Fluoxetine; Hydroxymethylglutaryl- | 2009 |
Effects of fluoxetine on mast cell morphology and protease-1 expression in gastric antrum in a rat model of depression.
Topics: Animals; Cell Proliferation; Chemokine CCL2; Depression; Disease Models, Animal; Fluoxetine; Hyperpl | 2008 |
Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response.
Topics: Citalopram; Depression; DNA; Fluoxetine; Haplotypes; Humans; Monoamine Oxidase; Pharmacogenetics; Po | 2009 |
Nicotine exposure during adolescence induces a depression-like state in adulthood.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; De | 2009 |
[Effects of Xiaoyao Wan on the behavioral despair and stress depression mice].
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Chromatography, High Pressure Liq | 2008 |
Altered CB receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Autoradiography; Cyclohexanols; Depression; Disea | 2009 |
The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression.
Topics: Antidepressive Agents, Second-Generation; Case-Control Studies; Chromatography, High Pressure Liquid | 2009 |
Allostatic tumor-burden induces depression-associated changes in hepatoma-bearing mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic | 2009 |
Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Databases as Topic; Depression; Drug Co | 2009 |
Why are physicians reluctant to use estrogens for anything--or do they prefer 'PROFOX'?
Topics: Alendronate; Attitude of Health Personnel; Bone Density Conservation Agents; Depression; England; Es | 2009 |
Dissecting the pathophysiology of depression with a Swiss army knife.
Topics: Animals; Corticosterone; Depression; Disease Models, Animal; Fluoxetine; Hippocampus; Humans; Neurog | 2009 |
Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Anxiety; Arrestins; beta-Ar | 2009 |
Fluoxetine: new indication. Depression in children: too many uncertainties.
Topics: Adolescent; Aggression; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepress | 2008 |
Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization.
Topics: Animals; Antidepressive Agents; Depression; Endothelial Cells; Fluoxetine; Hippocampus; Male; Neuron | 2009 |
Induction of neuronal vascular endothelial growth factor expression by cAMP in the dentate gyrus of the hippocampus is required for antidepressant-like behaviors.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain-Der | 2009 |
Effects of chronic intracerebroventricular 3,4-methylenedioxy-N-methamphetamine (MDMA) or fluoxetine on the active avoidance test in rats with or without exposure to mild chronic stress.
Topics: Analysis of Variance; Animals; Avoidance Learning; Chronic Disease; Depression; Disease Models, Anim | 2009 |
Prognostic and diagnostic potential of the structural neuroanatomy of depression.
Topics: Adult; Case-Control Studies; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Fe | 2009 |
Acute renal failure following detergent ingestion.
Topics: Acetaminophen; Acute Kidney Injury; Adult; Depression; Detergents; Eating; Female; Fluoxetine; Human | 2009 |
Nasal bleeding associated with fluoxetine and risperidone interaction: a case report.
Topics: Depression; Drug Interactions; Epistaxis; Fluoxetine; Follow-Up Studies; Humans; Male; Risperidone; | 2009 |
Antidepressant actions of histone deacetylase inhibitors.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Depression; Dise | 2009 |
The lonely mouse: verification of a separation-induced model of depression in female mice.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Anxiety; Behavior, Animal; Conditioning, Classi | 2010 |
Sociodemographic correlates of antidepressant utilisation in Australia. Comment.
Topics: Adolescent; Child; Depression; Fluoxetine; Humans; Practice Guidelines as Topic; Selective Serotonin | 2009 |
The thyroid hormone, triiodothyronine, enhances fluoxetine-induced neurogenesis in rats: possible role in antidepressant-augmenting properties.
Topics: Animals; Antidepressive Agents; Depression; Doublecortin Protein; Drug Synergism; Drug Therapy, Comb | 2010 |
[Neurogenesis-dependent and independent effects of anti-depressant drugs].
Topics: Animals; Anti-Anxiety Agents; Anxiety; Depression; Fluoxetine; Hippocampus; Humans; Mice; Models, An | 2009 |
Chronic fluoxetine treatment has a larger effect on the density of a serotonin transporter in the Flinders Sensitive Line (FSL) rat model of depression than in normal rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Autoradiography; Brain; Depression; Disease Mo | 2010 |
Antidepressant-like effect of the methanolic extract from Bupleurum falcatum in the tail suspension test.
Topics: alpha-Methyltyrosine; Analysis of Variance; Animals; Antidepressive Agents; Bupleurum; Depression; D | 2010 |
Rhizomes of Gastrodia elata B(L) possess antidepressant-like effect via monoamine modulation in subchronic animal model.
Topics: Animals; Antidepressive Agents; Brain; Depression; Dopamine; Fluoxetine; Gastrodia; Male; Models, An | 2009 |
Shaping brain development: mouse communal nesting blunts adult neuroendocrine and behavioral response to social stress and modifies chronic antidepressant treatment outcome.
Topics: Animals; Behavior, Animal; Brain; Corticosterone; Depression; Drug Administration Schedule; Female; | 2010 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexano | 2009 |
Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Benzodiazepines; Chronic Disease; Depression; Depr | 2010 |
Role of the amygdala in antidepressant effects on hippocampal cell proliferation and survival and on depression-like behavior in the rat.
Topics: Amygdala; Animals; Antidepressive Agents, Second-Generation; Cell Proliferation; Cell Survival; Depr | 2010 |
Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors.
Topics: Acoustic Stimulation; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bromodeoxyuridine; | 2011 |
Circadian activity of corticosterone in an animal model of depression: response to muscarinic cholinergic stimulation.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Behavior, Animal; Cholinergic A | 2010 |
Potential role of glutamate neurotransmission in the pathogenesis of ischemic brain damage and of depression. Effects of L-kynurenine on the survival of the hippocampal neurons and on the corticocerebral blood flow in ischemic animal models.
Topics: Animals; Brain Ischemia; Cell Survival; Cerebrovascular Circulation; Chromatography, High Pressure L | 2010 |
Differential involvement of 5-HT(1A) and 5-HT(1B/1D) receptors in human interferon-alpha-induced immobility in the mouse forced swimming test.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Depression; Fluoxetine; Interferon-alpha | 2010 |
The treatment of comorbid insomnia.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Follow-Up Studies; | 2009 |
Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression.
Topics: Animals; Antidepressive Agents; Atropine; Behavior, Animal; Carbolines; Depression; Disease Models, | 2010 |
Antidepressant-like effect of genipin in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Blepharoptosis; Depression; D | 2010 |
A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Antidepressive Agents, Second-Generation; Blood Press | 2010 |
Effects of antidepressants on the performance in the forced swim test of two psychogenetically selected lines of rats that differ in coping strategies to aversive conditions.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Behavior, Animal; Clomipramine; Depression; Desi | 2010 |
Involvement of monoaminergic system in the antidepressant-like effect of the flavonoid naringenin in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Depress | 2010 |
Intermittent and continuous swim stress-induced behavioral depression: sensitivity to norepinephrine- and serotonin-selective antidepressants.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agen | 2010 |
Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion.
Topics: Amitriptyline; Analgesics; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression; | 2010 |
Fluoxetine treatment induces dose dependent alterations in depression associated behavior and neural plasticity in female mice.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cell Proliferati | 2010 |
Interleukin-15 affects serotonin system and exerts antidepressive effects through IL15Rα receptor.
Topics: Animals; Antidepressive Agents; Cells, Cultured; Depression; Dose-Response Relationship, Drug; Drug | 2011 |
Fluoxetine reverts chronic restraint stress-induced depression-like behaviour and increases neuropeptide Y and galanin expression in mice.
Topics: Amygdala; Animals; Brain; Dentate Gyrus; Depression; Fluoxetine; Galanin; Male; Mice; Neuropeptide Y | 2011 |
miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants.
Topics: 3' Untranslated Regions; Animals; Antidepressive Agents, Second-Generation; Cell Line; Depression; F | 2010 |
Profiling of hypothalamic and hippocampal gene expression in chronically stressed rats treated with St. John's wort extract (STW 3-VI) and fluoxetine.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Response Relationship, Drug | 2011 |
Screening for depression in adults.
Topics: Antidepressive Agents, Second-Generation; Depression; Fluoxetine; Follow-Up Studies; Humans; Male; M | 2010 |
Involvement of monoaminergic systems in the antidepressant-like effect of nobiletin.
Topics: Adrenergic Antagonists; Animals; Antidepressive Agents; Benzazepines; Cyproheptadine; Depression; Di | 2011 |
Repeated rat-forced swim test: reducing the number of animals to evaluate gradual effects of antidepressants.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Drug Administr | 2011 |
Selective serotonin-reuptake inhibitors and recovery after stroke.
Topics: Depression; Fluoxetine; Humans; Recovery of Function; Selective Serotonin Reuptake Inhibitors; Strok | 2011 |
Icariin attenuates social defeat-induced down-regulation of glucocorticoid receptor in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal | 2011 |
Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat.
Topics: Age Factors; Amygdala; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Body Wei | 2011 |
Infant maternal separation impairs adult cognitive performance in BALB/cJ mice.
Topics: Age Factors; Animals; Animals, Newborn; Anxiety; Behavior, Animal; Cognition Disorders; Depression; | 2011 |
Behaviour of a genetic mouse model of depression in the learned helplessness paradigm.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Disease Models, Ani | 2011 |
Behavioral destabilization induced by the selective serotonin reuptake inhibitor fluoxetine.
Topics: Animals; Anxiety; Behavior, Animal; Depression; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Motor Ac | 2011 |
Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging.
Topics: Aging; Animals; Biomarkers; Body Weight; Depression; Disease Models, Animal; Fluoxetine; Grooming; H | 2011 |
[Study of self-regulating behavior at different stages of psychogenic stress before the formation of depressive-like state in rats].
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Escape Reaction; Fluoxetine; | 2011 |
The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Depression; Diseas | 2011 |
Current source density measures of electroencephalographic alpha predict antidepressant treatment response.
Topics: Adult; Alpha Rhythm; Analysis of Variance; Antidepressive Agents; Brain Mapping; Depression; Electro | 2011 |
Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression.
Topics: Benzodiazepines; Controlled Clinical Trials as Topic; Depression; Drug Combinations; Drug Resistance | 2011 |
Fluoxetine alleviates behavioral depression while decreasing acetylcholine release in the nucleus accumbens shell.
Topics: Acetylcholine; Animals; Behavior, Animal; Depression; Female; Fluoxetine; Injections, Subcutaneous; | 2011 |
Antidepressants recruit new neurons to improve stress response regulation.
Topics: Animals; Antidepressive Agents; Cell Count; Corticosterone; Depression; Dexamethasone; Disease Model | 2011 |
An uncommon case of hypersexual behaviour with frotteurism.
Topics: Antidepressive Agents, Second-Generation; Child; Clonazepam; Depression; Female; Fluoxetine; GABA Mo | 2010 |
Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice.
Topics: Animals; Antidepressive Agents; Arachidonic Acids; Benzamides; Cannabinoid Receptor Modulators; Carb | 2011 |
Flow rates and inorganic composition of whole saliva in purging bulimic patients treated with a fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Bulimia; Calcium; Colorimetry; Depression; Electrol | 2011 |
Predicting potential placebo effect in drug treated subjects.
Topics: Clinical Trials as Topic; Depression; Fluoxetine; Humans; Models, Statistical; Placebo Effect; Selec | 2009 |
Chronic mild stress induces fluoxetine-reversible decreases in hippocampal and cerebrospinal fluid levels of the neurotrophic factor S100B and its specific receptor.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Chronic Disease; Depression; Fl | 2010 |
Effects of chronic administration of tryptophan with or without concomitant fluoxetine in depression-related and anxiety-like behaviors on adult rat.
Topics: Age Factors; Animals; Anxiety; Depression; Drug Therapy, Combination; Fluoxetine; Male; Rats; Rats, | 2011 |
Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats.
Topics: Animals; Antidepressive Agents; Aspirin; Depression; Drug Therapy, Combination; Fluoxetine; Hippocam | 2011 |
Antidepressant-like effect of altered Korean red ginseng in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Fluoxetine; Ginsenosides; Male; Mice; | 2011 |
Eszopiclone facilitation of the antidepressant efficacy of fluoxetine using a social defeat stress model.
Topics: Animals; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Brain-Derived Neurotrophic | 2011 |
Eagle's syndrome treated with dissection of the styloid process via an extraoral approach combined with antidepressants.
Topics: Adult; Antidepressive Agents; Calcinosis; Depression; Female; Fluoxetine; Humans; Ligaments; Male; M | 2011 |
Influence of Neuropeptide Y and antidepressants upon cerebral monoamines involved in depression: an in vivo electrochemical study.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anx | 2011 |
LPS inhibits the effects of fluoxetine on depression-like behavior and hippocampal neurogenesis in rats.
Topics: Animals; Behavior, Animal; Depression; Drug Interactions; Fluoxetine; Hippocampus; Lipopolysaccharid | 2011 |
Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Intranasal; Animals; Antidepressive Agents; | 2012 |
[Approximate entropy of the placebo effect in clinical trials of newer antidepressants].
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depression; Fluox | 2010 |
Chronic agomelatine and fluoxetine induce antidepressant-like effects in H/Rouen mice, a genetic mouse model of depression.
Topics: Acetamides; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Fluoxetine; Locomoti | 2011 |
N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice.
Topics: Administration, Oral; Amides; Animals; Antidepressive Agents; Cannabinoid Receptor Modulators; Depre | 2011 |
TASK-3 as a potential antidepressant target.
Topics: Animals; Antidepressive Agents, Second-Generation; Arousal; Behavior, Animal; Circadian Rhythm; Depr | 2011 |
Flouxetine treatment acts selectively increasing myocardial beta1-adrenoceptor mRNA expression in stress-induced depression.
Topics: Analysis of Variance; Animals; Depression; DNA, Complementary; Fluoxetine; Heart; Male; Myocardium; | 2011 |
Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Arip | 2012 |
Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Body Weight; Depression; Doublecortin Dom | 2011 |
Tianeptine in the combined treatment of combat related posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety; Combat D | 2011 |
Fluoxetine affects hippocampal plasticity, apoptosis and depressive-like behavior of chronically isolated rats.
Topics: Animals; Apoptosis; Depression; Fluoxetine; Hippocampus; Male; Neuronal Plasticity; Rats; Rats, Wist | 2012 |
Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration.
Topics: Animals; Anxiety; Autoreceptors; Corticosterone; Depression; Drug Resistance; Drug Therapy, Combinat | 2012 |
Acute administration of fluoxetine normalizes rapid eye movement sleep abnormality, but not depressive behaviors in olfactory bulbectomized rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antidepressive Agents, Second-Generat | 2012 |
Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus.
Topics: Animals; Antidepressive Agents; Blotting, Western; Cell Proliferation; Cyclin-Dependent Kinase Inhib | 2011 |
[Drug treatment of depression in children and adolescents].
Topics: Adolescent; Antidepressive Agents; Antidepressive Agents, Second-Generation; Child; Depression; Depr | 2011 |
Peony glycosides reverse the effects of corticosterone on behavior and brain BDNF expression in rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain; Br | 2012 |
Antidepressant-like effect of the extracted of Kai Xin San, a traditional Chinese herbal prescription, is explained by modulation of the central monoaminergic neurotransmitter system in mouse.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain; Depression; Disease Mo | 2012 |
Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress.
Topics: Animals; Antidepressive Agents; Antioxidants; Ascorbic Acid; Catalase; Cerebral Cortex; Corticostero | 2012 |
[Chronic psychogenic stress as a factor of formation depressive behavior in rats].
Topics: Acoustic Stimulation; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
Piperine protects epilepsy associated depression: a study on role of monoamines.
Topics: Alkaloids; Anhedonia; Animals; Anticonvulsants; Behavior, Animal; Benzodioxoles; Biogenic Monoamines | 2011 |
Making the brain young to treat depression.
Topics: Amygdala; Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depression; Exti | 2012 |
The declining use of reboxetine in years 2000 to 2006: a pharmacoepidemiological comparative study.
Topics: Antidepressive Agents; Depression; Fluoxetine; Humans; Morpholines; Paroxetine; Pharmacoepidemiology | 2012 |
Antidepressant-suicide link in children questioned.
Topics: Adolescent; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Drug Prescriptions | 2012 |
Anti-depressant effects of Xiaoyaosan on rat model of chronic unpredictable mild stress: a plasma metabonomics study based on NMR spectroscopy.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biomarkers; Chronic Disease; Cyclohexanols; Depres | 2012 |
Interleukin-1β causes fluoxetine resistance in an animal model of epilepsy-associated depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; Drug Resistan | 2012 |
Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Creatine; Depression; Dietary Supplements; | 2012 |
Serotonin transporter polyadenylation polymorphism modulates the retention of fear extinction memory.
Topics: Alleles; Animals; Anxiety; Depression; Fear; Fluoxetine; Genetic Variation; Humans; Memory; Mice; Po | 2012 |
Antidepressant-like activity of gallic acid in mice subjected to unpredictable chronic mild stress.
Topics: Animals; Antidepressive Agents; Antioxidants; Brain; Catalase; Corticosterone; Depression; Fluoxetin | 2013 |
Alterations on the morphology, nitric oxide synthesis and activity of platelets reproduced in rats as possible biomarkers for depression are reversed by fluoxetine.
Topics: Animals; Behavior, Animal; Biomarkers; Blood Platelets; Depression; Fluoxetine; Male; Membrane Poten | 2012 |
MPTP-induced hippocampal effects on serotonin, dopamine, neurotrophins, adult neurogenesis and depression-like behavior are partially influenced by fluoxetine in adult mice.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Bromodeoxyuridine; Cell Count; Conditioning, Op | 2012 |
A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Capsaicin; Depression; Disease Models, Animal; Do | 2012 |
Antinociceptive effects of fluoxetine in a mouse model of anxiety/depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Chronic Pain; Cold Temperature; Corticos | 2012 |
Neurogenomic evidence for a shared mechanism of the antidepressant effects of exercise and chronic fluoxetine in mice.
Topics: Animals; Antidepressive Agents; Depression; Exercise Therapy; Fluoxetine; Gene Expression; Hippocamp | 2012 |
Differential environmental regulation of neurogenesis along the septo-temporal axis of the hippocampus.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Antimetabolites; Anxiety; Bromo | 2012 |
Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Drug Administration Schedule; Female; | 2012 |
Synergistic effect of estradiol and fluoxetine in young adult and middle-aged female rats in two models of experimental depression.
Topics: Aging; Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Depression; Disease | 2012 |
Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cyclohexanols; Depression; Depressive Dis | 2012 |
Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression.
Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Biomarkers; Bromodeoxyuridine; Cell Pr | 2012 |
Rosmarinus officinalis L. hydroalcoholic extract, similar to fluoxetine, reverses depressive-like behavior without altering learning deficit in olfactory bulbectomized mice.
Topics: Acetylcholinesterase; Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Depression; E | 2012 |
Neurobiological sequelae of witnessing stressful events in adult mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal; Fluoxetine; | 2013 |
Antidepressants prevent hierarchy destabilization induced by lipopolysaccharide administration in mice: a neurobiological approach to depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cytokines; Depression; Disease Models, Animal; Flu | 2012 |
Trypanosoma cruzi-induced depressive-like behavior is independent of meningoencephalitis but responsive to parasiticide and TNF-targeted therapeutic interventions.
Topics: Animals; Antidepressive Agents, Second-Generation; Chagas Disease; Depression; Emotions; Exploratory | 2012 |
Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats.
Topics: Acute Disease; Administration, Oral; Analysis of Variance; Animals; Antidepressive Agents; Behavior, | 2011 |
[Concentration increase in Hcy and anti-CCP antibody in the serum of depression rat model induced by chronic unpredictable mild stress].
Topics: Animals; Autoantibodies; Depression; Disease Models, Animal; Fluoxetine; Homocysteine; Male; Peptide | 2012 |
Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm.
Topics: Amygdala; Animals; Behavior, Animal; Corticotropin-Releasing Hormone; Depression; Fluorescent Antibo | 2013 |
Evidence for the involvement of the serotonergic 5-HT(1A) receptors in the antidepressant-like effect caused by hesperidin in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Exploratory Behavior; Fluoxetine; Hesp | 2013 |
Adolescence fluoxetine increases serotonergic activity in the raphe-hippocampus axis and improves depression-like behaviors in female rats that experienced neonatal maternal separation.
Topics: Animals; Animals, Newborn; Behavior, Animal; Body Weight; Corticosterone; Corticotropin-Releasing Ho | 2013 |
Both chronic treatments by epothilone D and fluoxetine increase the short-term memory and differentially alter the mood status of STOP/MAP6 KO mice.
Topics: Affect; Animals; Antineoplastic Agents; Depression; Disease Models, Animal; Epothilones; Female; Flu | 2012 |
Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Biomarkers; Dentate | 2012 |
Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Benzodiazepines; Depr | 2012 |
Aberrant light directly impairs mood and learning through melanopsin-expressing neurons.
Topics: Affect; Animals; Antidepressive Agents; Body Temperature Regulation; Circadian Rhythm; Cognition; Co | 2012 |
Effect of fluoxetine and adenosine receptor NECA agonist on G alpha q/11 protein of C6 glioma cells.
Topics: Adenosine-5'-(N-ethylcarboxamide); Animals; Brain Neoplasms; Cell Line, Tumor; Citalopram; Depressio | 2012 |
A depressive phenotype induced by Bacille Calmette Guérin in 'susceptible' animals: sensitivity to antidepressants.
Topics: Animals; Antidepressive Agents; BCG Vaccine; Chronic Disease; Depression; Desipramine; Diazepam; Dis | 2013 |
Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anhedonia; Animals; Brain Chemistry; Cognition Disorders; | 2013 |
Secreted frizzled-related protein 3 (sFRP3) regulates antidepressant responses in mice and humans.
Topics: Adaptation, Ocular; Animals; Antidepressive Agents; Cohort Studies; Depression; Fluoxetine; Gene Exp | 2013 |
L-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats.
Topics: Animals; Antidepressive Agents; Contraindications; Depression; Drug Therapy, Combination; Fluoxetine | 2013 |
Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes.
Topics: Analysis of Variance; Animals; Central Nervous System; Cytokine Receptor gp130; Depression; Depressi | 2012 |
Bidirectional crosstalk between stress-induced gastric ulcer and depression under chronic stress.
Topics: Animals; Anti-Ulcer Agents; Corticosterone; Depression; Fluoxetine; Male; Mifepristone; Ranitidine; | 2012 |
Impacts of early intervention with fluoxetine following early neonatal immune activation on depression-like behaviors and body weight in mice.
Topics: Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Behavior, Animal; Body W | 2013 |
GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.
Topics: Acoustic Stimulation; Action Potentials; Animals; Antidepressive Agents; Brain; Conditioning, Operan | 2013 |
Chronic fluoxetine treatment affects gene expression of catecholamine enzymes in the heart of depression model rats.
Topics: Animals; Catecholamines; Depression; Disease Models, Animal; Dopamine beta-Hydroxylase; Fluoxetine; | 2012 |
A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Choice Behavior; Depression; Depressi | 2013 |
Sustained remission from depressive-like behavior depends on hippocampal neurogenesis.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Astrocytes; Behavior, Animal; Cell Proliferati | 2013 |
Involvement of extracellular signal regulated kinases in traumatic brain injury-induced depression in rodents.
Topics: Animals; Anxiety; Blotting, Western; Brain Injuries; Coloring Agents; Depression; Extracellular Sign | 2013 |
Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543.
Topics: Aggression; Animals; Antidepressive Agents; Behavior, Animal; Brain; Deep Brain Stimulation; Depress | 2013 |
Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior.
Topics: Acetylcholinesterase; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cholinergic Antagon | 2013 |
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.
Topics: Adult; Antipsychotic Agents; Depression; Drug Interactions; Drug Therapy, Combination; Female; Fluox | 2002 |
Personality disorders and depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cluster Analysis; Comorbidity; Depression; Female; F | 2002 |
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Depression; Female; Fluoxetine; Humans; Male; Mental | 2002 |
Antidepressant activity of aqueous extracts of Curcuma longa in mice.
Topics: Administration, Oral; Animals; Antidepressive Agents; Brain; Curcuma; Depression; Dose-Response Rela | 2002 |
In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Gene | 2002 |
Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients. A demonstration project.
Topics: Algorithms; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; Male; | 2002 |
Neonatal treatment with fluoxetine reduces depressive behavior induced by forced swim in adult rats.
Topics: Animals; Animals, Newborn; Behavior, Animal; Body Weight; Depression; Escape Reaction; Fluoxetine; I | 2002 |
[Do dogs become happy on Prozac?].
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Dog Diseases; Dogs; | 2003 |
Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression.
Topics: Analysis of Variance; Animals; Depression; Disease Models, Animal; Drug Administration Routes; Fluox | 2003 |
Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice.
Topics: Animals; Depression; Disease Models, Animal; Drug Therapy, Combination; Fluoxetine; Male; Mice; Mice | 2003 |
Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Bromodeoxyuridine; Cell Count; | 2003 |
Differential neurochemical properties of central serotonergic transmission in Roman high- and low-avoidance rats.
Topics: Animals; Anxiety; Autoradiography; Avoidance Learning; Behavior, Animal; Binding, Competitive; Brain | 2003 |
Neuroscience. Depression drugs' powers may rest on new neurons.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2003 |
Reduction of hippocampal Na+, K+-ATPase activity in rats subjected to an experimental model of depression.
Topics: Animals; Antidepressive Agents; Chronic Disease; Depression; Eating; Female; Fluoxetine; Hippocampus | 2003 |
Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice.
Topics: Animals; Antidepressive Agents; Arginine; Ascorbic Acid; Behavior, Animal; Chlorides; Depression; Di | 2003 |
Those high-cholesterol blues.
Topics: Antidepressive Agents; Cholesterol; Depression; Fluoxetine; Humans; Hypercholesterolemia; Nortriptyl | 2003 |
Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Fluids; Body Temperature; Body Weig | 2004 |
Serotonergic symptoms in neonates exposed to SSRIs during pregnancy.
Topics: Chemical and Drug Induced Liver Injury; Depression; Female; Fluoxetine; Humans; Infant, Newborn; Pre | 2003 |
Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
Topics: Animals; Antidepressive Agents; Antidiuretic Hormone Receptor Antagonists; Depression; Disease Model | 2004 |
Fluoxetine versus placebo in advanced cancer outpatients.
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Interactions; Fluoxetine; Humans; Neoplas | 2004 |
Antidepressant-like effect of nicotinamide adenine dinucleotide in the forced swim test in rats.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2004 |
Drug suicide risks prompt call for FDA action.
Topics: Adolescent; Antidepressive Agents; Child; Depression; Drug and Narcotic Control; Fluoxetine; Humans; | 2004 |
Antidepressant activity of quercetin, a bioflavonoid, in streptozotocin-induced diabetic mice.
Topics: Animals; Antidepressive Agents; Depression; Diabetes Mellitus, Experimental; Disease Models, Animal; | 2003 |
Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression.
Topics: Animals; Antidepressive Agents; Depression; Desipramine; Disease Models, Animal; Dose-Response Relat | 2004 |
Pharmaceutical branding: identity, individuality, and illness.
Topics: Advertising; Depression; Drug Industry; Female; Fluoxetine; Humans; Individuality; Marketing; Patien | 2002 |
Self-induced hyperemesis in pregnancy.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depression; Female; Fluoxetine; Humans; Hy | 2004 |
Effects of chronic fluoxetine in animal models of anxiety and depression.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Depression; Disease Models, Animal; Dose-R | 2004 |
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Dopamine beta-Hydroxylase; Drox | 2004 |
Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine [correction of flouxetine].
Topics: Animals; Antidepressive Agents; Depression; Drug Administration Schedule; Drug Interactions; Drug Sy | 2004 |
Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans.
Topics: Adult; Cytochrome P-450 CYP2D6; Depression; Desipramine; Double-Blind Method; Fluoxetine; Humans; Hy | 2004 |
[Diagnostic image (189). A man with a tongue disorder. Black hairy tongue].
Topics: Antidepressive Agents, Second-Generation; Depression; Diagnosis, Differential; Diet; Fluoxetine; Hum | 2004 |
The effects of antidepressant treatment on serum cytokines and nutritional status in hemodialysis patients.
Topics: Adult; Antidepressive Agents, Second-Generation; C-Reactive Protein; Cytokines; Depression; Electric | 2004 |
Serotonin syndrome and linezolid.
Topics: Acetamides; Anti-Infective Agents; Burns; Child, Preschool; Depression; Drug Interactions; Female; F | 2004 |
Gender based response to fluoxetine hydrochloride medication in endogenous depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; Hydrocortis | 2004 |
Ejaculation failure on the day of oocyte retrieval for IVF: case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Cryopreservation; Depression; Ejaculation; | 2004 |
A follow-up study of male sexual disorders: the neurophysiological assessments, anxiety-depression levels, and response to fluoxetine treatment.
Topics: Adult; Aged; Anxiety; Depression; Fluoxetine; Follow-Up Studies; Humans; Male; Middle Aged; Sexual D | 2004 |
Neonatal complications after intrauterine exposure to SSRI antidepressants.
Topics: Antidepressive Agents; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; F | 2004 |
[Unfortunate title?].
Topics: Adolescent; Child; Depression; Fluoxetine; Humans; Paroxetine; Practice Guidelines as Topic; Selecti | 2004 |
Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; D | 2004 |
Evaluation of cognitive function of fluoxetine, sertraline and tianeptine in isolation and chronic unpredictable mild stress-induced depressive Wistar rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cognition Disorders; Depression; Female; Fluoxetin | 2003 |
The impaired coping induced by early deprivation is reversed by chronic fluoxetine treatment in adult fischer rats.
Topics: Adaptation, Psychological; Animals; Avoidance Learning; Depression; Disease Models, Animal; Escape R | 2004 |
Antidepressants: bitter pills.
Topics: Access to Information; Adolescent; Antidepressive Agents; Child; Clinical Trials as Topic; Contraind | 2004 |
Phenotypic assessment of galanin overexpressing and galanin receptor R1 knockout mice in the tail suspension test for depression-related behavior.
Topics: Animals; Autoradiography; Brain; Depression; Desipramine; DNA Mutational Analysis; Female; Fluoxetin | 2005 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; | 2004 |
Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test.
Topics: Agmatine; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Depression; Diseas | 2004 |
Nelumbinis Semen reverses a decrease in 5-HT1A receptor binding induced by chronic mild stress, a depression-like symptom.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Autoradiography; Depression; | 2004 |
[Placebo to antidepressant effects ratio by electroencephalographic data].
Topics: Adult; Alpha Rhythm; Antidepressive Agents, Second-Generation; Depression; Electroencephalography; F | 2004 |
How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Fluoxetine; Male; Mice; Mice, Inbred | 2005 |
Sex differences in the regulation of serotonergic transmission and behavior in 5-HT receptor knockout mice.
Topics: Animals; Behavior, Animal; Brain; Depression; Extracellular Space; Female; Fenclonine; Fluoxetine; H | 2005 |
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.
Topics: Aggression; Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Genera | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2005 |
Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: a 3-year follow-up study.
Topics: Adolescent; Alcoholism; Combined Modality Therapy; Comorbidity; Depression; Diagnosis, Dual (Psychia | 2005 |
Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI).
Topics: Antidepressive Agents, Tricyclic; Chromatography, High Pressure Liquid; Citalopram; Cyclohexanols; D | 2005 |
Depression in general clinical practice.
Topics: Age Factors; Aged; Antidepressive Agents; Citalopram; Depression; Family Practice; Female; Fluoxetin | 2004 |
Regulation of activin mRNA and Smad2 phosphorylation by antidepressant treatment in the rat brain: effects in behavioral models.
Topics: Activins; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Blotting, Western; | 2005 |
Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.
Topics: Adult; Citalopram; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Netherlands; Paroxetin | 2005 |
Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum.
Topics: Animals; Antidepressive Agents, Second-Generation; Arylalkylamine N-Acetyltransferase; Behavior, Add | 2005 |
[Selective serotonin reuptake inhibitors (SSRI's) are not indicated for children and adolescents with depression].
Topics: Adolescent; Adolescent Behavior; Antidepressive Agents, Second-Generation; Child; Child Behavior; Co | 2005 |
Career path. David T. Wong.
Topics: Antidepressive Agents, Second-Generation; Career Choice; Depression; Fluoxetine; History, 20th Centu | 2005 |
Sex-dependent effects of fluoxetine and triiodothyronine in the forced swim test in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Male; Motor Activ | 2006 |
Antidepressants and suicide: a commentary on a significant contribution to this debate.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricycl | 2005 |
Proposed mechanisms of action of SSRIs.
Topics: Adolescent; Child; Depression; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors | 2005 |
Joint analysis of repeatedly observed continuous and ordinal measures of disease severity.
Topics: Biometry; Clinical Trials as Topic; Computer Simulation; Data Interpretation, Statistical; Depressio | 2006 |
Antidepressant-like effect of hyperbaric oxygen treatment in forced-swimming test in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depression; Flu | 2005 |
Mental health: Prozac changes moods...and minds.
Topics: Antidepressive Agents, Second-Generation; Depression; Fluoxetine; Humans; Mental Disorders; Psychoth | 2005 |
Recognizing and treating depression in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Child, Preschool; Clinical Trials as Topic; Counseling; De | 2006 |
Antidepressant-like activity of Glycyrrhiza glabra L. in mouse models of immobility tests.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Respo | 2006 |
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress.
Topics: Aggression; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Dominance | 2006 |
Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report.
Topics: Antidepressive Agents, Second-Generation; Basal Ganglia; Depression; Female; Fluoxetine; Humans; Ina | 2006 |
Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Aspirin; Depression; Drug Synergism; Escap | 2006 |
Depression and consumption: psychopharmaceuticals, branding, and new identity practices.
Topics: Adult; Attitude to Health; Depression; Female; Fluoxetine; Health Behavior; Humans; Physician-Patien | 2005 |
Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK.
Topics: Adolescent; Advisory Committees; Antidepressive Agents; Child; Depression; Fluoxetine; Humans; Pract | 2006 |
Suicide rates and antidepressant prescribing: a casual or causal relationship?
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; | 2006 |
Could treatment with arundic acid (ONO-2506) increase vulnerability for depression?
Topics: Alzheimer Disease; Animals; Caprylates; Clinical Trials as Topic; Comorbidity; Depression; Disease M | 2006 |
Facilitating antidepressant-like actions of estrogens are mediated by 5-HT1A and estrogen receptors in the rat forced swimming test.
Topics: Animals; Antidepressive Agents; Depression; Estradiol; Estrogen Antagonists; Estrogens; Female; Fluo | 2006 |
Anorexia nervosa and brain tumor in a 14-year-old girl.
Topics: Adolescent; Anorexia Nervosa; Brain Neoplasms; Depression; Female; Fluoxetine; Humans; Magnetic Reso | 2006 |
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bulimia; Depression; Diabetes | 2006 |
Is it just a marker for increased care?
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Prescriptions; Fluoxetine; Humans; Practi | 2006 |
Were Eli Lilly unaware of this study?
Topics: Antidepressive Agents, Second-Generation; Awareness; Depression; Drug Industry; Fluoxetine; Humans; | 2006 |
Night sweats and elevated follicle-stimulating hormone levels while taking selective serotonin reuptake inhibitors.
Topics: Adult; Depression; Female; Fluoxetine; Follicle Stimulating Hormone; Humans; Infertility, Female; Pa | 2006 |
A mouse model of posttraumatic stress disorder that distinguishes between conditioned and sensitised fear.
Topics: Administration, Oral; Animals; Arousal; Association Learning; Conditioning, Classical; Depression; D | 2007 |
[Effect of chronic stress on PKA and P-CREB expression in hippocampus of rats and the antagonism of antidepressors].
Topics: Animals; Antidepressive Agents, Second-Generation; Cyclic AMP Response Element-Binding Protein; Cycl | 2006 |
Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine.
Topics: Adult; Alanine Transaminase; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Asparta | 2006 |
Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Delirium; Depressi | 2006 |
Does trazodone have a role in palliating symptoms?
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Interactions; Fluoxetine; Humans; Neoplas | 2007 |
Fluoxetine and suicide rates: suicide and the economy.
Topics: Antidepressive Agents, Second-Generation; Depression; Fluoxetine; Humans; Suicide | 2006 |
Behavioral, neurochemical and neuroendocrine effects of the ethanolic extract from Curcuma longa L. in the mouse forced swimming test.
Topics: Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Curcuma; Depression; Dopamine; Etha | 2007 |
Antidepressant-like effect of the extract from leaves of Schinus molle L. in mice: evidence for the involvement of the monoaminergic system.
Topics: Anacardiaceae; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Biogenic Mono | 2007 |
Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever.
Topics: Acute-Phase Reaction; Adolescent; Adult; Blood Sedimentation; C-Reactive Protein; Colchicine; Depres | 2007 |
Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression.
Topics: Adolescent; Child; Child, Preschool; Depression; Epilepsy; Female; Fluoxetine; Humans; Male; Neurolo | 2007 |
Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system.
Topics: Animals; Antibodies, Anti-Idiotypic; Antidepressive Agents, Second-Generation; Autoimmunity; Brain; | 2007 |
Depression in Dhat syndrome.
Topics: Adult; Cultural Characteristics; Depression; Ejaculation; Erectile Dysfunction; Fluoxetine; Humans; | 2008 |
Icariin from Epimedium brevicornum attenuates chronic mild stress-induced behavioral and neuroendocrinological alterations in male Wistar rats.
Topics: Adrenocorticotropic Hormone; Animals; Behavior, Animal; Body Weight; Brain Chemistry; Chronic Diseas | 2007 |
Antidepressant management in the context of suicidal ideation.
Topics: Adolescent; Depression; Fluoxetine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Suicide, | 2007 |
Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits.
Topics: Animals; Antidepressive Agents, Second-Generation; Blood Pressure; Brain Ischemia; Carotid Arteries; | 2007 |
Trouble in a 'black box'.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Contraindications; Depression; Fluoxetine; Hum | 2007 |
Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Topics: Aged; Aged, 80 and over; Algorithms; Bayes Theorem; Citalopram; Cost-Benefit Analysis; Depression; D | 2007 |
The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Arousal; Cell Count; Cell Division; Cond | 2008 |
The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors.
Topics: Animals; Antidepressive Agents; Curcuma; Curcumin; Depression; Disease Models, Animal; Dose-Response | 2008 |
Pontine and extrapontine osmotic myelinolysis after the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report.
Topics: Antidepressive Agents, Second-Generation; Basal Ganglia; Depression; Female; Fluoxetine; Humans; Hyp | 2007 |
Effect of fluoxetine on depression-induced changes in the expression of vasoactive intestinal polypeptide and corticotrophin releasing factor in rat duodenum.
Topics: Adrenocorticotropic Hormone; Animals; Depression; Duodenum; Fluoxetine; Male; Rats; Rats, Sprague-Da | 2007 |
Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Depression; Female; Fenclonine; Fluoxe | 2008 |
Changes in prescription habits with the introduction of generic fluoxetine.
Topics: Databases as Topic; Depression; Drug Industry; Drug Prescriptions; Drugs, Generic; Fluoxetine; Human | 2008 |
The truth about Prozac: an exchange.
Topics: Antidepressive Agents; Contraindications; Depression; Drug Industry; Fluoxetine; History, 20th Centu | 2008 |
Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice.
Topics: Adrenal Glands; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; | 2008 |
[Effects of acute and chronic introduction of fluoxetine on anxiety-depressive condition of male and female mice].
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Depression; Female; Fl | 2007 |
Antidepressant effect of Yueju-Wan ethanol extract and its fractions in mice models of despair.
Topics: 1-Butanol; Acetates; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antid | 2008 |
Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults.
Topics: Adolescent; Adult; Antidepressive Agents; Anxiety Disorders; Child; Child, Preschool; Depression; Dr | 2008 |
Poor neonatal adaptation in term infant. Fluoxetine toxicity.
Topics: Depression; Female; Fluoxetine; Humans; Infant, Newborn; Male; Maternal Welfare; Pregnancy; Prenatal | 2008 |
Long-lasting depression-like behavior and epigenetic changes of BDNF gene expression induced by perinatal exposure to methylmercury.
Topics: Animals; Brain-Derived Neurotrophic Factor; Depression; Epigenesis, Genetic; Female; Fluoxetine; Gen | 2008 |
Pre- and postsynaptic serotonergic manipulations in an animal model of depression.
Topics: 5-Hydroxytryptophan; Amitriptyline; Animals; Depression; Disease Models, Animal; Drug Synergism; Flu | 1980 |
Concern over Prozac-induced tumor growth may dwindle following FDA study.
Topics: Amitriptyline; Animals; Depression; Fluoxetine; Humans; Loratadine; Neoplasms; Recurrence; United St | 1995 |
Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine.
Topics: Adult; C-Reactive Protein; Depression; Female; Fluoxetine; Humans; Interleukin-6; Male; Orosomucoid | 1995 |
Antidepressants and suicide.
Topics: Adult; Aged; Antidepressive Agents; Case-Control Studies; Cohort Studies; Depression; Drug Administr | 1995 |
Hyperphagia and weight loss during fluoxetine treatment.
Topics: Adult; Depression; Eating; Female; Fluoxetine; Humans; Hyperphagia; Weight Loss | 1994 |
[Fluoxetine in perspective].
Topics: Amitriptyline; Depression; Double-Blind Method; Fluoxetine; Humans; Paroxetine | 1994 |
Realities of the fluoxetine-to-sertraline switch.
Topics: 1-Naphthylamine; Cost-Benefit Analysis; Depression; Fluoxetine; Humans; Selective Serotonin Reuptake | 1995 |
A case of lipomeningocele reported with fluoxetine (and alprazolam, vitamins B1 and B6, heptaminol) prescribed during pregnancy.
Topics: Adult; Alprazolam; Depression; Drug Therapy, Combination; Female; Fluoxetine; Heptaminol; Humans; In | 1995 |
Fluoxetine and oculomotor activity during sleep in depressed patients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Depression; Electroencephalography; Electromyography; Elec | 1995 |
Inaccuracy in fluoxetine comparison.
Topics: Antidepressive Agents, Tricyclic; Depression; Fluoxetine; Humans; United States | 1994 |
Hair loss during fluoxetine treatment.
Topics: Aged; Alopecia; Depression; Female; Fluoxetine; Humans | 1993 |
Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar Kyoto (WKY) rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Body Weight; Brain; Carrier Prot | 1994 |
Fluoxetine in family practice patients.
Topics: Adolescent; Adult; Age Factors; Aged; Body Weight; Depression; Drug Administration Schedule; Family | 1994 |
Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Dru | 1993 |
Response to "Fluoxetine-associated side effects and suicidality".
Topics: Depression; Fluoxetine; Humans; Research Design; Suicide | 1993 |
Fluoxetine hepatotoxicity.
Topics: Depression; Female; Fluoxetine; Humans; Liver; Liver Function Tests; Middle Aged | 1994 |
Pharmacologic management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Antidepressive Agents; Anxiety Disorders; Clomipramine; Depression; Dopamine; Fluox | 1994 |
Validation of the Quality of Life in Depression Scale in a population of adult depressive patients aged 60 and above.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Depression; Female; Fluoxetine; Humans; Male; Middle | 1994 |
Fluoxetine withdrawal and thalamic pain.
Topics: Cerebral Infarction; Depression; Female; Fluoxetine; Humans; Middle Aged; Pain; Thalamus; Time Facto | 1994 |
Fluoxetine treatment of depression caused by interferon-alpha.
Topics: Adult; Depression; Fluoxetine; Hepatitis C; Humans; Interferon Type I; Male; Recombinant Proteins | 1993 |
Priapism of the clitoris: a case report following trazodone use.
Topics: Adjustment Disorders; Adult; Clitoris; Depression; Female; Fluoxetine; Humans; Muscle Contraction; M | 1993 |
Desensitization of the D1 dopamine receptors in rats reproduces a model of escape deficit reverted by imipramine, fluoxetine and clomipramine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Clomipramine; Depression; Disea | 1995 |
Deciding which selective serotonin reuptake inhibitor to prescribe.
Topics: Antidepressive Agents, Second-Generation; Depression; Fluoxetine; Humans; Practice Patterns, Physici | 1995 |
A depressed workman with heatstroke.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Temperature Regulation; Depres | 1996 |
L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Attention; Carbamazepine; Depressi | 1996 |
Hypoglycemia associated with the use of fluoxetine.
Topics: Antidepressive Agents, Second-Generation; Depression; Diabetes Mellitus, Type 2; Fluoxetine; Humans; | 1996 |
Treating depression in pregnancy.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents; Depression; Female; Fluoxetine; Humans; Infant, | 1996 |
Study addresses question of preferred initial therapy for depression.
Topics: Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Depression; Desipramine; Drug Costs; Fluoxe | 1996 |
SSRI or tricyclics for depression?
Topics: Adult; Depression; Depressive Disorder; Desipramine; Family Practice; Fluoxetine; Humans; Imipramine | 1996 |
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Cerebrovascular Disorders; C | 1996 |
Fluoxetine prescribing in a South African patient population.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depression; Female; Fluoxetine; Humans; Male; Middle | 1996 |
Acute cholestasis by fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Bile Ducts, Intrahepatic; Biopsy; Cholestasis, Intr | 1996 |
Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk.
Topics: Adult; Antidepressive Agents, Second-Generation; Breast Feeding; Depression; Female; Fluoxetine; Hum | 1996 |
An investigation into the prescribing patterns of selective serotonin re-uptake inhibitors in South Africa.
Topics: Adolescent; Adult; Age Distribution; Aged; Animals; Depression; Female; Fluoxetine; Humans; Male; Mi | 1996 |
Birth outcomes in pregnant women taking fluoxetine.
Topics: Abnormalities, Drug-Induced; Adult; Clinical Trials as Topic; Depression; Female; Fluoxetine; Humans | 1997 |
Influence of antidepressant drugs on learning and memory paradigms in mice.
Topics: Aged; Amitriptyline; Animals; Antidepressive Agents; Depression; Female; Fluoxetine; Humans; Imipram | 1996 |
Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Topics: 1-Naphthylamine; Aggression; Animals; Anxiety; Binding, Competitive; Citalopram; Depression; Fluoxet | 1997 |
Sensitivity of the six-item Hamilton Depression Rating Scale.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; | 1997 |
Co-administration of fluoxetine and sumatriptan: the Canadian experience.
Topics: Canada; Depression; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Migraine Disor | 1997 |
Nortriptyline for the treatment of depression in progressive supranuclear palsy.
Topics: Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, | 1997 |
Anorexia nervosa in a 7-year-old girl.
Topics: Age of Onset; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Child; Depression; Female; | 1997 |
Fluoxetine-associated stomatitis.
Topics: Adult; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; H | 1997 |
Movement disorder with fluoxetine.
Topics: Antidepressive Agents, Second-Generation; Child; Depression; Dyskinesia, Drug-Induced; Female; Fluox | 1998 |
[Effectiveness of fluoxetine (portal) in atypical depressions].
Topics: Adolescent; Adult; Chronic Disease; Depression; Female; Fluoxetine; Follow-Up Studies; Humans; Male; | 1998 |
Photosensitivity reaction to fluoxetine and alprazolam.
Topics: Adult; Alprazolam; Antidepressive Agents, Second-Generation; Depression; Ethiopia; Fluoxetine; Human | 1998 |
[For some it is a matter of necessity. Worry about the overuse of an antidepressant].
Topics: Depression; Dose-Response Relationship, Drug; Fluoxetine; Humans; Selective Serotonin Reuptake Inhib | 1998 |
Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Biotransformation; Chronic Di | 1998 |
Serotonin syndrome with mirtazapine-fluoxetine combination.
Topics: Adrenergic alpha-Antagonists; Aged; Antidepressive Agents, Tricyclic; Depression; Drug Interactions; | 1998 |
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Buspirone; Citalopram; Depression; Disease Models, Animal; Dose-Resp | 1998 |
Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Fluoxetine; In Situ Hybridization; Li | 1998 |
Fluoxetine and pregnancy a safe mix?
Topics: Depression; Female; Fibromyalgia; Fluoxetine; Humans; Pregnancy; Pregnancy Complications; Safety; Se | 1998 |
[Mirtazapin--fast and strong effects].
Topics: Antidepressive Agents, Tricyclic; Depression; Fluoxetine; Humans; Mianserin; Mirtazapine; Selective | 1998 |
Extrapyramidal side effects and serotonin syndrome with fluoxetine and biperiden.
Topics: Aged; Basal Ganglia Diseases; Biperiden; Depression; Fluoxetine; Humans; Male; Parasympatholytics; S | 1998 |
Visual hallucinations associated with fluoxetine and sertraline.
Topics: Adult; Antidepressive Agents; Depression; Fluoxetine; Hallucinations; Humans; Male; Sertraline | 1998 |
Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings.
Topics: 1-Naphthylamine; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Drug Costs; Dr | 1995 |
Can Prozac cut health costs?
Topics: Absenteeism; Cost Control; Cost of Illness; Depression; Fluoxetine; Health Care Costs; Humans; New M | 1997 |
Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT1A receptor function.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Second-Generation; Anxiety; | 1999 |
Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression.
Topics: Amygdala; Animals; Antidepressive Agents, Second-Generation; Arcuate Nucleus of Hypothalamus; Brain | 1999 |
Bootstrap methods for adaptive designs.
Topics: Antidepressive Agents, Second-Generation; Clinical Trials, Phase III as Topic; Computer Simulation; | 1999 |
Cholinergic, M1 receptors in the nucleus accumbens mediate behavioral depression. A possible downstream target for fluoxetine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acetylcholine; Animals; Arecoline; Depression; Female; Fluox | 1999 |
[Exasperating hematomas].
Topics: Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents, Second-Generation; Depression; Female; Fl | 1999 |
Mutual influences between paroxysmal hypertension and psychiatric disturbance.
Topics: Aged; Antidepressive Agents, Second-Generation; Autonomic Nervous System Diseases; Blood Pressure; D | 1999 |
[The combined effect of psychotherapy and fluoxetine on obesity].
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Depression; Female; Fluoxetine; Huma | 1999 |
Bullous pemphigoid induced by fluoxetine.
Topics: Aged; Depression; Female; Fluoxetine; Humans; Pemphigoid, Bullous; Selective Serotonin Reuptake Inhi | 1999 |
Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism.
Topics: Alcoholism; Animals; Antidepressive Agents; Depression; Drug Evaluation, Preclinical; Female; Fluoxe | 1999 |
Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride.
Topics: Adolescent; Awareness; Depression; Diabetes Mellitus, Type 1; Fluoxetine; Humans; Hypoglycemia; Male | 2000 |
The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Animals; Body Temperature; Columbidae; | 2000 |
TCAs or SSRIs as initial therapy for depression?
Topics: Adult; Antidepressive Agents, Tricyclic; Costs and Cost Analysis; Depression; Depressive Disorder; D | 1999 |
Sex differences in forced-swim and open-field test behaviours after chronic administration of melatonin.
Topics: Animals; Antioxidants; Behavior, Animal; Depression; Female; Fluoxetine; Male; Melatonin; Motor Acti | 2000 |
Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Cost-Be | 2000 |
Central 5-hydroxytryptamine-2A receptor expression in transgenic mice bearing a glucocorticoid receptor antisense.
Topics: Animals; Cerebral Cortex; Depression; DNA, Antisense; Female; Fluoxetine; Gene Expression; Hippocamp | 2001 |
Dose-dependent seizure activity associated with fluoxetine therapy.
Topics: Depression; Female; Fluoxetine; Humans; Middle Aged; Seizures; Selective Serotonin Reuptake Inhibito | 2001 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Halo | 2001 |
Dopaminergic activity in transgenic mice underexpressing glucocorticoid receptors: effect of antidepressants.
Topics: Amitriptyline; Animals; Antidepressive Agents; Binding Sites; Carrier Proteins; Depression; Disease | 2001 |
Fluoxetine (Prozac) as a cause of QT prolongation.
Topics: Depression; Electrophysiology; Fluoxetine; Humans; Long QT Syndrome; Male; Middle Aged; Selective Se | 2001 |
Fluoxetine and side effects in the geriatric population.
Topics: Aged; Depression; Drug Interactions; Drug Utilization; Female; Fluoxetine; Homes for the Aged; Human | 2001 |
Animal models for the study of antidepressant activity.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2001 |
Prozac weekly.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Depression; Dose-Response Relationship, Drug; | 2001 |
Prefrontal changes and treatment response prediction in depression.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Electroencephal | 2001 |
[Antidepressant effect of water decoction of Rhizoma acori tatarinowii in the behavioural despair animal models of depression].
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Drugs, Chinese | 2001 |
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Topics: Aminopyridines; Amphetamine; Amphetamine-Related Disorders; Animals; Body Weight; Brain; Depression; | 2001 |
The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Behavior, Animal; Darkness; Depression; Disease Mode | 2001 |
Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine.
Topics: Adult; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Cytochrome P-450 Enzyme System; De | 2001 |
Myoclonus secondary to the concurrent use of trazodone and fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Drug Synergism; Fluoxetine; HIV Infecti | 2001 |
Acute paroxysmal dystonia induced by fluoxetine.
Topics: Acute Disease; Adult; Depression; Dystonia; Female; Fluoxetine; Humans | 2001 |
The effects of the introduction of medication on the psychoanalytic process: a case study.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Combined Modality Therapy; Defen | 2001 |
A study of the antidepressant activity of Hypericum perforatum on animal models.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2001 |
[Prozac treatment of chronic tension headache].
Topics: Adolescent; Adult; Affective Symptoms; Antidepressive Agents, Second-Generation; Anxiety; Chronic Di | 1999 |
Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study.
Topics: Activities of Daily Living; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; C | 2001 |
Fluoxetine inhibits dendrite atrophy of hippocampal neurons by decreasing nitric oxide synthase expression in rat depression model.
Topics: Animals; Antidepressive Agents, Second-Generation; Atrophy; Dendrites; Depression; Fluoxetine; Hippo | 2001 |
Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy.
Topics: Depression; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndro | 2001 |
Fluoxetine toxicity in a breastfed infant.
Topics: Antidepressive Agents, Second-Generation; Breast Feeding; Depression; Female; Fluoxetine; Humans; In | 2001 |
Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects.
Topics: Adult; Algorithms; Antidepressive Agents, Second-Generation; Depression; Dose-Response Relationship, | 2002 |
In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Biogenic Monoamines; Brain; Depression | 2002 |
Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac).
Topics: Animals; Antidepressive Agents, Second-Generation; Cerebral Cortex; Corpus Striatum; Depression; Dis | 2002 |
The ethics of the broader usage of Prozac: social choice or social bias?
Topics: Behavior Control; Depression; Female; Fluoxetine; Humans; Mood Disorders; Risk Assessment; Self Conc | 1995 |
SSRIs in pregnancy--are they safe?
Topics: Animals; Antidepressive Agents, Second-Generation; Contraindications; Depression; Female; Fetus; Flu | 2002 |
Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth.
Topics: Acid-Base Equilibrium; Animals; Antidepressive Agents, Second-Generation; Blood Gas Analysis; Blood | 2002 |
Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury.
Topics: Adult; Anti-Anxiety Agents; Bipolar Disorder; Brain Injuries; Buspirone; Depression; Drug Interactio | 2002 |
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antid | 2002 |
And now, transcriptomics.
Topics: Animals; Depression; Fluoxetine; Humans; Mice; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; RN | 2002 |
Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims.
Topics: Adult; Animals; Depression; Fluoxetine; Humans; Male; Mice; Middle Aged; Prefrontal Cortex; Receptor | 2002 |
A chronic treatment with fluoxetine decreases 5-HT(1A) receptors labeling in mice selected as a genetic model of helplessness.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Binding, Competitive; Brain; Depression; Disease Mo | 2002 |
[Severe hyponatremia associated with the use of fluoxetine in the elderly].
Topics: Aged; Aged, 80 and over; Depression; Female; Fluoxetine; Humans; Hyponatremia; Selective Serotonin R | 2002 |
Antidepressant reversal of interferon-alpha-induced anhedonia.
Topics: Animals; Antidepressive Agents; Antiviral Agents; Depression; Desipramine; Drinking Behavior; Drug A | 2002 |
SSRIs: take your pick.
Topics: Depression; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Fluoxetine-induced extrapyramidal symptoms in an adolescent: a case report.
Topics: Adolescent; Basal Ganglia Diseases; Conduct Disorder; Depression; Drug Hypersensitivity; Female; Flu | 2002 |
Evidence for serotonergic modulation of progesterone-induced hyperphagia, depression and algesia in female mice.
Topics: Analgesics; Animals; Antidepressive Agents, Second-Generation; Brain; Depression; Disease Models, An | 2002 |
Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant.
Topics: Adult; Antidepressive Agents; Blood Platelets; Depression; Dystonia; Extrapyramidal Tracts; Female; | 1979 |
Potential fluoxetine-selegiline interaction.
Topics: Aged; Ataxia; Depression; Drug Interactions; Female; Fluoxetine; Humans; Parkinson Disease; Selegili | 1992 |
Fluoxetine-induced psoriasis.
Topics: Adult; Depression; Female; Fluoxetine; Humans; Lithium; Middle Aged; Psoriasis | 1992 |
Fluoxetine/norfluoxetine concentrations in human milk.
Topics: Adult; Breast Feeding; Depression; Female; Fluoxetine; Humans; Infant; Infant, Newborn; Milk, Human; | 1992 |
[Parkinsonism following addition of fluoxetine to treatment with neuroleptics or carbamazepine].
Topics: Depression; Female; Fluoxetine; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, | 1992 |
If at first you do succeed.
Topics: 1-Naphthylamine; Antidepressive Agents; Benzamides; Depression; Fluoxetine; Half-Life; Humans; Moclo | 1991 |
Fluoxetine dose.
Topics: Depression; Dose-Response Relationship, Drug; Fluoxetine; Humans | 1991 |
Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine.
Topics: Alleles; Amitriptyline; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Debris | 1991 |
Fluoxetine and suicide.
Topics: Depression; Fluoxetine; Humans; Suicide | 1991 |
Depression: the news isn't depressing.
Topics: Brain; Depression; Fluoxetine; Humans; Serotonin | 1991 |
Fluoxetine treatment of depressive symptoms in acute intermittent porphyria.
Topics: Acute Disease; Adult; Depression; Female; Fluoxetine; Humans; Porphyrias | 1991 |
[Acute hepatitis during treatment with fluoxetine].
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Depression; Female; Fluoxetine; Humans | 1991 |
The serotonin syndrome.
Topics: Aged; Brain; Depression; Drug Interactions; Female; Fluoxetine; Humans; Monoamine Oxidase Inhibitors | 1991 |
High-dose fluoxetine: safety and efficacy in 27 cases.
Topics: Adult; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Safety | 1991 |
Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine.
Topics: Adult; Depression; Drug Interactions; Female; Fluoxetine; Humans; Sleep Initiation and Maintenance D | 1990 |
Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Clomipramine; Depression; Fluoxetine; Humans | 1990 |
Fluoxetine treatment of premenstrual syndrome.
Topics: Adult; Depression; Depressive Disorder; Female; Fluoxetine; Humans; Premenstrual Syndrome | 1990 |
Fluoxetine and the bleeding time.
Topics: Adult; Bleeding Time; Blood Platelets; Depression; Female; Fluoxetine; Humans; Purpura | 1990 |
Fluoxetine (Prozac) revisited.
Topics: Arousal; Depression; Drug Interactions; Fluoxetine; Humans; Nervous System Diseases | 1990 |
Open trial of fluoxetine in obsessive-compulsive disorder.
Topics: Adult; Depression; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Personality Test | 1989 |